FR2833968A1 - Thematic biochip, useful e.g. for diagnosis, particularly of breast cancer, and treatment selection, comprises thematic probes and probes for interpretation - Google Patents

Thematic biochip, useful e.g. for diagnosis, particularly of breast cancer, and treatment selection, comprises thematic probes and probes for interpretation Download PDF

Info

Publication number
FR2833968A1
FR2833968A1 FR0116962A FR0116962A FR2833968A1 FR 2833968 A1 FR2833968 A1 FR 2833968A1 FR 0116962 A FR0116962 A FR 0116962A FR 0116962 A FR0116962 A FR 0116962A FR 2833968 A1 FR2833968 A1 FR 2833968A1
Authority
FR
France
Prior art keywords
sep
protein
factor
kinase
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
FR0116962A
Other languages
French (fr)
Inventor
Yves Jean Bignon
Veronique Vidal
Incan Chantal D
Chambaud Valerie Laplace
Vidal Valerie Sylvain
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CT MEDICO CHIRURGICAL DE TRONQ
Original Assignee
CT MEDICO CHIRURGICAL DE TRONQ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CT MEDICO CHIRURGICAL DE TRONQ filed Critical CT MEDICO CHIRURGICAL DE TRONQ
Priority to FR0116962A priority Critical patent/FR2833968A1/en
Publication of FR2833968A1 publication Critical patent/FR2833968A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A thematic biochip (A) comprising, on at least one carrier, at least one chip carrying molecular probes (I) corresponding to a theme and at least one associated or coupled research module (RM) comprising molecular probes (II) to assist interpretation of the general theme of (A), is new. Independent claims are also included for: (1) a biochip (A') comprising at least one combination of special molecular probes, expression of which allows evaluation of the repair of DNA and at least one similar combination that allows evaluation of resistance, or sensitivity, of a tumor to a particular treatment or drug; and (2) 3 specific sets of molecular probes: (a) for the theme of breast cancer; (b) for DNA repair; and (c) for chemosensitivity.

Description

<Desc/Clms Page number 1> <Desc / Clms Page number 1>

Biopuces thématiques, comportant des modules de recherche associés ou couplés, leur procédé de préparation, et leurs applications.  Thematic biochips, including associated or coupled search modules, their method of preparation, and their applications.

Secteur technique de l'invention : La présente invention concerne le secteur technique des biopuces

Figure img00010001

(dénommées biochips ou plus récemment microarrays ) c'est-à-dire, comme le sait l'homme de métier, des supports par exemple du type verre, verre-silice, matières plastiques ou membrane de NylonTM, ou tout autre support approprié, comme on le verra dans les exemples non limitatifs donnés ci-dessous, sur lesquels sont fixés ou déposés ( spotted ) des fragments de gènes, des ADNc ou des fragments d'ADNc, ou des oligonucléotides. TECHNICAL FIELD OF THE INVENTION The present invention relates to the technical sector of biochips
Figure img00010001

(called biochips or more recently microarrays) that is to say, as known to those skilled in the art, supports for example glass, glass-silica, plastics or NylonTM membrane, or any other suitable medium, as will be seen in the nonlimiting examples given below, on which are fixed or spotted gene fragments, cDNAs or cDNA fragments, or oligonucleotides.

On peut aussi fixer ou déposer les acides nucléiques échantillons sur des surfaces à plots électroniques, en faisant appel à l'attraction électrostatique de charges + et-, ou des supports couplés à des semi-conducteurs. It is also possible to fix or deposit the sample nucleic acids on surfaces with electronic pads, by using the electrostatic attraction of + and - charges, or supports coupled to semiconductors.

Le verre est préféré comme support car il est inerte, résiste aux températures élevées, présente une faible fluorescence naturelle, et est facile à employer pour le dépôt des échantillons, mais on peut utiliser maintenant d'autres supports, comme indiqué ci-dessous. Glass is preferred as a carrier because it is inert, resistant to high temperatures, has low natural fluorescence, and is easy to use for depositing samples, but other supports can now be used, as shown below.

Une utilisation fréquente de telles biopuces, entre autres utilisations, est de vérifier la présence de transcrits (ARNm) dans un milieu biologique donné, en recherchant si ce milieu hybride ou non avec les ADN d'une puce donnée. A frequent use of such biochips, among other uses, is to verify the presence of transcripts (mRNA) in a given biological medium, by looking for whether this hybrid medium or not with the DNA of a given chip.

La détection peut se faire par des méthodes classiques de fluorescence ou par le moyen de radioisotopes, ou toute autre méthode de détection connue ou qui serait jugée appropriée par l'homme de métier, telles que méthodes colorimétriques et analogues ou via des semi-conducteurs. Detection can be by conventional fluorescence or radioisotope methods, or any other known detection method or that would be deemed appropriate by those skilled in the art, such as colorimetric and analog methods or semiconductors.

On sait que l'information génétique de toute espèce vivante est codée sous la forme d'une très longue séquence de bases nucléotidiques, l'ADN, composé de quatre nucléotides dénommés G, C, T, et A. La chaîne de ADN forme la double hélice bien connue. Chaque brin de l'hélice est complémentaire de l'autre car les nucléotides sont capables de reconnaître leur nucléotide complémentaire, ce qui donne des liaisons A-T et GC. It is known that the genetic information of any living species is coded as a very long nucleotide base sequence, the DNA, composed of four nucleotides called G, C, T, and A. The DNA chain forms the well known double helix. Each strand of the helix is complementary to the other because the nucleotides are able to recognize their complementary nucleotide, which gives AT and GC bonds.

<Desc/Clms Page number 2> <Desc / Clms Page number 2>

Le principe de la reconnaissance par une biopuce consiste à fixer sur un support une sélection donnée de gènes ou de fragments de gènes sous la forme d'un seul brin ( capture probe ). On procède ensuite à une incubation en présence du milieu à déterminer, et, si la séquence complémentaire de gènes (ADN visé ou target ADN ) est présente dans ledit milieu d'essai, cette séquence va reconnaître spécifiquement sur la biopuce sa séquence complémentaire et former un double brin d'ADN. Ce processus est dénommé hybridation. Il résulte de collisions entre les divers brins et formation progressive de l'hélice double au fur et à mesure de la reconnaissance des complémentaires. The principle of recognition by a biochip is to fix on a support a given selection of genes or gene fragments in the form of a single strand (capture probe). An incubation is then carried out in the presence of the medium to be determined, and if the complementary sequence of genes (targeted DNA or target DNA) is present in said test medium, this sequence will specifically recognize on the biochip its complementary sequence and form a double strand of DNA. This process is called hybridization. It results from collisions between the various strands and progressive formation of the double helix as and when the recognition of the complementary.

De manière habituelle, les biopuces sont constituées d'un support sur lequel on a fixé ou déposé des sélections multiples de gènes ou de fragments de gènes, chacune étant a priori spécifique pour l'hybridation avec les, et donc la détection des, séquences d'ADN recherchées. Usually, the biochips consist of a support on which multiple selections of genes or gene fragments have been fixed or deposited, each being a priori specific for the hybridization with, and therefore the detection of, DNA sequences. DNA sought.

En l'état actuel de la technique, on vise à détecter en un seul essai l'expression (ou, plus précisément, les transcrite ) de nombreuses séquences de génomes. In the current state of the art, it is intended to detect in a single test the expression (or, more specifically, the transcribed) of many genome sequences.

La technologie des biopuces à ADN consiste donc en l'hybridation de molécules d'ADN sur un support solide avec une sonde marquée. Il existe différents types de supports. Les plus couramment utilisés sont les lames de

Figure img00020001

TM verre et les membranes de Nylon Il existe deux procédés de fabrication des biopuces. DNA microarray technology therefore consists of the hybridization of DNA molecules on a solid support with a labeled probe. There are different types of media. The most commonly used are the blades of
Figure img00020001

TM Glass and Nylon Membranes There are two methods of manufacturing biochips.

Le premier consiste en des micro-dépôts de molécules d'ADN (ADN complémentaire ou oligonucléotides). The first consists of micro-deposits of DNA molecules (complementary DNA or oligonucleotides).

Le deuxième est développé par la société Affymetrix : il s'agit de la synthèse in situ d'oligonucléotides. The second is developed by Affymetrix: this is the in situ synthesis of oligonucleotides.

Plusieurs applications des bio puces ADN sont possibles. Un intérêt est l'étude du transcriptome. Cela permet de mesurer simultanément l'expression de centaines (voire milliers) de gènes. Plusieurs travaux scientifiques ont montré l'intérêt des biopuces à ADN et de l'analyse du transcriptome en médecine. Several applications of biochips DNA are possible. An interest is the study of the transcriptome. This makes it possible to simultaneously measure the expression of hundreds (or even thousands) of genes. Several scientific works have shown the interest of DNA microarrays and transcriptome analysis in medicine.

<Desc/Clms Page number 3> <Desc / Clms Page number 3>

En termes de produits, des biopuces sont commercialisées (société ClontechT,) Incyte, Research Genetics, Affymetrix). In terms of products, biochips are marketed (ClontechT company, Incyte, Research Genetics, Affymetrix).

Ce sont des biopuces dites thématiques qui permettent l'étude d'un processus biologique donné au niveau moléculaire. Par exemple, cela peut concerner l'apoptose (mort cellulaire), le cycle cellulaire, la réponse immunitaire. Ces biopuces sont de densité relativement faible (de l'ordre de 200-800 gènes/cm2). These so-called thematic biochips allow the study of a given biological process at the molecular level. For example, this may concern apoptosis (cell death), the cell cycle, the immune response. These biochips are of relatively low density (of the order of 200-800 genes / cm 2).

Il existe également des biopuces dites de criblage . Il s'agit alors de biopuces de haute densité permettant le dépôt de plusieurs milliers de gènes sur un support unique. There are also so-called screening biochips. It is then high density biochips allowing the deposit of several thousand genes on a single support.

Problème technique posé : Les biopuces de criblage de haute densité avec le dépôt de plusieurs illiers de gènes apportent plus d'informations que l'on ne peut en interpréter, compte-tenu d'une analyse multiparamétrique intégrative impossible à l'esprit humain ou aux logiciels bio-informatiques. Technical problem raised: Microchips of high density screening with the deposition of several ills of genes provide more information than can be interpreted, taking into account an integrative multiparametric analysis impossible to the human mind or bioinformatics software.

Les biopuces thématiques, par l'ordonnancement de sondes moléculaires choisies par rapport à une question scientifique posée, permettent par contre une interprétation adaptée d'un phénomène biologique, physiologique ou pathologique. The thematic biochips, by the ordering of molecular probes chosen in relation to a scientific question asked, allow on the other hand an adapted interpretation of a biological, physiological or pathological phenomenon.

Cependant, il serait très souhaitable de diposer de biopuces thématiques capables de permettre une interprétation plus fine. However, it would be very desirable to have thematic biochips capable of allowing a more precise interpretation.

La qualité des biopuces connues est de plus très contreversée. En effet, suite à des problèmes de contamination survenus lors de la préparation technique des capture probes)), les gènes déposés sur les supports ne correspondent pas toujours à ceux supposés être théoriquement présents. The quality of known biochips is also very controversial. Indeed, following contamination problems that occurred during the technical preparation of the probes)), the genes deposited on the supports do not always correspond to those supposed to be theoretically present.

L'interprétation des résultats est alors entachée de de nombreuses imprécisions, voire erreurs, qui ne peuvent être corrigées que par l'utilisation d'autres techniques alternatives de biologie moléculaire (PCR quantitative, The interpretation of the results is then vitiated by many inaccuracies, even errors, which can only be corrected by the use of other alternative techniques of molecular biology (quantitative PCR,

<Desc/Clms Page number 4><Desc / Clms Page number 4>

Northern blots ,...). On note également des problèmes de séquences, de positions sur la lame. On ne sait pas, actuellement, fabriquer des bipuces de haute qualité. Les diagnostics posés à l'aide des biopuces connues sont soit très imprécis, soit erronés, ce qui oblige à les valider ou les infirmer par des techniques alternatives. L'intérêt de l'emploi des biopuces connues s'en trouve donc fortement diminué.    Northern blots, ...). There are also problems of sequences, positions on the blade. It is currently not known how to make high quality bipiles. The diagnoses made using known biochips are either very imprecise or erroneous, which requires validating or reversing them by alternative techniques. The interest of the use of known biochips is therefore greatly reduced.

La fabrication de biopuces de haute qualité est donc un réel besoin en raison de la recherche d'une plus grande précision dans les diagnostics biologiques, et d'un besoin accru de diagnostics thématiques plus fins pour répondre aux attentes scientifiques, et économiques, dans le domaine de la santé publique et de toutes les sciences du vivant. The production of high-quality biochips is therefore a real need because of the search for greater precision in biological diagnoses, and an increased need for thematic diagnoses that are finer in order to meet scientific and economic expectations. public health and all life sciences.

De plus, il serait très intéressant de développer des biopuces précisément adaptées à l'étude d'un processus biologique dans un modèle donné. In addition, it would be very interesting to develop microchips precisely adapted to the study of a biological process in a given model.

Il serait également de la plus haute importance, notamment en cancérologie, de développer des biopuces qui soient des outils de diagnostic précis, fiables, et complets pour le praticien. It would also be of utmost importance, especially in oncology, to develop biochips that are accurate, reliable, and comprehensive diagnostic tools for the practitioner.

Une première solution intéressante est apportée par la fabrication de biopuces thématiques ou non, dites de haute qualité , par la Demande de brevet français déposée le même jour au nom du Demandeur, et intitulée Procédé pour préparer des biopuces thématiques ou non, de haute qualité contrôlée, les biopuces ainsi préparées, et leurs applications . A first interesting solution is provided by the production of thematic or non-thematic biochips, said to be of high quality, by the French patent application filed the same day in the name of the Applicant, and entitled Process for preparing thematic or non-thematic biochips, of high quality controlled. , the biochips thus prepared, and their applications.

Cependant, il serait très intéressant de développer des biopuces thématiques encore plus précisément adaptées à l'étude d'un processus biologique dans un modèle donné. However, it would be very interesting to develop thematic biochips even more specifically adapted to the study of a biological process in a given model.

L'invention concerne, dans ce but, des biopuces thématiques quelque soit le type de sondes moléculaires déposées (c'est-à-dire par micro-dépôts d'ADN ou de fragments d'ADN, ou d'ADNc, ou d' oligonucléotides, ou par synthèse in situ d'oligonucléotides) soit de qualité normale c'est-à-dire préparées par les procédés de l'art antérieur, The invention relates, for this purpose, thematic biochips whatever the type of deposited molecular probes (that is to say by micro-deposits of DNA or DNA fragments, or cDNA, or of oligonucleotides, or by in situ synthesis of oligonucleotides) of normal quality that is to say, prepared by the methods of the prior art,

<Desc/Clms Page number 5><Desc / Clms Page number 5>

soit dites de très haute qualité c'est-à-dire préparées par un procédé tel que décrit dans la demande de brevet précitée, et caractérisées en ce qu'elles sont associées à au moins un module de recherche".  either of very high quality that is to say, prepared by a method as described in the aforementioned patent application, and characterized in that they are associated with at least one search module ".

L'invention concerne également lesdites biopuces employées dans, et adaptées pour, les études et diagnostics en médecine humaine et vétérinaire et dans d'autres domaines technologiques, comme le domaine phytosanitaire et tous les domaines analogues des sciences du vivant. The invention also relates to said biochips employed in and adapted for studies and diagnoses in human and veterinary medicine and in other technological fields, such as the phytosanitary field and all similar fields of life sciences.

Résumé de l'invention : La présente invention vise à concevoir et fabriquer des biopuces thématiques de qualité soit normale soit de très haute qualité (contrôlée), pour l'étude moléculaire de maladies précises, notamment dans le secteur médical et plus particulièrement de l'oncologie, notamment (mais à titre non limitatif) du cancer mammaire, capable de représenter de réels outils de diagnostic, mais aussi, avec les adaptations nécessaires, dans les sciences du vivant comme le phytosanitaire. SUMMARY OF THE INVENTION The present invention aims to design and manufacture quality thematic biochips of either normal quality or very high quality (controlled), for the molecular study of specific diseases, particularly in the medical sector and more particularly the oncology, including (but not limited to) breast cancer, capable of representing real diagnostic tools, but also, with the necessary adaptations, in the life sciences as phytosanitary.

L'invention concerne également l'utilisation de telles biopuces dans les domaines précités (cf. aussi section (applications))). The invention also relates to the use of such biochips in the aforementioned fields (see also section (applications))).

Description détaillée de l'invention : L'invention concerne en premier lieu de nouvelles biopuces associées à des modules capables de remplir des fonctions de diagnostic impossibles à obtenir à ce jour, ou bien pas avec la même précision, le même ciblage et donc la même facilité d'utilisation. DETAILED DESCRIPTION OF THE INVENTION The invention relates first of all to new biochips associated with modules capable of fulfilling diagnostic functions that are impossible to obtain at the present time, or else not with the same precision, the same targeting and therefore the same ease of use.

Il s'agit d'un concept entièrement nouveau, et le mérite de l'invention est de s'être donné l'ambition d'une recherche de pointe dans ce secteur scientifique et technique très ardu, comme on le verra ci-dessous, et ce concept conduit à des avantages pratiques d'une très grande portée médicale (ou dans d'autres domaines). It is an entirely new concept, and the merit of the invention is to have set itself the ambition of cutting-edge research in this very difficult scientific and technical sector, as will be seen below, and this concept leads to practical benefits of a very wide medical scope (or in other areas).

<Desc/Clms Page number 6><Desc / Clms Page number 6>

Selon un mode de réalisation de l'invention, les biopuces selon l'invention sont donc caractérisés en ce qu'elles comportent, sur au moins un support, au moins une biopuce thématique et au moins un module de recherche associé ou couplé.  According to one embodiment of the invention, the biochips according to the invention are therefore characterized in that they comprise, on at least one support, at least one thematic biochip and at least one associated or coupled search module.

Plus précisément, l'invention concerne des biopuces thématiques caractérisés en ce qu'elles comportent, sur au moins un support, au moins une biopuce thématique comportant des sondes moléculaires correspondant à un thème et au moins un module de recherche associé ou couplé, comportant des sondes moléculaires dont la fonction est d'aider le praticien à interpréter le thème général de la biopuce. More specifically, the invention relates to thematic biochips characterized in that they comprise, on at least one support, at least one thematic biochip comprising molecular probes corresponding to a theme and at least one associated or coupled search module, comprising Molecular probes whose function is to help the practitioner to interpret the general theme of the biochip.

Selon encore un mode de réalisation particulier, les biopuces sont caractérisés en ce qu'elles comportent, sur au moins un support, au moins une biopuce thématique et plusieurs modules de recherche associés ou couplés. According to another particular embodiment, the biochips are characterized in that they comprise, on at least one support, at least one thematic biochip and several associated or coupled search modules.

Selon encore un mode de réalisation particulier, les biopuces et les modules de recherche associés sont déposés sur plusieurs supports différents. According to another particular embodiment, the biochips and the associated research modules are deposited on several different supports.

L'homme de métier aura compris que les modules de recherche ont pour fonction d'aider le praticien à interpréter le thème général, par exemple le thème général cancer du sein . The person skilled in the art will have understood that the function of the research modules is to help the practitioner to interpret the general theme, for example the general theme of breast cancer.

On distinguera des modules généraux, c'est-à-dire valables ou utilisables pour de nombreuses pathologies, et des modules spécifiques d'une seule pathologie (ou d'un petit groupe de pathologies), par exemple spécifiques du cancer du sein.  We will distinguish general modules, that is to say valid or usable for many pathologies, and specific modules of a single pathology (or a small group of pathologies), for example specific breast cancer.

Selon un mode de réalisation particulier, les biopuces selon l'invention sont caractérisées en ce que en ce qu'elles comportent au moins un module général et au moins un module spécifique.  According to a particular embodiment, the biochips according to the invention are characterized in that they comprise at least one general module and at least one specific module.

Selon un mode de réalisation particulier, les biopuces utilisées sont de qualité normale, c'est-à-dire fabriquées par les procédés connus de l'art antérieur, comme celle obtenue par la voie oligonucléotidique, ou par la voie ADN c, et comportent par exemple des sondes nucléotidiques.  According to a particular embodiment, the biochips used are of normal quality, that is to say manufactured by the methods known from the prior art, such as that obtained by the oligonucleotide route, or by the c-DNA route, and comprise for example nucleotide probes.

Selon encore un mode de réalisation particulier, les biopuces sont caractérisées en ce qu'elles sont de très haute qualité et comportent, sur au moins un support, au moins une sonde moléculaire qui est : - de haute pureté - en quantité connue déposée sur ledit support ; et  According to another particular embodiment, the biochips are characterized in that they are of very high quality and comprise, on at least one support, at least one molecular probe which is: - of high purity - in known quantity deposited on said support; and

<Desc/Clms Page number 7><Desc / Clms Page number 7>

identifiée dans sa séquence nucléotidique .    identified in its nucleotide sequence.

Les termes entre sont connus de l'homme de métier, ou bien compréhensibles par l'homme de métier, mais on en donnera la définition suivante, qui sera valable dans toute la présente demande, y compris les revendications : sonde moléculaire : désigne la totalité ou un fragment d'ADN, ou d'ADNc, caractéristique d'un gène donné et répondant (dans le cadre de la présente invention) aux trois exigences qui viennent d'être précisées.  The terms between are known to those skilled in the art, or understandable to those skilled in the art, but the following definition will be given, which will be valid throughout the present application, including the claims: molecular probe: designates the totality or a DNA fragment, or cDNA, characteristic of a given gene and responding (in the context of the present invention) to the three requirements that have just been specified.

Dans le cadre général connu de l'art antérieur et des connaissances générales de l'homme de métier, la définition est naturellement identique, mais les trois exigences ne sont pas présentes ou rassemblées. In the general framework known from the prior art and general knowledge of the skilled person, the definition is naturally identical, but the three requirements are not present or collected.

de haute pureté ou ou de très haute pureté signifie que la sonde moléculaire est débarrassée de tous les réactifs chimiques, des oligonucléotides libres, et des fragments nucléotidiques ne correspondant pas à la sonde (fragments de sonde et/ou amorces ou primers ) ; on opère comme on le verra et à titre non limitatif, au moyen de membranes ou d'autres technologies équivalentes connues de l'homme de métier.   high purity or very high purity means that the molecular probe is freed of all chemical reagents, free oligonucleotides, and nucleotide fragments that do not correspond to the probe (probe fragments and / or primers or primers); one operates as will be seen and not limited to, by means of membranes or other equivalent technologies known to those skilled in the art.

en quantité connues signifie que l'on a accès à la quantité précise déposée car elle résulte d'un dépôt sur le support d'un volume connu de suspension de départ, elle même de concentration connue.   in known quantity means that one has access to the precise amount deposited because it results from a deposit on the support of a known volume of starting suspension, itself of known concentration.

identifiée dans sa séquence nucléotidique signifie de manière plus précise identifiée dans sa séquence nucléotidique informative par rapport aux fonctions du gène , ce qui à son tour signifie que l'on a procédé à l'identification de la séquence des bases nucléotidiques correspondant à tout ou partie d'un gène identifié juste avnt son dépôt.   identified in its nucleotide sequence means more specifically identified in its nucleotide sequence informative with respect to the functions of the gene, which in turn means that one has proceeded to the identification of the nucleotide base sequence corresponding to all or part of a gene identified just before its deposit.

Par tout ou partie zu on désignera ici le nombre minimal de bases suffisant pour définir la spécificité d'un gène. By all or part of this, the minimum number of bases sufficient to define the specificity of a gene will be designated here.

On parlera encore de longueur de la séquence vérifiée De telles sondes, et leurs procédé de préparation, sont décrites dans la demande de brevet français précitée intitulée Procédé pour préparer des biopuces thématiques ou non, de haute qualité contrôlée, les We will still talk about the length of the verified sequence. Such probes, and their method of preparation, are described in the aforementioned French patent application entitled Process for preparing thematic or non-thematic biochips of controlled high quality.

<Desc/Clms Page number 8><Desc / Clms Page number 8>

biopuces ainsi préparées, et leurs applications et déposée au nom du Demandeur.  biochips thus prepared, and their applications and filed in the name of the Applicant.

L'homme de métier pourra s'y référer utilement. The skilled person can usefully refer to it.

Pour encore clarifier ces définitions indispensables à la clarté du texte, on rapellera brièvement un minimum de données scientifiques connues de l'homme de métier. To further clarify these definitions essential to the clarity of the text, briefly recall a minimum of scientific data known to those skilled in the art.

Un gène est composé de nombreux fragments et représente une information génétique codée. A gene is composed of many fragments and represents coded genetic information.

Les fragments sont constitués d'alternaces d'exons et d'introns. The fragments consist of alternates of exons and introns.

La cellule va supprimer toute la partie intronique, ( maturation du gène dans la celleule) ce qui réduit le fragment considéré à une suite d'exons séparés ou raccordés entre eux par des jonctions , l'ensemble formant l'ARN messager mature. The cell will remove all the intronic part, (maturation of the gene in the cell) which reduces the fragment considered to a sequence of exons separated or interconnected by junctions, the assembly forming the mature messenger RNA.

Cet ARN va servir de matrice pour être traduit en protéines, qui sont les molécules chimiques ayant une fonction biologique dans la cellule. This RNA will serve as a template to be translated into proteins, which are the chemical molecules having a biological function in the cell.

Une sonde moléculaire sera constituée de fragments de la séquence exonique et de ses jonctions. Une sonde peut comporter un nombre variable de bases depuis par exemple un nombre aussi élevé que quelques milliers de bases jusqu'à aussi faible que 50 bases. A molecular probe will consist of fragments of the exonic sequence and its junctions. A probe may comprise a variable number of bases from for example a number as high as a few thousand bases up to as low as 50 bases.

Pour identifier la spécificité d'un gène, les scientifiques ont recours à des méthodes mathématiques bien connues. To identify the specificity of a gene, scientists use well-known mathematical methods.

En général, il suffira d'une vingtaine de bases pour assurer la spécificité du gène identifié (c'est-à-dire être certain que la succession des bases nucléotidiques est caractéristique du gène ou unique dans le génôme de l'organisme étudié) et permettre une identification, mais dans la plupart des cas, les scientifiques s'accordent pour considérer que l'identification n'est fiable qu'à partir d'un nombre de l'ordre de 50 à 70 bases. In general, it will take about twenty bases to ensure the specificity of the identified gene (ie to be certain that the succession of nucleotide bases is characteristic of the gene or unique in the genome of the organism studied) and allow identification, but in most cases scientists agree that identification is reliable only from a number of 50 to 70 bases.

On verra que, selon l'invention, on pourra employer jusqu'à quelques milliers de bases, par exemple. It will be seen that, according to the invention, it will be possible to use up to a few thousand bases, for example.

Selon un mode de réalisation particulier et non limitatif, les biopuces selon l'invention sont des biopuces thématiques de très haute qualité . According to a particular and non-limiting embodiment, the biochips according to the invention are thematic biochips of very high quality.

Selon encore un mode de réalisation particulier et non limitatif, les biopuces selon l'invention sont des biopuces thématique de qualité normale. According to another particular and nonlimiting embodiment, the biochips according to the invention are thematic biochips of normal quality.

<Desc/Clms Page number 9><Desc / Clms Page number 9>

Selon un mode de réalisation particulier et non limitatif, les biopuces selon l'invention sont caractérisées en ce qu'elles comportent une combinaison de une ou plusieurs combinaisons de sondes moléculaires thématiques de très haute qualité et de une ou plusieurs combinaisons de sondes moléculaires thématiques de qualité normale.  According to a particular and non-limiting embodiment, the biochips according to the invention are characterized in that they comprise a combination of one or more combinations of thematic molecular probes of very high quality and one or more combinations of thematic molecular probes of normal quality.

(éventuellement sur des supports différents, comme indiqué plus haut) Biopuces thématiques : A la différence des biopuces à thème connues, qui comportent un très grand nombre de gènes et qui ne peuvent pas former un outil précis de diagnostic (les utilisateurs étant contraints à corréler les 500 etc.... gènes présents avec les résultats obtenus, c'est-à-dire à procéder par approximations et interprétations successives), les biopuces selon l'invention sont caractérisées par un nombre beaucoup plus réduit de gènes, eux-mêmes ciblés sur une pathologie précise, par exemple le cancer du sein, et de très haute qualité ou pureté. On se référera utilement en ce domaine à la demande de brevet français déposée le même jour au nom des Demandeurs, et intitulée Biopuces à thèmes et à modules de recherche associés . (possibly on different supports, as mentioned above) Thematic biochips: Unlike known themed biochips, which have a very large number of genes and can not form an accurate diagnostic tool (users are forced to correlate the 500 etc ... genes present with the results obtained, that is to say proceed by approximations and successive interpretations), the biochips according to the invention are characterized by a much smaller number of genes, themselves targeted on a specific pathology, for example breast cancer, and of very high quality or purity. Useful reference will be made in this field to the French patent application filed the same day on behalf of the Applicants, and entitled Thematic biochips and associated research modules.

Ces caractéristiques ouvrent la voie pour la première fois à de vrais outils de diagnostic, capables de permettre au médecin ou au biologiste aussi bien de caractériser, de classer une tumeur, que d'évaluer ses facteurs pronostiques. These characteristics pave the way for the first time to real diagnostic tools, capable of allowing the doctor or the biologist both to characterize, to classify a tumor, and to evaluate its prognostic factors.

L'invention concerne donc également - des biopuces à thème telles que définies ci-dessus - caractérisées en ce qu'elles comportent une combinaison de sondes moléculaires spéciales adaptées pour - comprendre des gènes dont l'expression donne une indication sur le tissu tumoral (stade de la tumeur, son aggressivité, les cellules atteintes, le pouvoir invasif, la résistance ou au contraire la sensibilité aux traitements anti-tumoraux...). The invention therefore also relates to - themed biochips as defined above - characterized in that they comprise a combination of special molecular probes adapted to - understand genes whose expression gives an indication on the tumor tissue (stage the tumor, its aggressiveness, the cells affected, the invasiveness, the resistance or, on the contrary, the sensitivity to anti-tumor treatments ...).

L'invention concerne également les biopuces module de recherche qui comportent seulement une combinaison de sondes moléculaires spéciales dont l'expression permet d'évaluer la réparation de l'ADN. The invention also relates to the research module biochips which comprise only a combination of special molecular probes whose expression makes it possible to evaluate the repair of the DNA.

<Desc/Clms Page number 10><Desc / Clms Page number 10>

L'invention concerne également les biopuces module de recherche qui comportent seulement une combinaison de sondes moléculaires spéciales dont l'expression permet d'évaluer la résistance (ou la sensibilité) de la tumeur à tel traitement ou à telle molécule pharmacologique.  The invention also relates to research module biochips which comprise only a combination of special molecular probes the expression of which makes it possible to evaluate the resistance (or the sensitivity) of the tumor to such a treatment or to such a pharmacological molecule.

L'invention concerne encore les biopuces qui comportent simultanément - au moins une combinaison de sondes moléculaires spéciales module de recherche ) dont l'expression permet d'évaluer le réparation de l'ADN et - au moins une combinaison de sondes moléculaires spéciales module de recherche ) dont l'expression permet d'évaluer la résistance (ou la sensibilité) de la tumeur à tel traitement ou à telle molécule pharmacologique. The invention also relates to biochips which comprise simultaneously - at least one combination of special molecular probes research module) whose expression makes it possible to evaluate the repair of the DNA and - at least one combination of special molecular probes research module ) whose expression makes it possible to evaluate the resistance (or the sensitivity) of the tumor to such a treatment or to such a pharmacological molecule.

Comme indiqué ci-dessus, ces modules de recherche peuvent être combinés à des combinaisons de sondes moléculaires thématiques de haute qualité ou de qualité normale, sur un ou plusieurs supports identiques ou différents, et également à des biopuces de criblage. As indicated above, these research modules can be combined with combinations of thematic molecular probes of high quality or normal quality, on one or more identical or different supports, and also with screening biochips.

L'invention concerne également des biopuces thématiques du type cidessus, caractérisées en ce que elles comportent de plus au moins une biopuce de criblage de qualité normale, c'est-à-dire selon l'art antérieur, outre une ou plusieurs biopuces thématiques de très haute qualité. The invention also relates to thematic biochips of the above type, characterized in that they additionally comprise at least one screening biochip of normal quality, that is to say according to the prior art, in addition to one or more thematic biochips of very high quality.

L'invention concerne également des biopuces thématiques caractérisées en ce que elles comportent au moins une biopuce thématique de qualité normale, c'est-à-dire selon l'art antérieur, outre une ou plusieurs biopuces de criblage de très haute qualité. The invention also relates to thematic biochips characterized in that they comprise at least one thematic biochip of normal quality, that is to say according to the prior art, in addition to one or more biochips screening very high quality.

De manière tout à fait préférée, lesdites biopuces comportent en totalité ou au moins en partie des sondes moléculaires de haute pureté préparées par l'un des procédés décrits dans la Demande précitée, et de préférence en totalité. Most preferably, said biochips comprise in whole or at least in part high purity molecular probes prepared by one of the methods described in the aforementioned Application, and preferably entirely.

Cependant, l'homme de métier comprendra qu'il pourra concevoir, à partir de la présente description et des exemples non limitatifs donnés, et de However, one skilled in the art will understand that he can conceive, from the present description and non-limiting examples given, and from

<Desc/Clms Page number 11><Desc / Clms Page number 11>

ses connaissance générales, d'autres combinaisons qui lui apparaîtront logiquement en fonction de la maladie spécifique étudiée.  his general knowledge, other combinations which will appear to him logically according to the specific disease studied.

PROCEDE
Les biopuces selon l'invention sont préparées soit par un procédé de l'art antérieur, comme la voie oligonucléotidique, ou par la voie ADNc soit normale, soit telle que décrite dans la Demande précitée. PROCESS
The biochips according to the invention are prepared either by a method of the prior art, such as the oligonucleotide route, or by the cDNA pathway is normal, or as described in the aforementioned Application.

Afin de replacer l'invention dans son contexte, un exemple non limitatif de procédé selon la Demande précitée est caractérisé par une combinaison de 10 étapes connues en soi, mais jamais combinées entre elles ou du moins pas entièrement, ou pas de la manière dont procède l'invention :
1. Extractiond'ADN plasmidiques. In order to place the invention in context, a non-limiting example of a method according to the above-mentioned Application is characterized by a combination of 10 steps known per se, but never combined with each other or at least not entirely, or not in the manner in which the invention:
1. Extraction of plasmid DNAs.

2. Dosage des ADN plasmidiques ;
3. Dilution des ADN plasmidiques. 2. Assay of plasmid DNAs;
3. Dilution of the plasmid DNAs.

4. Amplification des ADN complémentaires (ADNc) ou fragments d'ADNc, ou fragment d'ADN,
5. Amplification des ADN complémentaires (ADNc)
6. Purification des produits d'amplification obtenus. 4. Amplification of complementary DNAs (cDNA) or cDNA fragments, or DNA fragment,
5. Amplification of complementary DNAs (cDNA)
6. Purification of the obtained amplification products.

7. Dosage de ces produits.  7. Dosage of these products.

8. Dilution à une même concentration.  8. Dilution at the same concentration.

9. Préparation d'un plaque où tous les ADNc sont à la même quantité.  9. Preparation of a plate where all the cDNAs are at the same amount.

10. Séquençage des ADNc.  10. Sequencing of cDNAs.

11. Dépôt sur le support (lame de verre ou tout autre support).  11. Deposit on the support (glass slide or other support).

Selon un mode de réalisation particulier, ce procédé est caractérisé par le fait qu'il comporte au moins les étapes 6 (dosage), 7 (dilution) et 9 (séquençage). According to a particular embodiment, this method is characterized in that it comprises at least steps 6 (assay), 7 (dilution) and 9 (sequencing).

Sans être absolument essentielle, car elle peut ne pas être employée dans certains cas d'applications ou de niveau de qualité souhaité, l'étape 5 de purification est également importante. While not absolutely essential, as it may not be employed in certain applications or desired level of quality, the purification step is also important.

Exemple non limitatif de fabrication : + Fabrication des biopuces de qualité contrôlé. selon le procédé ci-dessus  Non-limiting example of manufacturing: + Manufacture of biochips of controlled quality. according to the method above

<Desc/Clms Page number 12><Desc / Clms Page number 12>

(Demande précitée).  (Application above).

La préparation des sondes de très haute qualité contrôlée se fait dans des plaques 96 puits (ou analogues) et se déroule comme suit :
1. Extraction d'ADN plasmidiques. The preparation of probes of very high quality controlled is done in 96-well plates (or similar) and proceeds as follows:
1. Extraction of plasmid DNAs.

2. Dosage des ADN plasmidiques ;
3. Dilution des ADN plasmidiques. 2. Assay of plasmid DNAs;
3. Dilution of the plasmid DNAs.

4. Amplification des ADN complémentaires (ADNc) ou fragments d'ADNc, ou fragment d'ADN,
5. Purification des produits d'amplification obtenus. 4. Amplification of complementary DNAs (cDNA) or cDNA fragments, or DNA fragment,
5. Purification of the obtained amplification products.

6. Dosage de ces produits.  6. Dosage of these products.

7. Dilution à une même concentration.  7. Dilution at the same concentration.

8. Préparation d'une plaque où tous les ADNc sont à la même quantité.  8. Preparation of a plate where all the cDNAs are at the same amount.

9. Séquençage des ADNc.  9. Sequencing of cDNAs.

10. Dépôt sur la lame de verre ou tout autre support.  10. Deposit on the glass slide or other support.

On obtient des ADNc d'une qualité optimale. Ainsi, l'identité des ADNc déposés sur la lame correspond strictement à la liste théorique des gènes étudiés. CDNAs of optimal quality are obtained. Thus, the identity of the cDNAs deposited on the slide corresponds strictly to the theoretical list of the genes studied.

Comme support, le verre est nettement préféré, mais on pourra aussi utiliser des supports par exemple du type verre, verre-silice, polymères et matières plastiques, ou membrane de NylonTM, ou tout autre support approprié, comme on le verra dans les exemples non limitatifs donnés cidessous, sur lesquels sont fixés ou déposés ( spotted ) des fragments de gènes, des ADNc ou des fragments d'ADNc, ou des oligonucléotides. As a support, glass is clearly preferred, but it is also possible to use supports, for example glass, glass-silica, polymers and plastics, or NylonTM membrane, or any other suitable support, as will be seen in the non-conventional examples. The following are the limiting ones, to which are attached or spotted gene fragments, cDNAs or cDNA fragments, or oligonucleotides.

On peut aussi fixer ou déposer les acides nucléiques échantillons sur des surfaces à plots électroniques, en faisant appel à l'attraction électrostatique de charges + et-, ou des supports couplés à des semi-conducteurs. It is also possible to fix or deposit the sample nucleic acids on surfaces with electronic pads, by using the electrostatic attraction of + and - charges, or supports coupled to semiconductors.

Les fixations ou dépôts pourront être effectués, notamment en cas de combinaisons, sur un ou éventuellement plusieurs supports, identiques ou différents, ce que l'homme de métier saura déterminer. The fasteners or deposits may be made, especially in case of combinations, on one or possibly more supports, identical or different, which the skilled person can determine.

On rappellera les définitions des étapes considérées. We will recall the definitions of the steps considered.

<Desc/Clms Page number 13> <Desc / Clms Page number 13>

L'homme de métier comprendra que les précisons techniques données dans les définitions qui suivent le sont à titre de simple illustration, de portée évidemment non limitative
PROCEDURE TECHNIQUE DE PREPARATION DE SONDES
MOLECULAIRES (ADN ou ADN COMPLEMENTAIRES HUMAINS) ET
DEPOT SUR LAME DE VERRE par le procédé dit de très haute qualité
Ce procédé consiste en des dépôts d'ADN ou d'ADN complémentaire sur lame de verre ou tout autre support approprié. Ces ADN ou ADNc correspondent à la totalité ou à des fragments de gènes humains dont ils sont caractéristiques. Les ADN déposés sont appelés sondes moléculaires. Ces sondes ont été, selon une variante non limitative de l'invention, obtenues à partir de clones bactériens commercialisés par la société Incyte (Etats-
Unis), à l'issue de différentes étapes techniques. Those skilled in the art will understand that the technical details given in the following definitions are merely illustrative, obviously non-limiting in scope
TECHNICAL PROCEDURE FOR PREPARING PROBES
MOLECULAR (HUMAN COMPLEMENTARY DNA OR DNA) AND
DEPOSITION ON GLASS BLADE by the so-called high quality process
This process consists of DNA or complementary DNA deposits on a glass slide or any other suitable support. These DNAs or cDNAs correspond to all or fragments of human genes of which they are characteristic. The deposited DNAs are called molecular probes. These probes were, according to a non-limiting variant of the invention, obtained from bacterial clones marketed by the company Incyte (USA).
United States), following various technical steps.

1. Extraction d'ADN plasmidiques.  1. Extraction of plasmid DNAs.

Il s'agit d'une molécule d'ADN circulaire d'origine bactérienne qui contient l'ADN complémentaire humain. Une fois extrait, chaque ADN plasmidique servira de matrice pour les réactions d'amplification. It is a circular DNA molecule of bacterial origin that contains the human complementary DNA. Once extracted, each plasmid DNA will serve as a template for the amplification reactions.

2. Dosage des ADN plasmidiques : Il permet d'estimer la quantité d'ADN plasmidique obtenu après extraction.  2. Plasmid DNA assay: It allows to estimate the amount of plasmid DNA obtained after extraction.

3. Dilution des ADN plasmidiques : Elle permet d'ajuster tous les ADN à la même concentration.  3. Dilution of plasmid DNAs: It allows to adjust all the DNAs at the same concentration.

4. Amplification des ADN complémentaires :
Le but est d'obtenir le maximum de molécules d'ADN en vue des dépôts sur lame de verre ou tout autre support approprié. Lors de cette réaction, l'ADN est mis en présence de différents réactifs (sels, tampon, enzyme pin \ 4. Amplification of complementary DNAs:
The goal is to obtain the maximum of DNA molecules for glass slide deposits or any other suitable medium. During this reaction, the DNA is put in the presence of different reagents (salts, buffer,

<Desc/Clms Page number 14><Desc / Clms Page number 14>

5. Purification : On peut utiliser des plaques 96 puits (Multiscreen PCR, Millipore) qui se composent d'une membrane qui retient uniquement les molécules d'ADN amplifiés. Les réactifs en excès sont éliminés. Cette étape est essentielle dans le procédé selon l'invention car elle permet d'obtenir une solution d'ADN pure. De la qualité des ADN dépendra la qualité du signal fluorescent obtenu lors de l'étude de la biopuce.  5. Purification: 96-well plates (Multiscreen PCR, Millipore) can be used which consist of a membrane that retains only the amplified DNA molecules. Excess reagents are removed. This step is essential in the process according to the invention because it makes it possible to obtain a solution of pure DNA. The quality of the DNA will depend on the quality of the fluorescent signal obtained during the study of the biochip.

On aurait pu utiliser d'autres formats, comme l'aura compris l'homme de métier, comme des plaques à 384 puits ou tout autre format. Other formats, as understood by those skilled in the art, could have been used, such as 384-well plates or any other format.

De même, il aurait été possible d'utiliser d'autres procédés de purifications, autres que sur membrane, tels qu'il en apparaît régulièrement et qui sont bien connus de l'homme de métier, comme par exemple des systèmes de gel filtration, colonne, purification chimique, 6. Dosage : Le rendement des réactions d'amplification n'est pas identique pour tous les ADN. Il est donc important d'estimer la quantité des ADN obtenus. Likewise, it would have been possible to use other purifications methods, other than membrane, as it appears regularly and which are well known to those skilled in the art, such as gel filtration systems, column, chemical purification, 6. Assay: The yield of amplification reactions is not identical for all DNAs. It is therefore important to estimate the amount of DNA obtained.

7. Dilution : Les résultats obtenus avec une biopuce dépendent, en partie, de la quantité d'ADN déposée sur la lame. Or, pour étudier un mécanisme moléculaire, i est souvent nécessaire d'étudier le niveau d'expression de plusieurs gènes à la fois, et de les comparer entre eux. Afin que cette comparaison soit possible, les ADN sont donc dilués à une même concentration. 7. Dilution: The results obtained with a biochip depend, in part, on the amount of DNA deposited on the slide. Now, to study a molecular mechanism, it is often necessary to study the level of expression of several genes at once, and to compare them with each other. So that this comparison is possible, the DNAs are diluted to the same concentration.

8. Préparation d'une plaque dépôt : Il s'agit ici d'une étape où les ADN sont en quantité identique (même concentration, même volume).

Figure img00140001
8. Preparation of a deposit plate: This is a step where the DNAs are in identical quantity (same concentration, same volume).
Figure img00140001

9. Séquençage : Il est essentiel pour l'obtention de la très haute qualité des biopuces selon l'invention car il garantit l'identité du gène étudié et sa position sur la lame (voir document précédemment envoyé). 9. Sequencing: It is essential for obtaining the very high quality of biochips according to the invention because it guarantees the identity of the gene studied and its position on the slide (see document previously sent).

<Desc/Clms Page number 15> <Desc / Clms Page number 15>

On pourra aussi préparer les biopuces selon l'invention par un procédé de ce type, mais tel que déjà décrit dans l'art antérieur, c'est-à-dire très simplifié et ne conduisant pas à la très haute pureté. It will also be possible to prepare the biochips according to the invention by a process of this type, but as already described in the prior art, that is to say very simplified and not leading to the very high purity.

BASE DE DONNEES L'invention concerne également une base de données et son emploi qui assure la traçabilité de toutes les étapes techniques de préparation des gènes (paramètres techniques, numéros de lots des réactifs utilisés...). Les résultats obtenus lors des différentes étapes techniques sont inclus dans cette base de données. DATABASE The invention also relates to a database and its use which ensures the traceability of all the technical steps of gene preparation (technical parameters, batch numbers of reagents used ...). The results obtained during the various technical steps are included in this database.

Plus particulièrement, l'invention concerne le procédé tel que décrit ci-dessus, caractérisé en ce que la mise en oeuvre d'au moins une de ses étapes, de préférence plusieurs, et de préférences toutes, est consignée et répertoriée, y compris les résultats de l'étape ou des étapes en cause, dans une base de données. More particularly, the invention relates to the method as described above, characterized in that the implementation of at least one of its stages, preferably several, and preferably all, is recorded and listed, including the results of the relevant step (s) in a database.

L'invention concerne également le procédé tel que décrit ci dessus, caractérisé en ce que en ce que ladite base de données contient tout ou partie des fragments de codes utilisés pour la fabrication des biopuces.

Figure img00150001

BIOPUCES THEMATIQUES SELON L'INVENTION On a sélectionné des séries réduites de gènes. La pertinence de ces biopuces réside dans le fait que la combinaison des gènes choisis permet l'étude d'un processus biologique dans un modèle donné. D'un point de vue moléculaire, l'étude de ces gènes permet pour la première fois de répondre à une question scientifique précise. The invention also relates to the method as described above, characterized in that said database contains all or part of the code fragments used for the manufacture of biochips.
Figure img00150001

THEMATIC BIOPUCES ACCORDING TO THE INVENTION Reduced sets of genes have been selected. The relevance of these biochips lies in the fact that the combination of genes chosen allows the study of a biological process in a given model. From a molecular point of view, the study of these genes makes it possible for the first time to answer a specific scientific question.

On a développé la biopuces cancer du sein et deux modules de recherche associés, réparation d'ADN et chimiosensibilité . Breast cancer biochips and two associated research modules, DNA repair and chemosensitivity were developed.

<Desc/Clms Page number 16> <Desc / Clms Page number 16>

La biopuce cancer du sein Cette biopuces permet une classification des tumeurs mammaires afin d'améliorer le diagnostic, donc le pronostic et le choix thérapeutique. Le profil d'expression permet d'étudier les propriétés physiologiques des tumeurs mammaires.  The breast cancer biochip This biochips allows a classification of mammary tumors in order to improve the diagnosis, thus the prognosis and the therapeutic choice. The expression profile makes it possible to study the physiological properties of mammary tumors.

Elle comporte une sélection de seulement environ 330 sondes moléculaires dont la liste est donnée en Annexe 1 SEQ 1. It comprises a selection of only about 330 molecular probes, the list of which is given in Appendix 1 SEQ 1.

Module de recherche réparation des lésions de l'ADN Son but est d'apprécier les mécanismes mis en jeu et la qualité de la réparation des lésions.  Research module DNA damage repair Its purpose is to appreciate the mechanisms involved and the quality of the repair of the lesions.

Il comporte une sélection de seulement environ 130 sondes moléculaires dont la liste est donnée en Annexe 2 SEQ 2. It comprises a selection of only about 130 molecular probes, the list of which is given in Appendix 2 SEQ 2.

Module de recherche chimio sensibilité Son but est de permettre au praticien de prédire la sensibilité d'une tumeur à un médicament anticancéreux afin d'orienter les protocoles lors du traitement des patients.  Chemo Sensitivity Research Module Its purpose is to enable the practitioner to predict the sensitivity of a tumor to an anticancer drug in order to guide the protocols during the treatment of patients.

Ce module comporte une sélection de sondes moléculaires dont la liste est donnée en Annexe 3 SEQ 3. This module includes a selection of molecular probes listed in Appendix 3 SEQ 3.

+ Avantages : + Advantages:

<Desc/Clms Page number 17><Desc / Clms Page number 17>

- Le cancer mammaire est un problème de santé public.  - Breast cancer is a public health problem.

- Les biopuces sont de haute qualité.  - Biochips are of high quality.

- Les biopuces selon l'invention forment des outils de diagnostic simples : le nombre de gènes de chaque biopuces n'est pas élevé.
Chacun des gènes ou la combinaison de seulement quelques gènes a été choisi pour que l'analyse des résultats apporte des réponses précises. The biochips according to the invention form simple diagnostic tools: the number of genes of each biochip is not high.
Each of the genes or the combination of only a few genes has been chosen for the analysis of the results to provide precise answers.

Par exemple, si les gènes A et B sont surexprimés alors la tumeur sera résistante au Taxol TM (drogue anticancéreuse). For example, if genes A and B are overexpressed then the tumor will be resistant to Taxol TM (anticancer drug).

- Compte tenu de la faible densité des biopuces, on peut envisager la production de biopuces à coût réduit.  - Given the low density of biochips, we can consider the production of biochips at reduced cost.

APPLICATIONS L'invention concerne également les diverses applications des biopuces, des combinaisons de sondes moléculaires précitées et des procédés selon l'invention comme moyen de diagnostic dans toutes les sciences du vivant, notamment le domaine médical, vétérinaire, phytosanitaire. The invention also relates to the various applications of biochips, combinations of the aforementioned molecular probes and methods according to the invention as diagnostic means in all life sciences, in particular the medical, veterinary, phytosanitary field.

L'invention concerne également les diverses applications des biopuces, des combinaisons de sondes moléculaires précitées et des procédés selon l'invention, à toute étude de génome connu par exemple génome bovin, végétal, bactérien ; pour vérifier la fonctionnalité d'un gène chez des organismes génétiquement modifiés ; et en virologie, les biopuces étant alors utilisées pour caractériser la présence et le type de virus infectant un organisme ; et pour l'appréciation des mécanismes mis en jeu et de la qualité de la réparation des lésions de l'ADN, et notamment en oncologie, notamment pour le cancer mammaire ; et comme moyen de diagnostic dans le domaine de toutes les sciences du vivant, et notamment dans le domaine médical ou vétérinairedans le domaine phytosanitaire. des biopuces et des procédés selon l'invention comme moyen de diagnostic. The invention also relates to the various applications of biochips, combinations of molecular probes mentioned above and methods according to the invention, to any known genome study, for example a bovine, plant or bacterial genome; to verify the functionality of a gene in genetically modified organisms; and in virology, the biochips being then used to characterize the presence and the type of virus infecting an organism; and for the evaluation of the mechanisms involved and the quality of repair of DNA lesions, and in particular in oncology, in particular for breast cancer; and as a means of diagnosis in the field of all life sciences, and in particular in the medical or veterinary field in the phytosanitary field. biochips and methods according to the invention as diagnostic means.

L'homme de métier comprendra que les biopuces et combinaisons de sondes moléculaires selon l'invention s'appliquent à l'étude de toutes les grandes fonctions cellulaires, notamment apoptose, cycle cellulaire, transduction du signal, prolifération cellullaire, protéolyse, mobilité et invasivité cellulaire, etc.... et à tous les types de maladies, notamment inflammatoires, Those skilled in the art will understand that the biochips and molecular probe combinations according to the invention are applicable to the study of all the major cellular functions, in particular apoptosis, cell cycle, signal transduction, cell proliferation, proteolysis, mobility and invasiveness. cell, etc .... and all types of diseases, including inflammatory,

<Desc/Clms Page number 18><Desc / Clms Page number 18>

infectieuses, endocriniennes, autoimmunes, héréditaires, nutritionnelles, dégénaratives, chroniques ou aigües, etc....  infectious, endocrine, autoimmune, hereditary, nutritional, degenerative, chronic or acute, etc.

L'invention sera mieux comprise à la lecture de la description qui va suivre, et des exemples donnés en Annexe 1 SEQ 1 et Annexe 2 SEQ 2. The invention will be better understood on reading the description which follows, and examples given in Annex 1 SEQ 1 and Annex 2 SEQ 2.

L'invention couvre également les combinaisons de sondes moléculaires décrites, comme produit industriel nouveau, et l'utilisation des combinaisons de sondes moléculaires des annexes 2 et 3 comme module (s) de recherche associé (s) ou couplé (s) à au moins une biopuce thématique L'invention couvre également tous les modes de réalisation et toutes les applications qui seront directement accessibles à l'homme de métier à la lecture de la présente demande, de ses connaissances propres, et éventuellement d'essais simples de routine. The invention also covers the combinations of molecular probes described, as a new industrial product, and the use of the combinations of molecular probes of Annexes 2 and 3 as research module (s) associated with or coupled with at least The invention also covers all the embodiments and all the applications that will be directly accessible to those skilled in the art upon reading the present application, its own knowledge, and possibly simple routine tests.

<Desc/Clms Page number 19> <Desc / Clms Page number 19>

Figure img00190001
Figure img00190001

<tb>
<tb> ANNEXE <SEP> 1 <SEP> SEQ <SEP> 1
<tb>
BIOPUCE THEMATIQUE : CANCER MAMMAIRE. 333 SONDES MOLECULAIRES

Figure img00190002
<Tb>
<tb> ANNEX <SEP> 1 <SEP> SEQ <SEP> 1
<Tb>
THEMATIC BIOPUCE: MAMMARY CANCER. 333 MOLECULAR PROBES
Figure img00190002

<tb>
<tb> Nom <SEP> du <SEP> gèneUnigene
<tb> 5T4 <SEP> oncofetal <SEP> trophoblast <SEP> glycoprotein <SEP> Hs.82128
<tb> acid <SEP> phosphatase <SEP> 5, <SEP> tartrate <SEP> resistant <SEP> Hs.1211
<tb> actin, <SEP> alpha <SEP> 2, <SEP> smooth <SEP> muscle, <SEP> aorta <SEP> Hs. <SEP> 195851
<tb> activating <SEP> transcription <SEP> factor <SEP> 3 <SEP> H2.460
<tb> adrenergic, <SEP> beta, <SEP> receptor <SEP> kinase <SEP> 1 <SEP> Hs.83636
<tb> alcohol <SEP> dehvdroqenase <SEP> 2 <SEP> (class <SEP> l), <SEP> beta <SEP> polvpeptide <SEP> Hs.4
<tb> alcohol <SEP> dehydrogenase <SEP> 2 <SEP> (class <SEP> l), <SEP> beta <SEP> polypeptide <SEP> Hs. <SEP> 4
<tb> aldehyde <SEP> dehydrogenase <SEP> 1, <SEP> soluble <SEP> Hs. <SEP> 76392
<tb> alpha-2-macroglobulin <SEP> Hs.74561
<tb> androgen <SEP> receptor <SEP> (dihydrotestosterone <SEP> receptor <SEP> ; <SEP> testicular <SEP> feminization <SEP> ; <SEP> Hs. <SEP> 99915
<tb> spinal <SEP> and <SEP> bulbar <SEP> muscular <SEP> atrophy <SEP> ; <SEP> Kennedy <SEP> disease)
<tb> annexin <SEP> A1 <SEP> Hs. <SEP> 78225
<tb> annexin <SEP> A8 <SEP> Hs. <SEP> 87268
<tb> anti <SEP> en <SEP> identified <SEP> b <SEP> monoclonal <SEP> antibod <SEP> Ki-67 <SEP> Hs. <SEP> 80976
<tb> apoi <SEP> ! <SEP> poprotein <SEP> A- <SEP> ! <SEP> Hs. <SEP> 93194
<tb> apolipoprotein <SEP> D <SEP> Hs. <SEP> 75736
<tb> apoptosis <SEP> inhibitor <SEP> 4 <SEP> (survivin) <SEP> Hs. <SEP> 1578
<tb> <Tb>
<tb> Name <SEP> of <SEP> geneUnigene
<tb> 5T4 <SEP> oncofetal <SEP> trophoblast <SEP> glycoprotein <SEP> Hs.82128
<tb> acid <SEP> phosphatase <SEP> 5, <SEP> tartrate <SEP> resistant <SEP> Hs.1211
<tb> actin, <SEP> alpha <SEP> 2, <SEP> smooth <SEP> muscle, <SEP> aorta <SEP> Hs. <SEP> 195851
<tb> activating <SEP> transcription <SEP> factor <SEP> 3 <SEP> H2.460
<tb> adrenergic, <SEP> beta, <SEP> receptor <SEP> kinase <SEP> 1 <SEP> Hs.83636
<tb> alcohol <SEP> dehydrogenase <SEP> 2 <SEP> (class <SEP> 1), <SEP> beta <SEP> polypeptide <SEP> Hs.4
<tb> alcohol <SEP> dehydrogenase <SEP> 2 <SEP> (class <SEP> 1), <SEP> beta <SEP> polypeptide <SEP> Hs. <SEP> 4
<tb> aldehyde <SEP> dehydrogenase <SEP> 1, <SEP> soluble <SEP> Hs. <SEP> 76392
<tb> alpha-2-macroglobulin <SEP> Hs.74561
<tb> androgen <SEP> receptor <SEP> (dihydrotestosterone <SEP> receptor <SEP>;<SEP> testicular <SEP> feminization <SEP>;<SEP> Hs. <SEP> 99915
<tb> spinal <SEP> and <SEP> bulbar <SEP> muscular <SEP> atrophy <SEP>;<SEP> Kennedy <SEP> disease)
<tb> annexin <SEP> A1 <SEP> Hs. <SEP> 78225
<tb> annexin <SEP> A8 <SEP> Hs. <SEP> 87268
<tb> anti <SEP> in <SEP> identified <SEP> b <SEP> monoclonal <SEP> antibod <SEP> Ki-67 <SEP> Hs. <SEP> 80976
<tb> apoi <SEP>! <SEP> poprotein <SEP> A- <SEP>! <SEP> Hs. <SEP> 93194
<tb> apolipoprotein <SEP> D <SEP> Hs. <SEP> 75736
<tb> apoptosis <SEP> inhibitor <SEP> 4 <SEP> (survivin) <SEP> Hs. <SEP> 1578
<Tb>

<Desc/Clms Page number 20> <Desc / Clms Page number 20>

Figure img00200001
Figure img00200001

<tb>
<tb> aquaporin <SEP> 1 <SEP> (channel-forminq <SEP> inteqral <SEP> protein, <SEP> 28kO) <SEP> Hs. <SEP> 74602
<tb> aquaporin <SEP> 7 <SEP> Hs. <SEP> 25475
<tb> armadillo <SEP> repeat <SEP> gène <SEP> deletes <SEP> in <SEP> velocardiofacial <SEP> syndrome <SEP> Hs. <SEP> 171900
<tb> ARP1 <SEP> (actin-related <SEP> protein <SEP> 1, <SEP> yeast) <SEP> homolog <SEP> A <SEP> (centractin <SEP> alpha) <SEP> Hs. <SEP> 2477
<tb> ATP-binding <SEP> cassette, <SEP> sub-family <SEP> C <SEP> (CFTR/MRP), <SEP> member <SEP> 5 <SEP> Hs. <SEP> 108660
<tb> basonuclin <SEP> Hs. <SEP> 64025
<tb> B-cell <SEP> ll <SEP> CLL/lymphoma <SEP> 2 <SEP> Hs. <SEP> 79241
<tb> bcl2 <SEP> assocaited <SEP> athanogene <SEP> Hs. <SEP> 41714
<tb> bcl2 <SEP> associated <SEP> X <SEP> protein <SEP> Hs. <SEP> 159428
<tb> beta-2-microglobulin <SEP> Hs. <SEP> 75415
<tb> Brca1 <SEP> associated <SEP> RING <SEP> domain <SEP> 1 <SEP> Hs. <SEP> 54089
<tb> breast <SEP> and <SEP> bladder <SEP> overexpressed <SEP> gene <SEP> 1 <SEP> Hs. <SEP> 78768
<tb> Breast <SEP> cancer <SEP> 1, <SEP> early <SEP> onset <SEP> Hs. <SEP> 194143
<tb> breast <SEP> cancer <SEP> antiestrogen <SEP> resistance <SEP> 1 <SEP> Hs.273219
<tb> breast <SEP> cancer <SEP> antiestrogen <SEP> resistance <SEP> 3 <SEP> Hs.6564
<tb> breast <SEP> cancer <SEP> specic <SEP> gene <SEP> 1 <SEP> ou <SEP> synculein <SEP> gamma <SEP> Hs.63236
<tb> budding <SEP> uninhibited <SEP> by <SEP> benzimidazoles <SEP> 1 <SEP> (yeast <SEP> homolog), <SEP> beta <SEP> Hs. <SEP> 36708
<tb> bullous <SEP> pemphigoid <SEP> antigen <SEP> 1 <SEP> (230/240kD) <SEP> Hs. <SEP> 620
<tb> butyrate <SEP> response <SEP> factor <SEP> 1 <SEP> (EGF-response <SEP> factor <SEP> 1) <SEP> Hs. <SEP> 85155
<tb> bystin-like <SEP> Hs. <SEP> 106880
<tb> <Tb>
<tb> aquaporin <SEP> 1 <SEP> (channel-forminq <SEP> Integer <SEP> protein, <SEP> 28kO) <SEP> Hs. <SEP> 74602
<tb> aquaporin <SEP> 7 <SEP> Hs. <SEP> 25475
<tb> armadillo <SEP> repeat <SEP> gene <SEP> deletes <SEP> in <SEP> velocardiofacial <SEP> syndrome <SEP> Hs. <SEP> 171900
<tb> ARP1 <SEP> (actin-related <SEP> protein <SEP> 1, <SEP> yeast) <SEP> homolog <SEP> A <SEP> (centractin <SEP> alpha) <SEP> Hs. <SEP> 2477
<tb> ATP-binding <SEP> cassette, <SEP> sub-family <SEP> C <SEP> (CFTR / MRP), <SEP> member <SEP> 5 <SEP> Hs. <SEP> 108660
<tb> basonuclin <SEP> Hs. <SEP> 64025
<tb> B-cell <SEP> ll <SEP> CLL / Lymphoma <SEP> 2 <SEP> Hs. <SEP> 79241
<tb> bcl2 <SEP> assocaited <SEP> athanogenic <SEP> Hs. <SEP> 41714
<tb> bcl2 <SEP> associated <SEP><SEP> protein <SEP> Hs. <SEP> 159428
<tb> beta-2-microglobulin <SEP> Hs. <SEP> 75415
<tb> Brca1 <SEP> associated <SEP> RING <SEP> domain <SEP> 1 <SEP> Hs. <SEP> 54089
<tb> breast <SEP> and <SEP> bladder <SEP> overexpressed <SEP> gene <SEP> 1 <SEP> Hs. <SEP> 78768
<tb> Breast <SEP> cancer <SEP> 1, <SEP> early <SEP> onset <SEP> Hs. <SEP> 194143
<tb> breast <SEP> cancer <SEP> antiestrogen <SEP> resistance <SEP> 1 <SEP> Hs.273219
<tb> breast <SEP> cancer <SEP> antiestrogen <SEP> resistance <SEP> 3 <SEP> Hs.6564
<tb> breast <SEP> cancer <SEP> specic <SEP> gene <SEP> 1 <SEP> or <SEP> synculein <SEP> gamma <SEP> Hs.63236
<tb> budding <SEP> uninhibited <SEP> by <SEP> benzimidazoles <SEP> 1 <SEP> (yeast <SEP> homolog), <SEP> beta <SEP> Hs. <SEP> 36708
<tb> bullous <SEP> pemphigoid <SEP> antigen <SEP> 1 <SEP> (230 / 240kD) <SEP> Hs. <SEP> 620
<tb> butyrate <SEP> response <SEP> factor <SEP> 1 <SEP> (EGF-response <SEP> factor <SEP> 1) <SEP> Hs. <SEP> 85155
<tb> bystin-like <SEP> Hs. <SEP> 106880
<Tb>

<Desc/Clms Page number 21> <Desc / Clms Page number 21>

Figure img00210001
Figure img00210001

<tb>
<tb> cadherin <SEP> 1 <SEP> ; <SEP> E-cadherinHs. <SEP> 194657
<tb> cadherin <SEP> 13 <SEP> ; <SEP> H-cadherin <SEP> Hs. <SEP> 63894
<tb> cadherin <SEP> 15 <SEP> ; <SEP> M-cadherin <SEP> Hs. <SEP> 148090
<tb> cadherin <SEP> 3, <SEP> P-cadherin <SEP> (placental) <SEP> Hs. <SEP> 2877
<tb> carboxypeptidase <SEP> 81 <SEP> Hs. <SEP> 180884
<tb> carcinoembryonic <SEP> antigen <SEP> Hs. <SEP> 220529
<tb> cartilage <SEP> oligomeric <SEP> matrix <SEP> protein <SEP> (pseudoachond <SEP> roplasia, <SEP> epiphyseal <SEP> Hs. <SEP> 1584
<tb> dysplasia <SEP> 1, <SEP> multiple)
<tb> catenin, <SEP> delta <SEP> 1 <SEP> Hs. <SEP> 166011
<tb> cathepsin <SEP> C <SEP> Hs. <SEP> 10029
<tb> cathepsin <SEP> D <SEP> (lysosomal <SEP> aspartyl <SEP> protease) <SEP> Hs. <SEP> 79572
<tb> cathepsin <SEP> Z <SEP> Hs. <SEP> 71388
<tb> caveolin-1 <SEP> Hs. <SEP> 323469
<tb> CD2 <SEP> antigen <SEP> (p50), <SEP> sheep <SEP> red <SEP> blood <SEP> cell <SEP> receptor <SEP> Hs. <SEP> 89476
<tb> CD34 <SEP> antigen <SEP> Hs. <SEP> 85289
<tb> CD36 <SEP> antigen <SEP> (collaqen <SEP> type <SEP> 1 <SEP> receptor, <SEP> thrombospondin <SEP> receptor) <SEP> Hs. <SEP> 75613
<tb> CD3D <SEP> antigen, <SEP> delta <SEP> polypeptide <SEP> (TiT3 <SEP> complex) <SEP> Hs. <SEP> 95327
<tb> CD3G <SEP> antigen, <SEP> gamma <SEP> polypeptide <SEP> (TiT3 <SEP> complex) <SEP> Hs. <SEP> 2259
<tb> CD68 <SEP> antigen <SEP> Hs. <SEP> 240615
<tb> CDC28 <SEP> protein <SEP> kinase <SEP> 2 <SEP> Hs. <SEP> 83758
<tb> CDC6 <SEP> (cell <SEP> division <SEP> cycle <SEP> 6, <SEP> S. <SEP> cerevisiae) <SEP> homolog <SEP> Hs. <SEP> 69563
<tb> <Tb>
<tb> cadherin <SEP> 1 <SEP>;<SEP> E-cadherinHs. <SEP> 194657
<tb> cadherin <SEP> 13 <SEP>;<SEP> H-cadherin <SEP> Hs. <SEP> 63894
<tb> cadherin <SEP> 15 <SEP>;<SEP> M-cadherin <SEP> Hs. <SEP> 148090
<tb> cadherin <SEP> 3, <SEP> P-cadherin <SEP> (placental) <SEP> Hs. <SEP> 2877
<tb> carboxypeptidase <SEP> 81 <SEP> Hs. <SEP> 180884
<tb> carcinoembryonic <SEP> antigen <SEP> Hs. <SEP> 220529
<tb> cartilage <SEP> oligomeric <SEP> matrix <SEP> protein <SEP> (pseudoachound <SEP> roplasia, <SEP> epiphyseal <SEP> Hs. <SEP> 1584
<tb> dysplasia <SEP> 1, <SEP> multiple)
<tb> catenin, <SEP> delta <SEP> 1 <SEP> Hs. <SEP> 166011
<tb> cathepsin <SEP> C <SEP> Hs. <SEP> 10029
<tb> cathepsin <SEP> D <SEP> (lysosomal <SEP> aspartyl <SEP> protease) <SEP> Hs. <SEP> 79572
<tb> cathepsin <SEP> Z <SEP> Hs. <SEP> 71388
<tb> caveolin-1 <SEP> Hs. <SEP> 323469
<tb> CD2 <SEP> antigen <SEP> (p50), <SEP> sheep <SEP> red <SEP> blood <SEP> cell <SEP> receptor <SEP> Hs. <SEP> 89476
<tb> CD34 <SEP> antigen <SEP> Hs. <SEP> 85289
<tb> CD36 <SEP> antigen <SEP> (collagen <SEP> type <SEP> 1 <SEP> receptor, <SEP> thrombospondin <SEP> receptor) <SEP> Hs. <SEP> 75613
<tb> CD3D <SEP> antigen, <SEP> delta <SEP> polypeptide <SEP> (TiT3 <SEP> complex) <SEP> Hs. <SEP> 95327
<tb> CD3G <SEP> antigen, <SEP> gamma <SEP> polypeptide <SEP> (TiT3 <SEP> complex) <SEP> Hs. <SEP> 2259
<tb> CD68 <SEP> antigen <SEP> Hs. <SEP> 240615
<tb> CDC28 <SEP> protein <SEP> kinase <SEP> 2 <SEP> Hs. <SEP> 83758
<tb> CDC6 <SEP> (cell <SEP> division <SEP> cycle <SEP> 6, <SE> S. <SEP> cerevisiae) <SEP> homolog <SEP> Hs. <SEP> 69563
<Tb>

<Desc/Clms Page number 22> <Desc / Clms Page number 22>

Figure img00220001
Figure img00220001

<tb>
<tb> CDC7 <SEP> (cell <SEP> division <SEP> cycle <SEP> 7, <SEP> S. <SEP> cerevisiae, <SEP> homolog)-like <SEP> 1 <SEP> Hs. <SEP> 28853
<tb> cell <SEP> division <SEP> cycle <SEP> 20, <SEP> S. <SEP> cerevisiae <SEP> homoloq <SEP> Hs. <SEP> 82906
<tb> cell <SEP> division <SEP> cycle <SEP> 25C <SEP> Hs. <SEP> 656
<tb> cellular <SEP> retinoic <SEP> acid-binding <SEP> protein <SEP> 2 <SEP> Hs. <SEP> 183650
<tb> centromere <SEP> protein <SEP> E <SEP> (312kD) <SEP> Hs. <SEP> 75573
<tb> centromere <SEP> protein <SEP> F <SEP> (350/400kD, <SEP> mitosin) <SEP> Hs. <SEP> 77204
<tb> chitinase <SEP> 1 <SEP> Hs. <SEP> 91093
<tb> chitinase <SEP> 3-like <SEP> 1 <SEP> (cartilage <SEP> glycoprotein-39) <SEP> Hs. <SEP> 75184
<tb> CHK1 <SEP> (checkpoint, <SEP> S. <SEP> pombe) <SEP> homolog <SEP> Hs. <SEP> 20295
<tb> chromobox <SEP> homolog <SEP> 3 <SEP> (drosophila <SEP> HP1 <SEP> gamma) <SEP> Hs. <SEP> 8123
<tb> collagen, <SEP> type <SEP> l, <SEP> alpha <SEP> 1 <SEP> Hs. <SEP> 172928
<tb> collagen, <SEP> type <SEP> 111, <SEP> alpha <SEP> 1 <SEP> (Ehlers-Danlos <SEP> syndrome <SEP> type <SEP> IV, <SEP> autosomal <SEP> Hs. <SEP> 119571
<tb> dominant)
<tb> collagen, <SEP> type <SEP> VI, <SEP> alpha <SEP> 1 <SEP> Hs. <SEP> 108885
<tb> colony <SEP> stimulating <SEP> factor <SEP> 1 <SEP> (macrophage) <SEP> Hs. <SEP> 173894
<tb> CREB <SEP> binding <SEP> protein <SEP> (Rubinstein-Taybi <SEP> syndrome) <SEP> Hs. <SEP> 23598
<tb> cullin <SEP> 4A <SEP> Hs. <SEP> 183874
<tb> cyclin <SEP> B1 <SEP> Hs. <SEP> 23960
<tb> Cyclin <SEP> Dl <SEP> Hs. <SEP> 82932
<tb> cyclin <SEP> E1 <SEP> Hs. <SEP> 9700
<tb> cvciin <SEP> G <SEP> 1 <SEP> Hs. <SEP> 79101
<tb> <Tb>
<tb> CDC7 <SEP> (cell <SEP> division <SEP> cycle <SEP> 7, <SE> S. <SEP> cerevisiae, <SEP> homolog) -like <SEP> 1 <SEP> Hs. <SEP> 28853
<tb> cell <SEP> division <SEP> cycle <SEP> 20, <SE> S. <SEP> cerevisiae <SEP> homology <SEP> Hs. <SEP> 82906
<tb> cell <SEP> division <SEP> cycle <SEP> 25C <SEP> Hs. <SEP> 656
<tb> cellular <SEP> retinoic <SEP> acid-binding <SEP> protein <SEP> 2 <SEP> Hs. <SEP> 183650
<tb> centromere <SEP> protein <SEP> E <SEP> (312kD) <SEP> Hs. <SEP> 75573
<tb> centromere <SEP> protein <SEP> F <SEP> (350 / 400kD, <SEP> mitosin) <SEP> Hs. <SEP> 77204
<tb> chitinase <SEP> 1 <SEP> Hs. <SEP> 91093
<tb> chitinase <SEP> 3-like <SEP> 1 <SEP> (cartilage <SEP> glycoprotein-39) <SEP> Hs. <SEP> 75184
<tb> CHK1 <SEP> (checkpoint, <SE> S. <SEP> pombe) <SEP> peer <SEP> Hs. <SEP> 20295
<tb> chromobox <SEP> homolog <SEP> 3 <SEP> (drosophila <SEP> HP1 <SEP> gamma) <SEP> Hs. <SEP> 8123
<tb> collagen, <SEP> type <SEP> l, <SEP> alpha <SEP> 1 <SEP> Hs. <SEP> 172928
<tb> collagen, <SEP> type <SEP> 111, <SEP> alpha <SEP> 1 <SEP> (Ehlers-Danlos <SEP> syndrome <SEP> type <SEP> IV, <SEP> autosomal <SEP> Hs <SEP> 119571
<tb> dominant)
<tb> collagen, <SEP> type <SEP> VI, <SEP> alpha <SEP> 1 <SEP> Hs. <SEP> 108885
<tb> colony <SEP> stimulating <SEP> factor <SEP> 1 <SEP> (macrophage) <SEP> Hs. <SEP> 173894
<tb> CREB <SEP> binding <SEP> protein <SEP> (Rubinstein-Taybi <SEP> syndrome) <SEP> Hs. <SEP> 23598
<tb> cullin <SEP> 4A <SEP> Hs. <SEP> 183874
<tb> cyclin <SEP> B1 <SEP> Hs. <SEP> 23960
<tb> Cyclin <SEP> Dl <SEP> Hs. <SEP> 82932
<tb> cyclin <SEP> E1 <SEP> Hs. <SEP> 9700
<tb> cvciin <SEP> G <SEP> 1 <SEP> Hs. <SEP> 79101
<Tb>

<Desc/Clms Page number 23> <Desc / Clms Page number 23>

Figure img00230001
Figure img00230001

<tb>
<tb> Cyclin-dependent <SEP> kinase <SEP> 4 <SEP> Hs. <SEP> 95577
<tb> cyclin-dependent <SEP> kinase <SEP> inhibitor <SEP> 1 <SEP> C <SEP> (p57, <SEP> Kip2) <SEP> Hs. <SEP> 106070
<tb> cystatin <SEP> E/MHs. <SEP> 83393
<tb> cysteine-rich <SEP> protein <SEP> 1 <SEP> (intestinal) <SEP> Hs. <SEP> 17409
<tb> cytochrome <SEP> c <SEP> oxidase <SEP> subunit <SEP> Vlc <SEP> Hs. <SEP> 74649
<tb> Cytochrome <SEP> c <SEP> oxidase <SEP> subunit <SEP> Vila <SEP> polypeptide <SEP> 2 <SEP> like <SEP> Hs. <SEP> 30888
<tb> D123 <SEP> gene <SEP> product <SEP> Hs. <SEP> 82043
<tb> DEAD/H <SEP> (Asp-Glu-Ala-Asp/His) <SEP> box <SEP> polypeptide <SEP> 11 <SEP> (S. <SEP> cerevisiae <SEP> CHL <SEP> 1-like <SEP> Hs. <SEP> 27424
<tb> helicase)
<tb> density <SEP> regulated <SEP> protein <SEP> Hs. <SEP> 22393
<tb> desmin <SEP> Hs. <SEP> 171185
<tb> dihvdrofolate <SEP> reductase <SEP> Hs. <SEP> 83765
<tb> diphtheria <SEP> toxin <SEP> receptor <SEP> (heparin-binding <SEP> epidermal <SEP> growth <SEP> factor-like <SEP> Hs. <SEP> 799
<tb> growth <SEP> factor)
<tb> discoïdin <SEP> domain <SEP> receptor <SEP> family, <SEP> member <SEP> 1 <SEP> Hs. <SEP> 75562
<tb> DNA <SEP> (cytosine-5-) <SEP> -methyltransferase <SEP> 1 <SEP> Hs. <SEP> 77462
<tb> dynein, <SEP> axonemal, <SEP> light <SEP> intermediate <SEP> polypeptide <SEP> Hs.33846
<tb> E2F <SEP> transcription <SEP> factor <SEP> 3 <SEP> Hs. <SEP> 1189
<tb> E74-like <SEP> factor <SEP> 3 <SEP> Hs. <SEP> 166096
<tb> early <SEP> development <SEP> regulartor <SEP> 2 <SEP> (homolog <SEP> of <SEP> polyhomeotic <SEP> 2) <SEP> Hs.75878
<tb> endoglin <SEP> Hs.76753
<tb> <Tb>
<tb> Cyclin-dependent <SEP> kinase <SEP> 4 <SEP> Hs. <SEP> 95577
<tb> cyclin-dependent <SEP> kinase <SEP> inhibitor <SEP> 1 <SEP> C <SEP> (p57, <SEP> Kip2) <SEP> Hs. <SEP> 106070
<tb> cystatin <SEP> E / MHs. <SEP> 83393
<tb> cysteine-rich <SEP> protein <SEP> 1 <SEP> (intestinal) <SEP> Hs. <SEP> 17409
<tb> cytochrome <SEP> c <SEP> oxidase <SEP> subunit <SEP> Vlc <SEP> Hs. <SEP> 74649
<tb> Cytochrome <SEP> c <SEP> oxidase <SEP> subunit <SEP> Vila <SEP> polypeptide <SEP> 2 <SEP> like <SEP> Hs. <SEP> 30888
<tb> D123 <SEP> gene <SEP> product <SEP> Hs. <SEP> 82043
<tb> DEAD / H <SEP> (Asp-Glu-Ala-Asp / His) <SEP> box <SEP> polypeptide <SEP> 11 <SEP> (S. <SEP> cerevisiae <SEP> CHL <SEP> 1 -like <SEP> Hs. <SEP> 27424
<tb> helicase)
<tb> density <SEP> regulated <SEP> protein <SEP> Hs. <SEP> 22393
<tb> desmin <SEP> Hs. <SEP> 171185
<tb> dihvdrofolate <SEP> reductase <SEP> Hs. <SEP> 83765
<tb> diphtheria <SEP> toxin <SEP> receptor <SEP> (heparin-binding <SEP> epidermal <SEP> growth <SEP> factor-like <SEP> Hs. <SEP> 799
<tb> growth <SEP> factor)
<tb> discointer <SEP> domain <SEP> Receiver <SEP> family, <SEP> member <SEP> 1 <SEP> Hs. <SEP> 75562
<tb> DNA <SEP> (cytosine-5-) <SEP> -methyltransferase <SEP> 1 <SEP> Hs. <SEP> 77462
<tb> dynein, <SEP> axonemal, <SEP> light <SEP> intermediate <SEP> polypeptide <SEP> Hs.33846
<tb> E2F <SEP> transcription <SEP> factor <SEP> 3 <SEP> Hs. <SEP> 1189
<tb> E74-like <SEP> factor <SEP> 3 <SEP> Hs. <SEP> 166096
<tb> early <SEP> development <SEP> regulartor <SEP> 2 <SEP> (homologous <SEP> of <SEP> polyhomeotic <SEP> 2) <SEP> Hs.75878
<tb> endoglin <SEP> Hs.76753
<Tb>

<Desc/Clms Page number 24> <Desc / Clms Page number 24>

Figure img00240001
Figure img00240001

<tb>
<tb> endothelin <SEP> receptor <SEP> type <SEP> B <SEP> Hs. <SEP> 82002
<tb> enhancer <SEP> of <SEP> zeste <SEP> (Drosophila) <SEP> homolog <SEP> 2 <SEP> Hs. <SEP> 77256
<tb> Epidermal <SEP> growth <SEP> factor <SEP> Hs. <SEP> 2230
<tb> epidermal <SEP> growth <SEP> factor <SEP> receptor <SEP> (avian <SEP> erythroblastic <SEP> leukemia <SEP> viral <SEP> (v-erb-b) <SEP> Hs. <SEP> 77432
<tb> oncogene <SEP> homolog)
<tb> estrogen <SEP> receptor <SEP> 1 <SEP> (alpha) <SEP> Hs.1657
<tb> estrogen <SEP> receptor <SEP> beta <SEP> Hs.103504
<tb> Estrogen <SEP> receptor <SEP> binding <SEP> site <SEP> associated, <SEP> antigen, <SEP> 9 <SEP> Hs. <SEP> 9222
<tb> eukaryotic <SEP> translation <SEP> elongation <SEP> factor <SEP> 1 <SEP> epsilon <SEP> 1 <SEP> Hs. <SEP> 172247
<tb> eukaryotic <SEP> translation <SEP> initiation <SEP> factor <SEP> 3, <SEP> subunit <SEP> 4 <SEP> (delta, <SEP> 44ko) <SEP> Hs. <SEP> 28081
<tb> exportin, <SEP> tRNA <SEP> (nuclear <SEP> export <SEP> receptor <SEP> for <SEP> tRNAs) <SEP> Hs. <SEP> 85951
<tb> fatty <SEP> acid <SEP> bindinq <SEP> protein <SEP> 4, <SEP> adipocvte <SEP> HS. <SEP> 83213
<tb> fatty <SEP> acid <SEP> binding <SEP> protein <SEP> 7, <SEP> brain <SEP> Hs. <SEP> 26770
<tb> fibroblast <SEP> growth <SEP> factor <SEP> 8 <SEP> Hs. <SEP> 57710
<tb> fibroblast <SEP> growth <SEP> factor <SEP> receptor <SEP> 1 <SEP> (fms-related <SEP> tyrosine <SEP> kinase <SEP> 2, <SEP> Pfeiffei <SEP> Hs. <SEP> 748
<tb> syndrome)
<tb> flap <SEP> structure-specific <SEP> endonuclease <SEP> 1 <SEP> Hs. <SEP> 4756
<tb> forkhead <SEP> (Drosophila) <SEP> -like <SEP> 16 <SEP> HS. <SEP> 239
<tb> four <SEP> and <SEP> a <SEP> half <SEP> LIM <SEP> domains <SEP> 1 <SEP> Hs. <SEP> 239069
<tb> fragile <SEP> histidine <SEP> triad <SEP> gene <SEP> Hs.77252
<tb> fructose-bisphosphatase <SEP> 1 <SEP> Hs.574
<tb> <Tb>
<tb> endothelin <SEP> receptor <SEP> type <SEP> B <SEP> Hs. <SEP> 82002
<tb> enhancer <SEP> of <SEP> peel <SEP> (Drosophila) <SEP> homolog <SEP> 2 <SEP> Hs. <SEP> 77256
<tb> Epidermal <SEP> growth <SEP> factor <SEP> Hs. <SEP> 2230
<tb> epidermal <SEP> growth <SEP> factor <SEP> receptor <SEP> (avian <SEP> erythroblastic <SEP> leukemia <SEP> viral <SEP> (v-erb-b) <SEP> Hs. <SEP > 77432
<tb> oncogene <SEP> homolog
<tb> estrogen <SEP> receptor <SEP> 1 <SEP> (alpha) <SEP> Hs.1657
<tb> estrogen <SEP> receptor <SEP> beta <SEP> Hs.103504
<tb> Estrogen <SEP> receptor <SEP> binding <SEP><SEP> associated site, <SEP> antigen, <SEP> 9 <SEP> Hs. <SEP> 9222
<tb> eukaryotic <SEP> translation <SEP> elongation <SEP> factor <SEP> 1 <SEP> epsilon <SEP> 1 <SEP> Hs. <SEP> 172247
<tb> eukaryotic <SEP> translation <SEP> initiation <SEP> factor <SEP> 3, <SEP> subunit <SEP> 4 <SEP> (delta, <SEP> 44kB) <SEP> Hs. <SEP> 28081
<tb> exportin, <SEP> tRNA <SEP> (nuclear <SEP> export <SEP> receptor <SEP> for <SEP> tRNAs) <SEP> Hs. <SEP> 85951
<tb> fatty acid <SEP> acid <SEP> bindinq <SEP> protein <SEP> 4, <SEP> adipose <SEP> HS. <SEP> 83213
<tb> fatty <SEP> acid <SEP> binding <SEP> protein <SEP> 7, <SEP> brain <SEP> Hs. <SEP> 26770
<tb> fibroblast <SEP> growth <SEP> factor <SEP> 8 <SEP> Hs. <SEP> 57710
<tb> fibroblast <SEP> growth <SEP> factor <SEP> receptor <SEP> 1 <SEP> (fms-related <SEP> tyrosine <SEP> kinase <SEP> 2, <SEP> Pfeiffei <SEP> Hs. <SEP> 748
<tb> syndrome)
<tb> flap <SEP> structure-specific <SEP> endonuclease <SEP> 1 <SEP> Hs. <SEP> 4756
<tb> forkhead <SEP> (Drosophila) <SEP> -like <SEP> 16 <SEP> HS. <SEP> 239
<tb> four <SEP> and <SEP><SEP> half <SEP><SEP> domains <SEP> 1 <SEP> Hs. <SEP> 239069
<tb> fragile <SEP> histidine <SEP> triad <SEP> gene <SEP> Hs.77252
<tb> fructose-bisphosphatase <SEP> 1 <SEP> Hs.574
<Tb>

<Desc/Clms Page number 25> <Desc / Clms Page number 25>

Figure img00250001
Figure img00250001

<tb>
<tb> gamma-glutamyl <SEP> hydrolase <SEP> (conjugase, <SEP> folylpolygammagjutamyl <SEP> hydrolase) <SEP> Hs. <SEP> 78619
<tb> gap <SEP> junction <SEP> protein <SEP> alpha <SEP> 1,43 <SEP> kD <SEP> ou <SEP> connexin <SEP> 43 <SEP> Hs. <SEP> 74471
<tb> GATA-binding <SEP> protein <SEP> 3 <SEP> Hs. <SEP> 169946
<tb> glutamate <SEP> receptor, <SEP> ionotropie, <SEP> N-methyl <SEP> D-aspartate <SEP> 2A <SEP> Hs.167464
<tb> glutamate <SEP> receptor, <SEP> ionotropic, <SEP> N-methy <SEP> ! <SEP> D-aspartate <SEP> 2C <SEP> Hs. <SEP> 36451
<tb> glutathione <SEP> S <SEP> transferase <SEP> pi <SEP> Hs. <SEP> 226795
<tb> glycerol-3-phosphate <SEP> dehydrogenase <SEP> 1 <SEP> (soluble) <SEP> Hs. <SEP> 25478
<tb> granzyme <SEP> A <SEP> (granzyme <SEP> 1, <SEP> cytotoxic <SEP> T-lymphocyte-associated <SEP> serine <SEP> Hs. <SEP> 90708
<tb> esterase <SEP> 3)
<tb> hepatocyte <SEP> nuclear <SEP> factor <SEP> 3, <SEP> alpha <SEP> Hs.105440
<tb> hepsin <SEP> Hs.823
<tb> high <SEP> mobility <SEP> group <SEP> (nonhistone <SEP> chromosomal) <SEP> protein <SEP> isoforms <SEP> I <SEP> and <SEP> Y <SEP> Hs. <SEP> 139800
<tb> high-mobility <SEP> group <SEP> (nonhistone <SEP> chromosomal) <SEP> protein <SEP> 2 <SEP> Hs. <SEP> 80684
<tb> HIV-1 <SEP> Rev <SEP> binding <SEP> protein <SEP> Hs. <SEP> 171545
<tb> Homo <SEP> sapiens <SEP> ataxia-telangiectasia <SEP> group <SEP> D-associated <SEP> protein <SEP> mRNA, <SEP> Hs. <SEP> 82237
<tb> complete <SEP> cds
<tb> Homo <SEP> sapiens <SEP> clone <SEP> 24703 <SEP> beta-tubulin <SEP> mRNA, <SEP> complete <SEP> cds <SEP> Hs.179661
<tb> Homo <SEP> sapiens <SEP> HPV16 <SEP> E1 <SEP> proteni <SEP> binding <SEP> protein <SEP> mRNA, <SEP> complete <SEP> cds <SEP> Hs.6566
<tb> Human <SEP> BRCA2 <SEP> region, <SEP> mRNA <SEP> sequence <SEP> CG006 <SEP> Hs. <SEP> 110630
<tb> Human <SEP> breast <SEP> cancer, <SEP> estrogen <SEP> regulated <SEP> LIV-1 <SEP> protein <SEP> (LIV-1) <SEP> mRNA, <SEP> Hs. <SEP> 79136
<tb> partial <SEP> cds
<tb> <Tb>
<tb> gamma-glutamyl <SEP> hydrolase <SEP> (conjugase, <SEP> folylpolygammagjutamyl <SEP> hydrolase) <SEP> Hs. <SEP> 78619
<tb> gap <SEP> junction <SEP> protein <SEP> alpha <SEP> 1.43 <SEP> kD <SEP> or <SEP> connexin <SEP> 43 <SEP> Hs. <SEP> 74471
<tb> GATA-binding <SEP> protein <SEP> 3 <SEP> Hs. <SEP> 169946
<tb> glutamate <SEP> receptor, <SEQ> ionotropy, <SEP> N-methyl <SEP> D-aspartate <SEP> 2A <SEP> Hs.167464
<tb> glutamate <SEP> receptor, <SEQ> ionotropic, <SEP> N-methy <SEP>! <SEP> D-aspartate <SEP> 2C <SEP> Hs. <SEP> 36451
<tb> glutathione <SEP> S <SEP> transferase <SEP> pi <SEP> Hs. <SEP> 226795
<tb> glycerol-3-phosphate <SEP> dehydrogenase <SEP> 1 <SEP> (soluble) <SEP> Hs. <SEP> 25478
<tb> granzyme <SEP> A <SEP> (granzyme <SEP> 1, <SEP> cytotoxic <SEP> T-lymphocyte-associated <SEP> serine <SEP> Hs. <SEP> 90708
<tb> esterase <SEP> 3)
<tb> hepatocyte <SEP> nuclear <SEP> factor <SEP> 3, <SEQ> alpha <SEP> Hs.105440
<tb> hepsin <SEP> Hs.823
<tb> high <SEP> mobility <SEP> group <SEP> (nonhistone <SEP> chromosomal) <SEP> protein <SEP> isoforms <SEP> I <SEP> and <SEP> Y <SEP> Hs. <SEP> 139800
<tb> high-mobility <SEP> group <SEP> (nonhistone <SEP> chromosomal) <SEP> protein <SEP> 2 <SEP> Hs. <SEP> 80684
<tb> HIV-1 <SEP> Rev <SEP> binding <SEP> protein <SEP> Hs. <SEP> 171545
<tb> Homo <SEP> sapiens <SEP> ataxia-telangiectasia <SEP> group <SEP> D-associated <SEP> protein <SEP> mRNA, <SEP> Hs. <SEP> 82237
<tb> complete <SEP> cds
<tb> Homo <SEP> sapiens <SEP> clone <SEP> 24703 <SEP> beta-tubulin <SEP> mRNA, <SEP> complete <SEP> cds <SEP> Hs.179661
<tb> Homo <SEP> sapiens <SEP> HPV16 <SEP> E1 <SEP> proteni <SEP> binding <SEQ> protein <SEP> mRNA, <SEQ> complete <SEP> cds <SEP> Hs.6566
<tb> Human <SEP> BRCA2 <SEP> region, <SEP> mRNA <SEP> sequence <SEP> CG006 <SEP> Hs. <SEP> 110630
<tb> Human <SEP> breast <SEP> cancer, <SEP> estrogen <SEP> regulated <SEP> LIV-1 <SEP> protein <SEP> (LIV-1) <SEP> mRNA, <SEP> Hs. <SEP> 79136
<tb> partial <SEP> cds
<Tb>

<Desc/Clms Page number 26> <Desc / Clms Page number 26>

Figure img00260001
Figure img00260001

<tb>
<tb> Human <SEP> cellular <SEP> oncogene <SEP> c-fos <SEP> Hs. <SEP> 25647
<tb> Human <SEP> lg <SEP> J <SEP> chain <SEP> gene <SEP> Hs.76325
<tb> Human <SEP> phosphatidylinositol <SEP> (4,5)bisphosphate <SEP> 5-phosphatase <SEP> homolog <SEP> Hs.21492
<tb> mRNA, <SEP> partial <SEP> cds
<tb> Human <SEP> ubiquitin <SEP> carrier <SEP> protein <SEP> (E2-EPF) <SEP> mRNA, <SEP> complete <SEP> cds <SEP> Hs.174070
<tb> hyaluronan-mediated <SEP> motility <SEP> receptor <SEP> (RHAMM) <SEP> Hs.72550
<tb> hydroxyacyl-Coenzyme <SEP> A <SEP> dehydrogenase/3-ketoacyl-Coenzyme <SEP> A <SEP> Hs. <SEP> 75860
<tb> th <SEP> iolase/en <SEP> oyl-Coenzyme <SEP> A <SEP> hydratase <SEP> (trifunctional <SEP> protein), <SEP> alpha <SEP> subunit
<tb> immunoglobulin <SEP> gamma <SEP> 3 <SEP> (Gm <SEP> marker) <SEP> Hs. <SEP> 140
<tb> inhibitor <SEP> of <SEP> growth <SEP> 1 <SEP> Hs.46700
<tb> inhibitor <SEP> of <SEP> growth <SEP> 2
<tb> inositol <SEP> polyphosphate-4-phosphatase, <SEP> type <SEP> ll, <SEP> 105kD <SEP> Hs.153687
<tb> insulin-like <SEP> growth <SEP> factor <SEP> 1 <SEP> (somatomedin <SEP> C) <SEP> Hs. <SEP> 85112
<tb> insulin-like <SEP> growth <SEP> factor <SEP> 2 <SEP> (somatomedin <SEP> A) <SEP> Hs. <SEP> 241317
<tb> insulin-like <SEP> growth <SEP> factor <SEP> binding <SEP> protein <SEP> 2 <SEP> Hs. <SEP> 162
<tb> insulin-like <SEP> growth <SEP> factor <SEP> binding <SEP> protein <SEP> 5 <SEP> Hs. <SEP> 102122
<tb> insulin-like <SEP> growth <SEP> factor <SEP> receptor <SEP> 1 <SEP> Hs. <SEP> 239176
<tb> insulin-like <SEP> growth <SEP> factor <SEP> receptor <SEP> 2 <SEP> Hs. <SEP> 76473
<tb> integrin, <SEP> alpha <SEP> 3 <SEP> Hs. <SEP> 265829
<tb> integrin, <SEP> alpha <SEP> 7 <SEP> Hs. <SEP> 74369
<tb> integrin, <SEP> alpha <SEP> L <SEP> (antigen <SEP> CD11A <SEP> (p180), <SEP> lymphocyte <SEP> function-associated <SEP> Hs.174103
<tb> <Tb>
<tb> Human <SEP> cellular <SEP> oncogene <SEP> c-fos <SEP> Hs. <SEP> 25647
<tb> Human <SEP><SEP> J <SEP> chain <SEP> gene <SEP> Hs.76325
<tb> Human <SEP> Phosphatidylinositol <SEP> (4,5) bisphosphate <SEP> 5-phosphatase <SEP> homolog <SEP> Hs.21492
<tb> mRNA, <SEP> partial <SEP> cds
<tb> Human <SEP> ubiquitin <SEP> carrier <SEP> protein <SEP> (E2-EPF) <SEP> mRNA, <SEP> complete <SEP> cds <SEP> Hs.174070
<tb> hyaluronan-mediated <SEP> motility <SEP> receptor <SEP> (RHAMM) <SEP> Hs.72550
<tb> hydroxyacyl-Coenzyme <SEP> A <SEP> dehydrogenase / 3-ketoacyl-Coenzyme <SEP> A <SEP> Hs. <SEP> 75860
<tb> th <SEP> iolase / en <SEP> oyl-Coenzyme <SEP> A <SEP> hydratase <SEP> (trifunctional <SEP> protein), <SEP> alpha <SEP> subunit
<tb> immunoglobulin <SEP> gamma <SEP> 3 <SEP> (Gm <SEP> marker) <SEP> Hs. <SEP> 140
<tb> inhibitor <SEP> of <SEP> growth <SEP> 1 <SEP> Hs.46700
<tb> inhibitor <SEP> of <SEP> growth <SEP> 2
<tb> inositol <SEP> polyphosphate-4-phosphatase, <SEP> type <SEP> ll, <SEP> 105kD <SEP> Hs.153687
<tb> insulin-like <SEP> growth <SEP> factor <SEP> 1 <SEP> (somatomedin <SEP> C) <SEP> Hs. <SEP> 85112
<tb> insulin-like <SEP> growth <SEP> factor <SEP> 2 <SEP> (somatomedin <SEP> A) <SEP> Hs. <SEP> 241317
<tb> insulin-like <SEP> growth <SEP> factor <SEP> binding <SEP> protein <SEP> 2 <SEP> Hs. <SEP> 162
<tb> insulin-like <SEP> growth <SEP> factor <SEP> binding <SEP> protein <SEP> 5 <SEP> Hs. <SEP> 102122
<tb> insulin-like <SEP> growth <SEP> factor <SEP> receptor <SEP> 1 <SEP> Hs. <SEP> 239176
<tb> insulin-like <SEP> growth <SEP> factor <SEP> receptor <SEP> 2 <SEP> Hs. <SEP> 76473
<tb> integrin, <SEP> alpha <SEP> 3 <SEP> Hs. <SEP> 265829
<tb> integrin, <SEP> alpha <SEP> 7 <SEP> Hs. <SEP> 74369
<tb> integrin, <SEP> alpha <SEP> L <SEP> (antigen <SEP> CD11A <SEP> (p180), <SEP> lymphocyte <SEP> function-associated <SEP> Hs.174103
<Tb>

<Desc/Clms Page number 27> <Desc / Clms Page number 27>

Figure img00270001
Figure img00270001

<tb>
<tb> antigen <SEP> 1 <SEP> ; <SEP> alpha <SEP> polypeptide)
<tb> integrin, <SEP> beta <SEP> 2 <SEP> (antigen <SEP> CD18 <SEP> (p95), <SEP> lymphocyte <SEP> function-associated <SEP> Hs. <SEP> 83968
<tb> antigen <SEP> 1 <SEP> ; <SEP> macrophage <SEP> antigen <SEP> 1 <SEP> (mac-1) <SEP> beta <SEP> subunit)
<tb> inteorin, <SEP> beta <SEP> 4 <SEP> Hs. <SEP> 85266
<tb> integrin, <SEP> beta <SEP> 8 <SEP> Hs. <SEP> 184908
<tb> intercellular <SEP> adhesion <SEP> molecule <SEP> 2 <SEP> Hs. <SEP> 83733
<tb> interferon <SEP> alpha <SEP> inducible <SEP> protein <SEP> 27 <SEP> Hs. <SEP> 278613
<tb> interferon-induced <SEP> protein <SEP> 17 <SEP> Hs. <SEP> 146360
<tb> interferon-induced, <SEP> hepatitis <SEP> C-associated <SEP> microtubular <SEP> aggregate <SEP> protein <SEP> Hs. <SEP> 82316
<tb> (44kD)
<tb> interleukin <SEP> 10 <SEP> receptor, <SEP> alpha <SEP> Hs. <SEP> 327
<tb> interleukin <SEP> 2 <SEP> receptor, <SEP> beta <SEP> Hs. <SEP> 75596
<tb> interleukin <SEP> 3 <SEP> receptor, <SEP> alpha <SEP> (low <SEP> affinity) <SEP> Hs. <SEP> 172689
<tb> kallikrein <SEP> 10 <SEP> Hs. <SEP> 69423
<tb> kallikrein <SEP> 13 <SEP> Hs. <SEP> 165296
<tb> kallikrein <SEP> 3, <SEP> (prostate <SEP> specific <SEP> antigen) <SEP> Hs. <SEP> 171995
<tb> kallikrein <SEP> 6 <SEP> Hs. <SEP> 79361
<tb> kanga'f <SEP> 1 <SEP> Hs. <SEP> 323946
<tb> keratin <SEP> 17 <SEP> Hs. <SEP> 2785
<tb> keratin <SEP> 18 <SEP> Hs. <SEP> 65114
<tb> keratin <SEP> 19 <SEP> Hs. <SEP> 182265
<tb> <Tb>
<tb> antigen <SEP> 1 <SEP>;<SEP> alpha <SEP> polypeptide)
<tb> integrin, <SEP> beta <SEP> 2 <SEP> (antigen <SEP> CD18 <SEP> (p95), <SEP> lymphocyte <SEP> function-associated <SEP> Hs. <SEP> 83968
<tb> antigen <SEP> 1 <SEP>;<SEP> macrophage <SEP> antigen <SEP> 1 <SEP> (mac-1) <SEP> beta <SEP> subunit
<tb> inteorin, <SEP> beta <SEP> 4 <SEP> Hs. <SEP> 85266
<tb> integrin, <SEP> beta <SEP> 8 <SEP> Hs. <SEP> 184908
<tb> intercellular <SEP> adhesion <SEP> molecule <SEP> 2 <SEP> Hs. <SEP> 83733
<tb> interferon <SEP> alpha <SEP> inducible <SEP> protein <SEP> 27 <SEP> Hs. <SEP> 278613
<tb> interferon-induced <SEP> protein <SEP> 17 <SEP> Hs. <SEP> 146360
<tb> interferon-induced, <SEP> hepatitis <SEP> C-associated <SEP> microtubular <SEP> aggregate <SEP> protein <SEP> Hs. <SEP> 82316
<tb> (44kD)
<tb> interleukin <SEP> 10 <SEP> receptor, <SEP> alpha <SEP> Hs. <SEP> 327
<tb> interleukin <SEP> 2 <SEP> receptor, <SEP> beta <SEP> Hs. <SEP> 75596
<tb> interleukin <SEP> 3 <SEP> receptor, <SEP> alpha <SEP> (low <SEP> affinity) <SEP> Hs. <SEP> 172689
<tb> kallikrein <SEP> 10 <SEP> Hs. <SEP> 69423
<tb> kallikrein <SEP> 13 <SEP> Hs. <SEP> 165296
<tb> kallikrein <SEP> 3, <SEP> (prostate <SEP> specific <SEP> antigen) <SEP> Hs. <SEP> 171995
<tb> kallikrein <SEP> 6 <SEP> Hs. <SEP> 79361
<tb>kanga'f<SEP> 1 <SEP> Hs. <SEP> 323946
<tb> keratin <SEP> 17 <SEP> Hs. <SEP> 2785
<tb> keratin <SEP> 18 <SEP> Hs. <SEP> 65114
<tb> keratin <SEP> 19 <SEP> Hs. <SEP> 182265
<Tb>

<Desc/Clms Page number 28> <Desc / Clms Page number 28>

Figure img00280001
Figure img00280001

<tb>
<tb> keratin <SEP> 5 <SEP> (epidermolysis <SEP> bullosa <SEP> simplex, <SEP> Dowlig-Meara/Kobner/Weber- <SEP> Hs. <SEP> 195850
<tb> Cockayne <SEP> types)
<tb> keratin <SEP> 7 <SEP> HS. <SEP> 23881
<tb> keratin <SEP> 8 <SEP> Hs. <SEP> 104624
<tb> KlAA0008 <SEP> gene <SEP> product <SEP> Hs. <SEP> 77695
<tb> KlAAA0042 <SEP> gene <SEP> product <SEP> Hs.3104
<tb> KlAA0074 <SEP> protein <SEP> Hs.1192
<tb> KlAA0101 <SEP> gene <SEP> product <SEP> Hs. <SEP> 81892
<tb> KlAA0125 <SEP> gene <SEP> product <SEP> Hs. <SEP> 38365
<tb> KIAA0159 <SEP> gene <SEP> product <SEP> Hs. <SEP> 5719
<tb> KIAA0166 <SEP> qene <SEP> product <SEP> Hs. <SEP> 115778
<tb> KIAA0430 <SEP> gene <SEP> product <SEP> Hs. <SEP> 166163
<tb> KIAA0758 <SEP> protein <SEP> HS. <SEP> 22039
<tb> KIAA0788 <SEP> protein <SEP> Hs. <SEP> 181043
<tb> Kiss-1 <SEP> Hs.95008
<tb> lactate <SEP> dehydrogenase <SEP> B <SEP> Hs. <SEP> 234489
<tb> ladinin <SEP> 1 <SEP> Hs. <SEP> 18141
<tb> lamin <SEP> B2 <SEP> Hs. <SEP> 76084
<tb> laminin, <SEP> alpha <SEP> 3 <SEP> (nicein <SEP> (150kD), <SEP> kalinin <SEP> (165kD), <SEP> BM600 <SEP> (150kD), <SEP> epilegrin) <SEP> Hs. <SEP> 83450
<tb> laminin, <SEP> gamma <SEP> 2 <SEP> (nicein <SEP> (100kD), <SEP> kalinin <SEP> (105kD), <SEP> BM600 <SEP> (100kD), <SEP> Herlitz <SEP> Hs. <SEP> 54451
<tb> junctional <SEP> ional <SEP> epidermolysis <SEP> bullosa))
<tb> <Tb>
<tb> keratin <SEP> 5 <SEP> (epidermolysis <SEP> bullosa <SEP> simplex, <SEP> Dowlig-Meara / Kobner / Weber- <SEP> Hs. <SEP> 195850
<tb> Cockayne <SEP> types)
<tb> keratin <SEP> 7 <SEP> HS. <SEP> 23881
<tb> keratin <SEP> 8 <SEP> Hs. <SEP> 104624
<tb> klAA0008 <SEP> gene <SEP> product <SEP> Hs. <SEP> 77695
<tb> klAAA0042 <SEP> gene <SEP> product <SEP> Hs.3104
<tb> KlAA0074 <SEQ> protein <SEP> Hs.1192
<tb> KlAA0101 <SEP> gene <SEP> product <SEP> Hs. <SEP> 81892
<tb> KlAA0125 <SEP> gene <SEP> product <SEP> Hs. <SEP> 38365
<tb> KIAA0159 <SEP> gene <SEP> product <SEP> Hs. <SEP> 5719
<tb> KIAA0166 <SEQ> qene <SEP> product <SEP> Hs. <SEP> 115778
<tb> KIAA0430 <SEP> gene <SEP> product <SEP> Hs. <SEP> 166163
<tb> KIAA0758 <SEP> protein <SEP> HS. <SEP> 22039
<tb> KIAA0788 <SEP> protein <SEP> Hs. <SEP> 181043
<tb> Kiss-1 <SEP> Hs.95008
<tb> lactate <SEP> dehydrogenase <SEP> B <SEP> Hs. <SEP> 234489
<tb> ladinin <SEP> 1 <SEP> Hs. <SEP> 18141
<tb> lamin <SEP> B2 <SEP> Hs. <SEP> 76084
<tb> laminin, <SEP> alpha <SEP> 3 <SEP> (nicein <SEP> (150kD), <SEP> kalinin <SEP> (165kD), <SEP> BM600 <SEP> (150kD), <SEP> epilegrin) <SEP> Hs. <SEP> 83450
<tb> laminin, <SEP> gamma <SEP> 2 <SEP> (nicein <SEP> (100kD), <SEP> kalinin <SEP> (105kD), <SEP> BM600 <SEP> (100kD), <SEP> Herlitz <SEP> Hs. <SEP> 54451
<tb> junctional <SEP> ional <SEP> epidermolysis <SEP> bullosa))
<Tb>

<Desc/Clms Page number 29> <Desc / Clms Page number 29>

Figure img00290001
Figure img00290001

<tb>
<tb> UM <SEP> and <SEP> SH <SEP> protein <SEP> 1 <SEP> Hs. <SEP> 334851
<tb> LIM <SEP> binding <SEP> domain <SEP> 2 <SEP> Hs. <SEP> 4980
<tb> LIM <SEP> domain <SEP> only <SEP> 4
<tb> lipocalin <SEP> 1 <SEP> Hs.204238
<tb> lipoprotein <SEP> lipase <SEP> Hs.180878
<tb> LPS-induced <SEP> TNF-alpha <SEP> factor <SEP> Hs. <SEP> 76507
<tb> lumican <SEP> Hs. <SEP> 79914
<tb> lymphocyte-specific <SEP> protein <SEP> tyrosine <SEP> kinase <SEP> Hs. <SEP> 1765
<tb> MAD2 <SEP> (mitotic <SEP> arrest <SEP> deficient, <SEP> yeast, <SEP> homolog)-like <SEP> 1 <SEP> Hs. <SEP> 79078
<tb> major <SEP> histocompatibility <SEP> complex, <SEP> class <SEP> ll, <SEP> DQ <SEP> beta <SEP> 1 <SEP> Hs. <SEP> 73931
<tb> mammaalobin <SEP> 1 <SEP> Hs. <SEP> 46452
<tb> manic <SEP> fringe <SEP> (Drosophila) <SEP> homolog <SEP> Hs.31939
<tb> matrix <SEP> metalloproteinase <SEP> 11 <SEP> (stromelysin <SEP> 3) <SEP> Hs.155324
<tb> matrix <SEP> metalloproteinase <SEP> 13 <SEP> Hs. <SEP> 2936
<tb> matrix <SEP> metalloproteinase <SEP> 14 <SEP> (membrane-inserted) <SEP> Hs. <SEP> 2399
<tb> matrix <SEP> metalloproteinase <SEP> 17 <SEP> Hs. <SEP> 159581
<tb> matrix <SEP> metalloproteinase <SEP> 9 <SEP> ; <SEP> gelatinase <SEP> B <SEP> Hs. <SEP> 151738
<tb> MAX-interacting <SEP> protein <SEP> 1 <SEP> Hs. <SEP> 118630
<tb> Meis <SEP> (mouse) <SEP> homoloa <SEP> 3 <SEP> HS. <SEP> 117313
<tb> metastasis <SEP> associated <SEP> 1 <SEP> Hs. <SEP> 101448
<tb> <Tb>
<tb> UM <SEP> and <SEP> SH <SEP> protein <SEP> 1 <SEP> Hs. <SEP> 334851
<tb> LIM <SEP> bind <SEP> domain <SEP> 2 <SEP> Hs. <SEP> 4980
<tb> LIM <SEP> domain <SEP> only <SEP> 4
<tb> lipocalin <SEP> 1 <SEP> Hs.204238
<tb> lipoprotein <SEP> lipase <SEP> Hs.180878
<tb> LPS-induced <SEP> TNF-alpha <SEP> factor <SEP> Hs. <SEP> 76507
<tb> lumican <SEP> Hs. <SEP> 79914
<tb> lymphocyte-specific <SEP> protein <SEP> tyrosine <SEP> kinase <SEP> Hs. <SEP> 1765
<tb> MAD2 <SEP> (mitotic <SEP> arrest <SEP> deficient, <SEP> yeast, <SEP> homolog) -like <SEP> 1 <SEP> Hs. <SEP> 79078
<tb> major <SEP> histocompatibility <SEP> complex, <SEP> class <SEP> 11, <SEP> DQ <SEP> beta <SEP> 1 <SEP> Hs. <SEP> 73931
<tb> mammaalobin <SEP> 1 <SEP> Hs. <SEP> 46452
<tb> manic <SEP> fringe <SEP> (Drosophila) <SEP> homolog <SEP> Hs.31939
<tb> matrix <SEP> metalloproteinase <SEP> 11 <SEP> (stromelysin <SEP> 3) <SEP> Hs.155324
<tb> matrix <SEP> metalloproteinase <SEP> 13 <SEP> Hs. <SEP> 2936
<tb> matrix <SEP> metalloproteinase <SEP> 14 <SEP> (membrane-inserted) <SEP> Hs. <SEP> 2399
<tb> matrix <SEP> metalloproteinase <SEP> 17 <SEP> Hs. <SEP> 159581
<tb> matrix <SEP> metalloproteinase <SEP> 9 <SEP>;<SEP> gelatinase <SEP> B <SEP> Hs. <SEP> 151738
<tb> MAX-interacting <SEP> protein <SEP> 1 <SEP> Hs. <SEP> 118630
<tb> Meis <SEP> (mouse) <SEP> homology <SEP> 3 <SEP> HS. <SEP> 117313
<tb> metastasis <SEP> associated <SEP> 1 <SEP> Hs. <SEP> 101448
<Tb>

<Desc/Clms Page number 30> <Desc / Clms Page number 30>

Figure img00300001
Figure img00300001

<tb>
<tb> microsomal <SEP> glutathione <SEP> S-transferase <SEP> 1 <SEP> Hs. <SEP> 790
<tb> minichromosome <SEP> maintenance <SEP> deficient <SEP> (S. <SEP> cerevisiae) <SEP> 2 <SEP> (mitotin) <SEP> Hs. <SEP> 57101
<tb> mucin1 <SEP> Hs. <SEP> 89603
<tb> multifunctional <SEP> polypeptide <SEP> similar <SEP> to <SEP> SA <SEP> ! <SEP> CAR <SEP> synthetase <SEP> and <SEP> AIR <SEP> Hs. <SEP> 117950
<tb> carboxylase
<tb> mut <SEP> L <SEP> (E. <SEP> coli) <SEP> homoloa <SEP> 1 <SEP> (colon <SEP> cancer, <SEP> nonpolyposis <SEP> type <SEP> 2) <SEP> Hs. <SEP> 57301
<tb> mut <SEP> S <SEP> (E. <SEP> coli) <SEP> homolog <SEP> 3 <SEP> Hs. <SEP> 42674
<tb> N-acetyltransferase <SEP> 1 <SEP> (arylamine <SEP> N-acetyltransferase) <SEP> Hs. <SEP> 155956
<tb> neutrophil <SEP> cytosolic <SEP> factor <SEP> 1 <SEP> (47kD, <SEP> chronic <SEP> granulomatous <SEP> disease, <SEP> Hs. <SEP> 1583
<tb> autosomal <SEP> 1)
<tb> N-myc <SEP> downstream <SEP> regulated <SEP> Hs. <SEP> 75789
<tb> non-metastatic <SEP> cells <SEP> 1, <SEP> protein <SEP> (NM23A) <SEP> expressed <SEP> in <SEP> Hs. <SEP> 118638
<tb> non-POU-domain <SEP> containing, <SEP> octamer <SEP> binding <SEP> Hs. <SEP> 172207
<tb> nuclear <SEP> receptor <SEP> coactivator <SEP> 3 <SEP> Hs.225977
<tb> nuclear <SEP> transcription <SEP> factor, <SEP> X-box <SEP> binding <SEP> 1 <SEP> Hs.3187
<tb> nucleophosmin <SEP> (nucleolar <SEP> phosphoprotein <SEP> B23, <SEP> numatrin) <SEP> Hs.173205
<tb> osteoblast <SEP> specific <SEP> factor <SEP> 2 <SEP> (fasciclin <SEP> l-like) <SEP> Hs.136348
<tb> parvalbumin <SEP> Hs.295449
<tb> pescadillo <SEP> (zebrafish) <SEP> homolog <SEP> 1, <SEP> containing <SEP> BRCT <SEP> domain <SEP> Hs.13501
<tb> phosphofructokinase, <SEP> platelet <SEP> Hs.99910
<tb> phospholemman <SEP> Hs.160318
<tb> <Tb>
<tb> microsomal <SEP> glutathione <SEP> S-transferase <SEP> 1 <SEP> Hs. <SEP> 790
<tb> minichromosome <SEP> maintenance <SEP> deficient <SEP> (S. <SEP> cerevisiae) <SEP> 2 <SEP> (mitotin) <SEP> Hs. <SEP> 57101
<tb> mucin1 <SEP> Hs. <SEP> 89603
<tb> multifunctional <SEP> polypeptide <SEP> similar <SEP> to <SEP> SA <SEP>! <SEP> CAR <SEP> synthetase <SEP> and <SEP> AIR <SEP> Hs. <SEP> 117950
<tb> carboxylase
<tb> mut <SEP> L <SEP> (E. <SEP> coli) <SEP> homology <SEP> 1 <SEP> (colon <SEP> cancer, <SEP> nonpolyposis <SEP> type <SEP> 2) <SEP> Hs. <SEP> 57301
<tb> mut <SEP> S <SEP> (E. <SEP> coli) <SEP> homolog <SEP> 3 <SEP> Hs. <SEP> 42674
<tb> N-acetyltransferase <SEP> 1 <SEP> (arylamine <SEP> N-acetyltransferase) <SEP> Hs. <SEP> 155956
<tb> neutrophil <SEP> cytosolic <SEP> factor <SEP> 1 <SEP> (47kD, <sep> chronic <SEP> granulomatous <SEP> disease, <SEQ> Hs. <SEP> 1583
<tb> autosomal <SEP> 1)
<tb> N-myc <SEP> downstream <SEP> regulated <SEP> Hs. <SEP> 75789
<tb> non-metastatic <SEP> cells <SEP> 1, <SEQ> protein <SEP> (NM23A) <SEP> expressed <SEP> in <SEP> Hs. <SEP> 118638
<tb> non-POU-domain <SEP> containing, <SEP> octamer <SEP> binding <SEP> Hs. <SEP> 172207
<tb> nuclear <SEP> receptor <SEP> coactivator <SEP> 3 <SEP> Hs.225977
<tb> nuclear <SEP> transcription <SEP> factor, <SEP> Xbox <SEP> binding <SEP> 1 <SEP> Hs.3187
<tb> nucleophosmin <SEP> (nucleolar <SEP> phosphoprotein <SEP> B23, <SEP> numatrin) <SEP> Hs.173205
<tb> osteoblast <SEP> specific <SEP> factor <SEP> 2 <SEP> (fasciclin <SEP> l-like) <SEP> Hs.136348
<tb> parvalbumin <SEP> Hs.295449
<tb> pescadillo <SEP> (zebrafish) <SEP> peer <SEP> 1 <SEP> containing <SEP> BRCT <SEP> domain <SEP> Hs.13501
<tb> phosphofructokinase, <SEP> platelet <SEP> Hs.99910
<tb> phospholemman <SEP> Hs.160318
<Tb>

<Desc/Clms Page number 31> <Desc / Clms Page number 31>

Figure img00310001
Figure img00310001

<tb>
<tb> phospholipase <SEP> A2, <SEP> group <SEP> llA <SEP> (platelets, <SEP> synovial <SEP> fluid) <SEP> Hs.76422
<tb> phospholipid <SEP> scramblase <SEP> 1 <SEP> Hs. <SEP> 198282
<tb> phospholipid <SEP> scramblase <SEP> 1 <SEP> Hs.198282
<tb> ptituitary <SEP> tumor-transforming <SEP> 1 <SEP> Hs.181195
<tb> plakoglobin <SEP> Hs.2340
<tb> plasminogen <SEP> Hs.75576
<tb> plasminogen <SEP> activator <SEP> inhibitor <SEP> 1 <SEP> Hs. <SEP> 82085
<tb> platelet/endothelial <SEP> cell <SEP> adhesion <SEP> molecule <SEP> (CD31 <SEP> antigen) <SEP> Hs. <SEP> 78146
<tb> platelet-derived <SEP> growth <SEP> factor <SEP> receptor, <SEP> beta <SEP> polypeptide <SEP> Hs. <SEP> 76144
<tb> polo <SEP> (Drosophia)-like <SEP> kinase <SEP> Hs. <SEP> 77597
<tb> polymyositis/scleroderma <SEP> autoantigen <SEP> 1 <SEP> (75kD) <SEP> Hs.91728
<tb> postmeiotie <SEP> segregation <SEP> increased <SEP> 2-like <SEP> 3 <SEP> Hs.278467
<tb> potassium <SEP> intermediate/small <SEP> conductance <SEP> calcium-activated <SEP> channel, <SEP> Hs.10082
<tb> subfamily <SEP> N, <SEP> member <SEP> 4
<tb> POU <SEP> domain, <SEP> class <SEP> 2, <SEP> transcription <SEP> factor <SEP> 2 <SEP> Hs.1101
<tb> primase, <SEP> polypeptide <SEP> 1 <SEP> (49kD) <SEP> Hs. <SEP> 82741
<tb> Progesterone <SEP> receptor <SEP> Hs. <SEP> 2905
<tb> prohibitin <SEP> Hs. <SEP> 75323
<tb> pro <SEP> ! <SEP> actin <SEP> Hs. <SEP> 1905
<tb> prolactin-induced <SEP> protein <SEP> Hs. <SEP> 99949
<tb> proliferating <SEP> cell <SEP> nuclear <SEP> antigen <SEP> Hs.78996
<tb> proliferation-associated <SEP> 2G4, <SEP> 38kD <SEP> Hs. <SEP> 5181
<tb> <Tb>
<tb> phospholipase <SEP> A2, <SEP> group <SEP> 11A <SEP> (platelets, <SEP> synovial <SEP> fluid) <SEP> Hs.76422
<tb> phospholipid <SEP> scramblase <SEP> 1 <SEP> Hs. <SEP> 198282
<tb> phospholipid <SEP> scramblase <SEP> 1 <SEP> Hs.198282
<tb> ptituitary <SEP> tumor-transforming <SEP> 1 <SEP> Hs.181195
<tb> Plakoglobin <SEP> Hs.2340
<tb> plasminogen <SEP> Hs.75576
<tb> plasminogen <SEP> activator <SEP> inhibitor <SEP> 1 <SEP> Hs. <SEP> 82085
<tb> platelet / endothelial <SEP> cell <SEP> adhesion <SEP> molecule <SEP> (CD31 <SEP> antigen) <SEP> Hs. <SEP> 78146
<tb> platelet-derived <SEP> growth <SEP> factor <SEP> receptor, <SEP> beta <SEP> polypeptide <SEP> Hs. <SEP> 76144
<tb> polo <SEP> (Drosophia) -like <SEP> kinase <SEP> Hs. <SEP> 77597
<tb> polymyositis / scleroderma <SEP> autoantigen <SEP> 1 <SEP> (75kD) <SEP> Hs.91728
<tb> postmeiotism <SEP> segregation <SEP> increased <SEP> 2-like <SEP> 3 <SEP> Hs.278467
<tb> potassium <SEP> intermediate / small <SEP> calcium-activated <SEP> conductance <SEP> channel, <SEP> Hs.10082
<tb> subfamily <SEP> N, <SEP> member <SEP> 4
<tb> POU <SEP> domain <SEP> class <SEP> 2 <SEP> transcription <SEP> factor <SEP> 2 <SEP> Hs.1101
<tb> primase, <SEP> polypeptide <SEP> 1 <SEP> (49kD) <SEP> Hs. <SEP> 82741
<tb> Progesterone <SEP> receptor <SEP> Hs. <SEP> 2905
<tb> prohibitin <SEP> Hs. <SEP> 75323
<tb> pro <SEP>! <SEP> actin <SEP> Hs. <SEP> 1905
<tb> prolactin-induced <SEP> protein <SEP> Hs. <SEP> 99949
proliferating SEP cell nuclear SEP antigen SEP Hs.78996
<tb> proliferation-associated <SEP> 2G4, <SEP> 38kD <SEP> Hs. <SEP> 5181
<Tb>

<Desc/Clms Page number 32> <Desc / Clms Page number 32>

Figure img00320001
Figure img00320001

<tb>
<tb> protease <SEP> inhibitor <SEP> 12 <SEP> (neuroserpin) <SEP> Hs. <SEP> 78589
<tb> protease, <SEP> serine, <SEP> 8 <SEP> (prostasin) <SEP> Hs. <SEP> 75799
<tb> proteasome <SEP> (prosome, <SEP> macropain) <SEP> 26S <SEP> subunit, <SEP> non-ATPase, <SEP> 12 <SEP> Hs. <SEP> 4295
<tb> protein <SEP> phosphatase <SEP> 1, <SEP> catalytic <SEP> subunit, <SEP> beta <SEP> isoform <SEP> Hs. <SEP> 21537
<tb> protein <SEP> tyrosine <SEP> kinase <SEP> 6 <SEP> Hs. <SEP> 51133
<tb> purinergic <SEP> receptor <SEP> P2X, <SEP> ligand-gated <SEP> ion <SEP> channel, <SEP> 4 <SEP> Hs. <SEP> 321709
<tb> RAD51 <SEP> Hs. <SEP> 343807
<tb> RAD54 <SEP> (S. <SEP> cerevisiae) <SEP> -like <SEP> Hs. <SEP> 667i8
<tb> RAP2A, <SEP> member <SEP> of <SEP> ras <SEP> oncogen <SEP> family <SEP> Hs. <SEP> 301746
<tb> ras <SEP> homolog <SEP> gene <SEP> family, <SEP> member <SEP> B <SEP> (rhoB) <SEP> Hs. <SEP> 204354
<tb> ras <SEP> homolog <SEP> gene <SEP> family, <SEP> member <SEP> H <SEP> Hs. <SEP> 109918
<tb> regulator <SEP> of <SEP> G-protein <SEP> signalling <SEP> 5 <SEP> Hs. <SEP> 24950
<tb> replication <SEP> factor <SEP> C <SEP> (activator <SEP> 1) <SEP> 4 <SEP> (37kD) <SEP> Hs. <SEP> 35120
<tb> RERG <SEP> (ds <SEP> collection <SEP> EST) <SEP> Hs. <SEP> 21594
<tb> retinoblastoma-like <SEP> 2 <SEP> (p130) <SEP> Hs. <SEP> 79362
<tb> retinoic <SEP> acid <SEP> receptor <SEP> responder <SEP> (tazarotene <SEP> induced) <SEP> 1 <SEP> Hs. <SEP> 82547
<tb> retinol-binding <SEP> protein <SEP> 4, <SEP> interstitial <SEP> Hs. <SEP> 76461
<tb> ribonucleotide <SEP> reductase <SEP> M1 <SEP> polypeptide <SEP> Hs. <SEP> 2934
<tb> ribosomal <SEP> protein <SEP> L <SEP> 13 <SEP> Hs. <SEP> 180842
<tb> S100 <SEP> calcium <SEP> binding <SEP> prtoein <SEP> A4 <SEP> Hs. <SEP> 81256
<tb> <Tb>
<tb> protease <SEP> inhibitor <SEP> 12 <SEP> (neuroserpin) <SEP> Hs. <SEP> 78589
<tb> protease, <SEP> serine, <SEP> 8 <SEP> (prostasin) <SEP> Hs. <SEP> 75799
<tb> proteasome <SEP> (prosome, <SEP> macropain) <SEP> 26S <SEP> subunit, <SEP> non-ATPase, <SEP> 12 <SEP> Hs. <SEP> 4295
<tb> protein <SEP> phosphatase <SEP> 1, <SEP> catalytic <SEP> subunit, <SEP> beta <SEP> isoform <SEP> Hs. <SEP> 21537
<tb> protein <SEP> tyrosine <SEP> kinase <SEP> 6 <SEP> Hs. <SEP> 51133
<tb> purinergic <SEP> receptor <SEP> P2X, <SEP> ligand-gated <SEP> ion <SEP> channel, <SEP> 4 <SEP> Hs. <SEP> 321709
<tb> RAD51 <SEP> Hs. <SEP> 343807
<tb> RAD54 <SEP> (S. <SEP> cerevisiae) <SEP> -like <SEP> Hs. <SEP> 667i8
<tb> RAP2A, <SEP> member <SEP> of <SEP> ras <SEP> oncogen <SEP> family <SEP> Hs. <SEP> 301746
<tb> ras <SEP> peer <SEP> gene <SEP> family <SEP> member <SEP> B <SEP> (rhoB) <SEP> Hs. <SEP> 204354
<tb> ras <SEP> peer <SEP> gene <SEP> family, <SEP> member <SEP> H <SEP> Hs. <SEP> 109918
<tb> regulator <SEP> of <SEP> G-protein <SEP> signaling <SEP> 5 <SEP> Hs. <SEP> 24950
<tb> replication <SEP> factor <SEP> C <SEP> (activator <SEP> 1) <SEP> 4 <SEP> (37kD) <SEP> Hs. <SEP> 35120
<tb> RERG <SEP> (ds <SEP><SEP> EST Collection) <SEP> Hs. <SEP> 21594
<tb> retinoblastoma-like <SEP> 2 <SEP> (p130) <SEP> Hs. <SEP> 79362
<tb> retinoic <SEP> acid <SEP> receptor <SEP> responder <SEP> (tazarotene <SEP> induced) <SEP> 1 <SEP> Hs. <SEP> 82547
<tb> retinol-binding <SEP> protein <SEP> 4, <SEP> interstitial <SEP> Hs. <SEP> 76461
<tb> ribonucleotide <SEP> reductase <SEP> M1 <SEP> polypeptide <SEP> Hs. <SEP> 2934
<tb> ribosomal <SEP> protein <SEP> L <SEP> 13 <SEP> Hs. <SEP> 180842
<tb> S100 <SEP> calcium <SEP> binding <SEP> pronein <SEP> A4 <SEP> Hs. <SEP> 81256
<Tb>

<Desc/Clms Page number 33> <Desc / Clms Page number 33>

Figure img00330001
Figure img00330001

<tb>
<tb> S100 <SEP> calcium-binding <SEP> protein <SEP> A2 <SEP> Hs. <SEP> 38991
<tb> S100 <SEP> calcium-binding <SEP> protein <SEP> A8 <SEP> Hs. <SEP> 100000
<tb> S100 <SEP> ca <SEP> ! <SEP> cium-b <SEP> ! <SEP> nding <SEP> protein <SEP> A9 <SEP> (catgranu <SEP> ! <SEP> in <SEP> B) <SEP> Hs. <SEP> 112405
<tb> S100 <SEP> calcium-binding <SEP> protein <SEP> P <SEP> Hs. <SEP> 2962
<tb> S100 <SEP> calcium-binging <SEP> protein, <SEP> beta <SEP> (neural) <SEP> Hs. <SEP> 83384
<tb> secreted <SEP> frizzled <SEP> related <SEP> protein <SEP> 1 <SEP> Hs. <SEP> 7306
<tb> secretory <SEP> leukocyte <SEP> protease <SEP> inhibitor <SEP> (antileukoproteinase) <SEP> Hs. <SEP> 251754
<tb> selenium <SEP> binding <SEP> protein <SEP> 1 <SEP> Hs. <SEP> 334841
<tb> SELENOPHOSPHATE <SEP> SYNTHETASE <SEP> ; <SEP> Human <SEP> selenium <SEP> donor <SEP> protein <SEP> Hs. <SEP> 118725
<tb> serine <SEP> proteinase <SEP> inhibitor, <SEP> clade <SEP> B, <SEP> member <SEP> 5 <SEP> (maspin) <SEP> Hs. <SEP> 55279
<tb> serine/threonine <SEP> kinase <SEP> 15 <SEP> Hs. <SEP> 48915
<tb> serum <SEP> constituent <SEP> protein <SEP> Hs.148101
<tb> singed <SEP> (Drosophila)-like <SEP> (sea <SEP> urchin <SEP> fascin <SEP> homolog <SEP> like) <SEP> Hs.118400
<tb> small <SEP> inducible <SEP> cytokine <SEP> subfamily <SEP> A <SEP> (Cys-Cys), <SEP> member <SEP> 18, <SEP> pulmonary <SEP> and <SEP> Hs. <SEP> 16530
<tb> activation-regulated
<tb> small <SEP> inducible <SEP> cytokine <SEP> subfamily <SEP> D <SEP> (Cys-X3-Cys), <SEP> member <SEP> 1 <SEP> (fractalkine, <SEP> Hs. <SEP> 80420
<tb> neurotactin)
<tb> small <SEP> nuclear <SEP> ribonucleoprotein <SEP> polypeptide <SEP> B" <SEP> Hs. <SEP> 82575
<tb> solute <SEP> carrier <SEP> family <SEP> 7 <SEP> ly <SEP> 7 <SEP> (cationic <SEP> amino <SEP> acid <SEP> transporter, <SEP> y+ <SEP> system), <SEP> membner <SEP> 5 <SEP> Hs. <SEP> 184601
<tb> solute <SEP> carrier <SEP> family <SEP> 9 <SEP> (sodium/hydrogen <SEP> exchanger), <SEP> isoform <SEP> 3 <SEP> regulato <SEP> Hs. <SEP> 184276
<tb> factor <SEP> 1
<tb> <Tb>
<tb> S100 <SEP> calcium-binding <SEP> protein <SEP> A2 <SEP> Hs. <SEP> 38991
<tb> S100 <SEP> calcium-binding <SEP> protein <SEP> A8 <SEP> Hs. <SEP> 100000
<tb> S100 <SEP> ca <SEP>! <SEP> cium-b <SEP>! <SEP> nding <SEP> protein <SEP> A9 <SEP> (catgranu <SEP>! <SEP> in <SEP> B) <SEP> Hs. <SEP> 112405
<tb> S100 <SEP> calcium-binding <SEP> protein <SEP> P <SEP> Hs. <SEP> 2962
<tb> S100 <SEP> calcium-binging <SEP> protein, <SEP> beta <SEP> (neural) <SEP> Hs. <SEP> 83384
<tb> secreted <SEP> frizzled <SEP> related <SEP> protein <SEP> 1 <SEP> Hs. <SEP> 7306
<tb> secretory <SEP> leukocyte <SEP> protease <SEP> inhibitor <SEP> (antileukoproteinase) <SEP> Hs. <SEP> 251754
<tb> selenium <SEP> binding <SEP> protein <SEP> 1 <SEP> Hs. <SEP> 334841
<tb> SELENOPHOSPHATE <SEP> SYNTHETASE <SEP>;<SEP> Human <SEP> selenium <SEP> donor <SEP> protein <SEP> Hs. <SEP> 118725
<tb> serine <SEP> proteinase <SEP> inhibitor, <SEP> clade <SEP> B, <SEP> member <SEP> 5 <SEP> (maspin) <SEP> Hs. <SEP> 55279
<tb> serine / threonine <SEP> kinase <SEP> 15 <SEP> Hs. <SEP> 48915
<tb> serum <SEP> constitute <SEP> protein <SEP> Hs.148101
<tb> singed <SEP> (Drosophila) -like <SEP> (sea <SEP> urchin <SEP> fascinate <SEP> homolog <SEP> like) <SEP> Hs.118400
<tb> small <SEP> inducible <SEP> cytokine <SEP> subfamily <SEP> A <SEP> (Cys-Cys), <SEP> member <SEP> 18, <SEP> pulmonary <SEP> and <SEP> Hs . <SEP> 16530
<tb> activation-regulated
<tb> small <SEP> inducible <SEP> cytokine <SEP> subfamily <SEP> D <SEP> (Cys-X3-Cys), <SEP> member <SEP> 1 <SEP> (fractalkine, <SEP> Hs. <SEP> 80420
<tb> neurotactin)
<tb> small <SEP> nuclear <SEP> ribonucleoprotein <SEP> polypeptide <SEP> B "<SEP> Hs. <SEP> 82575
<tb> solute <SEP> carrier <SEP> family <SEP> 7 <SEP> ly <SEP> 7 <SEP> (cationic <SEP> amino <SEP> acid <SEP> transport, <SEP> y + <SEP> system ), <SEP> member <SEP> 5 <SEP> Hs. <SEP> 184601
<tb> solute <SEP> carrier <SEP> family <SEP> 9 <SEP> (sodium / hydrogen <SEP> exchanger), <SEP> isoform <SEP> 3 <SEP> regulato <SEP> Hs. <SEP> 184276
<tb> factor <SEP> 1
<Tb>

<Desc/Clms Page number 34> <Desc / Clms Page number 34>

Figure img00340001
Figure img00340001

<tb>
<tb> splicing <SEP> factor, <SEP> arginine/serine-rich <SEP> 5 <SEP> Hs. <SEP> 166975
<tb> stanniocalcin <SEP> 2 <SEP> Hs. <SEP> 155223
<tb> superoxide <SEP> dismutase <SEP> 3, <SEP> extracellular <SEP> Hs. <SEP> 2420
<tb> suppression <SEP> of <SEP> tumorogenicity <SEP> Hs. <SEP> 56937
<tb> suppression <SEP> of <SEP> tumorogenicity <SEP> Hs. <SEP> 301974
<tb> T-cell <SEP> receptor, <SEP> beta <SEP> cluster <SEP> Hs. <SEP> 2003
<tb> T-cell <SEP> receptor, <SEP> delta <SEP> (V, <SEP> D, <SEP> J, <SEP> C) <SEP> Hs. <SEP> 2014
<tb> TEK <SEP> tyrosine <SEP> kinase, <SEP> endothelial <SEP> (venous <SEP> malformations, <SEP> multiple <SEP> cutaneous <SEP> Hs. <SEP> 89640
<tb> and <SEP> mucosal)
<tb> Telomerase <SEP> reverse <SEP> transcriptase <SEP> HS. <SEP> 115256
<tb> TGFB1-induced <SEP> anti-apoptotic <SEP> factor <SEP> 1 <SEP> Hs. <SEP> 75822
<tb> thrombospondin <SEP> 1 <SEP> Hs. <SEP> 87409
<tb> Thy-1 <SEP> cell <SEP> surface <SEP> antigen <SEP> Hs. <SEP> 125359
<tb> thymidylate <SEP> synthetase <SEP> Hs. <SEP> 82962
<tb> tissue <SEP> factor <SEP> pathway <SEP> inhibitor <SEP> (lipoprotein-associated <SEP> coagulation <SEP> inhibitor) <SEP> Hs. <SEP> 170279
<tb> tissue <SEP> inhibitor <SEP> of <SEP> metalloproteinase <SEP> 1 <SEP> (erythroid <SEP> potentiating <SEP> activity, <SEP> Hs. <SEP> 5831
<tb> collaqenase <SEP> inhibitor)
<tb> tissue <SEP> inhibtor <SEP> of <SEP> metalloproteinase <SEP> 3 <SEP> Hs. <SEP> 245188
<tb> TNF <SEP> associated <SEP> factor <SEP> 4 <SEP> Hs. <SEP> 8375
<tb> TNF <SEP> receptor-associated <SEP> factor <SEP> 6 <SEP> Hs. <SEP> 90957
<tb> topoisomerase <SEP> (DNA) <SEP> 11 <SEP> alpha <SEP> (1 <SEP> 70kD) <SEP> Hs. <SEP> 156346
<tb> <Tb>
<tb> splicing <SEP> factor, <SEP> arginine / serine-rich <SEP> 5 <SEP> Hs. <SEP> 166975
<tb> stanniocalcin <SEP> 2 <SEP> Hs. <SEP> 155223
<tb> superoxide <SEP> dismutase <SEP> 3, <SEP> extracellular <SEP> Hs. <SEP> 2420
<tb> suppression <SEP> of <SEP> tumorogenicity <SEP> Hs. <SEP> 56937
<tb> suppression <SEP> of <SEP> tumorogenicity <SEP> Hs. <SEP> 301974
<tb> T-cell <SEP> receptor, <SEP> beta <SEP> cluster <SEP> Hs. <SEP> 2003
<tb> T-cell <SEP> receptor, <SEP> delta <SEP> (V, <SEP> D, <SEP> J, <SEP> C) <SEP> Hs. <SEP> 2014
<tb> TEK <SEP> tyrosine <SEP> kinase, <SEP> endothelial <SEP> (venous <SEP> malformations, <SEP> multiple <SEP> cutaneous <SEP> Hs. <SEP> 89640
<tb> and <SEP> mucosal)
<tb> Telomerase <SEP> reverse <SEP> transcriptase <SEP> HS. <SEP> 115256
<tb> TGFB1-induced <SEP> anti-apoptotic <SEP> factor <SEP> 1 <SEP> Hs. <SEP> 75822
<tb> thrombospondin <SEP> 1 <SEP> Hs. <SEP> 87409
<tb> Thy-1 <SEP> cell <SEP> surface <SEP> antigen <SEP> Hs. <SEP> 125359
<tb> thymidylate <SEP> synthetase <SEP> Hs. <SEP> 82962
<tb> tissue <SEP> factor <SEP> pathway <SEP> inhibitor <SEP> (lipoprotein-associated <SEP> coagulation <SEP> inhibitor) <SEP> Hs. <SEP> 170279
<tb> tissue <SEP> inhibitor <SEP> of <SEP> metalloproteinase <SEP> 1 <SEP> (erythroid <SEP> potentiating <SEP> activity, <SEQ> Hs. <SEP> 5831
<tb> collaqenase <SEP> inhibitor)
<tb> tissue <SEP> inhibitor <SEP> of <SEP> metalloproteinase <SEP> 3 <SEP> Hs. <SEP> 245188
<tb> TNF <SEP> associated <SEP> factor <SEP> 4 <SEP> Hs. <SEP> 8375
<tb> TNF <SEP> receptor-associated <SEP> factor <SEP> 6 <SEP> Hs. <SEP> 90957
<tb> topoisomerase <SEP> (DNA) <SEP> 11 <SEP> alpha <SEP> (1 <SEP> 70kD) <SEP> Hs. <SEP> 156346
<Tb>

<Desc/Clms Page number 35> <Desc / Clms Page number 35>

Figure img00350001
Figure img00350001

<tb>
<tb> topoisomerase <SEP> (DNA) <SEP> ll <SEP> beta <SEP> (180kD) <SEP> Hs. <SEP> 75248
<tb> TP53 <SEP> Hs.149923
<tb> transcription <SEP> factor <SEP> AP-2 <SEP> alpha <SEP> (activating <SEP> enhancer-binding <SEP> protein <SEP> 2 <SEP> alpha) <SEP> Hs.18387
<tb> Transforming <SEP> growth <SEP> factor, <SEP> alpha <SEP> Hs. <SEP> 170009
<tb> transforming <SEP> growth <SEP> factor, <SEP> beta <SEP> receptor <SEP> III <SEP> (betaglycan, <SEP> 300kD) <SEP> Hs.79059
<tb> translin <SEP> Hs. <SEP> 75066
<tb> Trefoil <SEP> factor <SEP> 1 <SEP> (breast <SEP> cancer, <SEP> estrogen-inducible <SEP> sequence <SEP> expressed <SEP> in) <SEP> Hs. <SEP> 1406
<tb> trophinin-assisting <SEP> protein <SEP> (tastin) <SEP> Hs. <SEP> 171955
<tb> troponin <SEP> in <SEP> l, <SEP> skeletal, <SEP> fast <SEP> Hs. <SEP> 83760
<tb> tryptophanyl-tRNA <SEP> synthetase <SEP> Hs. <SEP> 82030
<tb> tyrosine <SEP> kinase <SEP> withimmunog <SEP> ! <SEP> obu <SEP> ! <SEP> in <SEP> and <SEP> EGF <SEP> homology <SEP> domains <SEP> Hs. <SEP> 78824
<tb> tyrosyl-tRNA <SEP> synthetase <SEP> Hs. <SEP> 239307
<tb> UDP-galactose <SEP> transporter <SEP> related <SEP> Hs. <SEP> 154073
<tb> UDP-N-acetyl-alpha-D-galactosamine <SEP> 3 <SEP> Hs.278611
<tb> uracil-DNA <SEP> glycosylase <SEP> Hs.78853
<tb> uridine <SEP> monophosphate <SEP> synthetase <SEP> (orotate <SEP> phosphoribosyl <SEP> transferase <SEP> Hs. <SEP> 2057
<tb> and <SEP> orotidine-5'-decarboxylase)
<tb> v-erb-b2 <SEP> avian <SEP> erythroblastic <SEP> leukemia <SEP> viral <SEP> oncogene <SEP> homolog <SEP> 2 <SEP> Hs. <SEP> 323910
<tb> very <SEP> low <SEP> density <SEP> lipoprotein <SEP> receptor <SEP> Hs. <SEP> 73729
<tb> v-Ha-ras <SEP> Harvey <SEP> rat <SEP> sarcoma <SEP> viral <SEP> oncogene <SEP> homolog <SEP> Hs. <SEP> 37003
<tb> vimentin <SEP> Hs. <SEP> 297753
<tb> <Tb>
<tb> topoisomerase <SEP> (DNA) <SEP> 11 <SEP> beta <SEP> (180kD) <SEP> Hs. <SEP> 75248
<tb> TP53 <SEP> Hs.149923
<tb> transcription <SEP> factor <SEP> AP-2 <SEP> alpha <SEP> (activating SEP> enhancer-binding SEP> protein <SEP> 2 <SEP> alpha) <SEP> Hs.18387
<tb> Transforming SEP> growth <SEP> factor, <SEP> alpha <SEP> Hs. <SEP> 170009
<tb> transforming <SEP> growth <SEP> factor, <SEP> beta <SEP> receptor <SEP> III <SEP> (Betaglycan, <SEP> 300kD) <SEP> Hs.79059
<tb> translin <SEP> Hs. <SEP> 75066
<tb> Trefoil <SEP> factor <SEP> 1 <SEP> (breast <SEP> cancer, <SEP> estrogen-inducible <SEP> sequence <SEP> expressed <SEP> in) <SEP> Hs. <SEP> 1406
<tb> trophinin-assisting <SEP> protein <SEP> (tastin) <SEP> Hs. <SEP> 171955
<tb> troponin <SEP> in <SEP> l, <SEP> skeletal, <SEP> fast <SEP> Hs. <SEP> 83760
<tb> tryptophanyl-tRNA <SEP> synthetase <SEP> Hs. <SEP> 82030
<tb> tyrosine <SEP> kinase <SEP> withimmunog <SEP>! <SEP> obu <SEP>! <SEP> in <SEP> and <SEP> EGF <SEP> homology <SEP> domains <SEP> Hs. <SEP> 78824
<tb> tyrosyl-tRNA <SEP> synthetase <SEP> Hs. <SEP> 239307
<tb> UDP-galactose <SEP> transport <SEP> related <SEP> Hs. <SEP> 154073
<tb> UDP-N-acetyl-alpha-D-galactosamine <SEP> 3 <SEP> Hs.278611
<tb> uracil-DNA <SEP> glycosylase <SEP> Hs.78853
<tb> uridine <SEP> monophosphate <SEP> synthetase <SEP> (orotate <SEP> phosphoribosyl <SEP> transferase <SEP> Hs. <SEP> 2057
<tb> and <SEP>orotidine-5'-decarboxylase)
<tb> v-erb-b2 <SEP> avian <SEP> erythroblastic <SEP> leukemia <SEP> viral <SEP> oncogene <SEP> homolog <SEP> 2 <SEP> Hs. <SEP> 323910
<tb> very <SEP> low <SEP> density <SEP> lipoprotein <SEP> receptor <SEP> Hs. <SEP> 73729
<tb> v-Ha-ras <SEP> Harvey <SEP> rat <SEP> sarcoma <SEP> viral <SEP> oncogene <SEP> homolog <SEP> Hs. <SEP> 37003
<tb> vimentin <SEP> Hs. <SEP> 297753
<Tb>

<Desc/Clms Page number 36> <Desc / Clms Page number 36>

Figure img00360001
Figure img00360001

<tb>
<tb> v-myb <SEP> avian <SEP> myeloblastosis <SEP> viral <SEP> oncogene <SEP> homolog-like <SEP> 2 <SEP> Hs. <SEP> 179718
<tb> v-myc <SEP> avian <SEP> myelocytomatosis <SEP> viral <SEP> oncogene <SEP> homolog <SEP> Hs. <SEP> 79070
<tb> von <SEP> Willebrand <SEP> factor <SEP> Hs.110802
<tb> WNT1 <SEP> inducible <SEP> signaling <SEP> pathway <SEP> protein <SEP> 2 <SEP> Hs. <SEP> 194679
<tb> X-box <SEP> binding <SEP> rotein <SEP> 1 <SEP> Hs. <SEP> 149923
<tb> Zinc <SEP> finger <SEP> protein <SEP> 147 <SEP> (estrogen-responsive <SEP> finger <SEP> protein) <SEP> Hs. <SEP> 1579
<tb> zinc <SEP> finger <SEP> protein <SEP> 161Hs. <SEP> 167558
<tb> zing <SEP> finger <SEP> protein <SEP> 217 <SEP> Hs.155040
<tb> <Tb>
<tb> v-myb <SEP> avian <SEP> myeloblastosis <SEP> viral <SEP> oncogene <SEP> homolog-like <SEP> 2 <SEP> Hs. <SEP> 179718
<tb> v-myc <SEP> avian <SEP> myelocytomatosis <SEP> viral <SEP> oncogene <SEP> homolog <SEP> Hs. <SEP> 79070
<tb> von <SEP> Willebrand <SEP> factor <SEP> Hs.110802
<tb> WNT1 <SEP> inducible <SEP> signaling <SEP> pathway <SEP> protein <SEP> 2 <SEP> Hs. <SEP> 194679
<tb> X-box <SEP> binding <SEP> rotein <SEP> 1 <SEP> Hs. <SEP> 149923
<tb> Zinc <SEP> finger <SEP> protein <SEP> 147 <SEP> (estrogen-responsive <SEP> finger <SEP> protein) <SEP> Hs. <SEP> 1579
<tb> zinc <SEP> finger <SEP> protein <SEP> 161Hs. <SEP> 167558
<tb> zing <SEP> Finger <SEP> Protein <SEP> 217 <SEP> Hs.155040
<Tb>

<Desc/Clms Page number 37> <Desc / Clms Page number 37>

Figure img00370001
Figure img00370001

<tb>
<tb> ANNEXE <SEP> 2 <SEP> SEQ <SEP> 2
<tb>
MODULE REPARATION DE L'ADN : 130 SONDES MOLECULAIRES

Figure img00370002
<Tb>
<tb> ANNEX <SEP> 2 <SEP> SEQ <SEP> 2
<Tb>
DNA REPAIR MODULE: 130 MOLECULAR PROBES
Figure img00370002

<tb>
<tb> Nom <SEP> du <SEP> gene <SEP> Unigene
<tb> 8-oxoguanine <SEP> DNA <SEP> glycosylase <SEP> Hs. <SEP> 96398
<tb> ADP-ribosyltransferase <SEP> (NAD+ <SEP> ; <SEP> poly <SEP> (ADP-ribose) <SEP> polymerase) <SEP> ; <SEP> poly <SEP> (ADP-Hs. <SEP> 177766
<tb> ribose) <SEP> polymerase
<tb> ADP-ribosyltransferase <SEP> (NAD+; <SEP> poly <SEP> (ADP-ribose) <SEP> polymerase)-like <SEP> 2 <SEP> Hs. <SEP> 24284
<tb> alkylation <SEP> DNA <SEP> repair <SEP> protein <SEP> alkb <SEP> homolog <SEP> Hs. <SEP> 54418
<tb> APEX <SEP> nuclease <SEP> (multifunctional <SEP> DNA <SEP> repair <SEP> enzyme) <SEP> ; <SEP> apurinic/apyridinicHs. <SEP> 73722
<tb> (abasic) <SEP> endonuclease
<tb> apurinic/apyrimidinic <SEP> endonuclease <SEP> (APEX <SEP> nuclease)-like <SEP> 2 <SEP> protein <SEP> Hs. <SEP> 154149
<tb> ataxia <SEP> telangiectasia <SEP> and <SEP> Rad3 <SEP> related <SEP> Hs. <SEP> 77613
<tb> ataxia <SEP> telangiectasia <SEP> mutated <SEP> (includes <SEP> complementation <SEP> groups <SEP> A, <SEP> C <SEP> and <SEP> D) <SEP> Hs. <SEP> 194382
<tb> ataxia <SEP> telangiectasia <SEP> mutated <SEP> (includes <SEP> complementation <SEP> groups <SEP> A, <SEP> C <SEP> and <SEP> D) <SEP> Hs. <SEP> 194382
<tb> Bloom <SEP> syndrome <SEP> Hs. <SEP> 36820
<tb> breast <SEP> cancer <SEP> 1, <SEP> early <SEP> onset <SEP> Hs. <SEP> 194143
<tb> breast <SEP> cancer <SEP> 2, <SEP> early <SEP> onset <SEP> Hs. <SEP> 34012
<tb> caltractin <SEP> (20kD <SEP> calcium-binding <SEP> protein); <SEP> centrin, <SEP> EF-hand <SEP> protein, <SEP> 2 <SEP> Hs. <SEP> 82794
<tb> <Tb>
<tb> Name <SEP> of the <SEP> gene <SEP> Unigene
<tb> 8-oxoguanine <SEP> DNA <SEP> glycosylase <SEP> Hs. <SEP> 96398
<tb> ADP-ribosyltransferase <SEP> (NAD + <SEP>;<SEP> poly <SEP> (ADP-ribose) <SEP> polymerase) <SEP>;<SEP> poly <SEP> (ADP-Hs. <SEP> 177766
<tb> ribose) <SEP> polymerase
<tb> ADP-ribosyltransferase <SEP> (NAD +; <SEP> poly <SEP> (ADP-ribose) <SEP> polymerase) -like <SEP> 2 <SEP> Hs. <SEP> 24284
<tb> alkylation <SEP> DNA <SEP> repair <SEP> protein <SEP> alkb <SEP> homolog <SEP> Hs. <SEP> 54418
<tb> APEX <SEP> nuclease <SEP> (multifunctional <SEP> DNA <SEP> repair <SEP> enzyme) <SEP>;<SEP> apurinic / apyridinicHs. <SEP> 73722
<tb> (abasic) <SEP> endonuclease
<tb> apurinic / apyrimidinic <SEP> endonuclease <SEP> (APEX <SEP> nuclease) -like <SEP> 2 <SEP> protein <SEP> Hs. <SEP> 154149
<tb> ataxia <SEP> telangiectasia <SEP> and <SEP> Rad3 <SEP> related <SEP> Hs. <SEP> 77613
<tb> ataxia <SEP> telangiectasia <SEP> mutated <SEP> (includes <SEP> complementation <SEP> groups <SEP> A <SEP> C <SEP> and <SEP> D) <SEP> Hs. <SEP> 194382
<tb> ataxia <SEP> telangiectasia <SEP> mutated <SEP> (includes <SEP> complementation <SEP> groups <SEP> A <SEP> C <SEP> and <SEP> D) <SEP> Hs. <SEP> 194382
<tb> Bloom <SEP> syndrome <SEP> Hs. <SEP> 36820
<tb> breast <SEP> cancer <SEP> 1, <SEP> early <SEP> onset <SEP> Hs. <SEP> 194143
<tb> breast <SEP> cancer <SEP> 2, <SEP> early <SEP> onset <SEP> Hs. <SEP> 34012
<tb> caltractin <SEP> (20kD <SEP> calcium-binding <SEP>protein);<SEP> centrin, <SEP> EF-hand <SEP> protein, <SEP> 2 <SEP> Hs. <SEP> 82794
<Tb>

<Desc/Clms Page number 38> <Desc / Clms Page number 38>

Figure img00380001
Figure img00380001

<tb>
<tb> CHK1 <SEP> (checkpoint, <SEP> S.pombe) <SEP> homolog <SEP> Hs.20295
<tb> CHK2 <SEP> (checkpoint, <SEP> S. <SEP> pombe) <SEP> homo <SEP> ! <SEP> og <SEP> Hs. <SEP> 146329
<tb> Cockayne <SEP> syndrome <SEP> 1 <SEP> (classical) <SEP> Hs.32967
<tb> cyclin <SEP> H <SEP> Hs.514
<tb> cyclin-dependent <SEP> kinase <SEP> 7 <SEP> (homolog <SEP> of <SEP> Xenopus <SEP> M015 <SEP> cdk-activating <SEP> Hs. <SEP> 184298
<tb> kinase)
<tb> damage-specific <SEP> DNA <SEP> binding <SEP> protein <SEP> 1 <SEP> (48kD) <SEP> Hs. <SEP> 108327
<tb> damage-specific <SEP> DNA <SEP> binding <SEP> protein <SEP> 2 <SEP> (48kD) <SEP> Hs. <SEP> 77602
<tb> DMC1 <SEP> Hs. <SEP> 37181
<tb> dUTP <SEP> pyrophosphatase <SEP> Hs. <SEP> 82113
<tb> ESTs <SEP> / <SEP> human <SEP> p53 <SEP> R2 <SEP> gene <SEP> for <SEP> ribonucleotide <SEP> reductase <SEP> Hs. <SEP> 94262
<tb> ESTs, <SEP> Weakly <SEP> similar <SEP> to <SEP> DNA <SEP> NUCLEOTIDYLEXOTRANSFERASE <SEP> Hs. <SEP> 46964
<tb> [H.sapiens] <SEP> / <SEP> similar <SEP> to <SEP> DNA <SEP> polymerase <SEP> tu
<tb> excision <SEP> repair <SEP> cross-complementing <SEP> rodent <SEP> repair <SEP> deficiency, <SEP> Hs. <SEP> 99987
<tb> complementation <SEP> group <SEP> (xeroderma <SEP> pigmentosum <SEP> group <SEP> D
<tb> complementing)
<tb> excision <SEP> repair <SEP> cross-complementing <SEP> rodent <SEP> repair <SEP> deficiency, <SEP> Hs. <SEP> 59544
<tb> complementation <SEP> group <SEP> 1 <SEP> (includes <SEP> overlapping <SEP> antisense <SEP> s quence)
<tb> excision <SEP> repair <SEP> cross-complementing <SEP> rodent <SEP> repair <SEP> deficiency, <SEP> Hs. <SEP> 77929
<tb> complementation <SEP> group <SEP> 3 <SEP> (xeroderma <SEP> pigmentosum <SEP> group <SEP> B
<tb> complementing)
<tb> excision <SEP> repair <SEP> cross-complementing <SEP> rodent <SEP> repair <SEP> deficiency, <SEP> Hs. <SEP> 89296
<tb> complementation <SEP> group <SEP> 4
<tb> excision <SEP> repair <SEP> cross-complementing <SEP> rodent <SEP> repair <SEP> deficiency, <SEP> Hs. <SEP> 48576
<tb> <Tb>
<tb> CHK1 <SEP> (checkpoint, <SEP> S.pombe) <SEP> peer <SEP> Hs.20295
<tb> CHK2 <SEP> (checkpoint, <SE> S. <SEP> pombe) <SEP> homo <SEP>! <SEP> og <SEP> Hs. <SEP> 146329
<tb> Cockayne <SEP> syndrome <SEP> 1 <SEP> (classical) <SEP> Hs.32967
<tb> cyclin <SEP> H <SEP> Hs.514
<tb> cyclin-dependent <SEP> kinase <SEP> 7 <SEP><SEP> of <SEP> Xenopus <SEP> M015 <SEP> cdk-activating <SEP> Hs. <SEP> 184298
<tb> kinase)
<tb> damage-specific <SEP> DNA <SEP> binding <SEQ> protein <SEP> 1 <SEP> (48kD) <SEP> Hs. <SEP> 108327
<tb> damage-specific <SEP> DNA <SEP> binding <SEQ> protein <SEP> 2 <SEP> (48kD) <SEP> Hs. <SEP> 77602
<tb> DMC1 <SEP> Hs. <SEP> 37181
<tb> dUTP <SEP> pyrophosphatase <SEP> Hs. <SEP> 82113
<tb> ESTs <SEP> / <SEP> human <SEP> p53 <SEP> R2 <SEP> gene <SEP> for <SEP> ribonucleotide <SEP> reductase <SEP> Hs. <SEP> 94262
<tb> ESTs, <SEP> Weakly <SEP> similar <SEP> to <SEP> DNA <SEP> NUCLEOTIDYLEXOTRANSFERASE <SEP> Hs. <SEP> 46964
<tb> [H.sapiens] <SEP> / <SEP> similar <SEP> to <SEP> DNA <SEP><SEP> polymerase
<tb> excision <SEP> repair <SEP> cross-complementing <SEP> repair <SEP> repair <SEP> deficiency, <SEP> Hs. <SEP> 99987
<tb> complementation <SEP> group <SEP> (xeroderma <SEP> pigmentosum <SEP> group <SEP> D
<tb> complementing)
<tb> excision <SEP> repair <SEP> cross-complementing <SEP> repair <SEP> repair <SEP> deficiency, <SEP> Hs. <SEP> 59544
<tb> complementation <SEP> group <SEP> 1 <SEP> (includes <SEP> overlapping <SEP> antisense <SEP> squency)
<tb> excision <SEP> repair <SEP> cross-complementing <SEP> repair <SEP> repair <SEP> deficiency, <SEP> Hs. <SEP> 77929
<tb> complementation <SEP> group <SEP> 3 <SEP> (xeroderma <SEP> pigmentosum <SEP> group <SEP> B
<tb> complementing)
<tb> excision <SEP> repair <SEP> cross-complementing <SEP> repair <SEP> repair <SEP> deficiency, <SEP> Hs. <SEP> 89296
<tb> complementation <SEP> group <SEP> 4
<tb> excision <SEP> repair <SEP> cross-complementing <SEP> repair <SEP> repair <SEP> deficiency, <SEP> Hs. <SEP> 48576
<Tb>

<Desc/Clms Page number 39> <Desc / Clms Page number 39>

Figure img00390001
Figure img00390001

<tb>
<tb> complementation <SEP> group <SEP> 5 <SEP> (xeroderma <SEP> pigmentosum, <SEP> complementation
<tb> group <SEP> G <SEP> (Cockayne <SEP> syndrome))
<tb> excision <SEP> repair <SEP> cross-complementing <SEP> rodent <SEP> repair <SEP> deficiency, <SEP> Hs. <SEP> 99924
<tb> corn <SEP> lementation <SEP> rou <SEP> 6
<tb> exonuclease <SEP> 1 <SEP> Hs. <SEP> 47504
<tb> Fanconi <SEP> anemia, <SEP> complementation <SEP> group <SEP> A <SEP> Hs.86297
<tb> Fanconi <SEP> anemia, <SEP> complementation <SEP> group <SEP> B
<tb> Fanconi <SEP> anemia, <SEP> complementation <SEP> group <SEP> C <SEP> Hs.37953
<tb> Fanconi <SEP> anemia, <SEP> complementation <SEP> group <SEP> D1
<tb> Fanconi <SEP> anemia, <SEP> complementation <SEP> group <SEP> D2 <SEP> Hs.15607
<tb> Fanconi <SEP> anemia, <SEP> complementation <SEP> group <SEP> E <SEP> Hs. <SEP> 302003
<tb> Fanconi <SEP> anemia, <SEP> complementation <SEP> group <SEP> F <SEP> Hs. <SEP> 65328
<tb> Fanconi <SEP> anemia, <SEP> complementation <SEP> group <SEP> G <SEP> Hs. <SEP> 8047
<tb> flap <SEP> structure-specific <SEP> endonuclease <SEP> 1 <SEP> Hs. <SEP> 4756
<tb> general <SEP> transcription <SEP> factor <SEP> IIH, <SEP> polypeptide <SEP> 1 <SEP> (62kD <SEP> subunit) <SEP> Hs. <SEP> 89578
<tb> general <SEP> transcription <SEP> factor <SEP> llH, <SEP> polypeptide <SEP> 2 <SEP> (30kD <SEP> subunit) <SEP> Hs.191356
<tb> general <SEP> transcription <SEP> factor <SEP> iiH, <SEP> poiypeptide <SEP> 3 <SEP> (34kD <SEP> subunit) <SEP> Hs. <SEP> 90304
<tb> general <SEP> transcription <SEP> factor <SEP> iiH, <SEP> poiypeptide <SEP> 4 <SEP> (52kD <SEP> subunit) <SEP> Hs. <SEP> 102910
<tb> H2A <SEP> histone <SEP> family, <SEP> member <SEP> X <SEP> Hs. <SEP> 147097
<tb> HCNP <SEP> protein <SEP> ; <SEP> XPA-binding <SEP> protein <SEP> 2Hs. <SEP> 9822
<tb> Homo <SEP> sapiens <SEP> mRNA; <SEP> cDNA <SEP> DKFZp586G1122 <SEP> (from <SEP> clone <SEP> Hs. <SEP> 20555
<tb> DKFZp586G1122) <SEP> (MRE11A)
<tb> <Tb>
<tb> complementation <SEP> group <SEP> 5 <SEP> (xeroderma <SEP> pigmentosum, <SEP> supplementation
<tb> group <SEP> G <SEP> (Cockayne <SEP> Syndrome))
<tb> excision <SEP> repair <SEP> cross-complementing <SEP> repair <SEP> repair <SEP> deficiency, <SEP> Hs. <SEP> 99924
<tb> corn <SEP> lementation <SEP> rou <SEP> 6
<tb> exonuclease <SEP> 1 <SEP> Hs. <SEP> 47504
<tb> Fanconi <SEP> anemia, <SEP> supplementation <SEP> group <SEP> A <SEP> Hs.86297
<tb> Fanconi <SEP> anemia, <SEP> supplementation <SEP> group <SEP> B
<tb> Fanconi <SEP> anemia, <SEP> supplementation <SEP> group <SEP> C <SEP> Hs.37953
<tb> Fanconi <SEP> anemia, <SEP> supplementation <SEP> group <SEP> D1
<tb> Fanconi <SEP> anemia, <SEP> supplementation <SEP> group <SEP> D2 <SEP> Hs.15607
<tb> Fanconi <SEP> anemia, <SEP> complementation <SEP> group <SEP> E <SEP> Hs. <SEP> 302003
<tb> Fanconi <SEP> anemia, <SEP> complementation <SEP> group <SEP> F <SEP> Hs. <SEP> 65328
<tb> Fanconi <SEP> anemia, <SEP> complementation <SEP> group <SEP> G <SEP> Hs. <SEP> 8047
<tb> flap <SEP> structure-specific <SEP> endonuclease <SEP> 1 <SEP> Hs. <SEP> 4756
<tb> general <SEP> transcription <SEP> factor <SEP> IIH, <SEP> polypeptide <SEP> 1 <SEP> (62kD <SEP> subunit) <SEP> Hs. <SEP> 89578
<tb> general <SEP> transcription <SEP> factor <SEQ ID> 11H, <SEP> polypeptide <SEP> 2 <SEP> (30kD <SEP> subunit) <SEQ> Hs.191356
<tb> general <SEP> transcription <SEP> factor <SEP> iiH, <SEP> polypeptide <SEP> 3 <SEP> (34kD <SEP> subunit) <SEP> Hs. <SEP> 90304
<tb> general <SEP> transcription <SEP> factor <SEP> iiH, <SEP> polypeptide <SEP> 4 <SEP> (52kD <SEP> subunit) <SEP> Hs. <SEP> 102910
<tb> H2A <SEP> histone <SEP> family, <SEP> member <SEP> X <SEP> Hs. <SEP> 147097
<tb> HCNP <SEP> protein <SEP>;<SEP> XPA-binding <SEP> protein <SEP> 2Hs. <SEP> 9822
<tb> Homo <SEP> sapiens <SEP>mRNA;<SEP> cDNA <SEP> DKFZp586G1122 <SEP> (from <SEP> clone <SEP> Hs. <SEP> 20555
<tb> DKFZp586G1122) <SEP> (MRE11A)
<Tb>

<Desc/Clms Page number 40> <Desc / Clms Page number 40>

Figure img00400001
Figure img00400001

<tb>
<tb> HUS1 <SEP> (S. <SEP> pombe) <SEP> checkpoint <SEP> homolog <SEP> Hs. <SEP> 152983
<tb> KIAA0086 <SEP> gene <SEP> product <SEP> Hs. <SEP> 1560
<tb> ligase <SEP> 1, <SEP> DNA, <SEP> ATP-dependent <SEP> Hs. <SEP> 1770
<tb> ligase <SEP> 111, <SEP> DNA, <SEP> ATP-dependent <SEP> Hs. <SEP> 100299
<tb> ligase <SEP> IV, <SEP> DNA, <SEP> ATP-dependent <SEP> Hs. <SEP> 166091
<tb> menage <SEP> a <SEP> trois1 <SEP> (CAK <SEP> assembly <SEP> factor <SEP> Hs.32380
<tb> methyl-CpG <SEP> binding <SEP> domain <SEP> protein <SEP> 4 <SEP> Hs. <SEP> 35947
<tb> mitotic <SEP> arrest <SEP> defience, <SEP> yeast,-like2 <SEP> Hs. <SEP> 19400
<tb> MMS19 <SEP> (MET18 <SEP> S. <SEP> cerevisiae)-I <SEP> like <SEP> Hs. <SEP> 288891
<tb> mutL <SEP> (E. <SEP> coli) <SEP> homolog <SEP> 1 <SEP> (colon <SEP> cancer, <SEP> nonpolyposis <SEP> type <SEP> 2) <SEP> Hs. <SEP> 57301
<tb> mutL <SEP> (E. <SEP> coli) <SEP> homolog3 <SEP> Hs. <SEP> 279842
<tb> mutS <SEP> (E. <SEP> coli) <SEP> homolog <SEP> 3 <SEP> Hs. <SEP> 42674
<tb> mutS <SEP> (E. <SEP> coli) <SEP> homolog <SEP> 4 <SEP> Hs. <SEP> 115246
<tb> mutS <SEP> (E. <SEP> coli) <SEP> homolog <SEP> 5 <SEP> Hs. <SEP> 112193
<tb> mutS <SEP> (E. <SEP> coli) <SEP> homolog <SEP> 5 <SEP> Hs. <SEP> 112193
<tb> mutS <SEP> (E. <SEP> coli) <SEP> homolog <SEP> 2 <SEP> Hs. <SEP> 78934
<tb> mutS <SEP> (E. <SEP> coli) <SEP> homolog <SEP> 6 <SEP> Hs. <SEP> 3248
<tb> mutY <SEP> (E. <SEP> coli) <SEP> homolog <SEP> Hs. <SEP> 271353
<tb> Nijmegen <SEP> breakage <SEP> syndrome <SEP> 1 <SEP> (nibrin) <SEP> Hs. <SEP> 25812
<tb> N-methylpurine-DNA <SEP> glycosylase <SEP> Hs. <SEP> 79396
<tb> <Tb>
<tb> HUS1 <SEP> (S. <SEP> pombe) <SEP> checkpoint <SEP> peer <SEP> Hs. <SEP> 152983
<tb> KIAA0086 <SEP> gene <SEP> product <SEP> Hs. <SEP> 1560
<tb> ligase <SEP> 1, <SEP> DNA, <SEP> ATP-dependent <SEP> Hs. <SEP> 1770
<tb> ligase <SEP> 111, <SEP> DNA, <SEP> ATP-dependent <SEP> Hs. <SEP> 100299
<tb> ligase <SEP> IV, <SEP> DNA, <SEP> ATP-dependent <SEP> Hs. <SEP> 166091
<tb> household <SEP><SEQ> three1 <SEP><SEP> assembly <SEP> factor <SEP> Hs.32380
<tb> methyl-CpG <SEP> binding <SEP> domain <SEP> protein <SEP> 4 <SEP> Hs. <SEP> 35947
<tb> mitotic <SEP> arrest <SEP> defiance, <SEP> yeast, -like2 <SEP> Hs. <SEP> 19400
<tb> MMS19 <SEP> (MET18 <SE> S. <SEP> cerevisiae) -I <SEP> like <SEP> Hs. <SEP> 288891
<tb> mutL <SEP> (E. <SEP> coli) <SEP> homolog <SEP> 1 <SEP> (colon <SEP> cancer, <SEP> nonpolyposis <SEP> type <SEP> 2) <SEP> Hs . <SEP> 57301
<tb> mutL <SEP> (E. <SEP> coli) <SEP> homolog3 <SEP> Hs. <SEP> 279842
<tb> mutS <SEP> (E. <SEP> coli) <SEP> homolog <SEP> 3 <SEP> Hs. <SEP> 42674
<tb> mutS <SEP> (E. <SEP> coli) <SEP> homolog <SEP> 4 <SEP> Hs. <SEP> 115246
<tb> mutS <SEP> (E. <SEP> coli) <SEP> homolog <SEP> 5 <SEP> Hs. <SEP> 112193
<tb> mutS <SEP> (E. <SEP> coli) <SEP> homolog <SEP> 5 <SEP> Hs. <SEP> 112193
<tb> mutS <SEP> (E. <SEP> coli) <SEP> homolog <SEP> 2 <SEP> Hs. <SEP> 78934
<tb> mutS <SEP> (E. <SEP> coli) <SEP> homolog <SEP> 6 <SEP> Hs. <SEP> 3248
<tb> mutY <SEP> (E. <SEP> coli) <SEP> homolog <SEP> Hs. <SEP> 271353
<tb> Nijmegen <SEP> breakage <SEP> syndrome <SEP> 1 <SEP> (nibrin) <SEP> Hs. <SEP> 25812
<tb> N-methylpurine-DNA <SEP> glycosylase <SEP> Hs. <SEP> 79396
<Tb>

<Desc/Clms Page number 41> <Desc / Clms Page number 41>

Figure img00410001
Figure img00410001

<tb>
<tb> nth <SEP> (E. <SEP> coli <SEP> endonuclease <SEP> III <SEP> -like <SEP> 1 <SEP> Hs. <SEP> 66196
<tb> nudix <SEP> (nucleoside <SEP> diphosphate <SEP> linked <SEP> moiety <SEP> X)-type <SEP> motif <SEP> 1 <SEP> Hs. <SEP> 388
<tb> 0-6-meth <SEP> 1 <SEP> uanine-DNA <SEP> meth <SEP> Itransferase <SEP> Hs. <SEP> 1384
<tb> polymerase <SEP> (DNA <SEP> directed) <SEP> eta <SEP> Hs. <SEP> 155573
<tb> polymerase <SEP> (DNA <SEP> directed) <SEP> gamma <SEP> Hs. <SEP> 80961
<tb> polymerase <SEP> (DNA <SEP> directed) <SEP> iota <SEP> Hs. <SEP> 271699
<tb> polymerase <SEP> (DNA <SEP> directed) <SEP> kappa <SEP> Hs. <SEP> 135756
<tb> polymerase <SEP> (DNA <SEP> directed) <SEP> lambda <SEP> Hs. <SEP> 129903
<tb> polymerase <SEP> (DNA <SEP> directed) <SEP> lambda <SEP> Hs. <SEP> 225951
<tb> polymerase <SEP> (DNA <SEP> directed), <SEP> beta <SEP> Hs. <SEP> 180107
<tb> polymerase <SEP> (DNA <SEP> directed), <SEP> delta <SEP> 1, <SEP> catalytic <SEP> subunit <SEP> (125kD) <SEP> Hs. <SEP> 99890
<tb> polymerase'DNA <SEP> directed), <SEP> epsilon <SEP> Hs. <SEP> 166846
<tb> polynucleotide <SEP> kinase <SEP> 3'phosphatase <SEP> Hs. <SEP> 78016
<tb> postmeiotic <SEP> segregation <SEP> increased <SEP> (S. <SEP> cerevisiae) <SEP> 1 <SEP> Hs. <SEP> 111749
<tb> postmeiotic <SEP> segregation <SEP> increased <SEP> (S. <SEP> cerevisiae) <SEP> 2 <SEP> Hs. <SEP> 177548
<tb> postmeiottc <SEP> s gr gation <SEP> increased <SEP> 2-like <SEP> 3 <SEP> Hs. <SEP> 278467
<tb> postmeiotic <SEP> segregation <SEP> increased <SEP> 2-like <SEP> 4 <SEP> Hs. <SEP> 278468
<tb> proliferating <SEP> cell <SEP> nuclear <SEP> antigen <SEP> Hs. <SEP> 78996
<tb> protein <SEP> kinase, <SEP> DNA-activated, <SEP> catalytic <SEP> polypeptide <SEP> Hs. <SEP> 155637
<tb> RAD1 <SEP> (S. <SEP> pombe) <SEP> homolog <SEP> Hs. <SEP> 7179
<tb> <Tb>
<tb> nth <SEP> (E. <SEP> coli <SEP> endonuclease <SEP> III <SEP> -like <SEP> 1 <SEP> Hs. <SEP> 66196
<tb> nudix <SEP> (nucleoside <SEP> diphosphate <SEP> linked <SEP> moiety <SEP> X) -type <SEP> pattern <SEP> 1 <SEP> Hs. <SEP> 388
<tb> 0-6-meth <SEP> 1 <SEP> uanine-DNA <SEP> meth <SEP> Itransferase <SEP> Hs. <SEP> 1384
<tb> polymerase <SEP> (DNA <SEP> directed) <SEP> eta <SEP> Hs. <SEP> 155573
<tb> polymerase <SEP> (DNA <SEP> directed) <SEP> gamma <SEP> Hs. <SEP> 80961
<tb> polymerase <SEP> (DNA <SEP> directed) <SEP> iota <SEP> Hs. <SEP> 271699
<tb> polymerase <SEP> (DNA <SEP> directed) <SEP> kappa <SEP> Hs. <SEP> 135756
<tb> polymerase <SEP> (DNA <SEP> directed) <SEP> lambda <SEP> Hs. <SEP> 129903
<tb> polymerase <SEP> (DNA <SEP> directed) <SEP> lambda <SEP> Hs. <SEP> 225951
<tb> polymerase <SEP> (DNA <SEP> directed), <SEP> beta <SEP> Hs. <SEP> 180107
<tb> polymerase <SEP> (DNA <SEP> directed), <SEP> delta <SEP> 1, <SEP> catalytic <SEP> subunit <SEP> (125kD) <SEP> Hs. <SEP> 99890
<tb>polymerase'DNA<SEP> directed), <SEP> epsilon <SEP> Hs. <SEP> 166846
<tb> polynucleotide <SEP> kinase <SEP>3'phosphatase<SEP> Hs. <SEP> 78016
<tb> postmeiotic <SEP> segregation <SEP> increased <SEP> (S. <SEP> cerevisiae) <SEP> 1 <SEP> Hs. <SEP> 111749
<tb> postmeiotic <SEP> segregation <SEP> increased <SEP> (S. <SEP> cerevisiae) <SEP> 2 <SEP> Hs. <SEP> 177548
<tb> postmeiottc <SEP> s <SEP> increased <SEP> 2-like <SEP> 3 <SEP> Hs. <SEP> 278467
<tb> postmeiotic <SEP> segregation <SEP> increased <SEP> 2-like <SEP> 4 <SEP> Hs. <SEP> 278468
<tb> proliferating <SEP> cell <SEP> nuclear <SEP> antigen <SEP> Hs. <SEP> 78996
<tb> protein <SEP> kinase, <SEP> DNA-activated, <SEP> catalytic <SEP> polypeptide <SEP> Hs. <SEP> 155637
<tb> RAD1 <SEP> (S. <SEP> pombe) <SEP> peer <SEP> Hs. <SEP> 7179
<Tb>

<Desc/Clms Page number 42> <Desc / Clms Page number 42>

Figure img00420001
Figure img00420001

<tb>
<tb> RAD18 <SEP> Hs. <SEP> 21320
<tb> RAD23 <SEP> (S. <SEP> cerevisiae) <SEP> homolog <SEP> A <SEP> Hs. <SEP> 180455
<tb> RAD23 <SEP> (S. <SEP> cerevisiae) <SEP> homolog <SEP> B <SEP> Hs. <SEP> 178658
<tb> RAD50 <SEP> (S. <SEP> cerevisiae) <SEP> homolog <SEP> Hs. <SEP> 41587
<tb> RAD51 <SEP> (S. <SEP> cerevisiae) <SEP> homolog <SEP> (E <SEP> coli <SEP> RecA <SEP> homolog) <SEP> Hs. <SEP> 153667
<tb> RAD51 <SEP> (S. <SEP> cerevisiae) <SEP> homolog <SEP> C <SEP> Hs. <SEP> 11393
<tb> RAD51 <SEP> L1 <SEP> Hs. <SEP> 100669
<tb> RAD51 <SEP> L3 <SEP> Hs. <SEP> 125244
<tb> RAD52 <SEP> (S. <SEP> cerevisiae) <SEP> homoloQ <SEP> HS. <SEP> 89571
<tb> RAD <SEP> 54 <SEP> (8. <SEP> cerevisiae) <SEP> -like <SEP> HS. <SEP> 66718
<tb> RAD54B <SEP> Hs. <SEP> 128501
<tb> RAD9 <SEP> (S. <SEP> pombe) <SEP> homolog <SEP> Hs. <SEP> 240457
<tb> RecQ <SEP> protein-like <SEP> 4 <SEP> Hs. <SEP> 31442
<tb> replication <SEP> protein <SEP> A1 <SEP> (70kD) <SEP> / <SEP> GS2 <SEP> gene <SEP> (=C9) <SEP> Hs. <SEP> 84318
<tb> replication <SEP> protein <SEP> A2 <SEP> (32kD) <SEP> Hs. <SEP> 79411
<tb> replication <SEP> protein <SEP> A2 <SEP> (32kD) <SEP> Hs. <SEP> 79411
<tb> replication <SEP> protein <SEP> A3 <SEP> (14kD) <SEP> Hs. <SEP> 1608
<tb> REV1 <SEP> (yeast <SEP> homolog)-like <SEP> Hs. <SEP> 110347
<tb> REV3 <SEP> (yeast <SEP> homolog)- <SEP> like, <SEP> catalytic <SEP> subunit <SEP> of <SEP> DNA <SEP> polymerase <SEP> zeta <SEP> Hs. <SEP> 115521
<tb> single-strand <SEP> monofunctionnal <SEP> uracil <SEP> DNA <SEP> glycosylase <SEP> Hs. <SEP> 5212
<tb> <Tb>
<tb> RAD18 <SEP> Hs. <SEP> 21320
<tb> RAD23 <SEP> (S. <SEP> cerevisiae) <SEP> homolog <SEP> A <SEP> Hs. <SEP> 180455
<tb> RAD23 <SEP> (S. <SEP> cerevisiae) <SEP> peer <SEP> B <SEP> Hs. <SEP> 178658
<tb> RAD50 <SEP> (S. <SEP> cerevisiae) <SEP> homolog <SEP> Hs. <SEP> 41587
<tb> RAD51 <SEP> (S. <SEP> cerevisiae) <SEP> homolog <SEP> (E <SEP> coli <SEP> RecA <SEP> homolog) <SEP> Hs. <SEP> 153667
<tb> RAD51 <SEP> (S. <SEP> cerevisiae) <SEP> homolog <SEP> C <SEP> Hs. <SEP> 11393
<tb> RAD51 <SEP> L1 <SEP> Hs. <SEP> 100669
<tb> RAD51 <SEP> L3 <SEP> Hs. <SEP> 125244
<tb> RAD52 <SEP> (SE <sep> cerevisiae) <SEP> homoloQ <SEP> HS. <SEP> 89571
<tb> RAD <SEP> 54 <SEP> (8. <SEP> cerevisiae) <SEP> -like <SEP> HS. <SEP> 66718
<tb> RAD54B <SEP> Hs. <SEP> 128501
<tb> RAD9 <SEP> (S. <SEP> pombe) <SEP> peer <SEP> Hs. <SEP> 240457
<tb> RecQ <SEP> protein-like <SEP> 4 <SEP> Hs. <SEP> 31442
<tb> replication <SEP> protein <SEP> A1 <SEP> (70kD) <SEP> / <SEP> GS2 <SEP> gene <SEP> (= C9) <SEP> Hs. <SEP> 84318
<tb> replication <SEP> protein <SEP> A2 <SEP> (32kD) <SEP> Hs. <SEP> 79411
<tb> replication <SEP> protein <SEP> A2 <SEP> (32kD) <SEP> Hs. <SEP> 79411
<tb> replication <SEP> protein <SEP> A3 <SEP> (14kD) <SEP> Hs. <SEP> 1608
<tb> REV1 <SEP> (yeast <SEP> peer) -like <SEP> Hs. <SEP> 110347
<tb> REV3 <SEP> (yeast <SEP> homolog) - <SEP> like, <SEP> catalytic <SEP> subunit <SEP> of <SEP> DNA <SEP> polymerase <SEP> zeta <SEP> Hs. <SEP> 115521
<tb> single-strand <SEP> monofunctional <SEP> uracil <SEP> DNA <SEP> glycosylase <SEP> Hs. <SEP> 5212
<Tb>

<Desc/Clms Page number 43> <Desc / Clms Page number 43>

Figure img00430001
Figure img00430001

<tb>
<tb> SP011, <SEP> meiotic <SEP> protein <SEP> covalently <SEP> bound <SEP> to <SEP> DSB <SEP> (S-cerevisiae)-like <SEP> Hs. <SEP> 159737
<tb> three <SEP> time <SEP> repair <SEP> exonuclease <SEP> 1 <SEP> Hs.278408
<tb> three <SEP> time <SEP> repair <SEP> exonuclease <SEP> 2 <SEP> Hs.251398
<tb> thymidine-DNA <SEP> glycosylase <SEP> Hs.173824
<tb> thyroid <SEP> autoantigen <SEP> 70kD <SEP> (Ku <SEP> antigen) <SEP> Hs. <SEP> 197345
<tb> topoisomerase <SEP> related <SEP> function <SEP> protein <SEP> 4-2 <SEP> Hs. <SEP> 294030
<tb> tumor <SEP> protein <SEP> 53-binding <SEP> protein, <SEP> 1 <SEP> Hs. <SEP> 170263
<tb> ubiquitin <SEP> activating <SEP> enzyme-2 <SEP> Hs. <SEP> 16695
<tb> ubiquitin-conjugating <SEP> enzyme <SEP> E2A <SEP> (RAD6 <SEP> homolog) <SEP> Hs. <SEP> 80612
<tb> ubiquitin-conjugating <SEP> enzyme <SEP> E2A <SEP> variant <SEP> 2 <SEP> Hs. <SEP> 79300
<tb> ubiquitin-conjugating <SEP> enzyme <SEP> E2N <SEP> (homologous <SEP> to <SEP> yeast <SEP> UBC13) <SEP> Hs. <SEP> 75355
<tb> uracil-DNA <SEP> glycosylase <SEP> Hs. <SEP> 78853
<tb> Werner <SEP> syndrome <SEP> Hs. <SEP> 150477
<tb> xeroderma <SEP> pigmentosum, <SEP> complementation <SEP> group <SEP> A <SEP> Hs. <SEP> 192803
<tb> xeroderma <SEP> pigmentosum, <SEP> complementation <SEP> group <SEP> C <SEP> Hs. <SEP> 320
<tb> X-ray <SEP> repair <SEP> compiementing <SEP> defective <SEP> repair <SEP> in <SEP> Chinese <SEP> hamster <SEP> cells <SEP> 1 <SEP> Hs. <SEP> 98493
<tb> X-ray <SEP> repair <SEP> complementing <SEP> defective <SEP> repair <SEP> in <SEP> Chinese <SEP> hamster <SEP> cells <SEP> 2 <SEP> Hs. <SEP> 129727
<tb> X-ray <SEP> repair <SEP> complementing <SEP> defective <SEP> repair <SEP> in <SEP> Chinese <SEP> hamster <SEP> cells <SEP> 3 <SEP> Hs. <SEP> 99742
<tb> X-ray <SEP> repair <SEP> complementing <SEP> defective <SEP> repair <SEP> in <SEP> Chinese <SEP> hamster <SEP> cells <SEP> 4 <SEP> Hs. <SEP> 150930
<tb> X-ray <SEP> repair <SEP> complementing <SEP> defective <SEP> repair <SEP> in <SEP> Chinese <SEP> hamster <SEP> cells <SEP> 5 <SEP> Hs. <SEP> 84981
<tb> (double-strand-break <SEP> rejoining <SEP> ; <SEP> Ku <SEP> autoantigen, <SEP> 80kD)
<tb> <Tb>
<tb> SP011, <SEP> meiotic <SEP> protein <SEP> covalently <SEP> bound <SEP> to <SEP> DSB <SEP> (S-cerevisiae) -like <SEP> Hs. <SEP> 159737
<tb> three <SEP> time <SEP> repair <SEP> exonuclease <SEP> 1 <SEP> Hs.278408
<tb> three <SEP> time <SEP> repair <SEP> exonuclease <SEP> 2 <SEP> Hs.251398
<tb> thymidine-DNA <SEP> glycosylase <SEP> Hs.173824
<tb> thyroid <SEP> autoantigen <SEP> 70kD <SEP> (Ku <SEP> antigen) <SEP> Hs. <SEP> 197345
<tb> topoisomerase <SEP> related <SEP> function <SEP> protein <SEP> 4-2 <SEP> Hs. <SEP> 294030
<tb> tumor <SEP> protein <SEP> 53-binding <SEP> protein, <SEP> 1 <SEP> Hs. <SEP> 170263
<tb> ubiquitin <SEP> activating <SEP> enzyme-2 <SEP> Hs. <SEP> 16695
<tb> ubiquitin-conjugating <SEP> enzyme <SEP> E2A <SEP> (RAD6 <SEP> homolog) <SEP> Hs. <SEP> 80612
<tb> ubiquitin-conjugating <SEP> enzyme <SEP> E2A <SEP> variant <SEP> 2 <SEP> Hs. <SEP> 79300
<tb> ubiquitin-conjugating <SEP> enzyme <SEP> E2N <SEP> (homologous <SEP> to <SEP> yeast <SEP> UBC13) <SEP> Hs. <SEP> 75355
<tb> uracil-DNA <SEP> glycosylase <SEP> Hs. <SEP> 78853
<tb> Werner <SEP> syndrome <SEP> Hs. <SEP> 150477
<tb> xeroderma <SEP> pigmentosum, <SEP> supplementation <SEP> group <SEP> A <SEP> Hs. <SEP> 192803
<tb> xeroderma <SEP> pigmentosum, <SEP> complementation <SEP> group <SEP> C <SEP> Hs. <SEP> 320
<tb> X-ray <SEP><SEP> repair <SEP><SEP> repair <SEP><SEP> Chinese <SEP> Hamster <SEP> cells <SEP> 1 <SEP> Hs. <SEP> 98493
<tb> X-ray <SEP><SEP> repairing <SEP> defective <SEP> repair <SEP> in <SEP> Chinese <SEP> hamster <SEP> cells <SEP> 2 <SEP> Hs. <SEP> 129727
<tb> X-ray <SEP><SEP> repair <SEP> defective <SEP> repair <SEP> in <SEP> Chinese <SEP> hamster <SEP> cells <SEP> 3 <SEP> Hs. <SEP> 99742
<tb> X-ray <SEP><SEP> repair <SEP> defective <SEP> repair <SEP> in <SEP> Chinese <SEP> hamster <SEP> cells <SEP> 4 <SEP> Hs. <SEP> 150930
<tb> X-ray <SEP><SEP> repair <SEP> defective <SEP> repair <SEP> in <SEP> Chinese <SEP> hamster <SEP> cells <SEP> 5 <SEP> Hs. <SEP> 84981
<tb> (double-strand-break <SEP> rejoining <SEP>;<SEP> Ku <SEP> autoantigen, <SEP> 80kD)
<Tb>

<Desc/Clms Page number 44> <Desc / Clms Page number 44>

Figure img00440001
Figure img00440001

<tb>
<tb> ANNEXE <SEP> 3 <SEP> SEQ <SEP> 3
<tb>
MODULE DE RECHERCHE CHIMIOSENSIBILITE

Figure img00440002
<Tb>
<tb> ANNEX <SEP> 3 <SEP> SEQ <SEP> 3
<Tb>
CHEMOSENSITIVITY RESEARCH MODULE
Figure img00440002

<tb>
<tb> G nes <SEP> Unigene <SEP> Ciuster
<tb> ABCB1 <SEP> = <SEP> MDR1 <SEP> = <SEP> P-glycoprotein <SEP> 1 <SEP> (ATP-binding <SEP> cassette, <SEP> sub-family <SEP> B, <SEP> Hs. <SEP> 21330
<tb> member <SEP> 1)
<tb> ABCB4 <SEP> = <SEP> MDR2 <SEP> =MDR3 <SEP> (ATP-binding <SEP> cassette, <SEP> sub-family <SEP> B, <SEP> member <SEP> 4) <SEP> Hs. <SEP> 73812
<tb> ABCC1 <SEP> = <SEP> MRP1 <SEP> (ATP-binding <SEP> cassette, <SEP> sub-family <SEP> C, <SEP> member <SEP> 1) <SEP> Hs. <SEP> 89433
<tb> ABCC2 <SEP> = <SEP> MRP2 <SEP> (ATP-binding <SEP> cassette, <SEP> sub-family <SEP> C, <SEP> member <SEP> 2) <SEP> Hs. <SEP> 193852
<tb> ABCC3 <SEP> = <SEP> MRP3 <SEP> (ATP-binding <SEP> cassette, <SEP> sub-family <SEP> C, <SEP> member <SEP> 3) <SEP> Hs. <SEP> 90786
<tb> ABCC4 <SEP> = <SEP> MRP4 <SEP> (ATP-binding <SEP> cassette, <SEP> sub-family <SEP> C, <SEP> member <SEP> 4) <SEP> Hs. <SEP> 139336
<tb> ABCC5 <SEP> = <SEP> MRP5 <SEP> (ATP-binding <SEP> cassette, <SEP> sub-family <SEP> C, <SEP> member <SEP> 5) <SEP> Hs. <SEP> 108660
<tb> ABCC6 <SEP> = <SEP> MRP6 <SEP> = <SEP> ARA <SEP> (ATP-binding <SEP> cassette, <SEP> sub-family <SEP> C, <SEP> member <SEP> 6) <SEP> Hs. <SEP> 274260
<tb> ABCG2=BCRP <SEP> (Breast <SEP> cancer <SEP> resistance <SEP> protein, <SEP> ATP-binding <SEP> cassette, <SEP> Hs. <SEP> 194720
<tb> sub-family <SEP> G, <SEP> member <SEP> 2)
<tb> ABL1 <SEP> = <SEP> c-abl <SEP> (v-abl <SEP> Abelson <SEP> murine <SEP> leukemia <SEP> viral <SEP> oncogene <SEP> homolog <SEP> 1) <SEP> Hs. <SEP> 146355
<tb> ACTB <SEP> (Actin, <SEP> beta) <SEP> Hs. <SEP> 288061
<tb> ACTG1 <SEP> (Actin, <SEP> gamma <SEP> 1) <SEP> Hs. <SEP> 14376
<tb> ADPRT <SEP> = <SEP> PARP <SEP> (ADP-ribosyltransferase <SEP> polymerase) <SEP> Hs. <SEP> 177766
<tb> <Tb>
<tb> G nes <SEP> Unigene <SEP> Ciuster
<tb> ABCB1 <SEP> = <SEP> MDR1 <SEP> = <SEP> P-glycoprotein <SEP> 1 <SEP> (ATP-binding <SEP> cassette, <SEP> sub-family <SEP> B, <SEP> Hs. <SEP> 21330
<tb> member <SEP> 1)
<tb> ABCB4 <SEP> = <SEP> MDR2 <SEP> = MDR3 <SEP> (ATP-binding <SEP> cassette, <SEP> sub-family <SEP> B, <SEP> member <SEP> 4) <SEP> Hs. <SEP> 73812
<tb> ABCC1 <SEP> = <SEP> MRP1 <SEP> (ATP-binding <SEP> cassette, <SEP> sub-family <SEP> C, <SEP> member <SEP> 1) <SEP> Hs. <SEP> 89433
<tb> ABCC2 <SEP> = <SEP> MRP2 <SEP> (ATP-binding <SEP> cassette, <SEP> sub-family <SEP> C, <SEP> member <SEP> 2) <SEP> Hs. <SEP> 193852
<tb> ABCC3 <SEP> = <SEP> MRP3 <SEP> (ATP-binding <SEP> cassette, <SEP> sub-family <SEP> C, <SEP> member <SEP> 3) <SEP> Hs. <SEP> 90786
<tb> ABCC4 <SEP> = <SEP> MRP4 <SEP> (ATP-binding <SEP> cassette, <SEP> sub-family <SEP> C, <SEP> member <SEP> 4) <SEP> Hs. <SEP> 139336
<tb> ABCC5 <SEP> = <SEP> MRP5 <SEP> (ATP-binding <SEP> cassette, <SEP> sub-family <SEP> C, <SEP> member <SEP> 5) <SEP> Hs. <SEP> 108660
<tb> ABCC6 <SEP> = <SEP> MRP6 <SEP> = <SEP> ARA <SEP> (ATP-binding <SEP> cassette, <SEP> sub-family <SEP> C, <SEP> member <SEP> 6) <SEP> Hs. <SEP> 274260
<tb> ABCG2 = BCRP <SEP> (Breast <SEP> cancer <SEP> resistance <SEP> protein, <SEP> ATP-binding <SEP> cassette, <SEP> Hs. <SEP> 194720
<tb> sub-family <SEP> G, <SEP> member <SEP> 2)
<tb> ABL1 <SEP> = <SEP> c-abl <SEP> (v-abl <SEP> Abelson <SEP> murine <SEP> leukemia <SEP> viral <SEP> oncogene <SEP> homolog <SEP> 1) <SEP> Hs. <SEP> 146355
<tb> ACTB <SEP> (Actin, <SEP> beta) <SEP> Hs. <SEP> 288061
<tb> ACTG1 <SEP> (Actin, <SEP> gamma <SEP> 1) <SEP> Hs. <SEP> 14376
<tb> ADPRT <SEP> = <SEP> PARP <SEP> (ADP-ribosyltransferase <SEP> polymerase) <SEP> Hs. <SEP> 177766
<Tb>

<Desc/Clms Page number 45> <Desc / Clms Page number 45>

Figure img00450001
Figure img00450001

<tb>
<tb> AKT1 <SEP> (v-akt <SEP> murine <SEP> thymona <SEP> viral <SEP> oncogene <SEP> homolog <SEP> 1) <SEP> Hs. <SEP> 71816
<tb> AKT2 <SEP> (v-akt <SEP> murine <SEP> thymona <SEP> viral <SEP> oncogene <SEP> homolog <SEP> 2) <SEP> Hs. <SEP> 326445
<tb> AKT2 <SEP> (v-akt <SEP> murine <SEP> thymona <SEP> viral <SEP> oncogene <SEP> homolog <SEP> 2) <SEP> Hs. <SEP> 326445
<tb> AKR1B1 <SEP> (Aldo-keto <SEP> reductase <SEP> family <SEP> 1, <SEP> member <SEP> B1 <SEP> (aldose <SEP> reductase)) <SEP> Hs. <SEP> 75313
<tb> ALDH1A1 <SEP> (A <SEP> ! <SEP> dehyde <SEP> dehydrogenase <SEP> 1) <SEP> Hs. <SEP> 76392
<tb> ALDH3A1 <SEP> (Aldéhyde <SEP> dehydrogenase <SEP> 3) <SEP> Hs. <SEP> 575
<tb> ANGPT1 <SEP> (Angiopoietin <SEP> 1) <SEP> Hs. <SEP> 2463
<tb> ANXA1 <SEP> (Annexin <SEP> l <SEP> ; <SEP> lipocortin <SEP> I) <SEP> Hs. <SEP> 78225
<tb> ANXA4 <SEP> (Annexin <SEP> IV) <SEP> Hs. <SEP> 77840
<tb> AP3S2 <SEP> (Adaptor-related <SEP> protein <SEP> complex <SEP> 3, <SEP> sigma <SEP> 2 <SEP> subunit) <SEP> Hs. <SEP> 154782
<tb> APAF1 <SEP> (Apoptotic <SEP> protease <SEP> activating <SEP> factor <SEP> 1) <SEP> Hs. <SEP> 77579
<tb> APP <SEP> (Amyloid <SEP> beta <SEP> A4 <SEP> precursor <SEP> protein) <SEP> Hs. <SEP> 177486
<tb> APRT <SEP> (Adenine <SEP> phosphoribosyltransferase) <SEP> Hs. <SEP> 28914
<tb> ARHB <SEP> (Rho <SEP> B) <SEP> Hs. <SEP> 204354
<tb> ARPC3 <SEP> (Actin <SEP> related <SEP> protein <SEP> 2/3 <SEP> complex, <SEP> subunit <SEP> 3, <SEP> 21 <SEP> kD) <SEP> Hs. <SEP> 6895
<tb> ATF4 <SEP> (Activating <SEP> transcription <SEP> factor <SEP> 4 <SEP> (tax-responsive <SEP> enhancer <SEP> element <SEP> Hs. <SEP> 181243
<tb> B67))
<tb> ATM <SEP> (Ataxia <SEP> Telangiectasia <SEP> mutated <SEP> (includes <SEP> complementation <SEP> group <SEP> A, <SEP> C <SEP> Hs. <SEP> 194382
<tb> and <SEP> D))
<tb> BAD <SEP> (BCL2-antagonist <SEP> of <SEP> cell <SEP> death) <SEP> Hs. <SEP> 76366
<tb> BAK1 <SEP> (BCL2-antagonist/killer <SEP> 1) <SEP> Hs. <SEP> 93213
<tb> BAX <SEP> (BCL2-associated <SEP> X <SEP> protein) <SEP> Hs. <SEP> 159428
<tb> <Tb>
<tb> AKT1 <SEP> (v-akt <SEP> murine <SEP> thymona <SEP> viral <SEP> oncogene <SEP> homolog <SEP> 1) <SEP> Hs. <SEP> 71816
<tb> AKT2 <SEP> (v-akt <SEP> murine <SEP> thymona <SEP> viral <SEP> oncogene <SEP> homolog <SEP> 2) <SEP> Hs. <SEP> 326445
<tb> AKT2 <SEP> (v-akt <SEP> murine <SEP> thymona <SEP> viral <SEP> oncogene <SEP> homolog <SEP> 2) <SEP> Hs. <SEP> 326445
<tb> AKR1B1 <SEP> (Aldo-keto <SEP> reductase <SEP> family <SEP> 1, <SEP> member <SEP> B1 <SEP> (aldose <SEP> reductase)) <SEP> Hs. <SEP> 75313
<tb> ALDH1A1 <SEP> (A <SEP>! <SEP> dehyde <SEP> dehydrogenase <SEP> 1) <SEP> Hs. <SEP> 76392
<tb> ALDH3A1 <SEP> (Aldehyde <SEP> dehydrogenase <SEP> 3) <SEP> Hs. <SEP> 575
<tb> ANGPT1 <SEP> (Angiopoietin <SEP> 1) <SEP> Hs. <SEP> 2463
<tb> ANXA1 <SEP> (Annexin <SEP><SEP>;<SEP> Lipocortin <SEP> I) <SEP> Hs. <SEP> 78225
<tb> ANXA4 <SEP> (Annexin <SEP> IV) <SEP> Hs. <SEP> 77840
<tb> AP3S2 <SEP> (Adaptor-related <SEP> protein <SEP> complex <SEP> 3, <SEP> sigma <SEP> 2 <SEP> subunit) <SEP> Hs. <SEP> 154782
<tb> APAF1 <SEP> (Apoptotic <SEP> protease <SEP> activating <SEP> factor <SEP> 1) <SEP> Hs. <SEP> 77579
<tb> APP <SEP> (Amyloid <SEP> beta <SEP> A4 <SEP> precursor <SEP> protein) <SEP> Hs. <SEP> 177486
<tb> APRT <SEP> (Adenine <SEP> Phosphoribosyltransferase) <SEP> Hs. <SEP> 28914
<tb> ARHB <SEP> (Rho <SEP> B) <SEP> Hs. <SEP> 204354
<tb> ARPC3 <SEP> (Actin <SEP> related <SEP> protein <SEP> 2/3 <SEP> complex, <SEP> subunit <SEP> 3, <SEP> 21 <SEP> kD) <SEP> Hs . <SEP> 6895
<tb> ATF4 <SEP> (Activating <SEP> transcription <SEP> factor <SEP> 4 <SEP> (tax-responsive <SEP> enhancer <SEP> element <SEP> Hs. <SEP> 181243
<tb> B67))
<tb> ATM <SEP> (Ataxia <SEP> Telangiectasia <SEP> mutated <SEP> (includes <SEP> complementation <SEP> group <SEP> A <SEP> C <SEP> Hs. <SEP> 194382
<tb> and <SEP> D))
<tb> BAD <SEP> (BCL2-antagonist <SEP> of <SEP> cell <SEP> death) <SEP> Hs. <SEP> 76366
<tb> BAK1 <SEP> (BCL2-antagonist / killer <SEP> 1) <SEP> Hs. <SEP> 93213
<tb> BAX <SEP> (BCL2-associated <SEP> X <SEP> protein) <SEP> Hs. <SEP> 159428
<Tb>

<Desc/Clms Page number 46> <Desc / Clms Page number 46>

Figure img00460001
Figure img00460001

<tb>
<tb> BCAR1 <SEP> (Breast <SEP> cancer <SEP> anti-estrogen <SEP> résistance <SEP> 1) <SEP> Hs. <SEP> 273219
<tb> BCAR3 <SEP> (Breast <SEP> cancer <SEP> anti-estrogen <SEP> resistance <SEP> 3) <SEP> Hs. <SEP> 6564
<tb> BCL2 <SEP> (B-cell <SEP> CLUlymphoma <SEP> 2) <SEP> Hs. <SEP> 79241
<tb> BCL2A1 <SEP> = <SEP> BFL1 <SEP> (BCL2-related <SEP> protein <SEP> A1) <SEP> Hs. <SEP> 227817
<tb> BCL2L1 <SEP> = <SEP> BCL-XL <SEP> (BCL2-like <SEP> 1) <SEP> Hs. <SEP> 305890
<tb> BCR <SEP> (Breakpoint <SEP> cluster <SEP> region) <SEP> Hs. <SEP> 234799
<tb> BCR <SEP> (Breakpoint <SEP> cluster <SEP> region) <SEP> Hs. <SEP> 234799
<tb> BIRC1 <SEP> (Baculoviral <SEP> IAP <SEP> repeat-containing <SEP> 1) <SEP> Hs. <SEP> 79019
<tb> BIRC2 <SEP> = <SEP> cIAP1 <SEP> (Baculoviral <SEP> IAP <SEP> repeat-containing <SEP> 2) <SEP> Hs. <SEP> 289107
<tb> BIRC3 <SEP> = <SEP> cIAP2 <SEP> (Baculoviral <SEP> IAP <SEP> repeat-containing <SEP> 3) <SEP> Hs. <SEP> 127799
<tb> BIRC4 <SEP> = <SEP> Xiap <SEP> (Baculoviral <SEP> IAP <SEP> repeat-containing <SEP> 4) <SEP> Hs. <SEP> 172777
<tb> BIRC5 <SEP> = <SEP> Survivin <SEP> (Baculoviral <SEP> IAP <SEP> repeat-containing <SEP> 5) <SEP> Hs. <SEP> 1578
<tb> BLMH <SEP> (Bleomycin <SEP> hydrolase) <SEP> Hs. <SEP> 78943
<tb> BRCA1 <SEP> (Breast <SEP> cancer <SEP> 1, <SEP> early <SEP> onset) <SEP> Hs. <SEP> 194143
<tb> BRCA2 <SEP> (Breast <SEP> cancer <SEP> 2, <SEP> early <SEP> onset) <SEP> Hs. <SEP> 34012
<tb> CACNA1D <SEP> (Ca <SEP> ! <SEP> cium <SEP> channet, <SEP> voitage-dpdt, <SEP> Ltype, <SEP> atpha <SEP> 1D <SEP> subunit) <SEP> Hs. <SEP> 23838
<tb> CASP1 <SEP> (Caspase <SEP> 1, <SEP> apoptosis-related <SEP> cysteine <SEP> protease) <SEP> Hs. <SEP> 2490
<tb> CASP3 <SEP> (Caspase <SEP> 3, <SEP> apoptosis-related <SEP> cysteine <SEP> protease) <SEP> Hs. <SEP> 74552
<tb> CASP6 <SEP> (Caspase <SEP> 6, <SEP> apoptosis-related <SEP> cysteine <SEP> protease) <SEP> Hs. <SEP> 3280
<tb> CASP7 <SEP> (Caspase <SEP> 7, <SEP> apoptosis-related <SEP> cysteine <SEP> protease) <SEP> Hs. <SEP> 9216
<tb> CASP8 <SEP> (Caspase <SEP> 8, <SEP> apoptosis-related <SEP> cysteine <SEP> protease) <SEP> Hs. <SEP> 19949
<tb> <Tb>
<tb> BCAR1 <SEP> (Breast <SEP> cancer <SEP> anti-estrogen <SEP> resistance <SEP> 1) <SEP> Hs. <SEP> 273219
<tb> BCAR3 <SEP> (Breast <SEP> cancer <SEP> anti-estrogen <SEP> resistance <SEP> 3) <SEP> Hs. <SEP> 6564
<tb> BCL2 <SEP> (B-cell <SEP> CLUlymphoma <SEP> 2) <SEP> Hs. <SEP> 79241
<tb> BCL2A1 <SEP> = <SEP> BFL1 <SEP> (BCL2-related <SEP> Protein <SEP> A1) <SEP> Hs. <SEP> 227817
<tb> BCL2L1 <SEP> = <SEP> BCL-XL <SEP> (BCL2-like <SEP> 1) <SEP> Hs. <SEP> 305890
<tb> BCR <SEP> (Breakpoint <SEP> Cluster <SEP> region) <SEP> Hs. <SEP> 234799
<tb> BCR <SEP> (Breakpoint <SEP> Cluster <SEP> region) <SEP> Hs. <SEP> 234799
<tb> BIRC1 <SEP> (Baculoviral <SEP> IAP <SEP> repeat-containing <SEP> 1) <SEP> Hs. <SEP> 79019
<tb> BIRC2 <SEP> = <SEP> cIAP1 <SEP> (Baculoviral <SEP> IAP <SEP> repeat-containing <SEP> 2) <SEP> Hs. <SEP> 289107
<tb> BIRC3 <SEP> = <SEP> cIAP2 <SEP> (Baculoviral <SEP> IAP <SEP> repeat-containing <SEP> 3) <SEP> Hs. <SEP> 127799
<tb> BIRC4 <SEP> = <SEP> Xiap <SEP> (Baculoviral <SEP> IAP <SEP> repeat-containing <SEP> 4) <SEP> Hs. <SEP> 172777
<tb> BIRC5 <SEP> = <SEP> Survivin <SEP> (Baculoviral <SEP> IAP <SEP> repeat-containing <SEP> 5) <SEP> Hs. <SEP> 1578
<tb> BLMH <SEP> (Bleomycin <SEP> hydrolase) <SEP> Hs. <SEP> 78943
<tb> BRCA1 <SEP> (Breast <SEP> cancer <SEP> 1, <SEP> early <SEP> onset) <SEP> Hs. <SEP> 194143
<tb> BRCA2 <SEP> (Breast <SEP> cancer <SEP> 2, <SEP> early <SEP> onset) <SEP> Hs. <SEP> 34012
<tb> CACNA1D <SEP> (C <SEP>! <SEP> cium <SEP> channet, <SEP> vage-dpdt, <SEP> Ltype, <SEP> atpha <SEP> 1D <SEP> subunit) <SEP> Hs. <SEP> 23838
<tb> CASP1 <SEP> (Caspase <SEP> 1, <SEP> apoptosis-related <SEP> cysteine <SEP> protease) <SEP> Hs. <SEP> 2490
<tb> CASP3 <SEP> (Caspase <SEP> 3, <SEP> apoptosis-related <SEP> cysteine <SEP> protease) <SEP> Hs. <SEP> 74552
<tb> CASP6 <SEP> (Caspase <SEP> 6, <SEP> apoptosis-related <SEP> cysteine <SEP> protease) <SEP> Hs. <SEP> 3280
<tb> CASP7 <SEP> (Caspase <SEP> 7, <SEP> apoptosis-related <SEP> cysteine <SEP> protease) <SEP> Hs. <SEP> 9216
<tb> CASP8 <SEP> (Caspase <SEP> 8, <SEP> apoptosis-related <SEP> cysteine <SEP> protease) <SEP> Hs. <SEP> 19949
<Tb>

<Desc/Clms Page number 47> <Desc / Clms Page number 47>

Figure img00470001
Figure img00470001

<tb>
<tb> CASP9 <SEP> (Caspase <SEP> 9, <SEP> apoptosis-related <SEP> cysteine <SEP> protease) <SEP> Hs. <SEP> 100641
<tb> CAV1 <SEP> (Caveolin <SEP> 1, <SEP> caveolae <SEP> protein, <SEP> 22kD) <SEP> Hs. <SEP> 323469
<tb> CCNB1 <SEP> (CydinBI) <SEP> Hs. <SEP> 23960
<tb> CCND1 <SEP> (CydinDI) <SEP> Hs. <SEP> 82932
<tb> CCNE1 <SEP> (Cydin <SEP> E1) <SEP> Hs. <SEP> 9700
<tb> CCNG1 <SEP> (Cyclin <SEP> G1) <SEP> Hs.79101
<tb> CD63 <SEP> (Melanoma <SEP> 1 <SEP> antigen) <SEP> Hs. <SEP> 76294
<tb> CDA <SEP> (Cytidine <SEP> deaminase) <SEP> Hs. <SEP> 72924
<tb> CDC2 <SEP> = <SEP> p34 <SEP> = <SEP> CDK1 <SEP> (Cell <SEP> division <SEP> cycle <SEP> 2) <SEP> Hs. <SEP> 184572
<tb> CDC25C <SEP> = <SEP> CDC25 <SEP> (Cell <SEP> division <SEP> cycle <SEP> 25C) <SEP> Hs. <SEP> 656
<tb> CDC27 <SEP> (Cell <SEP> division <SEP> cycle <SEP> 27) <SEP> Hs. <SEP> 172405
<tb> CDH1 <SEP> (Cadherin, <SEP> type <SEP> 1, <SEP> E-cadherin <SEP> (epithelial)) <SEP> Hs. <SEP> 194657
<tb> CDK2 <SEP> (Cyclin-dpt <SEP> kinase <SEP> 2) <SEP> Hs. <SEP> 19192
<tb> CDK4 <SEP> (Cyclin-dpt <SEP> kinase <SEP> 4) <SEP> Hs. <SEP> 95577
<tb> CDK6 <SEP> (Cyclin-dpt <SEP> kinase <SEP> 6) <SEP> Hs. <SEP> 38481
<tb> CDKN1A <SEP> = <SEP> p21 <SEP> (Cyclin-dpt <SEP> kinase <SEP> inhibitor <SEP> 1A <SEP> (p21, <SEP> Cip1)) <SEP> Hs. <SEP> 179665
<tb> CDKN1B <SEP> = <SEP> p27KIP-1 <SEP> (Cyclin-dpt <SEP> kinase <SEP> inhibitor <SEP> 1B <SEP> (p27, <SEP> Kip1)) <SEP> Hs. <SEP> 238990
<tb> CDKN2A <SEP> = <SEP> p16 <SEP> (Cyclin-dpt <SEP> kinase <SEP> inhibitor <SEP> 2A <SEP> (melanoma, <SEP> p16, <SEP> inhibit <SEP> Hs. <SEP> 1174
<tb> CDK4)
<tb> CGA <SEP> = <SEP> Chorionic <SEP> gonadotrophin <SEP> alpha <SEP> subunit <SEP> (Glycoprotein <SEP> hormones, <SEP> Hs. <SEP> 119689
<tb> alpha <SEP> polypeptide)
<tb> <Tb>
<tb> CASP9 <SEP> (Caspase <SEP> 9, <SEP> apoptosis-related <SEP> cysteine <SEP> protease) <SEP> Hs. <SEP> 100641
<tb> CAV1 <SEP> (Caveolin <SEP> 1, <SEP> caveolae <SEP> protein, <SEP> 22kD) <SEP> Hs. <SEP> 323469
<tb> CCNB1 <SEP> (CydinBI) <SEP> Hs. <SEP> 23960
<tb> CCND1 <SEP> (CydinDI) <SEP> Hs. <SEP> 82932
<tb> CCNE1 <SEP> (Cydin <SEP> E1) <SEP> Hs. <SEP> 9700
<tb> CCNG1 <SEP> (Cyclin <SEP> G1) <SEP> Hs.79101
<tb> CD63 <SEP> (Melanoma <SEP> 1 <SEP> antigen) <SEP> Hs. <SEP> 76294
<tb> CDA <SEP> (Cytidine <SEP> deaminase) <SEP> Hs. <SEP> 72924
<tb> CDC2 <SEP> = <SEP> p34 <SEP> = <SEP> CDK1 <SEP> (Cell <SEP> division <SEP> cycle <SEP> 2) <SEP> Hs. <SEP> 184572
<tb> CDC25C <SEP> = <SEP> CDC25 <SEP> (Cell <SEP> division <SEP> cycle <SEP> 25C) <SEP> Hs. <SEP> 656
<tb> CDC27 <SEP> (Cell <SEP> division <SEP> cycle <SEP> 27) <SEP> Hs. <SEP> 172405
<tb> CDH1 <SEP> (Cadherin, <SEP> type <SEP> 1, <SEQ> E-cadherin <SEP> (epithelial)) <SEP> Hs. <SEP> 194657
<tb> CDK2 <SEP> (Cyclin-dpt <SEP> kinase <SEP> 2) <SEP> Hs. <SEP> 19192
<tb> CDK4 <SEP> (Cyclin-dpt <SEP> kinase <SEP> 4) <SEP> Hs. <SEP> 95577
<tb> CDK6 <SEP> (Cyclin-dpt <SEP> Kinase <SEP> 6) <SEP> Hs. <SEP> 38481
<tb> CDKN1A <SEP> = <SEP> p21 <SEP> (Cyclin-dpt <SEP> kinase <SEP> inhibitor <SEP> 1A <SEP> (p21, <SEP> Cip1)) <SEP> Hs. <SEP> 179665
<tb> CDKN1B <SEP> = <SEP> p27KIP-1 <SEP> (Cyclin-dpt <SEP> kinase <SEP> inhibitor <SEP> 1B <SEP> (p27, <SEP> Kip1)) <SEP> Hs. <SEP> 238990
<tb> CDKN2A <SEP> = <SEP> p16 <SEP> (Cyclin-dpt <SEP> kinase <SEP> inhibitor <SEP> 2A <SEP> (melanoma, <SEP> p16, <SEP> inhibit <SEP> Hs <SEP> 1174
<tb> CDK4)
<tb> CGA <SEP> = <SEP> Chorionic <SEP> gonadotrophin <SEP> alpha <SEP> subunit <SEP> (Glycoprotein <SEP> hormones, <SEP> Hs. <SEP> 119689
<tb> alpha <SEP> polypeptide)
<Tb>

<Desc/Clms Page number 48> <Desc / Clms Page number 48>

Figure img00480001
Figure img00480001

<tb>
<tb> CHEK1 <SEP> = <SEP> CHK1 <SEP> (Checkpoint <SEP> homolog) <SEP> Hs <SEP> 20295
<tb> CKS1 <SEP> (CDC28 <SEP> protein <SEP> kinase <SEP> 1) <SEP> Hs. <SEP> 334883
<tb> CLU <SEP> = <SEP> TRPM-2 <SEP> (Clusterin <SEP> (complement <SEP> Iysis <SEP> inhibitor, <SEP> SP-40, <SEP> sulfate <SEP> Hs. <SEP> 75106
<tb> glycoprotein <SEP> 2, <SEP> testosterone-repressed <SEP> prostate <SEP> message <SEP> 2, <SEP> apolipoprotein
<tb> J
<tb> COL3A1 <SEP> (Collagen, <SEP> type <SEP> III, <SEP> alpha <SEP> 1) <SEP> Hs. <SEP> 119571
<tb> COL4A2 <SEP> (Collagen, <SEP> type <SEP> IV, <SEP> alpha <SEP> 2) <SEP> Hs. <SEP> 75617
<tb> COL4A3 <SEP> (Collagen, <SEP> type <SEP> IV, <SEP> alpha <SEP> 3) <SEP> Hs. <SEP> 530
<tb> COL4A5 <SEP> (Collagen, <SEP> type <SEP> IV, <SEP> alpha <SEP> 5) <SEP> Hs. <SEP> 169825
<tb> COL4A6 <SEP> (Collagen, <SEP> type <SEP> IV, <SEP> alpha <SEP> 6) <SEP> Hs. <SEP> 408
<tb> COX4 <SEP> (Cytochrome <SEP> c <SEP> oxidase <SEP> subunit <SEP> IV) <SEP> Hs. <SEP> 347969
<tb> CRA <SEP> = <SEP> Cisplatin <SEP> resistance <SEP> associated <SEP> Hs. <SEP> 166066
<tb> CRABP2 <SEP> (Cellular <SEP> retinoic <SEP> acid-binding <SEP> protein <SEP> 2) <SEP> Hs. <SEP> 183650
<tb> CRADD <SEP> (CASP2 <SEP> and <SEP> RIPK1 <SEP> domain <SEP> containing <SEP> adaptor <SEP> with <SEP> death <SEP> domain) <SEP> Hs. <SEP> 155566
<tb> CRMP1 <SEP> (Collapsin <SEP> response <SEP> mediator <SEP> protein <SEP> 1) <SEP> Hs. <SEP> 155392
<tb> CRR9P <SEP> (Cisplatin <SEP> resistance <SEP> related <SEP> protein) <SEP> Hs. <SEP> 323769
<tb> CSDA <SEP> (Cold <SEP> shock <SEP> domain <SEP> protein <SEP> A) <SEP> Hs. <SEP> 1139
<tb> CSF1 <SEP> R <SEP> (Co) <SEP> ony <SEP> stimutating <SEP> factor <SEP> 1 <SEP> receptor) <SEP> Hs. <SEP> 174142
<tb> CYP1A1 <SEP> (Cytochrome <SEP> P450, <SEP> subfamity <SEP> ! <SEP> (aromatic <SEP> compound-inducibie), <SEP> Hs. <SEP> 72912
<tb> polypeptide <SEP> 1)
<tb> CYP1B1 <SEP> (Cytochrome <SEP> P450, <SEP> subfamily <SEP> I <SEP> (dioxin-inducible), <SEP> polypeptide <SEP> 1 <SEP> Hs. <SEP> 154654
<tb> (glaucoma <SEP> 3, <SEP> primary <SEP> infantile))
<tb> <Tb>
<tb> CHEK1 <SEP> = <SEP> CHK1 <SEP> (Checkpoint <SEP> peer) <SEP> Hs <SEP> 20295
<tb> CKS1 <SEP> (CDC28 <SEP> protein <SEP> kinase <SEP> 1) <SEP> Hs. <SEP> 334883
<tb> CLU <SEP> = <SEP> TRPM-2 <SEP> (Clusterin <SEP> (complement <SEP> Iysis <SEP> inhibitor, <SEP> SP-40, <SEA> sulfate <SEP> Hs. <SEP> 75106
<tb> glycoprotein <SEP> 2, <SEQ> testosterone-repressed <SEP> prostate <SEP> message <SEP> 2, <SEP> apolipoprotein
<tb> J
<tb> COL3A1 <SEP> (Collagen, <SEP> type <SEP> III, <SEP> alpha <SEP> 1) <SEP> Hs. <SEP> 119571
<tb> COL4A2 <SEP> (Collagen, <SEP> type <SEP> IV, <SEP> alpha <SEP> 2) <SEP> Hs. <SEP> 75617
<tb> COL4A3 <SEP> (Collagen, <SEP> type <SEP> IV, <SEP> alpha <SEP> 3) <SEP> Hs. <SEP> 530
<tb> COL4A5 <SEP> (Collagen, <SEP> type <SEP> IV, <SEP> alpha <SEP> 5) <SEP> Hs. <SEP> 169825
<tb> COL4A6 <SEP> (Collagen, <SEP> type <SEP> IV, <SEP> alpha <SEP> 6) <SEP> Hs. <SEP> 408
<tb> COX4 <SEP> (Cytochrome <SEP> c <SEP> oxidase <SEP> subunit <SEP> IV) <SEP> Hs. <SEP> 347969
<tb> CRA <SEP> = <SEP> Cisplatin <SEP> resistance <SEP> associated <SEP> Hs. <SEP> 166066
<tb> CRABP2 <SEP> (Cellular <SEP> retinoic <SEP> acid-binding <SEP> protein <SEP> 2) <SEP> Hs. <SEP> 183650
<tb> CRADD <SEP> (CASP2 <SEP> and <SEP> RIPK1 <SEP> domain <SEP> containing <SEP> adaptor <SEP> with <SEP> death <SEP> domain) <SEP> Hs. <SEP> 155566
<tb> CRMP1 <SEP> (Collapsin <SEP> response <SEP> mediator <SEP> protein <SEP> 1) <SEP> Hs. <SEP> 155392
<tb> CRR9P <SEP> (Cisplatin <SEP> resistance <SEP> related <SEP> protein) <SEP> Hs. <SEP> 323769
<tb> CSDA <SEP> (Cold <SEP> Shock <SEP> domain <SEP> Protein <SEP> A) <SEP> Hs. <SEP> 1139
<tb> CSF1 <SEP> R <SEP> (Co) <SEP> ony <SEP> stimulating <SEP> factor <SEP> 1 <SEP> receptor) <SEP> Hs. <SEP> 174142
<tb> CYP1A1 <SEP> (Cytochrome <SEP> P450, <SEQ> Subfamity <SEP>! SEP> (aromatic compound-inducible), <SEP> Hs. <SEP> 72912
<tb> polypeptide <SEP> 1)
<tb> CYP1B1 <SEP> (Cytochrome <SEP> P450, <SE>> subfamily <SEP> I <SEP> (dioxin-inducible), <SEP> polypeptide <SEP> 1 <SEP> Hs. <SEP> 154654
<tb> (infant glaucoma <SEP> 3, <SEP> primary <SEP>))
<Tb>

<Desc/Clms Page number 49> <Desc / Clms Page number 49>

Figure img00490001
Figure img00490001

<tb>
<tb> CYP19 <SEP> (Aromatase) <SEP> Hs. <SEP> 79946
<tb> DAD1 <SEP> (Defender <SEP> against <SEP> ce <SEP> ! <SEP> ! <SEP> death <SEP> 1) <SEP> Hs. <SEP> 82890
<tb> DDB1 <SEP> (Damage-specific <SEP> DNA <SEP> bind <SEP> ! <SEP> ng <SEP> protein <SEP> 1 <SEP> (127kD)) <SEP> Hs. <SEP> 108327
<tb> DDB2 <SEP> (Damage-specific <SEP> DNA <SEP> binding <SEP> protein <SEP> 2 <SEP> (48kD)) <SEP> Hs. <SEP> 77602
<tb> DDIT3 <SEP> = <SEP> GADD153 <SEP> (DNA-damage-inducible <SEP> transcript <SEP> 3) <SEP> Hs. <SEP> 337761
<tb> DDR <SEP> 1 <SEP> (Discoidin <SEP> domain <SEP> receptor <SEP> family, <SEP> member <SEP> 1) <SEP> Hs. <SEP> 75562
<tb> DFNA5 <SEP> (Deafness, <SEP> autosomal <SEP> dominant <SEP> 5) <SEP> Hs. <SEP> 13530
<tb> DHFR <SEP> (Dihydrofolate <SEP> reductase) <SEP> Hs. <SEP> 83765
<tb> DIA4 <SEP> = <SEP> DT-diaphorase <SEP> (Diaphorase <SEP> (NADH/NADPH) <SEP> (cytochrome <SEP> b-5 <SEP> Hs. <SEP> 80706
<tb> reductase))
<tb> DSP <SEP> (Desmoplakin <SEP> (DPI, <SEP> DPII)) <SEP> Hs. <SEP> 74316
<tb> DUSP1 <SEP> = <SEP> CL100/MKP-1 <SEP> (Dual <SEP> specificity <SEP> phosphatase <SEP> 1) <SEP> Hs. <SEP> 171695
<tb> DUSP8 <SEP> = <SEP> HVH-5 <SEP> (Dual <SEP> specificity <SEP> phosphatase <SEP> 8) <SEP> Hs. <SEP> 41688
<tb> ECGF1 <SEP> (Endothelial <SEP> cell <SEP> growth <SEP> factor <SEP> 1 <SEP> (platelet-derived)) <SEP> Hs. <SEP> 73946
<tb> EEF1A1 <SEP> (Eukaryotic <SEP> translation <SEP> elongation <SEP> factor <SEP> 1 <SEP> alpha <SEP> 1) <SEP> Hs. <SEP> 181165
<tb> EGF <SEP> (Epidermal <SEP> growth <SEP> factor) <SEP> Hs. <SEP> 2230
<tb> EGFR <SEP> (Epidermal <SEP> growth <SEP> factor <SEP> receptor <SEP> (avian <SEP> erythroblastic <SEP> leukemia <SEP> (v- <SEP> Hs. <SEP> 77432
<tb> erb-b) <SEP> oncogene <SEP> homolog))
<tb> ELK1 <SEP> (Member <SEP> of <SEP> ETS <SEP> oncogene <SEP> family) <SEP> Hs. <SEP> 181128
<tb> EN01 <SEP> (Enolase <SEP> 1, <SEP> alpha) <SEP> Hs. <SEP> 254105
<tb> EPAS1 <SEP> = <SEP> HIF <SEP> 2 <SEP> alpha <SEP> (Endothelial <SEP> PAS <SEP> domain <SEP> protein <SEP> 1) <SEP> Hs. <SEP> 8136
<tb> <Tb>
<tb> CYP19 <SEP> (Aromatase) <SEP> Hs. <SEP> 79946
<tb> DAD1 <SEP> (Defender <SEP> against <SEP> this <SEP>! <SEP>! <SEP> death <SEP> 1) <SEP> Hs. <SEP> 82890
<tb> DDB1 <SEP> (Damage-specific <SEP> DNA <SEP> bind <SEP>! <SEP> ng <SEP> protein <SEP> 1 <SEP> (127kD)) <SEP> Hs. <SEP> 108327
<tb> DDB2 <SEP> (Damage-specific <SEP> DNA <SEP> binding <SEP> protein <SEP> 2 <SEP> (48kD)) <SEP> Hs. <SEP> 77602
<tb> DDIT3 <SEP> = <SEP> GADD153 <SEP> (DNA-damage-inducible <SEP> transcript <SEP> 3) <SEP> Hs. <SEP> 337761
<tb> DDR <SEP> 1 <SEP> (Discoidin <SEP> domain <SEP> Receiver <SEP> family, <SEP> member <SEP> 1) <SEP> Hs. <SEP> 75562
<tb> DFNA5 <SEP> (Deafness, <SE> autosomal <SEP> dominant <SEP> 5) <SEP> Hs. <SEP> 13530
<tb> DHFR <SEP> (Dihydrofolate <SEP> reductase) <SEP> Hs. <SEP> 83765
<tb> DIA4 <SEP> = <SEP> DT-diaphorase <SEP> (Diaphorase <SEP> (NADH / NADPH) <SEP> (cytochrome <SEP> b-5 <SEP> Hs. <SEP> 80706
<tb> reductase))
<tb> DSP <SEP> (Desmoplakin <SEP> (DPI, <SEP> DPII)) <SEP> Hs. <SEP> 74316
<tb> DUSP1 <SEP> = <SEP> CL100 / MKP-1 <SEP> (Dual <SEP> specificity <SEP> phosphatase <SEP> 1) <SEP> Hs. <SEP> 171695
<tb> DUSP8 <SEP> = <SEP> HVH-5 <SEP> (Dual <SEP> specificity <SEP> phosphatase <SEP> 8) <SEP> Hs. <SEP> 41688
<tb> ECGF1 <SEP> (Endothelial <SEP> cell <SEP> growth <SEP> factor <SEP> 1 <SEP> (platelet-derived)) <SEP> Hs. <SEP> 73946
<tb> EEF1A1 <SEP> (Eukaryotic <SEP> translation <SEP> elongation <SEP> factor <SEP> 1 <SEP> alpha <SEP> 1) <SEP> Hs. <SEP> 181165
<tb> EGF <SEP> (Epidermal <SEP> growth <SEP> factor) <SEP> Hs. <SEP> 2230
<tb> EGFR <SEP> (Epidermal <SEP> growth <SEP> factor <SEP> receptor <SEP> (avian <SEP> erythroblastic <SEP> leukemia <SEP> (v- <SEP> Hs. <SEP> 77432
<tb> erb-b) <SEP> oncogene <SEP> homolog))
<tb> ELK1 <SEP> (Member <SEP> of <SEP> ETS <SEP> oncogene <SEP> family) <SEP> Hs. <SEP> 181128
<tb> EN01 <SEP> (Enolase <SEP> 1, <SEP> alpha) <SEP> Hs. <SEP> 254105
<tb> EPAS1 <SEP> = <SEP> HIF <SEP> 2 <SEP> alpha <SEP> (Endothelial <SEP> NOT <SEP> domain <SEP> protein <SEP> 1) <SEP> Hs. <SEP> 8136
<Tb>

<Desc/Clms Page number 50> <Desc / Clms Page number 50>

Figure img00500001
Figure img00500001

<tb>
<tb> EPHX1 <SEP> (Epoxide <SEP> hydrolase <SEP> 1, <SEP> microsomal <SEP> (xenobiotic)) <SEP> Hs. <SEP> 89649
<tb> ERBB2 <SEP> = <SEP> HER-2 <SEP> (v-erb-b2 <SEP> avian <SEP> erythroblastic <SEP> leukemia <SEP> viral <SEP> oncogene <SEP> Hs. <SEP> 323910
<tb> homolog <SEP> 2)
<tb> homolog <SEP> 2)
<tb> ERBB3 <SEP> (v-erb-b2 <SEP> avian <SEP> erythrobalstic <SEP> leukemia <SEP> viral <SEP> oncogene <SEP> homolog <SEP> 3) <SEP> Hs. <SEP> 199067
<tb> ERBB4 <SEP> = <SEP> (v-erb-b2 <SEP> avian <SEP> erythroblastic <SEP> leukemia <SEP> viral <SEP> oncogene <SEP> homolog <SEP> 4) <SEP> Hs. <SEP> 1939
<tb> ERCC1 <SEP> (Excision <SEP> repair <SEP> cross-complementing <SEP> rodent <SEP> repair <SEP> deficiency, <SEP> Hs. <SEP> 59544
<tb> complementation <SEP> group <SEP> 1)
<tb> ERCC2 <SEP> = <SEP> XPD <SEP> (Excision <SEP> repair <SEP> cross-complementing <SEP> rodent <SEP> repair <SEP> Hs. <SEP> 99987
<tb> deficiency, <SEP> complementation <SEP> group <SEP> 2)
<tb> ERCC3 <SEP> = <SEP> XPB <SEP> (Excision <SEP> repair <SEP> cross-complementing <SEP> rodent <SEP> repair <SEP> Hs. <SEP> 77929
<tb> deficiency, <SEP> complementation <SEP> group <SEP> 3)
<tb> ERCC4 <SEP> = <SEP> XPF <SEP> (Excision <SEP> repair <SEP> cross-complementing <SEP> rodent <SEP> repair <SEP> Hs. <SEP> 89296
<tb> deficiency, <SEP> complementation <SEP> group <SEP> 4)
<tb> ERCC5 <SEP> = <SEP> XPGC <SEP> (Excision <SEP> repair <SEP> cross-complementing <SEP> rodent <SEP> repair <SEP> Hs. <SEP> 48576
<tb> deficiency, <SEP> complementation <SEP> group <SEP> 5)
<tb> ERCC6 <SEP> (Excision <SEP> repair <SEP> cross-complementing <SEP> rodent <SEP> repair <SEP> deficiency, <SEP> Hs. <SEP> 99924
<tb> complementation <SEP> group <SEP> 6)
<tb> ESR1 <SEP> (Estrogen <SEP> receptor <SEP> 1 <SEP> (alpha)) <SEP> Hs. <SEP> 1657
<tb> ESR2 <SEP> (Estrogen <SEP> receptor <SEP> 2 <SEP> (beta)) <SEP> Hs. <SEP> 103504
<tb> FDFT1 <SEP> (Farnesyl <SEP> transferase <SEP> 1) <SEP> Hs. <SEP> 48876
<tb> FGF1 <SEP> (Fibroblast <SEP> growth <SEP> factor <SEP> (acidic)) <SEP> Hs. <SEP> 75297
<tb> FGF2 <SEP> (Fibroblast <SEP> growth <SEP> factor <SEP> (basic)) <SEP> Hs. <SEP> 284244
<tb> FGFR1 <SEP> (Fibroblast <SEP> growth <SEP> factor <SEP> receptor <SEP> 1) <SEP> Hs. <SEP> 748
<tb> <Tb>
<tb> EPHX1 <SEP> (Epoxide <SEP> hydrolase <SEP> 1, <SEP> microsomal <SEP> (xenobiotic)) <SEP> Hs. <SEP> 89649
<tb> ERBB2 <SEP> = <SEP> HER-2 <SEP> (v-erb-b2 <SEP> avian <SEP> erythroblastic <SEP> leukemia <SEP> viral <SEP> oncogene <SEP> Hs. <SEP > 323910
<tb> peer <SEP> 2)
<tb> peer <SEP> 2)
<tb> ERBB3 <SEP> (v-erb-b2 <SEP> avian <SEP> erythrobalstic <SEP> leukemia <SEP> viral <SEP> oncogene <SEP> homolog <SEP> 3) <SEP> Hs. <SEP> 199067
<tb> ERBB4 <SEP> = <SEP> (v-erb-b2 <SEP> avian <SEP> erythroblastic <SEP> leukemia <SEP> viral <SEP> oncogene <SEP> homolog <SEP> 4) <SEP> Hs . <SEP> 1939
<tb> ERCC1 <SEP> (Excision <SEP> repair <SEP> cross-complementing <SEP> repair <SEP> repair <SEP> deficiency, <SEQ> Hs. <SEP> 59544
<tb> complementation <SEP> group <SEP> 1)
<tb> ERCC2 <SEP> = <SEP> XPD <SEP> (Excision <SEP> repair <SEP> cross-complementing <SEP> repair <SEP> repair <SEP> Hs. <SEP> 99987
<tb> deficiency, <SEP> complementation <SEP> group <SEP> 2)
<tb> ERCC3 <SEP> = <SEP> XPB <SEP> (Excision <SEP> repair <SEP> cross-complementing <SEP> repair <SEP> repair <SEP> Hs. <SEP> 77929
<tb> deficiency, <SEP> complementation <SEP> group <SEP> 3)
<tb> ERCC4 <SEP> = <SEP> XPF <SEP> (Excision <SEP> repair <SEP> cross-complementing <SEP> repair <SEP> repair <SEP> Hs. <SEP> 89296
<tb> deficiency, <SEP> complementation <SEP> group <SEP> 4)
<tb> ERCC5 <SEP> = <SEP> XPGC <SEP> (Excision <SEP> repair <SEP> cross-complementing <SEP> repair <SEP> repair <SEP> Hs. <SEP> 48576
<tb> deficiency, <SEP> complementation <SEP> group <SEP> 5)
<tb> ERCC6 <SEP> (Excision <SEP> repair <SEP> cross-complementing <SEP> repair <SEP> repair <SEP> deficiency, <SEP> Hs. <SEP> 99924
<tb> complementation <SEP> group <SEP> 6)
<tb> ESR1 <SEP> (Estrogen <SEP> receptor <SEP> 1 <SEP> (alpha)) <SEP> Hs. <SEP> 1657
<tb> ESR2 <SEP> (Estrogen <SEP> receptor <SEP> 2 <SEP> (beta)) <SEP> Hs. <SEP> 103504
<tb> FDFT1 <SEP> (Farnesyl <SEP> transferase <SEP> 1) <SEP> Hs. <SEP> 48876
<tb> FGF1 <SEP> (Fibroblast <SEP> growth <SEP> factor <SEP> (acidic)) <SEP> Hs. <SEP> 75297
<tb> FGF2 <SEP> (Fibroblast <SEP> growth <SEP> factor <SEP> (basic)) <SEP> Hs. <SEP> 284244
<tb> FGFR1 <SEP> (Fibroblast <SEP> growth <SEP> factor <SEP> receptor <SEP> 1) <SEP> Hs. <SEP> 748
<Tb>

<Desc/Clms Page number 51> <Desc / Clms Page number 51>

Figure img00510001
Figure img00510001

<tb>
<tb> FGFR2 <SEP> (Fibrobiast <SEP> growth <SEP> factor <SEP> receptor <SEP> 2) <SEP> Hs. <SEP> 278581
<tb> FGFR4 <SEP> (Fibroblast <SEP> growth <SEP> factor <SEP> receptor <SEP> 4) <SEP> Hs. <SEP> 165950
<tb> FKBPL <SEP> = <SEP> DIR1 <SEP> (FK506-binding <SEP> protein <SEP> like) <SEP> Hs. <SEP> 99134
<tb> FL <SEP> T1 <SEP> (fms-related <SEP> tyrosine <SEP> kinase <SEP> 1 <SEP> (vascular <SEP> endothelial <SEP> growth <SEP> factor <SEP> Hs. <SEP> 138671
<tb> vascular <SEP> permeability <SEP> factor <SEP> receptor))
<tb> FN1 <SEP> (Fibronectin <SEP> 1) <SEP> Hs. <SEP> 287820
<tb> FOLR1 <SEP> = <SEP> Folate <SEP> binding <SEP> protein <SEP> alpha <SEP> (Folate <SEP> receptor <SEP> 1 <SEP> (adult)) <SEP> Hs. <SEP> 73769
<tb> FOS <SEP> = <SEP> c-fos <SEP> (v-fos <SEP> FBJ <SEP> murine <SEP> osteosarcoma <SEP> viral <SEP> oncogene <SEP> homolog) <SEP> Hs. <SEP> 25647
<tb> G6PD <SEP> (Glucose-6-phosphate <SEP> dehydrogenase) <SEP> Hs. <SEP> 80206
<tb> GADD45A <SEP> (Growth <SEP> arrest <SEP> and <SEP> DNA-damage-inducible, <SEP> alpha) <SEP> Hs. <SEP> 80409
<tb> GAPD <SEP> (Glyceraldehyde-3-phosphate <SEP> dehydrogenase) <SEP> Hs. <SEP> 169476
<tb> GCLC <SEP> (Glutamate-cysteine <SEP> ligase, <SEP> catalytic <SEP> subunit) <SEP> Hs. <SEP> 151393
<tb> Go) <SEP> 1 <SEP> (GDP <SEP> dissociation <SEP> inhibitor <SEP> 1) <SEP> Hs. <SEP> 74576
<tb> GGH <SEP> (Gamma-glutamyl <SEP> hydrolase <SEP> (conjugase, <SEP> folylpolygammaglutamyl <SEP> Hs. <SEP> 78619
<tb> hydrolase))
<tb> GGT1 <SEP> (Gamma-glutamyltransferase <SEP> 1) <SEP> Hs. <SEP> 284380
<tb> GGT2 <SEP> (Gamma-glutamyltransferase <SEP> 2) <SEP> Hs. <SEP> 289098
<tb> GLO1 <SEP> (Glyoxalase <SEP> I) <SEP> Hs. <SEP> 75207
<tb> GM2A <SEP> (GM2 <SEP> ganglioside <SEP> activator <SEP> protein) <SEP> Hs. <SEP> 289082
<tb> GNAS1 <SEP> (Guanine <SEP> nucleotide <SEP> binding <SEP> protein <SEP> (G <SEP> protein), <SEP> alpha <SEP> stimulating <SEP> Hs. <SEP> 273385
<tb> activity <SEP> polypeptide <SEP> 1)
<tb> <Tb>
<tb> FGFR2 <SEP> (Fibrobiast <SEP> growth <SEP> factor <SEP> receptor <SEP> 2) <SEP> Hs. <SEP> 278581
<tb> FGFR4 <SEP> (Fibroblast <SEP> growth <SEP> factor <SEP> receptor <SEP> 4) <SEP> Hs. <SEP> 165950
<tb> FKBPL <SEP> = <SEP> DIR1 <SEP> (FK506-binding <SEP> protein <SEP> like) <SEP> Hs. <SEP> 99134
<tb> FL <SEP> T1 <SEP> (fms-related <SEP> tyrosine <SEP> kinase <SEP> 1 <SEP> (vascular <SEP> endothelial <SEP> growth <SEP> factor <SEP> Hs. <SEP> 138671
<tb> vascular <SEP> permeability <SEP> factor <SEP> receptor))
<tb> FN1 <SEP> (Fibronectin <SEP> 1) <SEP> Hs. <SEP> 287820
<tb> FOLR1 <SEP> = <SEP> Folate <SEP> binding <SEP> protein <SEP> alpha <SEP> (Folate <SEP> receptor <SEP> 1 <SEP> (adult)) <SEP> Hs. <SEP> 73769
<tb> FOS <SEP> = <SEP> c-fos <SEP> (v-fos <SEP> FBJ <SEP> murine <SEP> osteosarcoma <SEP> viral <SEP> oncogene <SEP> homolog) <SEP> Hs . <SEP> 25647
<tb> G6PD <SEP> (Glucose-6-phosphate <SEP> dehydrogenase) <SEP> Hs. <SEP> 80206
<tb> GADD45A <SEP> (Growth <SEP> arrest <SEP> and <SEP> DNA-damage-inducible, <SEP> alpha) <SEP> Hs. <SEP> 80409
<tb> GAPD <SEP> (Glyceraldehyde-3-phosphate <SEP> dehydrogenase) <SEP> Hs. <SEP> 169476
<tb> GCLC <SEP> (Glutamate-Cysteine <SEP> Ligase, <SEP> Catalyst <SEP> Subunit) <SEP> Hs. <SEP> 151393
<tb> Go) <SEP> 1 <SEP> (GDP <SEP> dissociation <SEP> inhibitor <SEP> 1) <SEP> Hs. <SEP> 74576
<tb> GGH <SEP> (Gamma-glutamyl <SEP> hydrolase <SEP> (conjugase, <SEP> folylpolygammaglutamyl <SEP> Hs. <SEP> 78619
<tb> hydrolase))
<tb> GGT1 <SEP> (Gamma-glutamyltransferase <SEP> 1) <SEP> Hs. <SEP> 284380
<tb> GGT2 <SEP> (Gamma-glutamyltransferase <SEP> 2) <SEP> Hs. <SEP> 289098
<tb> GLO1 <SEP> (Glyoxalase <SEP> I) <SEP> Hs. <SEP> 75207
<tb> GM2A <SEP> (GM2 <SEP> ganglioside <SEP> activator <SEP> protein) <SEP> Hs. <SEP> 289082
<tb> GNAS1 <SEP> (Guanine <SEP> nucleotide <SEP> binding <SEQ> protein <SEP> (G <SEP> protein), <SEP> alpha <SEP> stimulating <SEP> Hs. <SEP> 273385
<tb> activity <SEP> polypeptide <SEP> 1)
<Tb>

<Desc/Clms Page number 52> <Desc / Clms Page number 52>

Figure img00520001
Figure img00520001

<tb>
<tb> GPX1 <SEP> (Glutathione <SEP> peroxidase <SEP> 1) <SEP> Hs. <SEP> 76686
<tb> GRN <SEP> (Granulin) <SEP> Hs. <SEP> 180577
<tb> GSS <SEP> (Glutathione <SEP> synthetase) <SEP> Hs. <SEP> 82327
<tb> GST <SEP> A <SEP> 1 <SEP> (Glutathlone <SEP> S-transferase <SEP> A1) <SEP> Nom-001320
<tb> GSTA2 <SEP> (Glutathione <SEP> S-transferase <SEP> A2) <SEP> Hs. <SEP> 89552
<tb> GSTA3 <SEP> (Giutathione <SEP> S-transferase <SEP> A3) <SEP> Hs. <SEP> 102484
<tb> GSTA4 <SEP> (Glutathione <SEP> S-transferase <SEP> A4) <SEP> Hs. <SEP> 169907
<tb> GSTM1 <SEP> (Glutathione <SEP> S-transferase <SEP> M1) <SEP> Hs. <SEP> 324730
<tb> GSTP1 <SEP> (Glutathione <SEP> S-transferase <SEP> pi) <SEP> Hs. <SEP> 226795
<tb> HDAC1 <SEP> (Histone <SEP> deacetylase <SEP> 1) <SEP> Hs. <SEP> 88556
<tb> HDAC2 <SEP> (Histone <SEP> deacetylase <SEP> 2) <SEP> Hs. <SEP> 3352
<tb> HGF <SEP> (Hepatocyte <SEP> growth <SEP> factor <SEP> (hepapoietin, <SEP> scatter <SEP> factor) <SEP> ) <SEP> Hs. <SEP> 809
<tb> HIF1 <SEP> A <SEP> (Hvpoxia-inducible <SEP> factor <SEP> 1, <SEP> alpha <SEP> subunit) <SEP> Hs. <SEP> 197540
<tb> HMG1 <SEP> (High-mobility <SEP> group <SEP> (nonhistone <SEP> chromosomal) <SEP> protein <SEP> 1) <SEP> Hs. <SEP> 337757
<tb> HRAS <SEP> (v-Ha-ras <SEP> Harvey <SEP> rat <SEP> sarcoma <SEP> viral <SEP> oncogene <SEP> homolog) <SEP> Hs. <SEP> 37003
<tb> HSPA2 <SEP> = <SEP> HS72 <SEP> (Heat <SEP> shock <SEP> 70kD <SEP> protein <SEP> 2) <SEP> Hs. <SEP> 75452
<tb> HSPA4 <SEP> = <SEP> HSP70 <SEP> (Heat <SEP> shock <SEP> 70kD <SEP> protein <SEP> 4) <SEP> Hs. <SEP> 90093
<tb> HSPA5 <SEP> = <SEP> GRP78 <SEP> (Heat <SEP> shock <SEP> 70kD <SEP> protein <SEP> 5 <SEP> (glucose-regulated <SEP> protein, <SEP> Hs. <SEP> 75410
<tb> 78kD))
<tb> HSPA8 <SEP> = <SEP> HSC70 <SEP> (Heat <SEP> shock <SEP> 70kDa <SEP> protein <SEP> 8) <SEP> Hs. <SEP> 180414
<tb> HSPB1 <SEP> = <SEP> HSP27 <SEP> (Heat <SEP> shock <SEP> 27kD <SEP> protein <SEP> 1) <SEP> Hs. <SEP> 76067
<tb> <Tb>
<tb> GPX1 <SEP> (Glutathione <SEP> peroxidase <SEP> 1) <SEP> Hs. <SEP> 76686
<tb> GRN <SEP> (Granulin) <SEP> Hs. <SEP> 180577
<tb> GSS <SEP> (Glutathione <SEP> synthetase) <SEP> Hs. <SEP> 82327
<tb> GST <SEP> A <SEP> 1 <SEP> (Glutathlon <SEP> S-transferase <SEP> A1) <SEP> Name-001320
<tb> GSTA2 <SEP> (Glutathione <SEP> S-transferase <SEP> A2) <SEP> Hs. <SEP> 89552
<tb> GSTA3 <SEP> (Giutathione <SEP> S-transferase <SEP> A3) <SEP> Hs. <SEP> 102484
<tb> GSTA4 <SEP> (Glutathione <SEP> S-transferase <SEP> A4) <SEP> Hs. <SEP> 169907
<tb> GSTM1 <SEP> (Glutathione <SEP> S-transferase <SEP> M1) <SEP> Hs. <SEP> 324730
<tb> GSTP1 <SEP> (Glutathione <SEP> S-transferase <SEP> pi) <SEP> Hs. <SEP> 226795
<tb> HDAC1 <SEP> (Histone <SEP> deacetylase <SEP> 1) <SEP> Hs. <SEP> 88556
<tb> HDAC2 <SEP> (Histone <SEP> deacetylase <SEP> 2) <SEP> Hs. <SEP> 3352
<tb> HGF <SEP> (Hepatocyte <SEP> growth <SEP> factor <SEP> (hepapoietin, <SEP> scatter <SEP> factor) <SEP>) <SEP> Hs. <SEP> 809
<tb> HIF1 <SEP> A <SEP> (Hvpoxia-inducible <SEP> factor <SEP> 1, <SEP> alpha <SEP> subunit) <SEP> Hs. <SEP> 197540
<tb> HMG1 <SEP> (High-mobility <SEP> group <SEP> (nonhistone <SEP> chromosomal) <SEP> protein <SEP> 1) <SEP> Hs. <SEP> 337757
<tb> HRAS <SEP> (v-Ha-ras <SEP> Harvey <SEP> rat <SEP> sarcoma <SEP> viral <SEP> oncogene <SEP> homolog) <SEP> Hs. <SEP> 37003
<tb> HSPA2 <SEP> = <SEP> HS72 <SEP> (Heat <SEP> Shock <SEP> 70kD <SEP> Protein <SEP> 2) <SEP> Hs. <SEP> 75452
<tb> HSPA4 <SEP> = <SEP> HSP70 <SEP> (Heat <SEP> Shock <SEP> 70kD <SEP> Protein <SEP> 4) <SEP> Hs. <SEP> 90093
<tb> HSPA5 <SEP> = <SEP> GRP78 <SEP> (Heat <SEP> Shock <SEP> 70kD <SEP> Protein <SEP> 5 <SEP> (glucose-regulated <SEP> protein, <SEP> Hs. <SEP> 75410
<tb> 78kD))
<tb> HSPA8 <SEP> = <SEP> HSC70 <SEP> (Heat <SEP> Shock <SEP> 70kDa <SEP> Protein <SEP> 8) <SEP> Hs. <SEP> 180414
<tb> HSPB1 <SEP> = <SEP> HSP27 <SEP> (Heat <SEP> Shock <SEP> 27kD <SEP> Protein <SEP> 1) <SEP> Hs. <SEP> 76067
<Tb>

<Desc/Clms Page number 53> <Desc / Clms Page number 53>

Figure img00530001
Figure img00530001

<tb>
<tb> HSPCB <SEP> = <SEP> HSP90beta <SEP> (Heat <SEP> shock <SEP> 90kD <SEP> protein <SEP> 1, <SEP> beta) <SEP> Hs. <SEP> 74335
<tb> HSPD1 <SEP> = <SEP> HSP60 <SEP> (Heat <SEP> shock <SEP> 60kD <SEP> protein <SEP> 1 <SEP> (chaperonin)) <SEP> Hs. <SEP> 79037
<tb> ICAM1 <SEP> = <SEP> CD54 <SEP> (Intercellular <SEP> adhesion <SEP> molecule <SEP> 1, <SEP> human <SEP> rhinovirus <SEP> Hs. <SEP> 168383
<tb> receptor)
<tb> IGF1 <SEP> (Insulin <SEP> growth <SEP> factor <SEP> 1 <SEP> (somatomedin <SEP> c)) <SEP> Hs. <SEP> 85112
<tb> IGF2 <SEP> = <SEP> (Insulin <SEP> growth <SEP> factor <SEP> 2 <SEP> (somatomedin <SEP> a)) <SEP> Hs. <SEP> 251664
<tb> IGF1R <SEP> (Insulin <SEP> growth <SEP> factor <SEP> 1 <SEP> receptor) <SEP> Hs. <SEP> 239176
<tb> IGFBP1 <SEP> (Insulin <SEP> growth <SEP> factor <SEP> binding <SEP> protein <SEP> 1) <SEP> Hs. <SEP> 102122
<tb> IGFBP3 <SEP> (Insulin <SEP> growth <SEP> factor <SEP> binding <SEP> protein <SEP> 3) <SEP> Hs. <SEP> 77326
<tb> IGFBP4 <SEP> (Insulin <SEP> growth <SEP> factor <SEP> binding <SEP> protein <SEP> 4) <SEP> Hs. <SEP> 1516
<tb> IL1A <SEP> (Interleukin <SEP> 1, <SEP> alpha) <SEP> Hs. <SEP> 1722
<tb> IL1B <SEP> (Interleukin <SEP> 1, <SEP> beta) <SEP> Hs. <SEP> 126256
<tb> ! <SEP> L6 <SEP> (hterteukin <SEP> 6 <SEP> (interferon, <SEP> beta <SEP> 2)) <SEP> Hs. <SEP> 93913
<tb> IL8 <SEP> (Interleukin <SEP> 8) <SEP> Hs. <SEP> 624
<tb> ISGF3G <SEP> = <SEP> IRF9 <SEP> Interferon-stimulated <SEP> transcri <SEP> tion <SEP> factor <SEP> 3, <SEP> gamma) <SEP> Hs. <SEP> 1706
<tb> ITGA2 <SEP> (Integrin, <SEP> alpha <SEP> 2 <SEP> (CD49B, <SEP> alpha <SEP> 2 <SEP> subunit <SEP> of <SEP> VLA-2 <SEP> receptor)) <SEP> Hs. <SEP> 271986
<tb> ITGA3 <SEP> (Integrin, <SEP> alpha <SEP> 3 <SEP> (antigen <SEP> CD49C, <SEP> alpha <SEP> 3 <SEP> subunit <SEP> of <SEP> VLA-3 <SEP> Hs. <SEP> 265829
<tb> receptor))
<tb> ITGA4 <SEP> (Integrin, <SEP> alpha <SEP> 4 <SEP> (antigen <SEP> CD49D, <SEP> alpha <SEP> 4 <SEP> subunit <SEP> of <SEP> VLA <SEP> z <SEP> Hs. <SEP> 40034
<tb> receptor))
<tb> ITGA6 <SEP> (integrin, <SEP> alpha <SEP> 6) <SEP> Hs. <SEP> 227730
<tb> <Tb>
<tb> HSPCB <SEP> = <SEP> HSP90beta <SEP> (Heat <SEP> shock <SEP> 90kD <SEP> protein <SEP> 1, <SEP> beta) <SEP> Hs. <SEP> 74335
<tb> HSPD1 <SEP> = <SEP> HSP60 <SEP> (Heat <SEP> shock <SEP> 60kD <SEP> protein <SEP> 1 <SEP> (chaperonin)) <SEP> Hs. <SEP> 79037
<tb> ICAM1 <SEP> = <SEP> CD54 <SEP> (Intercellular <SEP> adhesion <SEP> molecule <SEP> 1, <SEP> human <SEP> rhinovirus <SEP> Hs. <SEP> 168383
<tb> receptor)
<tb> IGF1 <SEP> (Insulin <SEP> growth <SEP> factor <SEP> 1 <SEP> (somatomedin <SEP> c)) <SEP> Hs. <SEP> 85112
<tb> IGF2 <SEP> = <SEP> (Insulin <SEP> growth <SEP> factor <SEP> 2 <SEP> (somatomedin <SEP> a)) <SEP> Hs. <SEP> 251664
<tb> IGF1R <SEP> (Insulin <SEP> growth <SEP> factor <SEP> 1 <SEP> receptor) <SEP> Hs. <SEP> 239176
<tb> IGFBP1 <SEP> (Insulin <SEP> growth <SEP> factor <SEP> binding <SEP> protein <SEP> 1) <SEP> Hs. <SEP> 102122
<tb> IGFBP3 <SEP> (Insulin <SEP> growth <SEP> factor <SEP> binding <SEP> protein <SEP> 3) <SEP> Hs. <SEP> 77326
<tb> IGFBP4 <SEP> (Insulin <SEP> growth <SEP> factor <SEP> binding <SEP> protein <SEP> 4) <SEP> Hs. <SEP> 1516
<tb> IL1A <SEP> (Interleukin <SEP> 1, <SEP> alpha) <SEP> Hs. <SEP> 1722
<tb> IL1B <SEP> (Interleukin <SEP> 1, <SEP> beta) <SEP> Hs. <SEP> 126256
<tb>! <SEP> L6 <SEP> (hterteukin <SEP> 6 <SEP> (interferon, <SEP> beta <SEP> 2)) <SEP> Hs. <SEP> 93913
<tb> IL8 <SEP> (Interleukin <SEP> 8) <SEP> Hs. <SEP> 624
<tb> ISGF3G <SEP> = <SEP> IRF9 <SEP> Interferon-stimulated <SEP> transcribed <SEP> tion <SEP> factor <SEP> 3, <SEP> gamma) <SEP> Hs. <SEP> 1706
<tb> ITGA2 <SEP> (Integrin, <SEP> alpha <SEP> 2 <SEP> (CD49B, <SEP> alpha <SEP> 2 <SEP> subunit <SEP> of <SEP> VLA-2 <SEP> receptor )) <SEP> Hs. <SEP> 271986
<tb> ITGA3 <SEP> (Integrin, <SEP> alpha <SEP> 3 <SEP> (antigen <SEP> CD49C, <SEP> alpha <SEP> 3 <SEP> subunit <SEP> of <SEP> VLA-3 <SEP> Hs. <SEP> 265829
<tb> receptor))
<tb> ITGA4 <SEP> (Integrin, <SEP> alpha <SEP> 4 <SEP> (antigen <SEP> CD49D, <SEP> alpha <SEP> 4 <SEP> subunit <SEP> of <SEP> VLA <SEP > z <SEP> Hs. <SEP> 40034
<tb> receptor))
<tb> ITGA6 <SEP> (integrin, <SEP> alpha <SEP> 6) <SEP> Hs. <SEP> 227730
<Tb>

<Desc/Clms Page number 54> <Desc / Clms Page number 54>

Figure img00540001
Figure img00540001

<tb>
<tb> ITGB1 <SEP> (Integrin, <SEP> beta <SEP> 1 <SEP> (fibronectin <SEP> receptor, <SEP> beta <SEP> polypeptide, <SEP> antigen <SEP> Hs. <SEP> 287797
<tb> CD29 <SEP> includes <SEP> MDF2, <SEP> MSK12))
<tb> ITGB3 <SEP> (Inteqrin, <SEP> beta <SEP> 3) <SEP> Hs. <SEP> 87149
<tb> JUN <SEP> = <SEP> c-jun <SEP> (v-jun <SEP> avian <SEP> sarcoma <SEP> virus <SEP> 17 <SEP> oncogene <SEP> homolog) <SEP> Hs. <SEP> 78465
<tb> K-ALPHA-1 <SEP> (Tubulin, <SEP> alpha, <SEP> ubiquitous) <SEP> Hs. <SEP> 334842
<tb> KDR <SEP> = <SEP> FLK1 <SEP> (Kinase <SEP> insert <SEP> domain <SEP> receptor <SEP> (a <SEP> type <SEP> III <SEP> receptor <SEP> tyrosine <SEP> Hs. <SEP> 12337
<tb> kinase)) <SEP> = <SEP> vegfr2
<tb> KRAS2 <SEP> (v-ki-ras2 <SEP> Kirsten <SEP> rat <SEP> sarcoma <SEP> 2 <SEP> viral <SEP> oncogene <SEP> homolog) <SEP> Hs. <SEP> 184050
<tb> KRT6A <SEP> (Keratin <SEP> 6A) <SEP> Hs. <SEP> 334309
<tb> KRT8 <SEP> (Keratin <SEP> 8) <SEP> Hs. <SEP> 242463
<tb> KRT18 <SEP> (Keratin <SEP> 18) <SEP> Hs. <SEP> 65114
<tb> KRT19 <SEP> (Keratin <SEP> 19) <SEP> Hs. <SEP> 182265
<tb> LAMA2 <SEP> (Laminin, <SEP> alpha <SEP> 2) <SEP> Hs. <SEP> 75279
<tb> LAMA3 <SEP> (Laminin, <SEP> alpha <SEP> 3) <SEP> Hs. <SEP> 83450
<tb> LIF <SEP> (Leukemia <SEP> inhibitory <SEP> factor <SEP> (cholinergic <SEP> differentiation <SEP> factor) <SEP> ) <SEP> Hs. <SEP> 2250
<tb> LMNB1 <SEP> (Lamin <SEP> B1) <SEP> Hs. <SEP> 89497
<tb> LMNB2 <SEP> (Lamin <SEP> B2) <SEP> Hs. <SEP> 334709
<tb> LSP1 <SEP> (Lymphocyte-specific <SEP> protein <SEP> 1) <SEP> Hs. <SEP> 56729
<tb> LTBP1 <SEP> (Latent <SEP> transforminq <SEP> growth <SEP> factor <SEP> beta <SEP> binding <SEP> protein <SEP> 1) <SEP> Hs. <SEP> 241257
<tb> LUC7A=CROP <SEP> (Cisplatin <SEP> resistance-associated <SEP> overexpressed) <SEP> Hs. <SEP> 3688
<tb> MAP2 <SEP> (Microtubule-associated <SEP> protein <SEP> 2) <SEP> Hs. <SEP> 167
<tb> <Tb>
<tb> ITGB1 <SEP> (Integrin, <SEP> beta <SEP> 1 <SEP> (fibronectin <SEP> receptor, <SEP> beta <SEP> polypeptide, <SEP> antigen <SEP> Hs. <SEP> 287797
<tb> CD29 <SEP> includes <SEP> MDF2, <SEP> MSK12))
<tb> ITGB3 <SEP> (Inteqrin, <SEP> beta <SEP> 3) <SEP> Hs. <SEP> 87149
<tb> JUN <SEP> = <SEP> c-jun <SEP> (v-jun <SEP> avian <SEP> sarcoma <SEP> virus <SEP> 17 <SEP> oncogene <SEP> homolog) <SEP> Hs . <SEP> 78465
<tb> K-ALPHA-1 <SEP> (Tubulin, <SEP> alpha, <SEP> ubiquitous) <SEP> Hs. <SEP> 334842
<tb> KDR <SEP> = <SEP> FLK1 <SEP> (Kinase <SEP> insert <SEP> domain <SEP> receptor <SEP> (a <SEP> type <SEP> III <SEP> receptor <SEP> tyrosine <SEP> Hs. <SEP> 12337
<tb> kinase)) <SEP> = <SEP> vegfr2
<tb> KRAS2 <SEP> (v-ki-ras2 <SEP> Kirsten <SEP> rat <SEP> sarcoma <SEP> 2 <SEP> viral <SEP> oncogene <SEP> homolog) <SEP> Hs. <SEP> 184050
<tb> KRT6A <SEP> (Keratin <SEP> 6A) <SEP> Hs. <SEP> 334309
<tb> KRT8 <SEP> (Keratin <SEP> 8) <SEP> Hs. <SEP> 242463
<tb> KRT18 <SEP> (Keratin <SEP> 18) <SEP> Hs. <SEP> 65114
<tb> KRT19 <SEP> (Keratin <SEP> 19) <SEP> Hs. <SEP> 182265
<tb> LAMA2 <SEP> (Laminin, <SEP> alpha <SEP> 2) <SEP> Hs. <SEP> 75279
<tb> LAMA3 <SEP> (Laminin, <SEP> alpha <SEP> 3) <SEP> Hs. <SEP> 83450
<tb> LIF <SEP> (Leukemia <SEP> inhibitory <SEP> factor <SEP> (cholinergic <SEP> differentiation <SEP> factor) <SEP>) <SEP> Hs. <SEP> 2250
<tb> LMNB1 <SEP> (Lamin <SEP> B1) <SEP> Hs. <SEP> 89497
<tb> LMNB2 <SEP> (Lamin <SEP> B2) <SEP> Hs. <SEP> 334709
<tb> LSP1 <SEP> (Lymphocyte-specific <SEP> protein <SEP> 1) <SEP> Hs. <SEP> 56729
<tb> LTBP1 <SEP> (Latent <SEP> transforminq <SEP> growth <SEP> factor <SEP> beta <SEP> bind <SEP> protein <SEP> 1) <SEP> Hs. <SEP> 241257
<tb> LUC7A = CROP <SEP> (Cisplatin <SEP> resistance-associated <SEP> overexpressed) <SEP> Hs. <SEP> 3688
<tb> MAP2 <SEP> (Microtubule-associated <SEP> protein <SEP> 2) <SEP> Hs. <SEP> 167
<Tb>

<Desc/Clms Page number 55> <Desc / Clms Page number 55>

Figure img00550001
Figure img00550001

<tb>
<tb> MAP2K1 <SEP> = <SEP> MEK1 <SEP> (Mitogen-activated <SEP> protein <SEP> kinase <SEP> kinase <SEP> 1) <SEP> Hs. <SEP> 3446
<tb> MAP2K2 <SEP> = <SEP> MEK2 <SEP> (Mitogen-activated <SEP> protein <SEP> kinase <SEP> kinase <SEP> 2) <SEP> Hs. <SEP> 72241
<tb> MAP3K3 <SEP> (Mitogen-activated <SEP> protein <SEP> kinase <SEP> kinase <SEP> kinase <SEP> 3) <SEP> Hs. <SEP> 29282
<tb> MAPK1 <SEP> = <SEP> ERK2 <SEP> (Mitogen-activated <SEP> protein <SEP> kinase <SEP> 1) <SEP> Hs. <SEP> 324473
<tb> MAPK3 <SEP> = <SEP> ERK1 <SEP> (Mitogen-activated <SEP> protein <SEP> kinase <SEP> 3) <SEP> Hs. <SEP> 861
<tb> MAPK8 <SEP> = <SEP> JNK1 <SEP> (Mitogen-activated <SEP> protein <SEP> kinase <SEP> 8) <SEP> Hs. <SEP> 190913
<tb> MAPK9 <SEP> = <SEP> JNK2 <SEP> (Mitogen-activated <SEP> protein <SEP> kinase <SEP> 9) <SEP> Hs. <SEP> 246857
<tb> MAPK11 <SEP> = <SEP> p38 <SEP> beta <SEP> (Mitogen-activated <SEP> protein <SEP> kinase <SEP> 11) <SEP> Hs. <SEP> 57732
<tb> MAPK12 <SEP> = <SEP> p38 <SEP> gamma <SEP> (Mitogen-activated <SEP> protein <SEP> kinase <SEP> 12) <SEP> Hs. <SEP> 55039
<tb> MAPK13 <SEP> = <SEP> p38 <SEP> delta <SEP> (Mitogen-activated <SEP> protein <SEP> kinase <SEP> 13) <SEP> Hs. <SEP> 178695
<tb> MAPK14 <SEP> = <SEP> p38 <SEP> (Mitogen-activated <SEP> protein <SEP> kinase <SEP> 14) <SEP> Hs. <SEP> 79107
<tb> MCL1 <SEP> (Myelo d <SEP> cel) <SEP> leukemia <SEP> sequence <SEP> 1, <SEP> BCL2-related) <SEP> Hs. <SEP> 86386
<tb> MDM2 <SEP> (Mouse <SEP> double <SEP> minute <SEP> 2, <SEP> human <SEP> homolog <SEP> of <SEP> p53-binding <SEP> protein) <SEP> Hs. <SEP> 170027
<tb> MGMT <SEP> (06-methylguanine-DNA <SEP> methyltransferase) <SEP> Hs. <SEP> 1384
<tb> MKI67 <SEP> (Antigen <SEP> identified <SEP> by <SEP> monoclonal <SEP> antibody <SEP> Ki-67) <SEP> Hs. <SEP> 80976
<tb> MLH1 <SEP> (mutl <SEP> homolog <SEP> 1 <SEP> (colon <SEP> cancer, <SEP> nonpolyposis <SEP> type <SEP> 2) <SEP> ) <SEP> Hs. <SEP> 57301
<tb> MMP1 <SEP> (Matrix <SEP> metalloproteinase <SEP> 1 <SEP> (interstitial <SEP> collagenase)) <SEP> Hs. <SEP> 83169
<tb> MMP2 <SEP> (Matrix <SEP> metalloproteinase <SEP> 2 <SEP> (ge) <SEP> atinase <SEP> A, <SEP> 72kD <SEP> gelatinase, <SEP> 72kD <SEP> type <SEP> Hs. <SEP> 111301
<tb> IV <SEP> collagenase))
<tb> MMP3 <SEP> (Matrix <SEP> metalloproteinase <SEP> 3 <SEP> (stromelysin <SEP> 1, <SEP> progelatinase)) <SEP> Hs. <SEP> 83326
<tb> MMP9 <SEP> (Matrix <SEP> metalloproteinase <SEP> 9 <SEP> (gelatinase <SEP> b)) <SEP> Hs. <SEP> 151738
<tb> <Tb>
<tb> MAP2K1 <SEP> = <SEQ> MEK1 <SEP> (Mitogen-activated <SEP> protein <SEP> kinase <SEP> kinase <SEP> 1) <SEP> Hs. <SEP> 3446
<tb> MAP2K2 <SEP> = <SEQ> MEK2 <SEP> (Mitogen-activated <SEP> protein <SEP> kinase <SEP> kinase <SEP> 2) <SEP> Hs. <SEP> 72241
<tb> MAP3K3 <SEP> (Mitogen-activated <SEP> protein <SEP> kinase <SEP> kinase <SEP> kinase <SEP> 3) <SEP> Hs. <SEP> 29282
<tb> MAPK1 <SEP> = <SEQ> ERK2 <SEP> (Mitogen-activated <SEP> protein <SEP> kinase <SEP> 1) <SEP> Hs. <SEP> 324473
<tb> MAPK3 <SEP> = <SEQ> ERK1 <SEP> (Mitogen-activated <SEP> protein <SEP> kinase <SEP> 3) <SEP> Hs. <SEP> 861
<tb> MAPK8 <SEP> = <SEP> JNK1 <SEP> (Mitogen-activated <SEP> protein <SEP> kinase <SEP> 8) <SEP> Hs. <SEP> 190913
<tb> MAPK9 <SEP> = <SEP> JNK2 <SEP> (Mitogen-activated <SEP> protein <SEP> kinase <SEP> 9) <SEP> Hs. <SEP> 246857
<tb> MAPK11 <SEP> = <SEP> p38 <SEP> beta <SEP> (Mitogen-activated <SEP> protein <SEP> kinase <SEP> 11) <SEP> Hs. <SEP> 57732
<tb> MAPK12 <SEP> = <SEP> p38 <SEP> gamma <SEP> (Mitogen-activated <SEP> protein <SEP> kinase <SEP> 12) <SEP> Hs. <SEP> 55039
<tb> MAPK13 <SEP> = <SEP> p38 <SEP> delta <SEP> (Mitogen-activated <SEP> protein <SEP> kinase <SEP> 13) <SEP> Hs. <SEP> 178695
<tb> MAPK14 <SEP> = <SEP> p38 <SEP> (Mitogen-activated <SEP> protein <SEP> kinase <SEP> 14) <SEP> Hs. <SEP> 79107
<tb> MCL1 <SEP> (Myelo d <SEP> cel) <SEP> leukemia <SEP> sequence <SEP> 1, <SEP> BCL2-related) <SEP> Hs. <SEP> 86386
<tb> MDM2 <SEP> (Mouse <SEP> double <SEP> minute <SEP> 2, <SEP> human <SEP> homolog <SEP> of <SEP> p53-binding <SEP> protein <SEP> Hs. <SEP> 170027
<tb> MGMT <SEP> (06-methylguanine-DNA <SEP> methyltransferase) <SEP> Hs. <SEP> 1384
<tb> MKI67 <SEP> (Antigen <SEP> identified <SEP> by <SEP> monoclonal <SEP> antibody <SEP> Ki-67) <SEP> Hs. <SEP> 80976
<tb> MLH1 <SEP> (mutl <SEP> homolog <SEP> 1 <SEP> (colon <SEP> cancer, <SEP> nonpolyposis <SEP> type <SEP> 2) <SEP>) <SEP> Hs. <SEP> 57301
<tb> MMP1 <SEP> (Matrix <SEP> metalloproteinase <SEP> 1 <SEP> (interstitial <SEP> collagenase)) <SEP> Hs. <SEP> 83169
<tb> MMP2 <SEP> (Matrix <SEP> metalloproteinase <SEP> 2 <SEP> (ge) <SEP> atinase <SEP> A, <SEP> 72kD <SEP> gelatinase, <SEP> 72kD <SEP> type <SEP> Hs. <SEP> 111301
<tb> IV <SEP> collagenase))
<tb> MMP3 <SEP> (Matrix <SEP> metalloproteinase <SEP> 3 <SEP> (stromelysin <SEP> 1, <SEP> progelatinase)) <SEP> Hs. <SEP> 83326
<tb> MMP9 <SEP> (Matrix <SEP> Metalloproteinase <SEP> 9 <SEP> (gelatinase <SEP> b)) <SEP> Hs. <SEP> 151738
<Tb>

<Desc/Clms Page number 56> <Desc / Clms Page number 56>

Figure img00560001
Figure img00560001

<tb>
<tb> MMP10 <SEP> (Matrix <SEP> metalloproteinase <SEP> 10 <SEP> (stromelysin <SEP> 2)) <SEP> Hs. <SEP> 2258
<tb> MMP11 <SEP> (Matrix <SEP> metahoproteinase <SEP> 11 <SEP> (strome) <SEP> ysin3)) <SEP> Hs. <SEP> 155324
<tb> MMP13 <SEP> (Matrix <SEP> metalloproteinase <SEP> 13 <SEP> (coffagenase <SEP> 3)) <SEP> Hs. <SEP> 2936
<tb> MMP16 <SEP> (Matrix <SEP> metalloproteinase <SEP> 16 <SEP> (membrane-inserted)) <SEP> Hs. <SEP> 90800
<tb> MSH2 <SEP> (mutS <SEP> homolog <SEP> 2 <SEP> (colon <SEP> cancer, <SEP> nonpolyposis <SEP> type <SEP> 1)) <SEP> Hs. <SEP> 78934
<tb> MSH3 <SEP> (mutS <SEP> homolog <SEP> 3) <SEP> Hs. <SEP> 42674
<tb> MSH6 <SEP> (mutS <SEP> homolog <SEP> 6) <SEP> Hs. <SEP> 3248
<tb> MSLN <SEP> (Mesothelin, <SEP> CAK1) <SEP> Hs. <SEP> 155981
<tb> MT1E <SEP> (Metallothionein <SEP> 1E <SEP> (functional)) <SEP> Hs. <SEP> 74170
<tb> MT1 <SEP> X <SEP> (Metallothionein <SEP> 1 <SEP> X) <SEP> Hs. <SEP> 278462
<tb> MT2A <SEP> Metallothionein <SEP> 2A <SEP> Hs. <SEP> 118786
<tb> MTC01 <SEP> (Cytochrome <SEP> c <SEP> oxidase <SEP> !) <SEP> NC001807
<tb> MTC02 <SEP> (Cytochrome <SEP> c <SEP> oxidase <SEP> tf) <SEP> NC001807
<tb> MTND1 <SEP> (NADH <SEP> dehydrogenase <SEP> subunit <SEP> 1 <SEP> (Complex <SEP> I)) <SEP> NC~001807
<tb> MTND2 <SEP> (NADH <SEP> dehydrogenase <SEP> subunit <SEP> 2 <SEP> (Complex <SEP> I)) <SEP> NC~001807
<tb> MTND3 <SEP> (NADH <SEP> dehydrogenase <SEP> subunit <SEP> 3 <SEP> (Complex <SEP> I)) <SEP> NC~001807
<tb> MTND4 <SEP> (NADH <SEP> dehydrogenase <SEP> subunit <SEP> 4 <SEP> (Complex <SEP> I)) <SEP> NC~001807
<tb> MTND4L <SEP> (NADH <SEP> dehydrogenase <SEP> subunit <SEP> 4L <SEP> (Complex <SEP> I)) <SEP> NC~001807
<tb> MTND5 <SEP> (NADH <SEP> dehydrogenase <SEP> subunit <SEP> 5 <SEP> (Complex <SEP> I)) <SEP> NC~001807
<tb> MTND6 <SEP> (NADH <SEP> dehydrogenase <SEP> subunit <SEP> 6 <SEP> (Complex <SEP> I)) <SEP> NC~001807
<tb> <Tb>
<tb> MMP10 <SEP> (Matrix <SEP> metalloproteinase <SEP> 10 <SEP> (stromelysin <SEP> 2)) <SEP> Hs. <SEP> 2258
<tb> MMP11 <SEP> (Matrix <SEP> metahoproteinase <SEP> 11 <SEP> (stromal) <SEP> ysin3)) <SEP> Hs. <SEP> 155324
<tb> MMP13 <SEP> (Matrix <SEP> Metalloproteinase <SEP> 13 <SEP> (coffagenase <SEP> 3)) <SEP> Hs. <SEP> 2936
<tb> MMP16 <SEP> (Matrix <SEP> Metalloproteinase <SEP> 16 <SEP> (membrane-inserted)) <SEP> Hs. <SEP> 90800
<tb> MSH2 <SEP> (mutS <SEP> homolog <SEP> 2 <SEP> (colon <SEP> cancer, <SEP> nonpolyposis <SEP> type <SEP> 1)) <SEP> Hs. <SEP> 78934
<tb> MSH3 <SEP> (mutS <SEP> homolog <SEP> 3) <SEP> Hs. <SEP> 42674
<tb> MSH6 <SEP> (mutS <SEP> homolog <SEP> 6) <SEP> Hs. <SEP> 3248
<tb> MSLN <SEP> (Mesothelin, <SEP> CAK1) <SEP> Hs. <SEP> 155981
<tb> MT1E <SEP> (Metallothionein <SEP> 1E <SEP> (functional)) <SEP> Hs. <SEP> 74170
<tb> MT1 <SEP> X <SEP> (Metallothionein <SEP> 1 <SEP> X) <SEP> Hs. <SEP> 278462
<tb> MT2A <SEP> Metallothionein <SEP> 2A <SEP> Hs. <SEP> 118786
<tb> MTC01 <SEP> (Cytochrome <SEP> c <SEP> Oxidase <SEP>!) <SEP> NC001807
<tb> MTC02 <SEP> (Cytochrome <SEP> c <SEP> Oxidase <SEP> tf) <SEP> NC001807
<tb> MTND1 <SEP> (NADH <SEP> dehydrogenase <SEP> subunit <SEP> 1 <SEP> (Complex <SEP> I)) <SEP> NC ~ 001807
<tb> MTND2 <SEP> (NADH <SEP> dehydrogenase <SEP> subunit <SEP> 2 <SEP> (Complex <SEP> I)) <SEP> NC ~ 001807
<tb> MTND3 <SEP> (NADH <SEP> dehydrogenase <SEP> subunit <SEP> 3 <SEP> (Complex <SEP> I)) <SEP> NC ~ 001807
<tb> MTND4 <SEP> (NADH <SEP> dehydrogenase <SEP> subunit <SEP> 4 <SEP> (Complex <SEP> I)) <SEP> NC ~ 001807
<tb> MTND4L <SEP> (NADH <SEP> dehydrogenase <SEP> subunit <SEP> 4L <SEP> (Complex <SEP> I)) <SEP> NC ~ 001807
<tb> MTND5 <SEP> (NADH <SEP> dehydrogenase <SEP> subunit <SEP> 5 <SEP> (Complex <SEP> I)) <SEP> NC ~ 001807
<tb> MTND6 <SEP> (NADH <SEP> dehydrogenase <SEP> subunit <SEP> 6 <SEP> (Complex <SEP> I)) <SEP> NC ~ 001807
<Tb>

<Desc/Clms Page number 57> <Desc / Clms Page number 57>

Figure img00570001
Figure img00570001

<tb>
<tb> MUC1 <SEP> (Mucin <SEP> 1) <SEP> Hs. <SEP> 89603
<tb> MUC2 <SEP> (Mucin <SEP> 2, <SEP> intestinal/tracheal) <SEP> Hs. <SEP> 315
<tb> MVP <SEP> = <SEP> LRP <SEP> (Major <SEP> vault <SEP> protein <SEP> ; <SEP> lung <SEP> resistance-related <SEP> protein) <SEP> Hs. <SEP> 80680
<tb> MYB <SEP> = <SEP> c-MYB <SEP> (v-myb <SEP> avian <SEP> myeloblastosis <SEP> viral <SEP> oncogene <SEP> homolog) <SEP> Hs. <SEP> 1334
<tb> MYBL2 <SEP> = <SEP> B-MYB <SEP> (v-myb <SEP> avian <SEP> myeloblastosis <SEP> viral <SEP> oncogene <SEP> homolog-like <SEP> 2) <SEP> Hs. <SEP> 179718
<tb> MYC <SEP> = <SEP> c-MYC <SEP> (v-myc <SEP> avian <SEP> myelocytomatosis <SEP> viral <SEP> oncogene <SEP> homolog) <SEP> Hs. <SEP> 79070
<tb> MYCN <SEP> (v-myc <SEP> avian <SEP> myelocytomatosis <SEP> viral <SEP> related <SEP> oncogene, <SEP> Hs. <SEP> 25960
<tb> neuroblastoma <SEP> derived)
<tb> MYLK <SEP> (Myosin, <SEP> light <SEP> polypeptide <SEP> kinase) <SEP> Hs. <SEP> 211582
<tb> NFKB1 <SEP> (Nuclear <SEP> factor <SEP> of <SEP> kappa <SEP> light <SEP> polypeptide <SEP> gene <SEP> enhancer <SEP> in <SEP> B-cells <SEP> 1 <SEP> Hs. <SEP> 83428
<tb> (p105))
<tb> NFKB2 <SEP> (Nuclear <SEP> factor <SEP> of <SEP> kappa <SEP> light <SEP> polypeptide <SEP> gene <SEP> enhancer <SEP> in <SEP> B-cells <SEP> 2 <SEP> Hs. <SEP> 73090
<tb> (p49/p100))
<tb> NFKBIA <SEP> = <SEP> IKBalpha <SEP> (Nuclear <SEP> factor <SEP> of <SEP> kappa <SEP> light <SEP> polypeptide <SEP> gene <SEP> Hs. <SEP> 81328
<tb> enhancer <SEP> in <SEP> B-cells <SEP> inhibitor, <SEP> alpha)
<tb> NK4 <SEP> (Natural <SEP> killer <SEP> cell <SEP> transcript <SEP> 4) <SEP> Hs. <SEP> 943
<tb> NME1 <SEP> = <SEP> nm23-H1 <SEP> (Non-metastatic <SEP> cells <SEP> 1, <SEP> protein <SEP> (NM23A) <SEP> expressed <SEP> in) <SEP> Hs. <SEP> 118638
<tb> NNMT <SEP> (Nicotinamide <SEP> N-methyltransferase) <SEP> Hs. <SEP> 76669
<tb> NRAS <SEP> (Neuroblastoma <SEP> RAS <SEP> viral <SEP> (v-ras) <SEP> oncogene <SEP> homolog) <SEP> Hs. <SEP> 260523
<tb> NRG1 <SEP> (Heregulin <SEP> alpha) <SEP> Hs. <SEP> 172816
<tb> NSEP1 <SEP> = <SEP> YB1 <SEP> (Nuclease <SEP> sensitive <SEP> element <SEP> binding <SEP> protein <SEP> 1) <SEP> Hs. <SEP> 74497
<tb> OXTR <SEP> (Oxytocin <SEP> receptor) <SEP> Hs. <SEP> 2820
<tb> <Tb>
<tb> MUC1 <SEP> (Mucin <SEP> 1) <SEP> Hs. <SEP> 89603
<tb> MUC2 <SEP> (Mucin <SEP> 2, <SEP> intestinal / tracheal) <SEP> Hs. <SEP> 315
<tb> MVP <SEP> = <SEP> LRP <SEP> (Major <SEP> vault <SEP> protein <SEP>;<SEP> lung <SEP> resistance-related <SEP> protein) <SEP> Hs. <SEP> 80680
<tb> MYB <SEP> = <SEP> c-MYB <SEP> (v-myb <SEP> avian <SEP> myeloblastosis <SEP> viral <SEP> oncogene <SEP> homolog) <SEP> Hs. <SEP> 1334
<tb> MYBL2 <SEP> = <SEP> B-MYB <SEP> (v-myb <SEP> avian <SEP> myeloblastosis <SEP> viral <SEP> oncogene <SEP> homolog-like <SEP> 2) <SEP > Hs. <SEP> 179718
<tb> MYC <SEP> = <SEP> c-MYC <SEP> (v-myc <SEP> avian <SEP> myelocytomatosis <SEP> viral <SEP> oncogene <SEP> homolog) <SEP> Hs. <SEP> 79070
<tb> MYCN <SEP> (v-myc <SEP> avian <SEP> myelocytomatosis <SEP> viral <SEP> related <SEP> oncogene, <SEP> Hs. <SEP> 25960
<tb> neuroblastoma <SEP> derived)
<tb> MYLK <SEP> (Myosin, <SEP> light <SEP> polypeptide <SEP> kinase) <SEP> Hs. <SEP> 211582
<tb> NFKB1 <SEP> (Nuclear <SEP> factor <SEP> of <SEP> kappa <SEP> light <SEP> polypeptide <SEP> gene <SEP> enhancer <SEP> in <SEP> B-cells <SEP> 1 <SEP> Hs. <SEP> 83428
<tb> (p105))
<tb> NFKB2 <SEP> (Nuclear <SEP> factor <SEP> of <SEP> kappa <SEP> light <SEP> polypeptide <SEP> gene <SEP> enhancer <SEP> in <SEP> B-cells <SEP> 2 <SEP> Hs. <SEP> 73090
<tb> (p49 / p100))
<tb> NFKBIA <SEP> = <SEP> IKBalpha <SEP> (Nuclear <SEP> factor <SEP> of <SEP> kappa <SEP> light <SEP> polypeptide <SEP> gene <SEP> Hs. <SEP> 81328
<tb> enhancer <SEP> in <SEP> B-cells <SEP> inhibitor, <SEP> alpha)
<tb> NK4 <SEP> (Natural <SEP> killer <SEP> cell <SEP> transcript <SEP> 4) <SEP> Hs. <SEP> 943
<tb> NME1 <SEP> = <SEP> nm23-H1 <SEP> (Non-metastatic <SEP> cells <SEP> 1, <SEQ> protein <SEP> (NM23A) <SEP> expressed <SEP> in) <SEP> Hs. <SEP> 118638
<tb> NNMT <SEP> (Nicotinamide <SEP> N-methyltransferase) <SEP> Hs. <SEP> 76669
<tb> NRAS <SEP> (Neuroblastoma <SEP> RAS <SEP> viral <SEP> (v-ras) <SEP> oncogene <SEP> homolog) <SEP> Hs. <SEP> 260523
<tb> NRG1 <SEP> (Heregulin <SEP> alpha) <SEP> Hs. <SEP> 172816
<tb> NSEP1 <SEP> = <SEP> YB1 <SEP> (Nuclease <SEP> sensitive <SEP> element <SEP> binding <SEP> protein <SEP> 1) <SEP> Hs. <SEP> 74497
<tb> OXTR <SEP> (Oxytocin <SEP> receptor) <SEP> Hs. <SEP> 2820
<Tb>

<Desc/Clms Page number 58> <Desc / Clms Page number 58>

Figure img00580001
Figure img00580001

<tb>
<tb> p14ARF <SEP> (Locus <SEP> INK4alpha/ARF)
<tb> PC4 <SEP> (Activated <SEP> RNA <SEP> polymerase <SEP> II <SEP> transcription <SEP> cofactor <SEP> 4) <SEP> Hs. <SEP> 74861
<tb> PCNA <SEP> (Proliferating <SEP> cell <SEP> nuclear <SEP> antigen) <SEP> Hs. <SEP> 78996
<tb> PDGFA <SEP> (Platelet-derived <SEP> growth <SEP> factor <SEP> a) <SEP> Hs. <SEP> 37040
<tb> PDGFB <SEP> (Platelet-derived <SEP> growth <SEP> factor <SEP> b) <SEP> Hs. <SEP> 1976
<tb> PES1 <SEP> Pescadillo <SEP> homolog <SEP> 1, <SEP> containing <SEP> BRCT <SEP> domain) <SEP> Hs. <SEP> 13501
<tb> PFDN4 <SEP> (Prefoldin <SEP> 4) <SEP> Hs. <SEP> 91161
<tb> PGK1 <SEP> (Phosphoglycerate <SEP> kinase <SEP> 1) <SEP> Hs. <SEP> 78771
<tb> PGR <SEP> (Progesterone <SEP> receptor) <SEP> Hs. <SEP> 2905
<tb> PHB <SEP> (Prohibitin) <SEP> Hs. <SEP> 75323
<tb> PIG3 <SEP> (Quinone <SEP> oxidoreductase <SEP> homolog) <SEP> Hs. <SEP> 50649
<tb> P) <SEP> G11 <SEP> (p53-induced <SEP> protein) <SEP> Hs. <SEP> 96908
<tb> PIK3CG <SEP> (Phosphatidylinositol-3-kinase, <SEP> catalytic <SEP> subunit, <SEP> gamma <SEP> Hs. <SEP> 32942
<tb> polypeptide)
<tb> PIK3R1 <SEP> (Phosphoinositide-3-kinase, <SEP> regulatory <SEP> subunit, <SEP> polypeptide <SEP> 1 <SEP> (p85 <SEP> Hs. <SEP> 6241
<tb> alpha))
<tb> PIK3R2 <SEP> (Phosphoinositide-3-kinase, <SEP> regulator <SEP> subunit, <SEP> polypeptide <SEP> 2 <SEP> (p85 <SEP> Hs. <SEP> 211586
<tb> beta))
<tb> PIK3R3 <SEP> (Phosphoinositide-3-kinase, <SEP> regulator <SEP> subunit, <SEP> polypeptide <SEP> 3 <SEP> (p55 <SEP> Hs. <SEP> 88051
<tb> gamma))
<tb> PLAU <SEP> (Plasminogen <SEP> activator, <SEP> urokinase) <SEP> Hs. <SEP> 77274
<tb> PLAUR <SEP> (Plasminogen <SEP> activator, <SEP> urokinase <SEP> receptor <SEP> (Upar)) <SEP> Hs. <SEP> 179657
<tb> <Tb>
<tb> p14ARF <SEP> (Locus <SEP> INK4alpha / ARF)
<tb> PC4 <SEP> (Activated <SEP> RNA <SEP> polymerase <SEP> II <SEP> transcript <SEP> cofactor <SEP> 4) <SEP> Hs. <SEP> 74861
<tb> PCNA <SEP> (Proliferating <SEP> cell <SEP> nuclear <SEP> antigen) <SEP> Hs. <SEP> 78996
<tb> PDGFA <SEP> (Platelet-derived <SEP> growth <SEP> factor <SEP> a) <SEP> Hs. <SEP> 37040
<tb> PDGFB <SEP> (Platelet-derived <SEP> growth <SEP> factor <SEP> b) <SEP> Hs. <SEP> 1976
<tb> PES1 <SEP> Pescadillo <SEP> peer <SEP> 1, <SEP> containing <SEP> BRCT <SEP> domain) <SEP> Hs. <SEP> 13501
<tb> PFDN4 <SEP> (Prefoldin <SEP> 4) <SEP> Hs. <SEP> 91161
<tb> PGK1 <SEP> (Phosphoglycerate <SEP> kinase <SEP> 1) <SEP> Hs. <SEP> 78771
<tb> PGR <SEP> (Progesterone <SEP> receptor) <SEP> Hs. <SEP> 2905
<tb> PHB <SEP> (Prohibitin) <SEP> Hs. <SEP> 75323
<tb> PIG3 <SEP> (Quinone <SEP> oxidoreductase <SEP> homolog) <SEP> Hs. <SEP> 50649
<tb> P) <SEP> G11 <SEP> (p53-induced <SEP> protein) <SEP> Hs. <SEP> 96908
<tb> PIK3CG <SEP> (Phosphatidylinositol-3-kinase, <SEP> Catalyst <SEP> Subunit, <SEP> Gamma <SEP> Hs. <SEP> 32942
<tb> polypeptide)
<tb> PIK3R1 <SEP> (Phosphoinositide-3-kinase, <SEP> regulatory <SEP> subunit, <SEP> polypeptide <SEP> 1 <SEP> (p85 <SEP> Hs. <SEP> 6241
<tb> alpha))
<tb> PIK3R2 <SEP> (Phosphoinositide-3-kinase, <SEP> regulator <SEP> subunit, <SEP> polypeptide <SEP> 2 <SEP> (p85 <SEP> Hs. <SEP> 211586
<tb> beta))
<tb> PIK3R3 <SEP> (Phosphoinositide-3-kinase, <SEP> regulator <SEP> subunit, <SEP> polypeptide <SEP> 3 <SEP> (p55 <SEP> Hs. <SEP> 88051
<tb> gamma))
<tb> PLAU <SEP> (Plasminogen <SEP> activator, <SEP> urokinase) <SEP> Hs. <SEP> 77274
<tb> PLAUR <SEP> (Plasminogen <SEP> activator, <SEP> urokinase <SEP> receptor <SEP> (Upar)) <SEP> Hs. <SEP> 179657
<Tb>

<Desc/Clms Page number 59> <Desc / Clms Page number 59>

Figure img00590001
Figure img00590001

<tb>
<tb> PLS3 <SEP> = <SEP> T-plastin <SEP> (Plastin <SEP> 3 <SEP> T <SEP> isoform) <SEP> Hs. <SEP> 4114
<tb> PLK <SEP> (Polo <SEP> (Drosophia)-like <SEP> kinase <SEP> Hs. <SEP> 77597
<tb> PMS1 <SEP> (Postmeiot <SEP> ! <SEP> c <SEP> ségrégation <SEP> increased <SEP> 1) <SEP> Hs. <SEP> 111749
<tb> PMS2 <SEP> Postmeiotic <SEP> se <SEP> re <SEP> ation <SEP> increased <SEP> 2 <SEP> Hs. <SEP> 177548
<tb> POLR2J <SEP> (Polymerase <SEP> RNA <SEP> II <SEP> polypeptide <SEP> J <SEP> (13.3kD)) <SEP> Hs. <SEP> 80475
<tb> PRAME <SEP> (Preferentially <SEP> expressed <SEP> antigen <SEP> in <SEP> melanoma) <SEP> Hs. <SEP> 30743
<tb> PRDX1 <SEP> (Peroxiredoxin <SEP> 1) <SEP> Hs. <SEP> 180909
<tb> PRDX2 <SEP> Peroxiredoxin <SEP> 2 <SEP> Hs. <SEP> 146354
<tb> PRG1 <SEP> = <SEP> Serglycin <SEP> (Proteoglycan <SEP> 1, <SEP> secretory <SEP> granule) <SEP> Hs. <SEP> 278687
<tb> PRG2 <SEP> = <SEP> BMPG <SEP> (Proteoglycan <SEP> 2, <SEP> bone <SEP> marrow <SEP> proteoglycan) <SEP> Hs. <SEP> 99962
<tb> PRKAR1 <SEP> (Protein <SEP> kinase, <SEP> cAMP-dpt, <SEP> regulatory, <SEP> type <SEP> I, <SEP> alpha <SEP> (tssue <SEP> Hs. <SEP> 183037
<tb> specific <SEP> extinguisher <SEP> 1) <SEP> )
<tb> PRKAR1B <SEP> (Protein <SEP> kinase, <SEP> cAMP-dpt, <SEP> regulatory, <SEP> type <SEP> 1, <SEP> beta) <SEP> Hs. <SEP> 1519
<tb> PRKCA <SEP> (Protein <SEP> kinase <SEP> C, <SEP> alpha) <SEP> Hs. <SEP> 169449
<tb> PRKCB1 <SEP> (Protein <SEP> kinase <SEP> C, <SEP> beta <SEP> 1) <SEP> Hs. <SEP> 77202
<tb> PRKCD <SEP> (Protein <SEP> kinase <SEP> C, <SEP> delta) <SEP> Hs. <SEP> 155342
<tb> PRKCE <SEP> (Protein <SEP> kinase <SEP> C, <SEP> epsilon) <SEP> Hs. <SEP> 211592
<tb> PRKCG <SEP> (Protein <SEP> kinase <SEP> C, <SEP> gamma) <SEP> Hs. <SEP> 2890
<tb> PRKCH <SEP> (Protein <SEP> kinase <SEP> C, <SEP> eta) <SEP> Hs. <SEP> 315366
<tb> PRKCI <SEP> (Protein <SEP> kinase <SEP> C, <SEP> iota) <SEP> Hs. <SEP> 1904
<tb> PRKCN <SEP> (Protein <SEP> kinase <SEP> C, <SEP> nu) <SEP> Hs. <SEP> 143460
<tb> <Tb>
<tb> PLS3 <SEP> = <SEP> T-plastin <SEP> (Plastin <SEP> 3 <SEP> T <SEP> isoform) <SEP> Hs. <SEP> 4114
<tb> PLK <SEP> (Polo <SEP> (Drosophia) -like <SEP> Kinase <SEP> Hs. <SEP> 77597
<tb> PMS1 <SEP> (Postmeiot <SEP>! <SEP> c <SEP> segregation <SEP> increased <SEP> 1) <SEP> Hs. <SEP> 111749
<tb> PMS2 <SEP> Postmeiotic <SEP> is <SEP> re <SEP> ation <SEP> increased <SEP> 2 <SEP> Hs. <SEP> 177548
<tb> POLR2J <SEP> (Polymerase <SEP> RNA <SEP> II <SEP> polypeptide <SEP> J <SEP> (13.3kD)) <SEP> Hs. <SEP> 80475
<tb> PRAME <SEP> (Preferentially <SEP> expressed <SEP> antigen <SEP> in <SEP> melanoma) <SEP> Hs. <SEP> 30743
<tb> PRDX1 <SEP> (Peroxiredoxin <SEP> 1) <SEP> Hs. <SEP> 180909
<tb> PRDX2 <SEP> Peroxiredoxin <SEP> 2 <SEP> Hs. <SEP> 146354
<tb> PRG1 <SEP> = <SEP> Serglycin <SEP> (Proteoglycan <SEP> 1, <SEP> secretory <SEP> granule) <SEP> Hs. <SEP> 278687
<tb> PRG2 <SEP> = <SEP> BMPG <SEP> (Proteoglycan <SEP> 2, <SEP> bone <SEP> marrow <SEP> proteoglycan) <SEP> Hs. <SEP> 99962
<tb> PRKAR1 <SEP> (Protein <SEP> kinase, <SEP> cAMP-dpt, <SEP> regulatory, <SEP> type <SEP> I, <SEP> alpha <SEP> (tssue <SEP> Hs. <SEP> 183037
<tb> specific <SEP> extinguisher <SEP> 1) <SEP>)
<tb> PRKAR1B <SEP> (Protein <SEP> kinase, <SEP> cAMP-dpt, <SEP> regulatory, <SEP> type <SEP> 1, <SEP> beta) <SEP> Hs. <SEP> 1519
<tb> PRKCA <SEP> (Protein <SEP> kinase <SEP> C, <SEP> alpha) <SEP> Hs. <SEP> 169449
<tb> PRKCB1 <SEP> (Protein <SEP> kinase <SEP> C, <SEP> beta <SEP> 1) <SEP> Hs. <SEP> 77202
<tb> PRKCD <SEP> (Protein <SEP> kinase <SEP> C, <SEP> delta) <SEP> Hs. <SEP> 155342
<tb> PRKCE <SEP> (Protein <SEP> kinase <SEP> C, <SEP> epsilon) <SEP> Hs. <SEP> 211592
<tb> PRKCG <SEP> (Protein <SEP> kinase <SEP> C, <SEP> gamma) <SEP> Hs. <SEP> 2890
<tb> PRKCH <SEP> (Protein <SEP> kinase <SEP> C, <SEP> eta) <SEP> Hs. <SEP> 315366
<tb> PRKCI <SEP> (Protein <SEP> kinase <SEP> C, <SEP> iota) <SEP> Hs. <SEP> 1904
<tb> PRKCN <SEP> (Protein <SEP> kinase <SEP> C, <SEP> nude) <SEP> Hs. <SEP> 143460
<Tb>

<Desc/Clms Page number 60> <Desc / Clms Page number 60>

Figure img00600001
Figure img00600001

<tb>
<tb> PRKCQ <SEP> (Protein <SEP> kinase <SEP> C, <SEP> theta) <SEP> Hs. <SEP> 211593
<tb> PRKCZ <SEP> (Protein <SEP> kinase <SEP> C, <SEP> zeta) <SEP> Hs. <SEP> 78793
<tb> PRKDC <SEP> = <SEP> XRCC7 <SEP> (Protein <SEP> kinase, <SEP> DNA-activated, <SEP> catalytic <SEP> polypeptide) <SEP> Hs. <SEP> 155637
<tb> PRNP <SEP> (Prion <SEP> protein <SEP> (p27-30)) <SEP> Hs. <SEP> 74621
<tb> PSMC1 <SEP> (Proteasome <SEP> (prosome, <SEP> macropain) <SEP> 26S <SEP> subunit, <SEP> ATPase, <SEP> 1) <SEP> Hs. <SEP> 4745
<tb> PSME1 <SEP> (Proteasome <SEP> (prosome, <SEP> macropain) <SEP> activator <SEP> subunit <SEP> 1, <SEP> PA28 <SEP> alpha) <SEP> Hs. <SEP> 75348
<tb> PTGES <SEP> = <SEP> PIG12 <SEP> (Prostaglandin <SEP> E <SEP> synthase) <SEP> Hs. <SEP> 146688
<tb> PTGS1 <SEP> = <SEP> COX-1 <SEP> (Prostaglandin-endoperoxide <SEP> synthase <SEP> 1) <SEP> Hs. <SEP> 88474
<tb> PTGS2 <SEP> = <SEP> COX-2 <SEP> (Prostaglandin-endoperoxide <SEP> synthase <SEP> 2 <SEP> (prostaglandin <SEP> Hs. <SEP> 196384
<tb> G/H <SEP> synthase <SEP> and <SEP> cyclooxygenase))
<tb> PTK2 <SEP> = <SEP> FAK <SEP> (Protein <SEP> tyrosine <SEP> kinase <SEP> 2) <SEP> Hs. <SEP> 740
<tb> PTPN1 <SEP> (Protein <SEP> tyrosine <SEP> phosphatase, <SEP> non-receptor <SEP> type <SEP> 1) <SEP> Hs. <SEP> 155894
<tb> RAB6C <SEP> (Rab6-like <SEP> protein) <SEP> Hs. <SEP> 333139
<tb> RABGGTA <SEP> (Gerany <SEP> ! <SEP> transferase, <SEP> alpha <SEP> subunit) <SEP> Hs. <SEP> 78920
<tb> RABGGTB <SEP> (Gerany) <SEP> transferase, <SEP> bêta <SEP> subunit) <SEP> Hs. <SEP> 78948
<tb> RAF1 <SEP> (v-raf-1 <SEP> murine <SEP> feukemia <SEP> virât <SEP> oncogene <SEP> homofog <SEP> 1) <SEP> Hs. <SEP> 85181
<tb> RANGAP1 <SEP> (Ran <SEP> GTPase <SEP> activating <SEP> protein <SEP> 1) <SEP> Hs. <SEP> 183800
<tb> RB1 <SEP> (Retinoblastoma <SEP> 1) <SEP> Hs. <SEP> 75770
<tb> RCV1 <SEP> (Recoverin) <SEP> Hs. <SEP> 80539
<tb> RELA <SEP> = <SEP> NFKB3 <SEP> (v-rel <SEP> avian <SEP> reticuloendotheliosis <SEP> viral <SEP> homolog <SEP> A <SEP> (nuclear <SEP> Hs. <SEP> 75569
<tb> factor <SEP> of <SEP> kappa <SEP> light <SEP> polypeptide <SEP> gene <SEP> enhancer <SEP> in <SEP> B-cells <SEP> 3 <SEP> (p65))
<tb> <Tb>
<tb> PRKCQ <SEP> (Protein <SEP> kinase <SEP> C, <SEP> theta) <SEP> Hs. <SEP> 211593
<tb> PRKCZ <SEP> (Protein <SEP> kinase <SEP> C, <SEP> zeta) <SEP> Hs. <SEP> 78793
<tb> PRKDC <SEP> = <SEP> XRCC7 <SEP> (Protein <SEP> kinase, <SEP> DNA-activated, <SEP> catalytic <SEP> polypeptide) <SEP> Hs. <SEP> 155637
<tb> PRNP <SEP> (Prion <SEP> protein <SEP> (p27-30)) <SEP> Hs. <SEP> 74621
<tb> PSMC1 <SEP> (Proteasome <SEP> (prosome, <SEP> macropain) <SEP> 26S <SEP> subunit, <SEP> ATPase, <SEP> 1) <SEP> Hs. <SEP> 4745
<tb> PSME1 <SEP> (Proteasome <SEP> (prosome, <SEP> macropain) <SEP> activator <SEP> subunit <SEP> 1, <SEP> PA28 <SEP> alpha) <SEP> Hs. <SEP> 75348
<tb> PTGES <SEP> = <SEP> PIG12 <SEP> (Prostaglandin <SEP> E <SEP> Synthase) <SEP> Hs. <SEP> 146688
<tb> PTGS1 <SEP> = <SEP> COX-1 <SEP> (Prostaglandin-Endoperoxide <SEP> Synthase <SEP> 1) <SEP> Hs. <SEP> 88474
<tb> PTGS2 <SEP> = <SEP> COX-2 <SEP> (Prostaglandin-Endoperoxide <SEP> Synthase <SEP> 2 <SEP> (Prostaglandin <SEP> Hs. <SEP> 196384
<tb> G / H <SEP> synthase <SEP> and <SEP> cyclooxygenase))
<tb> PTK2 <SEP> = <SEP> FAK <SEP> (Protein <SEP> tyrosine <SEP> kinase <SEP> 2) <SEP> Hs. <SEP> 740
<tb> PTPN1 <SEP> (Protein <SEP> tyrosine <SEP> phosphatase, <SEP> non-receptor <SEP> type <SEP> 1) <SEP> Hs. <SEP> 155894
<tb> RAB6C <SEP> (Rab6-like <SEP> protein) <SEP> Hs. <SEP> 333139
<tb> RABGGTA <SEP> (Gerany <SEP>! <SEP> transferase, <SEP> alpha <SEP> subunit) <SEP> Hs. <SEP> 78920
<tb> RABGGTB <SEP> (Gerany) <SEP> transferase, <SEP> beta <SEP> subunit) <SEP> Hs. <SEP> 78948
<tb> RAF1 <SEP> (v-raf-1 <SEP> murine <SEP> feukemia <SEP> virate <SEP> oncogene <SEP> homofog <SEP> 1) <SEP> Hs. <SEP> 85181
<tb> RANGAP1 <SEP> (Ran <SEP> GTPase <SEP> activating <SEP> protein <SEP> 1) <SEP> Hs. <SEP> 183800
<tb> RB1 <SEP> (Retinoblastoma <SEP> 1) <SEP> Hs. <SEP> 75770
<tb> RCV1 <SEP> (Recoverin) <SEP> Hs. <SEP> 80539
<tb> RELA <SEP> = <SEP> NFKB3 <SEP> (v-rel <SEP> avian <SEP> reticuloendotheliosis <SEP> viral <SEP> homolog <SEP> A <SEP> (nuclear <SEP> Hs. <SEP> 75569
<tb> factor <SEP> of <SEP> kappa <SEP> light <SEP> polypeptide <SEP> gene <SEP> enhancer <SEP> in <SEP> B-cells <SEP> 3 <SEP> (p65))
<Tb>

<Desc/Clms Page number 61> <Desc / Clms Page number 61>

Figure img00610001
Figure img00610001

<tb>
<tb> RPL9 <SEP> (Ribosomal <SEP> protein <SEP> L9) <SEP> Hs. <SEP> 157850
<tb> RPL12 <SEP> (Ribosomal <SEP> protein <SEP> L12) <SEP> Hs. <SEP> 182979
<tb> RPL15 <SEP> (Robosomal <SEP> protein <SEP> L15) <SEP> Hs. <SEP> 74267
<tb> RPL27A <SEP> (Ribosomal <SEP> protein <SEP> L27a) <SEP> Hs. <SEP> 76064
<tb> RPL41 <SEP> (Ribosoma <SEP> ! <SEP> protein <SEP> L41) <SEP> Hs. <SEP> 324406
<tb> RPLPO <SEP> (Ribosomai <SEP> protein, <SEP> ! <SEP> arge, <SEP> PO) <SEP> Hs. <SEP> 73742
<tb> RPS3A <SEP> (Ribosomal <SEP> protein <SEP> S3A) <SEP> Hs. <SEP> 77039
<tb> RPS6 <SEP> (Ribosomal <SEP> protein <SEP> S6) <SEP> Hs. <SEP> 241507
<tb> RPS15A <SEP> (Ribosomal <SEP> protein <SEP> S15a) <SEP> Hs. <SEP> 2953
<tb> RPS28 <SEP> (Ribosomal <SEP> protein <SEP> S28) <SEP> Hs. <SEP> 153177
<tb> SCA2 <SEP> (Spinocerebellar <SEP> ataxia <SEP> 2 <SEP> (olivopontocerebellar <SEP> ataxia <SEP> 2, <SEP> autosomal <SEP> Hs. <SEP> 76253
<tb> dominant, <SEP> ataxin <SEP> 2))
<tb> SEMA3C <SEP> = <SEP> Semaphorin <SEP> E <SEP> (Sema <SEP> domain, <SEP> immunoglobulin <SEP> domain <SEP> (Ig), <SEP> short <SEP> Hs. <SEP> 171921
<tb> basic <SEP> domain, <SEP> secreted, <SEP> (semaphorin) <SEP> 3C)
<tb> SERPIN <SEP> B5 <SEP> (Maspin) <SEP> Hs. <SEP> 55279
<tb> SERPIN <SEP> C1 <SEP> Antithrombin <SEP> III <SEP> Hs. <SEP> 75599
<tb> SERPINE1 <SEP> (Plasminogen <SEP> activator <SEP> inhibitor, <SEP> type <SEP> 1 <SEP> (Pai1)) <SEP> Hs. <SEP> 82085
<tb> SLC19A1 <SEP> = <SEP> Reduced <SEP> folate <SEP> carrier <SEP> (Solute <SEP> carrier <SEP> family <SEP> 19 <SEP> (folate <SEP> Hs. <SEP> 84190
<tb> transporter), <SEP> member <SEP> 1)
<tb> SLC29A1 <SEP> = <SEP> Equilibrative <SEP> nucleoside <SEP> transporter <SEP> 1 <SEP> (Solute <SEP> carrier <SEP> family <SEP> 29 <SEP> Hs. <SEP> 25450
<tb> (nucleosids <SEP> transporter), <SEP> member <SEP> 1)
<tb> SNCG <SEP> = <SEP> BCSG1 <SEP> (Synuclein, <SEP> gamma <SEP> (breast <SEP> cancer-specific <SEP> protein <SEP> 1)) <SEP> Hs. <SEP> 63236
<tb> <Tb>
<tb> RPL9 <SEP> (Ribosomal <SEP> protein <SEP> L9) <SEP> Hs. <SEP> 157850
<tb> RPL12 <SEP> (Ribosomal <SEP> protein <SEP> L12) <SEP> Hs. <SEP> 182979
<tb> RPL15 <SEP> (Robosomal <SEP> protein <SEP> L15) <SEP> Hs. <SEP> 74267
<tb> RPL27A <SEP> (Ribosomal <SEP> protein <SEP> L27a) <SEP> Hs. <SEP> 76064
<tb> RPL41 <SEP> (Ribosoma <SEP>! <SEP> protein <SEP> L41) <SEP> Hs. <SEP> 324406
<tb> RPLPO <SEP> (Ribosomai <SEP> protein, <SEP>! <SEP> arge, <SEP> PO) <SEP> Hs. <SEP> 73742
<tb> RPS3A <SEP> (Ribosomal <SEP> protein <SEP> S3A) <SEP> Hs. <SEP> 77039
<tb> RPS6 <SEP> (Ribosomal <SEP> protein <SEP> S6) <SEP> Hs. <SEP> 241507
<tb> RPS15A <SEP> (Ribosomal <SEP> protein <SEP> S15a) <SEP> Hs. <SEP> 2953
<tb> RPS28 <SEP> (Ribosomal <SEP> protein <SEP> S28) <SEP> Hs. <SEP> 153177
<tb> SCA2 <SEP> (Spinocerebellar <SEP> ataxia <SEP> 2 <SEP> (olivopontocerebellar <SEP> ataxia <SEP> 2, <SE> autosomal <SEP> Hs. <SEP> 76253
<tb> dominant, <SEP> ataxin <SEP> 2))
<tb> SEMA3C <SEP> = <SEP> Semaphorin <SEP> E <SEP> (Sema <SEP> domain, <SEQ> immunoglobulin <SEP> domain <SEP> (Ig), <SEP> short <SEP> Hs. <SEP> 171921
<tb> basic <SEP> domain, <SEP> secreted, <SEP> (semaphorin) <SEP> 3C)
<tb> SERPIN <SEP> B5 <SEP> (Maspin) <SEP> Hs. <SEP> 55279
<tb> SERPIN <SEP> C1 <SEP> Antithrombin <SEP> III <SEP> Hs. <SEP> 75599
<tb> SERPINE1 <SEP> (Plasminogen <SEP> activator <SEP> inhibitor, <SEP> type <SEP> 1 <SEP> (Pai1)) <SEP> Hs. <SEP> 82085
<tb> SLC19A1 <SEP> = <SEP> Reduced <SEP> folate <SEP> Carrier <SEP> (solute <SEP> Carrier <SEP> family <SEP> 19 <SEP> (folate <SEP> Hs. <SEP> 84190
<tb> transport), <SEP> member <SEP> 1)
<tb> SLC29A1 <SEP> = <SEP> Equilibrative <SEP> nucleoside <SEP> transport <SEP> 1 <SEP> (Solute SEP carrier <SEP> family <SEP> 29 <SEP> Hs. <SEP> 25450
<tb> (nucleosids <SEP> transport), <SEP> member <SEP> 1)
<tb> SNCG <SEP> = <SEP> BCSG1 <SEP> (Synuclein, <SEP> gamma <SEP> (breast <SEP> cancer-specific <SEP> protein <SEP> 1)) <SEP> Hs. <SEP> 63236
<Tb>

<Desc/Clms Page number 62> <Desc / Clms Page number 62>

Figure img00620001
Figure img00620001

<tb>
<tb> SOD2 <SEP> (Superoxide <SEP> dismutase <SEP> 2, <SEP> mitochondrial) <SEP> Hs. <SEP> 318885
<tb> SRC <SEP> (v-src <SEP> avian <SEP> sarcoma <SEP> viral <SEP> oncogene <SEP> homolog) <SEP> Hs. <SEP> 198298
<tb> SRI <SEP> (Sorcin) <SEP> Hs. <SEP> 300741
<tb> STAT1 <SEP> (Signal <SEP> transducer <SEP> and <SEP> activator <SEP> of <SEP> transcription <SEP> 1,91 <SEP> kD) <SEP> Hs. <SEP> 21486
<tb> STAT3 <SEP> (Signal <SEP> transducer <SEP> and <SEP> activator <SEP> of <SEP> transcription <SEP> 3 <SEP> (acute-phase <SEP> Hs. <SEP> 321677
<tb> response <SEP> factor))
<tb> STK4 <SEP> (Mst1) <SEP> Hs. <SEP> 35140
<tb> STK6 <SEP> (Aurora <SEP> IPL1-like <SEP> kinase) <SEP> Hs. <SEP> 333116
<tb> STK13 <SEP> (Serine/threonine <SEP> kinase <SEP> 13 <SEP> (Aurora/I <SEP> PL1-like)) <SEP> Hs. <SEP> 98338
<tb> STMN1 <SEP> (Stathmin <SEP> 1, <SEP> oncoprotein <SEP> 18) <SEP> Hs. <SEP> 81915
<tb> SYT1 <SEP> (Synaptotagmin <SEP> I) <SEP> Hs. <SEP> 154679
<tb> TAF2H <SEP> (TATA <SEP> box <SEP> binding <SEP> protein <SEP> (TBP)-associated <SEP> factor, <SEP> RNA <SEP> polymerase <SEP> Hs. <SEP> 89657
<tb> h, <SEP> H, <SEP> 30kD)
<tb> TAP1 <SEP> = <SEP> ABCB2 <SEP> (Transporter <SEP> 1, <SEP> ATP-binding <SEP> cassette, <SEP> sub-family <SEP> B) <SEP> Hs. <SEP> 158164
<tb> TAP2 <SEP> = <SEP> ABCB3 <SEP> (Transporter <SEP> 2, <SEP> ATP-binding <SEP> cassette, <SEP> sub-family <SEP> B) <SEP> Hs. <SEP> 502
<tb> TEK <SEP> = <SEP> TIE-2 <SEP> (Tyrosine <SEP> kinase, <SEP> endothelial <SEP> (venous <SEP> malformations, <SEP> multiple <SEP> Hs. <SEP> 89640
<tb> cutaneous <SEP> and <SEP> mucosal))
<tb> TERC <SEP> = <SEP> hTR <SEP> (Telomerase <SEP> RNA <SEP> component) <SEP> U86046
<tb> TERT <SEP> (Telomerase <SEP> reverse <SEP> transcriptase) <SEP> Hs. <SEP> 115256
<tb> TFF1 <SEP> = <SEP> HPS2 <SEP> (Trefoil <SEP> factor <SEP> 1 <SEP> (breast <SEP> cancer, <SEP> estrogen-inducible <SEP> sequence <SEP> Hs. <SEP> 337764
<tb> expressed <SEP> in))
<tb> TFRC <SEP> (Transferrin <SEP> receptor <SEP> (p90, <SEP> CD71)) <SEP> Hs. <SEP> 77356
<tb> <Tb>
<tb> SOD2 <SEP> (Superoxide <SEP> dismutase <SEP> 2, <SEP> mitochondrial) <SEP> Hs. <SEP> 318885
<tb> SRC <SEP> (v-src <SEP> avian <SEP> sarcoma <SEP> viral <SEP> oncogene <SEP> homolog) <SEP> Hs. <SEP> 198298
<tb> SRI <SEP> (Sorcine) <SEP> Hs. <SEP> 300741
<tb> STAT1 <SEP> (Signal <SEP> Transducer <SEP> and <SEP> Activator <SEP> of <SEP> Transcription <SEP> 1.91 <SEP> kD) <SEP> Hs. <SEP> 21486
<tb> STAT3 <SEP> (SEP signal> transducer <SEP> and <SEP> activator <SEP> of <SEP> transcript <SEP> 3 <SEP> (acute-phase <SEP> Hs. <SEP> 321677
<tb> response <SEP> factor))
<tb> STK4 <SEP> (Mst1) <SEP> Hs. <SEP> 35140
<tb> STK6 <SEP> (Aurora <SEP> IPL1-like <SEP> Kinase) <SEP> Hs. <SEP> 333116
<tb> STK13 <SEP> (Serine / threonine <SEP> kinase <SEP> 13 <SEP> (Aurora / I <SEP> PL1-like)) <SEP> Hs. <SEP> 98338
<tb> STMN1 <SEP> (Stathmin <SEP> 1, <SEP> oncoprotein <SEP> 18) <SEP> Hs. <SEP> 81915
<tb> SYT1 <SEP> (Synaptotagmin <SEP> I) <SEP> Hs. <SEP> 154679
<tb> TAF2H <SEP> (TATA <SEP> box <SEP> binding <SEP> protein <SEP> (TBP) -associated <SEP> factor, <SEP> RNA <SEP> polymerase <SEP> Hs. <SEP> 89657
<tb> h, <SEP> H, <SEP> 30kD)
<tb> TAP1 <SEP> = <SEP> ABCB2 <SEP> (Transporter <SEP> 1, <SEP> ATP-binding <SEP> cassette, <SEP> sub-family <SEP> B) <SEP> Hs. <SEP> 158164
<tb> TAP2 <SEP> = <SEP> ABCB3 <SEP> (Transporter <SEP> 2, <SEP> ATP-binding <SEP> cassette, <SEP> sub-family <SEP> B) <SEP> Hs. <SEP> 502
<tb> TEK <SEP> = <SEP> TIE-2 <SEP> (Tyrosin <SEP> kinase, <SEP> endothelial <SEP> (venous <SEP> malformations, <SEP> multiple <SEP> Hs. <SEP> 89640
<tb> cutaneous <SEP> and <SEP> mucosal))
<tb> TERC <SEP> = <SEP> hTR <SEP> (Telomerase <SEP> RNA <SEP> component) <SEP> U86046
<tb> TERT <SEP> (Telomerase <SEP> reverse <SEP> transcriptase) <SEP> Hs. <SEP> 115256
<tb> TFF1 <SEP> = <SEP> HPS2 <SEP> (Trefoil <SEP> factor <SEP> 1 <SEP> (breast <SEP> cancer, <SEP> estrogen-inducible <SEP> sequence <SEP> Hs. <SEP> 337764
<tb> expressed <SEP> in))
<tb> TFRC <SEP> (Transferrin <SEP> receptor <SEP> (p90, <SEP> CD71)) <SEP> Hs. <SEP> 77356
<Tb>

<Desc/Clms Page number 63> <Desc / Clms Page number 63>

Figure img00630001
Figure img00630001

<tb>
<tb> TGFA <SEP> (Transforming <SEP> growth <SEP> factor, <SEP> alpha) <SEP> Hs. <SEP> 170009
<tb> TGFB1 <SEP> (Transforming <SEP> growth <SEP> factor, <SEP> beta <SEP> 1) <SEP> Hs. <SEP> 1103
<tb> TGFBR2 <SEP> (Transforming <SEP> growth <SEP> factor, <SEP> beta <SEP> receptor <SEP> !) <SEP> (70-80kD)) <SEP> Hs. <SEP> 82028
<tb> TGFBR3 <SEP> (Transforming <SEP> growth <SEP> factor, <SEP> bêta <SEP> receptor <SEP> !)) <SEP> (betagiycan, <SEP> 300kD)) <SEP> Hs. <SEP> 342874
<tb> THBS1 <SEP> (Thrombospondin <SEP> 1) <SEP> Hs. <SEP> 87409
<tb> TIE <SEP> = <SEP> TIE-1 <SEP> (Tyrosine <SEP> kinase <SEP> with <SEP> immunoglobulin <SEP> and <SEP> epidermal <SEP> growth <SEP> Hs. <SEP> 78824
<tb> factor <SEP> homology <SEP> domains)
<tb> TIMP2 <SEP> (Tissue <SEP> inhibitor <SEP> of <SEP> metalloproteinase <SEP> 2) <SEP> Hs. <SEP> 325495
<tb> TK1 <SEP> (Thymidine <SEP> kinase <SEP> 1) <SEP> Hs. <SEP> 105097
<tb> TNFRSF6 <SEP> = <SEP> APO-1/CD95 <SEP> = <SEP> Fas <SEP> (Tumor <SEP> necrosis <SEP> factor <SEP> receptor <SEP> subfamily, <SEP> Hs. <SEP> 82359
<tb> member <SEP> 6)
<tb> TNFSF6 <SEP> = <SEP> CD95L <SEP> = <SEP> FasL <SEP> (Tumor <SEP> necrosis <SEP> factor <SEP> (ligand) <SEP> superfamily, <SEP> Hs. <SEP> 2007
<tb> member <SEP> 6)
<tb> TOP1 <SEP> (Topoisomerase <SEP> DNA)) <SEP> Hs. <SEP> 317
<tb> TOP2A <SEP> (Topoisomerase <SEP> DNA <SEP> II <SEP> alpha <SEP> (170kD)) <SEP> Hs. <SEP> 156346
<tb> TOP2B <SEP> (Topoisomerase <SEP> DNA <SEP> Il <SEP> bêta <SEP> (180kD)) <SEP> Hs. <SEP> 75248
<tb> TP53 <SEP> (Tumor <SEP> protein <SEP> p53 <SEP> (Li-Fraumeni <SEP> syndrome) <SEP> ) <SEP> Hs. <SEP> 1846
<tb> TP73 <SEP> (Tumor <SEP> protein <SEP> p73) <SEP> Hs. <SEP> 247753
<tb> TP <SEP> ! <SEP> 1 <SEP> (Triosephosphateisomerasel) <SEP> Hs. <SEP> 83848
<tb> TRAF1 <SEP> (TNF <SEP> receptor-associated <SEP> factor <SEP> 1) <SEP> Hs. <SEP> 2134
<tb> TRAG3 <SEP> (TXL <SEP> résistance <SEP> associated <SEP> gene <SEP> 3) <SEP> Hs. <SEP> 251377
<tb> <Tb>
<tb> TGFA <SEP> (Transforming <SEP> growth <SEP> factor, <SEP> alpha) <SEP> Hs. <SEP> 170009
<tb> TGFB1 <SEP> (Transforming <SEP> growth <SEP> factor, <SEP> beta <SEP> 1) <SEP> Hs. <SEP> 1103
<tb> TGFBR2 <SEP> (Transforming <SEP> growth <SEP> factor, <SEP> beta <SEP> receptor <SEP>!) <SEP> (70-80kD)) <SEP> Hs. <SEP> 82028
<tb> TGFBR3 <SEP> (Transforming <SEP> growth <SEP> factor, <SEP> beta <SEP> receptor <SEP>!)) <SEP> (betagiycan, <SEP> 300kD)) <SEP> Hs. <SEP> 342874
<tb> THBS1 <SEP> (Thrombospondin <SEP> 1) <SEP> Hs. <SEP> 87409
<tb> TIE <SEP> = <SEP> TIE-1 <SEP> (Tyrosine <SEP> kinase <SEP> with <SEQ> immunoglobulin <SEP> and <SEP> epidermal <SEP> growth <SEP> Hs. <SEP > 78824
<tb> factor <SEP> homology <SEP> domains
<tb> TIMP2 <SEP> (Tissue <SEP> inhibitor <SEP> of <SEP> metalloproteinase <SEP> 2) <SEP> Hs. <SEP> 325495
<tb> TK1 <SEP> (Thymidine <SEP> kinase <SEP> 1) <SEP> Hs. <SEP> 105097
<tb> TNFRSF6 <SEP> = <SEP> APO-1 / CD95 <SEP> = <SEP> Fas <SEP> (Tumor <SEP> necrosis <SEP> factor <SEP> receptor <SEP> subfamily, <SEP> Hs <SEP> 82359
<tb> member <SEP> 6)
<tb> TNFSF6 <SEP> = <SEP> CD95L <SEP> = <SEP> FasL <SEP> (Tumor <SEP> necrosis <SEP> factor <SEP> (ligand) <SEP> superfamily, <SEP> Hs. <SEP> 2007
<tb> member <SEP> 6)
<tb> TOP1 <SEP> (Topoisomerase <SEP> DNA)) <SEP> Hs. <SEP> 317
<tb> TOP2A <SEP> (Topoisomerase <SEP> DNA <SEP> II <SEP> alpha <SEP> (170kD)) <SEP> Hs. <SEP> 156346
<tb> TOP2B <SEP> (Topoisomerase <SEP> DNA <SEP> II <SEP> Beta <SEP> (180kD)) <SEP> Hs. <SEP> 75248
<tb> TP53 <SEP> (Tumor <SEP> protein <SEP> p53 <SEP> (Li-Fraumeni <SEP> syndrome) <SEP>) <SEP> Hs. <SEP> 1846
<tb> TP73 <SEP> (Tumor <SEP> protein <SEP> p73) <SEP> Hs. <SEP> 247753
<tb> TP <SEP>! <SEP> 1 <SEP> (Triosephosphateisomerasel) <SEP> Hs. <SEP> 83848
<tb> TRAF1 <SEP> (TNF <SEP> receptor-associated <SEP> factor <SEP> 1) <SEP> Hs. <SEP> 2134
<tb> TRAG3 <SEP> (TXL <SEP> resistance <SEP> associated <SEP> gene <SEP> 3) <SEP> Hs. <SEP> 251377
<Tb>

<Desc/Clms Page number 64> <Desc / Clms Page number 64>

Figure img00640001
Figure img00640001

<tb>
<tb> TUBB <SEP> (Tubulin, <SEP> beta <SEP> polypeptide) <SEP> Hs. <SEP> 336780
<tb> TUBB1 <SEP> (Tubulin, <SEP> beta <SEP> 1) <SEP> Hs. <SEP> 303023
<tb> TUBB2 <SEP> (Tubulin, <SEP> beta <SEP> 2) <SEP> Hs. <SEP> 251653
<tb> TUBB4 <SEP> = <SEP> Tubulin <SEP> beta <SEP> III <SEP> Tubulin, <SEP> beta, <SEP> 4 <SEP> Hs. <SEP> 159154
<tb> TXN <SEP> (Thioredoxin) <SEP> Hs. <SEP> 76136
<tb> TYMS <SEP> = <SEP> TS <SEP> (Thymidylate <SEP> synthetase) <SEP> Hs. <SEP> 82962
<tb> UMPS <SEP> (Uridine <SEP> monophosphate <SEP> synthetase <SEP> (orotate <SEP> Hs. <SEP> 2057
<tb> phosphoribosy <SEP> ! <SEP> transferase <SEP> and <SEP> orotidine-5'-decarbox <SEP> lase
<tb> UP <SEP> (Uridine <SEP> phosphorylase) <SEP> Hs. <SEP> 77573
<tb> VEGF <SEP> (Vascular <SEP> endothelial <SEP> growth <SEP> factor) <SEP> Hs. <SEP> 73793
<tb> VHL <SEP> (Von <SEP> hippie) <SEP> ! <SEP> indu <SEP> syndrome) <SEP> Hs. <SEP> 174007
<tb> VIM <SEP> (Vimentin) <SEP> Hs. <SEP> 297753
<tb> XPA <SEP> (Xeroderma <SEP> pigmentosum, <SEP> complementation <SEP> group <SEP> A) <SEP> Hs. <SEP> 192803
<tb> XRCC1 <SEP> (x-ray <SEP> repair <SEP> complementing <SEP> defective <SEP> repair <SEP> in <SEP> Chinese <SEP> hamster <SEP> Hs. <SEP> 98493
<tb> cells <SEP> 1)
<tb> ZNF161 <SEP> (Zinc <SEP> finger <SEP> protein <SEP> 161) <SEP> Hs. <SEP> 6557
<tb> <Tb>
<tb> TUBB <SEP> (Tubulin, <SEP> beta <SEP> polypeptide) <SEP> Hs. <SEP> 336780
<tb> TUBB1 <SEP> (Tubulin, <SEP> beta <SEP> 1) <SEP> Hs. <SEP> 303023
<tb> TUBB2 <SEP> (Tubulin, <SEP> beta <SEP> 2) <SEP> Hs. <SEP> 251653
<tb> TUBB4 <SEP> = <SEP> Tubulin <SEP> beta <SEP> III <SEP> Tubulin, <SEP> beta, <SEP> 4 <SEP> Hs. <SEP> 159154
<tb> TXN <SEP> (Thioredoxin) <SEP> Hs. <SEP> 76136
<tb> TYMS <SEP> = <SEP> TS <SEP> (Thymidylate <SEP> synthetase) <SEP> Hs. <SEP> 82962
<tb> UMPS <SEP> (Uridine <SEP> Monophosphate <SEP> Synthetase <SEP> (Orotate <SEP> Hs. <SEP> 2057
<tb> phosphoribosy <SEP>! <SEP> transferase <SEP> and <SEP>orotidine-5'-decarbox<SEP> lase
<tb> UP <SEP> (Uridine <SEP> phosphorylase) <SEP> Hs. <SEP> 77573
<tb> VEGF <SEP> (Vascular <SEP> endothelial <SEP> growth <SEP> factor) <SEP> Hs. <SEP> 73793
<tb> VHL <SEP> (Von <SEP> hippie) <SEP>! <SEP> indu <SEP> syndrome) <SEP> Hs. <SEP> 174007
<tb> VIM <SEP> (Vimentin) <SEP> Hs. <SEP> 297753
<tb> XPA <SEP> (Xeroderma <SEP> Pigmentosa, <SEP> Complementation <SEP> group <SEP> A) <SEP> Hs. <SEP> 192803
<tb> XRCC1 <SEP> (x-ray <SEP> repair <SEP> complementing <SEP> defective <SEP> repair <SEP> in <SEP> Chinese <SEP> hamster <SEP> Hs. <SEP> 98493
<tb> cells <SEP> 1)
<tb> ZNF161 <SEP> (Zinc <SEP> Finger <SEP> Protein <SEP> 161) <SEP> Hs. <SEP> 6557
<Tb>

Claims (37)

REVENDICATIONS 1 Biopuces thèmatiques caractérisés en ce qu'elles comportent, sur au moins un support, au moins une biopuce thématique comportant des sondes moléculaires correspondant à un thème et au moins un module de recherche associé ou couplé, comportant des sondes moléculaires dont la fonction est d'aider le praticien à interpréter le thème général de la biopuce.1 thematic biochips characterized in that they comprise, on at least one support, at least one thematic biochip comprising molecular probes corresponding to a theme and at least one associated or coupled search module, comprising molecular probes whose function is to help the practitioner to interpret the general theme of the biochip. 2 Biopuces selon la revendication 1 caractérisées en ce qu'elles comportent, sur au moins un support, au moins une biopuce thématique et plusieurs modules de recherche associés ou couplés. 2 biochips according to claim 1 characterized in that they comprise, on at least one support, at least one thematic biochip and several associated or coupled search modules. 3 Biopuces selon la revendication 1 ou 2 caractérisées en ce que les biopuces et les modules de recherche associés ou couplés sont déposés sur plusieurs supports différents. 3 biochips according to claim 1 or 2 characterized in that the biochips and the associated or coupled search modules are deposited on several different supports. 4 Biopuces selon l'une quelconque des revendications 1 à 3 caractérisées en ce que le ou les modules sont généraux, c'est-à-dire valables ou utilisables pour de nombreuses pathologies. 4 biochips according to any one of claims 1 to 3 characterized in that the module or modules are general, that is to say, valid or usable for many pathologies. 5 Biopuces selon l'une quelconque des revendications 1 à 3 caractérisées en ce que le ou les modules sont des modules spécifiques d'une seule pathologie (ou d'un petit groupe de pathologies). 5 biochips according to any one of claims 1 to 3 characterized in that the module or modules are specific modules of a single pathology (or a small group of pathologies). 6 Biopuces selon l'une quelconque des revendications 1 à 3 et 4 ou 5, caractérisées en ce qu'elles comportent au moins un module général et au moins un module spécifique. 6 biochips according to any one of claims 1 to 3 and 4 or 5, characterized in that they comprise at least one general module and at least one specific module. 7 Biopuces selon l'une quelconque des revendications 1 à 6 caractérisées en ce que les biopuces et le ou les modules sont de qualité normale comme celle obtenue par la voie oligonucléotidique, ou par la voie ADNc, et comportent notamment des sondes nucléotidiques. 7 biochips according to any one of claims 1 to 6 characterized in that the biochips and the module or modules are of normal quality such as that obtained by the oligonucleotide route, or by the cDNA, and include in particular nucleotide probes. <Desc/Clms Page number 66><Desc / Clms Page number 66> 8 Biopuces selon l'une quelconque des revendications 1 à 6 caractérisées en ce qu'elles sont de très haute qualité et comportent, sur au moins un support, au moins une sonde moléculaire qui est : - de haute pureté - en quantité connue déposée sur ledit support ; et - identifiée dans sa séquence nucléotidique où sonde moléculaire : désigne la totalité ou un fragment d'ADN, ou d'ADNc, caractéristique d'un gène donné et répondant (dans le cadre de la présente invention) aux trois exigences qui viennent d'être précisées ; de haute pureté ou de très haute pureté signifie que la sonde moléculaire est débarrassée de tous les réactifs chimiques, des oligonucléotides libres, et des fragments nucléotidiques ne correspondant pas à la sonde (fragments de sonde et/ou amorces ou primers > > ) ; on opère comme on le verra et à titre non limitatif, au moyen de membranes ou d'autres technologies équivalentes ; en quantité connue > signifie que l'on a accès à la quantité précise déposée car elle résulte d'un dépôt sur le support d'un volume connu de suspension de départ, elle même de concentration connue ; identifiée dans sa séquence nucléotidique > ) signifie de manière plus précise identifiée dans sa séquence nucléotidique informative par rapport aux fonctions du gène , ce qui à son tour signifie que l'on a procédé à l'identification de la séquence des bases nucléotidiques correspondant à tout ou partie d'un gène identifié juste avnt son dépôt ; tout ou partie désigne ici le nombre minimal de bases suffisant pour définir la spécificité d'un gène.  8 biochips according to any one of claims 1 to 6 characterized in that they are of very high quality and comprise, on at least one support, at least one molecular probe which is: - high purity - in known amount deposited on said support; and - identified in its nucleotide sequence where molecular probe: refers to all or a DNA fragment, or cDNA, characteristic of a given gene and responding (in the context of the present invention) to the three requirements which come from to be specified; high purity or very high purity means that the molecular probe is free of all chemical reagents, free oligonucleotides, and nucleotide fragments not corresponding to the probe (probe fragments and / or primers or primers>>); one operates as will be seen and not limited, by means of membranes or other equivalent technologies; in known quantity> means that the precise quantity deposited is accessed because it results from a deposit on the support of a known volume of starting suspension, itself of known concentration; identified in its nucleotide sequence>) means more precisely identified in its informative nucleotide sequence with respect to the functions of the gene, which in turn means that the sequence of the nucleotide bases corresponding to any sequence has been identified. or part of a gene identified just before its deposition; all or part here designates the minimum number of bases sufficient to define the specificity of a gene. <Desc/Clms Page number 67> <Desc / Clms Page number 67> 9 Biopuces selon l'une quelconque des revendications 1 à 6 et 8 caractérisées en ce qu'elles comportent une combinaison de une ou plusieurs combinaisons de sondes moléculaires thématiques de très haute qualité et de une ou plusieurs combinaisons de sondes moléculaires thématiques de qualité normale. 9 biochips according to any one of claims 1 to 6 and 8 characterized in that they comprise a combination of one or more combinations of thematic molecular probes of very high quality and one or more combinations of thematic molecular probes of normal quality. 10 Biopuces à thème selon l'une quelconque des revendications 1 à 9 - caractérisées en ce qu'elles comportent une combinaison de sondes moléculaires spéciales adaptées pour - comprendre des gènes dont l'expression donne une indication sur le tissu tumoral (stade de la tumeur, son aggressivité, les cellules atteintes, le pouvoir invasif, la résistance ou au contraire la sensibilité aux traitements anti-tumoraux...). 10 themed biochips according to any one of claims 1 to 9 - characterized in that they comprise a combination of special molecular probes adapted to - understand genes whose expression gives an indication on the tumor tissue (stage of the tumor , its aggressivity, the cells affected, the invasiveness, the resistance or, on the contrary, the sensitivity to anti-tumor treatments ...). 11 Biopuces selon l'une quelconque des revendications 1 à 9 caractérisées en ce qu'elles comportent seulement une combinaison de sondes moléculaires spéciales ( module de recherche ) dont l'expression permet d'évaluer le réparation des lésions de l'ADN. 11 biochips according to any one of claims 1 to 9 characterized in that they comprise only a combination of special molecular probes (research module) whose expression can evaluate the repair of DNA lesions. 12 Biopuces selon l'une quelconque des revendications 1 à 9 caractérisées en ce qu'elles comportent seulement une combinaison de sondes moléculaires spéciales ( module de recherche ) dont l'expression permet d'évaluer la chimiosensibilité de la tumeur aux traitements anti-cancéreux. 12 biochips according to any one of claims 1 to 9 characterized in that they comprise only a combination of special molecular probes (research module) whose expression can evaluate the chemosensitivity of the tumor to cancer treatment. 13 Biopuces caractérisées en ce que elles comportent simultanément - au moins une combinaison de sondes moléculaires spéciales ( module de recherche ) dont l'expression permet d'évaluer le réparation de l'ADN et - au moins une combinaison de sondes moléculaires spéciales ( module de recherche ) dont l'expression permet d'évaluer la résistance (ou la sensibilité) de la tumeur à tel traitement ou à telle molécule pharmacologique. 13 Microarrays characterized in that they comprise simultaneously - at least one combination of special molecular probes (search module) whose expression makes it possible to evaluate the repair of the DNA and - at least one combination of special molecular probes (module of research) whose expression makes it possible to evaluate the resistance (or the sensitivity) of the tumor to such a treatment or to such a pharmacological molecule. <Desc/Clms Page number 68><Desc / Clms Page number 68> 14 Biopuces thématiques selon l'une quelconque des revendications 1 à 13 caractérisées en ce que elles comportent de plus au moins une biopuce de criblage de qualité normale, et une ou plusieurs biopuces thématiques de très haute qualité.  14 thematic biochips according to any one of claims 1 to 13 characterized in that they further comprise at least a normal quality screening chip, and one or more thematic biochips of very high quality. 15 Biopuces thématiques selon l'une quelconque des revendications 1 à 13 caractérisées en ce que elles comportent au moins une biopuce thématique de qualité normale, et une ou plusieurs biopuces de criblage de très haute qualité. Thematic biochips according to any one of Claims 1 to 13, characterized in that they comprise at least one thematic biochip of normal quality, and one or more very high quality biochips of screening. 16 Biopuce selon l'une quelconque des revendications 1 à 15 caractérisée en ce qu'elle comporte une sélection de sondes moléculaires adaptée au thème du cancer mammaire, ci-dessous (également Annexe 1 SEQ 1) : 16 biochip according to any one of claims 1 to 15 characterized in that it comprises a selection of molecular probes adapted to the subject of breast cancer, below (also Appendix 1 SEQ 1): BIOPUCE THEMATIQUE : CANCER MAMMAIRE. 333 SONDESTHEMATIC BIOPUCE: MAMMARY CANCER. 333 PROBES MOLECULAIRES MOLECULAR
Figure img00680001
Figure img00680001
 <tb> <Tb> <tb> Nom <SEP> du <SEP> gène <SEP> Unigene<tb> Name <SEP> of <SEP> gene <SEP> Unigene <tb> 5T4 <SEP> oncofetal <SEP> trophoblast <SEP> glycoprotein <SEP> Hs. <SEP> 82128<tb> 5T4 <SEP> oncofetal <SEP> trophoblast <SEP> glycoprotein <SEP> Hs. <SEP> 82128 <tb> acid <SEP> phosphatase <SEP> 5, <SEP> tartrate <SEP> resistant <SEP> Hs. <SEP> 1211<tb> acid <SEP> phosphatase <SEP> 5, <SEP> tartrate <SEP> resistant <SEP> Hs. <SEP> 1211 <tb> actin, <SEP> alpha <SEP> 2, <SEP> smooth <SEP> muscle, <SEP> aorta <SEP> Hs. <SEP> 195851<tb> actin, <SEP> alpha <SEP> 2, <SEP> smooth <SEP> muscle, <SEP> aorta <SEP> Hs. <SEP> 195851 <tb> activating <SEP> transcription <SEP> factor <SEP> 3 <SEP> Hs.460<tb> activating <SEP> transcription <SEP> factor <SEP> 3 <SEP> Hs.460 <tb> adrenergic, <SEP> beta, <SEP> receptor <SEP> kinase <SEP> 1 <SEP> Hs. <SEP> 83636<tb> adrenergic, <SEP> beta, <SEP> receptor <SEP> kinase <SEP> 1 <SEP> Hs. <SEP> 83636 <tb> alcohol <SEP> dehydrogenase <SEP> 2 <SEP> (class <SEP> 1), <SEP> beta <SEP> polypeptide <SEP> Hs. <SEP> 4<tb> alcohol <SEP> dehydrogenase <SEP> 2 <SEP> (class <SEP> 1), <SEP> beta <SEP> polypeptide <SEP> Hs. <SEP> 4 <tb> aldehyde <SEP> dehydrogenase <SEP> 1, <SEP> soluble <SEP> Hs. <SEP> 76392<tb> aldehyde <SEP> dehydrogenase <SEP> 1, <SEP> soluble <SEP> Hs. <SEP> 76392 <tb> alpha-2-macroglobulin <SEP> Hs. <SEP> 74561<tb> alpha-2-macroglobulin <SEP> Hs. <SEP> 74561 <tb> androgen <SEP> receptor <SEP> (dihydrotestosterone <SEP> receptor <SEP> ; <SEP> testicular <SEP> feminization <SEP> ; <SEP> Hs. <SEP> 99915<tb> androgen <SEP> receptor <SEP> (dihydrotestosterone <SEP> receptor <SEP>; <SEP> testicular <SEP> feminization <SEP>; <SEP> Hs. <SEP> 99915 <tb> spinal <SEP> and <SEP> bulbar <SEP> muscular <SEP> atrophy <SEP> ; <SEP> Kennedy <SEP> disease)<tb> spinal <SEP> and <SEP> bulbar <SEP> muscular <SEP> atrophy <SEP>; <SEP> Kennedy <SEP> disease) <tb> <Tb> <Desc/Clms Page number 69> <Desc / Clms Page number 69>
Figure img00690001
Figure img00690001
 <tb> <Tb> <tb> annexin <SEP> A1 <SEP> Hs. <SEP> 78225<tb> annexin <SEP> A1 <SEP> Hs. <SEP> 78225 <tb> annexin <SEP> A8 <SEP> Hs. <SEP> 87268<tb> annexin <SEP> A8 <SEP> Hs. <SEP> 87268 <tb> antigen <SEP> identified <SEP> by <SEP> monoclonal <SEP> antibody <SEP> Ki-67 <SEP> Hs. <SEP> 80976<tb> antigen <SEP> identified <SEP> by <SEP> monoclonal <SEP> antibody <SEP> Ki-67 <SEP> Hs. <SEP> 80976 <tb> apolipoprotein <SEP> A-i <SEP> Hs. <SEP> 93194<tb> apolipoprotein <SEP> A-i <SEP> Hs. <SEP> 93194 <tb> apolipoprotein <SEP> D <SEP> Hs. <SEP> 75736<tb> apolipoprotein <SEP> D <SEP> Hs. <SEP> 75736 <tb> apoptosis <SEP> inhibitor <SEP> 4 <SEP> (survivin) <SEP> Hs. <SEP> 1578<tb> apoptosis <SEP> inhibitor <SEP> 4 <SEP> (survivin) <SEP> Hs. <SEP> 1578 <tb> aquaporin <SEP> 1 <SEP> (channel-forming <SEP> integral <SEP> protein, <SEP> 28kD) <SEP> Hs. <SEP> 74602<tb> aquaporin <SEP> 1 <SEP> (channel-forming <SEP> integral <SEP> protein, <SEP> 28kD) <SEP> Hs. <SEP> 74602 <tb> aquaporin <SEP> 7 <SEP> Hs. <SEP> 25475<tb> aquaporin <SEP> 7 <SEP> Hs. <SEP> 25475 <tb> armadillo <SEP> repeat <SEP> gene <SEP> deletes <SEP> in <SEP> velocardiofacial <SEP> syndrome <SEP> Hs. <SEP> 171900<tb> armadillo <SEP> repeat <SEP> gene <SEP> deletes <SEP> in <SEP> velocardiofacial <SEP> syndrome <SEP> Hs. <SEP> 171900 <tb> ARP1 <SEP> (actin-related <SEP> protein <SEP> 1, <SEP> yeast) <SEP> homolog <SEP> A <SEP> (centractin <SEP> alpha) <SEP> Hs. <SEP> 2477<tb> ARP1 <SEP> (actin-related <SEP> protein <SEP> 1, <SEP> yeast) <SEP> homolog <SEP> A <SEP> (centractin <SEP> alpha) <SEP> Hs. <SEP> 2477 <tb> ATP-binding <SEP> cassette, <SEP> sub-family <SEP> C <SEP> (CFTR/MRP), <SEP> member <SEP> 5 <SEP> Hs. <SEP> 108660<tb> ATP-binding <SEP> cassette, <SEP> sub-family <SEP> C <SEP> (CFTR / MRP), <SEP> member <SEP> 5 <SEP> Hs. <SEP> 108660 <tb> basonuclin <SEP> Hs. <SEP> 64025<tb> basonuclin <SEP> Hs. <SEP> 64025 <tb> B-cell <SEP> CLUlymphoma <SEP> 2 <SEP> Hs. <SEP> 79241<tb> B-cell <SEP> CLUlymphoma <SEP> 2 <SEP> Hs. <SEP> 79241 <tb> bcl2 <SEP> assocaited <SEP> athanoaene <SEP> Hs. <SEP> 41714<tb> bcl2 <SEP> assocaited <SEP> athanoaene <SEP> Hs. <SEP> 41714 <tb> bcl2 <SEP> associated <SEP> X <SEP> protein <SEP> Hs. <SEP> 159428<tb> bcl2 <SEP> associated <SEP> <SEP> protein <SEP> Hs. <SEP> 159428 <tb> beta-2-microqlobulin <SEP> Hs. <SEP> 75415<tb> beta-2-microqlobulin <SEP> Hs. <SEP> 75415 <tb> Brca1 <SEP> associated <SEP> RING <SEP> domain <SEP> 1 <SEP> HS. <SEP> 54089<tb> Brca1 <SEP> associated <SEP> RING <SEP> domain <SEP> 1 <SEP> HS. <SEP> 54089 <tb> breast <SEP> and <SEP> bladder <SEP> overexpressed <SEP> gene <SEP> 1 <SEP> Hs. <SEP> 78768<tb> breast <SEP> and <SEP> bladder <SEP> overexpressed <SEP> gene <SEP> 1 <SEP> Hs. <SEP> 78768 <tb> Breast <SEP> cancer <SEP> 1, <SEP> earlv <SEP> onset <SEP> Hs. <SEP> 194143<tb> Breast <SEP> cancer <SEP> 1, <SEP> earlv <SEP> onset <SEP> Hs. <SEP> 194143 <tb> breast <SEP> cancer <SEP> antiestrogen <SEP> resistance <SEP> 1 <SEP> Hs. <SEP> 273219<tb> breast <SEP> cancer <SEP> antiestrogen <SEP> resistance <SEP> 1 <SEP> Hs. <SEP> 273219 <tb> <Tb> <Desc/Clms Page number 70> <Desc / Clms Page number 70>
Figure img00700001
Figure img00700001
 <tb> <Tb> <tb> breast <SEP> cancer <SEP> antiestrogen <SEP> resistance <SEP> 3 <SEP> Hs. <SEP> 6564<tb> breast <SEP> cancer <SEP> antiestrogen <SEP> resistance <SEP> 3 <SEP> Hs. <SEP> 6564 <tb> breast <SEP> cancer <SEP> specic <SEP> gene <SEP> 1 <SEP> ou <SEP> synculein <SEP> gamma <SEP> Hs. <SEP> 63236<tb> breast <SEP> cancer <SEP> specic <SEP> gene <SEP> 1 <SEP> or <SEP> synculein <SEP> gamma <SEP> Hs. <SEP> 63236 <tb> budding <SEP> uninhibited <SEP> by <SEP> benzimidazoles <SEP> 1 <SEP> (yeast <SEP> homolog), <SEP> beta <SEP> Hs. <SEP> 36708<tb> budding <SEP> uninhibited <SEP> by <SEP> benzimidazoles <SEP> 1 <SEP> (yeast <SEP> homolog), <SEP> beta <SEP> Hs. <SEP> 36708 <tb> bullous <SEP> pemphigoid <SEP> antigen <SEP> 1 <SEP> (230/240kD) <SEP> Hs. <SEP> 620<tb> bullous <SEP> pemphigoid <SEP> antigen <SEP> 1 <SEP> (230 / 240kD) <SEP> Hs. <SEP> 620 <tb> butyrate <SEP> response <SEP> factor <SEP> 1 <SEP> (EGF-response <SEP> factor <SEP> 1) <SEP> Hs. <SEP> 85155<tb> butyrate <SEP> response <SEP> factor <SEP> 1 <SEP> (EGF-response <SEP> factor <SEP> 1) <SEP> Hs. <SEP> 85155 <tb> bvstin-like <SEP> Hs. <SEP> 106880<tb> bvstin-like <SEP> Hs. <SEP> 106880 <tb> cadherin <SEP> 1 <SEP> ; <SEP> E-cadherin <SEP> Hs. <SEP> 194657<tb> cadherin <SEP> 1 <SEP>; <SEP> E-cadherin <SEP> Hs. <SEP> 194657 <tb> cadherin <SEP> 13 <SEP> ; <SEP> H-cadherin <SEP> Hs. <SEP> 63894<tb> cadherin <SEP> 13 <SEP>; <SEP> H-cadherin <SEP> Hs. <SEP> 63894 <tb> cadherin <SEP> 15 <SEP> ; <SEP> M-cadherin <SEP> Hs. <SEP> 148090<tb> cadherin <SEP> 15 <SEP>; <SEP> M-cadherin <SEP> Hs. <SEP> 148090 <tb> cadherin <SEP> 3, <SEP> P-cadherin <SEP> (placenta) <SEP> Hs. <SEP> 2877<tb> cadherin <SEP> 3, <SEP> P-cadherin <SEP> (placenta) <SEP> Hs. <SEP> 2877 <tb> carboxypeptidase <SEP> B <SEP> 1 <SEP> Hs. <SEP> 180884<tb> carboxypeptidase <SEP> B <SEP> 1 <SEP> Hs. <SEP> 180884 <tb> carcinoembryonic <SEP> antigen <SEP> Hs. <SEP> 220529<tb> carcinoembryonic <SEP> antigen <SEP> Hs. <SEP> 220529 <tb> cartilage <SEP> oligomeric <SEP> matrix <SEP> protein <SEP> (pseudoachondroplasia, <SEP> epiphyseal <SEP> Hs. <SEP> 1584<tb> cartilage <SEP> oligomeric <SEP> matrix <SEP> protein <SEP> (pseudoachondroplasia, <SEP> epiphyseal <SEP> Hs. <SEQ> 1584 <tb> dysplasia <SEP> 1, <SEP> multiple)<tb> dysplasia <SEP> 1, <SEP> multiple) <tb> catenin, <SEP> delta <SEP> 1 <SEP> HS. <SEP> 166011<tb> catenin, <SEP> delta <SEP> 1 <SEP> HS. <SEP> 166011 <tb> cathepsin <SEP> C <SEP> Hs. <SEP> 10029<tb> cathepsin <SEP> C <SEP> Hs. <SEP> 10029 <tb> cathepsin <SEP> D <SEP> (lysosomal <SEP> aspartyl <SEP> protease) <SEP> Hs. <SEP> 79572<tb> cathepsin <SEP> D <SEP> (lysosomal <SEP> aspartyl <SEP> protease) <SEP> Hs. <SEP> 79572 <tb> cathepsin <SEP> Z <SEP> Hs. <SEP> 71388<tb> cathepsin <SEP> Z <SEP> Hs. <SEP> 71388 <tb> caveolin-1 <SEP> HS. <SEP> 323469<tb> caveolin-1 <SEP> HS. <SEP> 323469 <tb> CD2 <SEP> antigen <SEP> (p50), <SEP> sheep <SEP> red <SEP> blood <SEP> cell <SEP> receptor <SEP> Hs. <SEP> 89476<tb> CD2 <SEP> antigen <SEP> (p50), <SEP> sheep <SEP> red <SEP> blood <SEP> cell <SEP> receptor <SEP> Hs. <SEP> 89476 <tb> CD34 <SEP> antigen <SEP> Hs. <SEP> 85289<tb> CD34 <SEP> antigen <SEP> Hs. <SEP> 85289 <tb> <Tb> <Desc/Clms Page number 71> <Desc / Clms Page number 71>
Figure img00710001
Figure img00710001
 <tb> <Tb> <tb> CD36 <SEP> antigen <SEP> (collagen <SEP> type <SEP> I <SEP> receptor, <SEP> thrombospondin <SEP> receptor) <SEP> Hs. <SEP> 75613<tb> CD36 <SEP> antigen <SEP> (collagen <SEP> type <SEP> I <SEP> receptor, <SEP> thrombospondin <SEP> receptor) <SEP> Hs. <SEP> 75613 <tb> CD3D <SEP> antigen, <SEP> delta <SEP> polypeptide <SEP> (TiT3 <SEP> complex) <SEP> Hs. <SEP> 95327<tb> CD3D <SEP> antigen, <SEP> delta <SEP> polypeptide <SEP> (TiT3 <SEP> complex) <SEP> Hs. <SEP> 95327 <tb> CD3G <SEP> antigen, <SEP> gamma <SEP> polypeptide <SEP> (TiT3 <SEP> complex) <SEP> Hs. <SEP> 2259<tb> CD3G <SEP> antigen, <SEP> gamma <SEP> polypeptide <SEP> (TiT3 <SEP> complex) <SEP> Hs. <SEP> 2259 <tb> CD3D <SEP> antigen, <SEP> delta <SEP> polypeptide <SEP> (TiT3 <SEP> complex) <SEP> Hs.95327<tb> CD3D <SEP> antigen, <SEP> delta <SEP> polypeptide <SEP> (TiT3 <SEP> complex) <SEP> Hs.95327 <tb> CD3G <SEP> antigen, <SEP> gamma <SEP> polypeptide <SEP> (TiT3 <SEP> complex) <SEP> Hs.2259<tb> CD3G <SEP> antigen, <SEP> gamma <SEP> polypeptide <SEP> (TiT3 <SEP> complex) <SEP> Hs.2259 <tb> CD68 <SEP> antigen <SEP> Hs.240615<tb> CD68 <SEP> antigen <SEP> Hs.240615 <tb> CDC28 <SEP> protein <SEP> kinase <SEP> 2 <SEP> Hs.83758<tb> CDC28 <SEP> protein <SEP> kinase <SEP> 2 <SEP> Hs.83758 <tb> CDC6 <SEP> (cell <SEP> division <SEP> cycle <SEP> 6, <SEP> S. <SEP> cerevisiae) <SEP> homolog <SEP> Hs. <SEP> 69563<tb> CDC6 <SEP> (cell <SEP> division <SEP> cycle <SEP> 6, <SE> S. <SEP> cerevisiae) <SEP> homolog <SEP> Hs. <SEP> 69563 <tb> CDC7 <SEP> (cell <SEP> division <SEP> cycle <SEP> 7, <SEP> S. <SEP> cerevisiae, <SEP> homolog)-like <SEP> 1 <SEP> Hs. <SEP> 28853<tb> CDC7 <SEP> (cell <SEP> division <SEP> cycle <SEP> 7, <SE> S. <SEP> cerevisiae, <SEP> homolog) -like <SEP> 1 <SEP> Hs. <SEP> 28853 <tb> cell <SEP> division <SEP> cycle <SEP> 20, <SEP> S. <SEP> cerevisiae <SEP> homolog <SEP> Hs. <SEP> 82906<tb> cell <SEP> division <SEP> cycle <SEP> 20, <SE> S. <SEP> cerevisiae <SEP> homolog <SEP> Hs. <SEP> 82906 <tb> cell <SEP> division <SEP> c <SEP> cie <SEP> 25C <SEP> HS. <SEP> 656<tb> cell <SEP> division <SEP> c <SEP> cie <SEP> 25C <SEP> HS. <SEP> 656 <tb> cellular <SEP> retinoic <SEP> acid-binding <SEP> protein <SEP> 2 <SEP> Hs.183650<tb> cellular <SEP> retinoic <SEP> acid-binding <SEQ> protein <SEP> 2 <SEP> Hs.183650 <tb> centromere <SEP> protein <SEP> E <SEP> (312kD) <SEP> Hs.75573<tb> centromere <SEP> protein <SEP> E <SEP> (312kD) <SEQ> Hs.75573 <tb> centromere <SEP> protein <SEP> F <SEP> (350/400kD, <SEP> mitosin) <SEP> Hs. <SEP> 77204<tb> centromere <SEP> protein <SEP> F <SEP> (350 / 400kD, <SEP> mitosin) <SEP> Hs. <SEP> 77204 <tb> chitinase <SEP> 1 <SEP> Hs. <SEP> 91093<tb> chitinase <SEP> 1 <SEP> Hs. <SEP> 91093 <tb> chitinase <SEP> 3-like <SEP> 1 <SEP> (cartilage <SEP> glycoprotein-39) <SEP> Hs. <SEP> 75184<tb> chitinase <SEP> 3-like <SEP> 1 <SEP> (cartilage <SEP> glycoprotein-39) <SEP> Hs. <SEP> 75184 <tb> CHK1 <SEP> (checkpoint, <SEP> S. <SEP> pombe) <SEP> homolog <SEP> Hs. <SEP> 20295<tb> CHK1 <SEP> (checkpoint, <SE> S. <SEP> pombe) <SEP> peer <SEP> Hs. <SEP> 20295 <tb> chromobox <SEP> homolog <SEP> 3 <SEP> (drosophila <SEP> HP1 <SEP> gamma) <SEP> Hs. <SEP> 8123<tb> chromobox <SEP> homolog <SEP> 3 <SEP> (drosophila <SEP> HP1 <SEP> gamma) <SEP> Hs. <SEP> 8123 <tb> collagen, <SEP> type <SEP> I, <SEP> alpha <SEP> 1 <SEP> Hs.172928<tb> collagen, <SEP> type <SEP> I, <SEP> alpha <SEP> 1 <SEP> Hs.172928 <tb> collagen, <SEP> type <SEP> III, <SEP> alpha <SEP> 1 <SEP> (Ehlers-Danlos <SEP> syndrome <SEP> type <SEP> IV, <SEP> autosomal <SEP> Hs.119571<tb> collagen, <SEP> type <SEP> III, <SEP> alpha <SEP> 1 <SEP> (Ehlers-Danlos <SEP> syndrome <SEP> type <SEP> IV, <SEP> autosomal <SEP> Hs .119571 <tb> dominant)<tb> dominant) <tb> collagen, <SEP> type <SEP> VI, <SEP> alpha <SEP> 1 <SEP> Hs. <SEP> 108885<tb> collagen, <SEP> type <SEP> VI, <SEP> alpha <SEP> 1 <SEP> Hs. <SEP> 108885 <tb> colony <SEP> stimulating <SEP> factor <SEP> 1 <SEP> (macrophage) <SEP> Hs. <SEP> 173894<tb> colony <SEP> stimulating <SEP> factor <SEP> 1 <SEP> (macrophage) <SEP> Hs. <SEP> 173894 <tb> <Tb> <Desc/Clms Page number 72> <Desc / Clms Page number 72>
Figure img00720001
Figure img00720001
 <tb> <Tb> <tb> CREB <SEP> binding <SEP> protein <SEP> (Rubinstein-Taybi <SEP> syndrome) <SEP> Hs. <SEP> 23598<tb> CREB <SEP> binding <SEP> protein <SEP> (Rubinstein-Taybi <SEP> syndrome) <SEP> Hs. <SEP> 23598 <tb> cullin <SEP> 4A <SEP> Hs. <SEP> 183874<tb> cullin <SEP> 4A <SEP> Hs. <SEP> 183874 <tb> cyclin <SEP> B1 <SEP> Hs. <SEP> 23960<tb> cyclin <SEP> B1 <SEP> Hs. <SEP> 23960 <tb> Cyclin <SEP> D1 <SEP> Hs. <SEP> 82932<tb> Cyclin <SEP> D1 <SEP> Hs. <SEP> 82932 <tb> cyclin <SEP> E1 <SEP> Hs. <SEP> 9700<tb> cyclin <SEP> E1 <SEP> Hs. <SEP> 9700 <tb> cyclin <SEP> G <SEP> 1 <SEP> Hs. <SEP> 79101<tb> cyclin <SEP> G <SEP> 1 <SEP> Hs. <SEP> 79101 <tb> Cyclin-dependent <SEP> kinase <SEP> 4 <SEP> Hs. <SEP> 95577<tb> Cyclin-dependent <SEP> kinase <SEP> 4 <SEP> Hs. <SEP> 95577 <tb> cyclin-dependent <SEP> kinase <SEP> inhibitor <SEP> 1C <SEP> (p57, <SEP> Kip2) <SEP> Hs. <SEP> 106070<tb> cyclin-dependent <SEP> kinase <SEP> inhibitor <SEP> 1C <SEP> (p57, <SEP> Kip2) <SEP> Hs. <SEP> 106070 <tb> cystatin <SEP> E/M <SEP> Hs. <SEP> 83393<tb> cystatin <SEP> E / M <SEP> Hs. <SEP> 83393 <tb> cysteine-rich <SEP> protein <SEP> 1 <SEP> (intestinal) <SEP> Hs. <SEP> 17409<tb> cysteine-rich <SEP> protein <SEP> 1 <SEP> (intestinal) <SEP> Hs. <SEP> 17409 <tb> cytochrome <SEP> c <SEP> oxidase <SEP> subunit <SEP> Vlc <SEP> Hs. <SEP> 74649<tb> cytochrome <SEP> c <SEP> oxidase <SEP> subunit <SEP> Vlc <SEP> Hs. <SEP> 74649 <tb> Cytochrome <SEP> c <SEP> oxidase <SEP> subunit <SEP> Vlla <SEP> polypeptide <SEP> 2 <SEP> like <SEP> Hs. <SEP> 30888<tb> Cytochrome <SEP> c <SEP> Oxidase <SEP> subunit <SEP> Vlla <SEP> polypeptide <SEP> 2 <SEP> like <SEP> Hs. <SEP> 30888 <tb> D123 <SEP> gène <SEP> product <SEP> Hs. <SEP> 82043<tb> D123 <SEP> gene <SEP> product <SEP> Hs. <SEP> 82043 <tb> DEAD/H <SEP> (Asp-Glu-Ala-Asp/His) <SEP> box <SEP> polypeptide <SEP> 11 <SEP> (S. <SEP> cerevisiae <SEP> CHL1-like <SEP> Hs. <SEP> 27424<tb> DEAD / H <SEP> (Asp-Glu-Ala-Asp / His) <SEP> box <SEP> polypeptide <SEP> 11 <SEP> (S. <SEP> cerevisiae <SEP> CHL1-like <SEP > Hs. <SEP> 27424 <tb> helicase)<tb> helicase) <tb> density <SEP> regulated <SEP> protein <SEP> Hs. <SEP> 22393<tb> density <SEP> regulated <SEP> protein <SEP> Hs. <SEP> 22393 <tb> desmin <SEP> Hs. <SEP> 171185<tb> desmin <SEP> Hs. <SEP> 171185 <tb> dihydrofolate <SEP> reductase <SEP> Hs. <SEP> 83765<tb> dihydrofolate <SEP> reductase <SEP> Hs. <SEP> 83765 <tb> diphtheria <SEP> toxin <SEP> receptor <SEP> (heparin-binding <SEP> epidermal <SEP> growth <SEP> factor-like <SEP> Hs.799<tb> diphtheria <SEP> toxin <SEP> receptor <SEP> (heparin-binding <SEP> epidermal <SEP> growth <SEP> factor-like <SEP> Hs.799 <tb> growth <SEP> factor)<tb> growth <SEP> factor) <tb> discoïdin <SEP> domain <SEP> receptor <SEP> family, <SEP> member <SEP> 1 <SEP> Hs. <SEP> 75562<tb> discointer <SEP> domain <SEP> Receiver <SEP> family, <SEP> member <SEP> 1 <SEP> Hs. <SEP> 75562 <tb> <Tb> <Desc/Clms Page number 73> <Desc / Clms Page number 73>
Figure img00730001
Figure img00730001
 <tb> <Tb> <tb> DNA <SEP> (cytosine-5-)-methyltransferase <SEP> 1 <SEP> Hs.77462<tb> DNA <SEP> (cytosine-5 -) - methyltransferase <SEP> 1 <SEP> Hs.77462 <tb> dynein, <SEP> axonemal, <SEP> light <SEP> intermediate <SEP> polypeptide <SEP> Hs. <SEP> 33846<tb> dynein, <SEP> axonemal, <SEP> light <SEP> intermediate <SEP> polypeptide <SEP> Hs. <SEP> 33846 <tb> E2F <SEP> transcription <SEP> factor <SEP> 3 <SEP> Hs.1189<tb> E2F <SEP> transcription <SEP> factor <SEP> 3 <SEP> Hs.1189 <tb> E74-like <SEP> factor <SEP> 3 <SEP> Hs. <SEP> 166096<tb> E74-like <SEP> factor <SEP> 3 <SEP> Hs. <SEP> 166096 <tb> early <SEP> development <SEP> regulator <SEP> 2 <SEP> (homolog <SEP> of <SEP> polyhomeotic <SEP> 2) <SEP> Hs. <SEP> 75878<tb> early <SEP> development <SEP> regulator <SEP> 2 <SEP> (homolog <SEP> of <SEP> polyhomeotic <SEP> 2) <SEP> Hs. <SEP> 75878 <tb> endoglin <SEP> Hs. <SEP> 76753<tb> endoglin <SEP> Hs. <SEP> 76753 <tb> endothelin <SEP> receptor <SEP> type <SEP> B <SEP> Hs.82002<tb> endothelin <SEP> receptor <SEP> type <SEP> B <SEP> Hs.82002 <tb> enhancer <SEP> of <SEP> zeste <SEP> (Drosophila) <SEP> homolog <SEP> 2 <SEP> Hs.77256<tb> enhancer <SEP> of <SEP> peel <SEP> (Drosophila) <SEP> homolog <SEP> 2 <SEP> Hs.77256 <tb> Epidermal <SEP> growth <SEP> factor <SEP> Hs.2230<tb> Epidermal <SEP> growth <SEP> factor <SEP> Hs.2230 <tb> epidermal <SEP> growth <SEP> factor <SEP> receptor <SEP> (avian <SEP> erythroblastic <SEP> leukemia <SEP> viral <SEP> (v-erb-b) <SEP> Hs. <SEP> 77432<tb> epidermal <SEP> growth <SEP> factor <SEP> receptor <SEP> (avian <SEP> erythroblastic <SEP> leukemia <SEP> viral <SEP> (v-erb-b) <SEP> Hs. <SEP > 77432 <tb> oncoqene <SEP> homolog)<tb> oncoqene <SEP> homolog) <tb> estrogen <SEP> receptor <SEP> 1 <SEP> (alpha) <SEP> Hs. <SEP> 1657<tb> estrogen <SEP> receptor <SEP> 1 <SEP> (alpha) <SEP> Hs. <SEP> 1657 <tb> estrogen <SEP> receptor <SEP> beta <SEP> Hs.103504<tb> estrogen <SEP> receptor <SEP> beta <SEP> Hs.103504 <tb> Estrogen <SEP> receptor <SEP> binding <SEP> site <SEP> associated, <SEP> antigen, <SEP> 9 <SEP> Hs. <SEP> 9222<tb> Estrogen <SEP> receptor <SEP> binding <SEP> <SEP> associated site, <SEP> antigen, <SEP> 9 <SEP> Hs. <SEP> 9222 <tb> eukaryotic <SEP> transition <SEP> ebngation <SEP> factor <SEP> 1 <SEP> epsi <SEP> ! <SEP> on <SEP> 1Hs. <SEP> 172247<tb> eukaryotic <SEP> transition <SEP> ebngation <SEP> factor <SEP> 1 <SEP> epsi <SEP>! <SEP> on <SEP> 1Hs. <SEP> 172247 <tb> eukaryotic <SEP> translation <SEP> initiation <SEP> factor <SEP> 3, <SEP> subunit <SEP> 4 <SEP> (delta, <SEP> 44kD) <SEP> Hs. <SEP> 28081<tb> eukaryotic <SEP> translation <SEP> initiation <SEP> factor <SEP> 3, <SEP> subunit <SEP> 4 <SEP> (delta, <SEP> 44kD) <SEP> Hs. <SEP> 28081 <tb> exportin, <SEP> tRNA <SEP> (nuclear <SEP> export <SEP> receptor <SEP> for <SEP> tRNAs) <SEP> Hs. <SEP> 85951<tb> exportin, <SEP> tRNA <SEP> (nuclear <SEP> export <SEP> receptor <SEP> for <SEP> tRNAs) <SEP> Hs. <SEP> 85951 <tb> fatty <SEP> acid <SEP> binding <SEP> protein <SEP> 4, <SEP> adipocyte <SEP> Hs.83213<tb> fatty acid <SEP> acid <SEP> binding <SEP> protein <SEP> 4, <SEP> adipocyte <SEP> Hs.83213 <tb> fatty <SEP> acid <SEP> binding <SEP> protein <SEP> 7, <SEP> brain <SEP> Hs. <SEP> 26770<tb> fatty <SEP> acid <SEP> binding <SEP> protein <SEP> 7, <SEP> brain <SEP> Hs. <SEP> 26770 <tb> fibroblast <SEP> growth <SEP> factor <SEP> 8 <SEP> Hs. <SEP> 57710<tb> fibroblast <SEP> growth <SEP> factor <SEP> 8 <SEP> Hs. <SEP> 57710 <tb> f <SEP> ! <SEP> brob <SEP> ! <SEP> ast <SEP> growth <SEP> factor <SEP> receptor <SEP> 1 <SEP> (fms-re <SEP> ! <SEP> ated <SEP> tyrosine <SEP> kinase <SEP> 2, <SEP> Pfeiffer <SEP> Hs. <SEP> 748<tb> f <SEP>! <SEP> brob <SEP>! <SEP> ast <SEP> growth <SEP> factor <SEP> receptor <SEP> 1 <SEP> (fms-re <SEP>! <SEP> ated <SEP> tyrosine <SEP> kinase <SEP> 2, <SEP > Pfeiffer <SEP> Hs. <SEP> 748 <tb> <Tb> <Desc/Clms Page number 74> <Desc / Clms Page number 74>
Figure img00740001
Figure img00740001
 <tb> <Tb> <tb> syndrome)<tb> syndrome) <tb> flap <SEP> structure-specific <SEP> endonuclease <SEP> 1 <SEP> Hs.4756<tb> flap <SEP> structure-specific <SEP> endonuclease <SEP> 1 <SEP> Hs.4756 <tb> forkhead <SEP> (Drosophila)-like <SEP> 16 <SEP> Hs.239<tb> forkhead <SEP> (Drosophila) -like <SEP> 16 <SEP> Hs.239 <tb> four <SEP> and <SEP> a <SEP> half <SEP> LIM <SEP> domains <SEP> 1 <SEP> Hs. <SEP> 239069<tb> four <SEP> and <SEP> <SEP> half <SEP> <SEP> domains <SEP> 1 <SEP> Hs. <SEP> 239069 <tb> fragile <SEP> histidine <SEP> triad <SEP> gene <SEP> Hs.77252<tb> fragile <SEP> histidine <SEP> triad <SEP> gene <SEP> Hs.77252 <tb> fructose-bisphosphatase <SEP> 1 <SEP> Hs.574<tb> fructose-bisphosphatase <SEP> 1 <SEP> Hs.574 <tb> gamma-glutamyl <SEP> hydrolase <SEP> (conjugase, <SEP> folylpolyqammaglutamyl <SEP> hydrolase) <SEP> Hs. <SEP> 78619<tb> gamma-glutamyl <SEP> hydrolase <SEP> (conjugase, <SEP> folylpolyqammaglutamyl <SEP> hydrolase) <SEP> Hs. <SEP> 78619 <tb> gap <SEP> junction <SEP> protein <SEP> alpha <SEP> 1,43 <SEP> kD <SEP> ou <SEP> connexin <SEP> 43 <SEP> Hs. <SEP> 74471<tb> gap <SEP> junction <SEP> protein <SEP> alpha <SEP> 1.43 <SEP> kD <SEP> or <SEP> connexin <SEP> 43 <SEP> Hs. <SEP> 74471 <tb> GATA-binding <SEP> protein <SEP> 3 <SEP> Hs.169946<tb> GATA-binding <SEQ> protein <SEP> 3 <SEP> Hs.169946 <tb> glutamate <SEP> receptor, <SEP> ionotropic, <SEP> N-methyl <SEP> D-aspartate <SEP> 2A <SEP> Hs. <SEP> 167464<tb> glutamate <SEP> receptor, <SEQ> ionotropic, <SEP> N-methyl <SEP> D-aspartate <SEP> 2A <SEP> Hs. <SEP> 167464 <tb> glutamate <SEP> receptor, <SEP> ionotropic, <SEP> N-methyl <SEP> D-aspartate <SEP> 2C <SEP> Hs. <SEP> 36451<tb> glutamate <SEP> receptor, <SEQ> ionotropic, <SEP> N-methyl <SEP> D-aspartate <SEP> 2C <SEP> Hs. <SEP> 36451 <tb> glutathione <SEP> S <SEP> transferase <SEP> pi <SEP> Hs. <SEP> 226795<tb> glutathione <SEP> S <SEP> transferase <SEP> pi <SEP> Hs. <SEP> 226795 <tb> glycerol-3-phosphate <SEP> dehydrogenase <SEP> 1 <SEP> (soluble) <SEP> Hs. <SEP> 25478<tb> glycerol-3-phosphate <SEP> dehydrogenase <SEP> 1 <SEP> (soluble) <SEP> Hs. <SEP> 25478 <tb> granzyme <SEP> A <SEP> (granzyme <SEP> 1, <SEP> cytotoxic <SEP> T-lymphocyte-associated <SEP> serine <SEP> Hs. <SEP> 90708<tb> granzyme <SEP> A <SEP> (granzyme <SEP> 1, <SEP> cytotoxic <SEP> T-lymphocyte-associated <SEP> serine <SEP> Hs. <SEP> 90708 <tb> esterase <SEP> 3)<tb> esterase <SEP> 3) <tb> hepatocyte <SEP> nuclear <SEP> factor <SEP> 3, <SEP> alpha <SEP> Hs. <SEP> 105440<tb> hepatocyte <SEP> nuclear <SEP> factor <SEP> 3, <SEP> alpha <SEP> Hs. <SEP> 105440 <tb> hepsin <SEP> Hs. <SEP> 823<tb> hepsin <SEP> Hs. <SEP> 823 <tb> high <SEP> mobility <SEP> group <SEP> (nonhistone <SEP> chromosomal) <SEP> protein <SEP> isoforms <SEP> I <SEP> and <SEP> Y <SEP> Hs. <SEP> 139800<tb> high <SEP> mobility <SEP> group <SEP> (nonhistone <SEP> chromosomal) <SEP> protein <SEP> isoforms <SEP> I <SEP> and <SEP> Y <SEP> Hs. <SEP> 139800 <tb> high-mobility <SEP> group <SEP> (nonhistone <SEP> chromosomal) <SEP> protein <SEP> 2 <SEP> Hs. <SEP> 80684<tb> high-mobility <SEP> group <SEP> (nonhistone <SEP> chromosomal) <SEP> protein <SEP> 2 <SEP> Hs. <SEP> 80684 <tb> HIV-1 <SEP> Rev <SEP> binding <SEP> protein <SEP> Hs. <SEP> 171545<tb> HIV-1 <SEP> Rev <SEP> binding <SEP> protein <SEP> Hs. <SEP> 171545 <tb> Homo <SEP> sapiens <SEP> ataxia-telangiectasia <SEP> group <SEP> D-associated <SEP> protein <SEP> mRNA, <SEP> Hs. <SEP> 82237<tb> Homo <SEP> sapiens <SEP> ataxia-telangiectasia <SEP> group <SEP> D-associated <SEP> protein <SEP> mRNA, <SEP> Hs. <SEP> 82237 <tb> <Tb> <Desc/Clms Page number 75> <Desc / Clms Page number 75>
Figure img00750001
Figure img00750001
 <tb> <Tb> <tb> complete <SEP> cds<tb> complete <SEP> cds <tb> Homo <SEP> sapiens <SEP> clone <SEP> 24703 <SEP> beta-tubulin <SEP> mRNA, <SEP> complete <SEP> cds <SEP> Hs.179661<tb> Homo <SEP> sapiens <SEP> clone <SEP> 24703 <SEP> beta-tubulin <SEP> mRNA, <SEP> complete <SEP> cds <SEP> Hs.179661 <tb> Homo <SEP> sapiens <SEP> HPV16 <SEP> E1 <SEP> protein <SEP> binding <SEP> protein <SEP> mRNA, <SEP> complete <SEP> cds <SEP> Hs. <SEP> 6566<tb> Homo <SEP> sapiens <SEP> HPV16 <SEP> E1 <SEP> protein <SEP> binding <SEP> protein <SEP> mRNA, <SEP> complete <SEP> cds <SEP> Hs. <SEP> 6566 <tb> Human <SEP> BRCA2 <SEP> region, <SEP> mRNA <SEP> sequence <SEP> CG006 <SEP> Hs. <SEP> 110630<tb> Human <SEP> BRCA2 <SEP> region, <SEP> mRNA <SEP> sequence <SEP> CG006 <SEP> Hs. <SEP> 110630 <tb> Human <SEP> breast <SEP> cancer, <SEP> estrogen <SEP> regulated <SEP> LIV-1 <SEP> protein <SEP> (LIV-1) <SEP> mRNA, <SEP> Hs. <SEP> 79136<tb> Human <SEP> breast <SEP> cancer, <SEP> estrogen <SEP> regulated <SEP> LIV-1 <SEP> protein <SEP> (LIV-1) <SEP> mRNA, <SEP> Hs. <SEP> 79136 <tb> partial <SEP> cds<tb> partial <SEP> cds <tb> Human <SEP> cellular <SEP> oncogene <SEP> c-fos <SEP> Hs. <SEP> 25647<tb> Human <SEP> cellular <SEP> oncogene <SEP> c-fos <SEP> Hs. <SEP> 25647 <tb> Human) <SEP> g <SEP> J <SEP> chain <SEP> gène <SEP> Hs. <SEP> 76325<tb> Human) <SEP> g <SEP> J <SEP> chain <SEP> gene <SEP> Hs. <SEP> 76325 <tb> Human <SEP> phosphatidylinositol <SEP> (4,5) <SEP> bisphosphate <SEP> 5-phosphatase <SEP> homolog <SEP> Hs. <SEP> 21492<tb> Human <SEP> Phosphatidylinositol <SEP> (4,5) <SEP> bisphosphate <SEP> 5-phosphatase <SEP> homolog <SEP> Hs. <SEP> 21492 <tb> mRNA, <SEP> partial <SEP> cds<tb> mRNA, <SEP> partial <SEP> cds <tb> Human <SEP> ubiquitin <SEP> carrier <SEP> protein <SEP> (E2-EPF) <SEP> mRNA, <SEP> complete <SEP> cds <SEP> Hs. <SEP> 174070<tb> Human <SEP> ubiquitin <SEP> carrier <SEP> protein <SEP> (E2-EPF) <SEP> mRNA, <SEP> complete <SEP> cds <SEP> Hs. <SEP> 174070 <tb> hyaluronan-mediated <SEP> motility <SEP> receptor <SEP> (RHAMM) <SEP> Hs. <SEP> 72550<tb> hyaluronan-mediated <SEP> motility <SEP> receptor <SEP> (RHAMM) <SEP> Hs. <SEP> 72550 <tb> hydroxyacyi-Coenzyme <SEP> A <SEP> dehydrogenase/3-ketoacy <SEP> !-Coenzyme <SEP> A <SEP> Hs. <SEP> 75860<tb> hydroxyacyi-Coenzyme <SEP> A <SEP> dehydrogenase / 3-ketoacy <SEP>! -Coenzyme <SEP> A <SEP> Hs. <SEP> 75860 <tb> thiolase/enoyl-Coenzyme <SEP> A <SEP> hydratase <SEP> (trifunctional <SEP> protein), <SEP> alpha <SEP> subunit<tb> thiolase / enoyl-Coenzyme <SEP> A <SEP> Hydase <SEP> (trifunctional <SEP> protein), <SEP> alpha <SEP> subunit <tb> immunoglobulin <SEP> gamma <SEP> 3 <SEP> (Gm <SEP> marker) <SEP> Hs. <SEP> 140<tb> immunoglobulin <SEP> gamma <SEP> 3 <SEP> (Gm <SEP> marker) <SEP> Hs. <SEP> 140 <tb> inhibitor <SEP> of <SEP> growth <SEP> 1 <SEP> Hs. <SEP> 46700<tb> inhibitor <SEP> of <SEP> growth <SEP> 1 <SEP> Hs. <SEP> 46700 <tb> inhibitor <SEP> of <SEP> growth <SEP> 2<tb> inhibitor <SEP> of <SEP> growth <SEP> 2 <tb> inositol <SEP> polyphosphate-4-phosphatase, <SEP> type <SEP> 11, <SEP> 105kD <SEP> Hs. <SEP> 153687<tb> inositol <SEP> polyphosphate-4-phosphatase, <SEP> type <SEP> 11, <SEP> 105kD <SEP> Hs. <SEP> 153687 <tb> insulin-like <SEP> growth <SEP> factor <SEP> 1 <SEP> (somatomedin <SEP> C) <SEP> Hs. <SEP> 85112<tb> insulin-like <SEP> growth <SEP> factor <SEP> 1 <SEP> (somatomedin <SEP> C) <SEP> Hs. <SEP> 85112 <tb> insulin-like <SEP> growth <SEP> factor <SEP> 2 <SEP> (somatomedin <SEP> A) <SEP> Hs. <SEP> 241317<tb> insulin-like <SEP> growth <SEP> factor <SEP> 2 <SEP> (somatomedin <SEP> A) <SEP> Hs. <SEP> 241317 <tb> insulin-like <SEP> growth <SEP> factor <SEP> binding <SEP> protein <SEP> 2 <SEP> Hs. <SEP> 162<tb> insulin-like <SEP> growth <SEP> factor <SEP> binding <SEP> protein <SEP> 2 <SEP> Hs. <SEP> 162 <tb> insulin-like <SEP> growth <SEP> factor <SEP> binding <SEP> protein <SEP> 5 <SEP> Hs. <SEP> 102122<tb> insulin-like <SEP> growth <SEP> factor <SEP> binding <SEP> protein <SEP> 5 <SEP> Hs. <SEP> 102122 <tb> <Tb> <Desc/Clms Page number 76> <Desc / Clms Page number 76>
Figure img00760001
Figure img00760001
 <tb> <Tb> <tb> insulin-like <SEP> growth <SEP> factor <SEP> receptor <SEP> 1 <SEP> Hs.239176<tb> insulin-like <SEP> growth <SEP> factor <SEP> receptor <SEP> 1 <SEP> Hs.239176 <tb> insulin-like <SEP> growth <SEP> factor <SEP> receptor <SEP> 2 <SEP> Hs.76473<tb> insulin-like <SEP> growth <SEP> factor <SEP> receptor <SEP> 2 <SEP> Hs.76473 <tb> integrin, <SEP> alpha <SEP> 3 <SEP> Hs. <SEP> 265829<tb> integrin, <SEP> alpha <SEP> 3 <SEP> Hs. <SEP> 265829 <tb> integrin, <SEP> alpha <SEP> 7 <SEP> Hs. <SEP> 74369<tb> integrin, <SEP> alpha <SEP> 7 <SEP> Hs. <SEP> 74369 <tb> integrin, <SEP> alpha <SEP> L <SEP> (antigen <SEP> CD11 <SEP> A <SEP> (p180), <SEP> lymphocyte <SEP> function-associated <SEP> Hs. <SEP> 1741 <SEP> 03<tb> integrin, <SEP> alpha <SEP> L <SEP> (antigen <SEP> CD11 <SEP> A <SEP> (p180), <SEP> lymphocyte <SEP> function-associated <SEP> Hs. <SEP > 1741 <SEP> 03 <tb> antigen <SEP> 1 <SEP> ; <SEP> alpha <SEP> polypeptide)<tb> antigen <SEP> 1 <SEP>; <SEP> alpha <SEP> polypeptide) <tb> integrin, <SEP> beta <SEP> 2 <SEP> (antigen <SEP> CD18 <SEP> (p95), <SEP> lymphocyte <SEP> function-associated <SEP> Hs. <SEP> 83968<tb> integrin, <SEP> beta <SEP> 2 <SEP> (antigen <SEP> CD18 <SEP> (p95), <SEP> lymphocyte <SEP> function-associated <SEP> Hs. <SEP> 83968 <tb> antigen <SEP> 1 <SEP> ; <SEP> macrophage <SEP> antigen <SEP> 1 <SEP> (mac-1) <SEP> beta <SEP> subunit)<tb> antigen <SEP> 1 <SEP>; <SEP> macrophage <SEP> antigen <SEP> 1 <SEP> (mac-1) <SEP> beta <SEP> subunit <tb> inteqrin, <SEP> beta <SEP> 4 <SEP> Hs. <SEP> 85266<tb> inteqrin, <SEP> beta <SEP> 4 <SEP> Hs. <SEP> 85266 <tb> inteqrin, <SEP> beta <SEP> 8 <SEP> Hs. <SEP> 184908<tb> inteqrin, <SEP> beta <SEP> 8 <SEP> Hs. <SEP> 184908 <tb> intercellular <SEP> adhesion <SEP> molecule <SEP> 2 <SEP> Hs. <SEP> 83733<tb> intercellular <SEP> adhesion <SEP> molecule <SEP> 2 <SEP> Hs. <SEP> 83733 <tb> interferon <SEP> alpha <SEP> inducibfe <SEP> protein <SEP> 27 <SEP> Hs. <SEP> 278613<tb> interferon <SEP> alpha <SEP> inducible <SEP> protein <SEP> 27 <SEP> Hs. <SEP> 278613 <tb> interferon-induced <SEP> protein <SEP> 17 <SEP> Hs. <SEP> 146360<tb> interferon-induced <SEP> protein <SEP> 17 <SEP> Hs. <SEP> 146360 <tb> interferon-induced, <SEP> hepatitis <SEP> C-associated <SEP> microtubular <SEP> aggregate <SEP> protein <SEP> Hs. <SEP> 82316<tb> interferon-induced, <SEP> hepatitis <SEP> C-associated <SEP> microtubular <SEP> aggregate <SEP> protein <SEP> Hs. <SEP> 82316 <tb> (44kD)<tb> (44kD) <tb> interleukin <SEP> 10 <SEP> receptor, <SEP> alpha <SEP> Hs.327<tb> interleukin <SEP> 10 <SEP> receptor, <SEQ> alpha <SEP> Hs.327 <tb> interleukin <SEP> 2 <SEP> receptor, <SEP> beta <SEP> Hs. <SEP> 75596<tb> interleukin <SEP> 2 <SEP> receptor, <SEP> beta <SEP> Hs. <SEP> 75596 <tb> interleukin <SEP> 3 <SEP> receptor, <SEP> alpha <SEP> (low <SEP> affinity) <SEP> Hs. <SEP> 172689<tb> interleukin <SEP> 3 <SEP> receptor, <SEP> alpha <SEP> (low <SEP> affinity) <SEP> Hs. <SEP> 172689 <tb> kallikrein <SEP> 10 <SEP> Hs. <SEP> 69423<tb> kallikrein <SEP> 10 <SEP> Hs. <SEP> 69423 <tb> kallikrein <SEP> 13 <SEP> Hs. <SEP> 165296<tb> kallikrein <SEP> 13 <SEP> Hs. <SEP> 165296 <tb> kallikrein <SEP> 3, <SEP> (prostate <SEP> specific <SEP> antigen) <SEP> Hs. <SEP> 171995<tb> kallikrein <SEP> 3, <SEP> (prostate <SEP> specific <SEP> antigen) <SEP> Hs. <SEP> 171995 <tb> <Tb> <Desc/Clms Page number 77> <Desc / Clms Page number 77>
Figure img00770001
Figure img00770001
 <tb> <Tb> <tb> kallikrein <SEP> 6 <SEP> Hs. <SEP> 79361<tb> kallikrein <SEP> 6 <SEP> Hs. <SEP> 79361 <tb> kangaï <SEP> 1 <SEP> Hs. <SEP> 323946<tb> kangai <SEP> 1 <SEP> Hs. <SEP> 323946 <tb> keratin <SEP> 17 <SEP> Hs. <SEP> 2785<tb> keratin <SEP> 17 <SEP> Hs. <SEP> 2785 <tb> keratin <SEP> 18 <SEP> Hs. <SEP> 65114<tb> keratin <SEP> 18 <SEP> Hs. <SEP> 65114 <tb> keratin <SEP> 19 <SEP> Hs. <SEP> 182265<tb> keratin <SEP> 19 <SEP> Hs. <SEP> 182265 <tb> keratin <SEP> 5 <SEP> (epidermolysis <SEP> lysis <SEP> bullosa <SEP> simplex, <SEP> Dowling-Meara/Kobner/Weber- <SEP> Hs.195850<tb> keratin <SEP> 5 <SEP> (epidermolysis <SEP> lysis <SEP> bullosa <SEP> simplex, <SEP> Dowling-Meara / Kobner / Weber- <SEP> Hs.195850 <tb> Cockayne <SEP> types)<tb> Cockayne <SEP> types) <tb> keratin <SEP> 7 <SEP> Hs. <SEP> 23881<tb> keratin <SEP> 7 <SEP> Hs. <SEP> 23881 <tb> keratin <SEP> 8 <SEP> Hs. <SEP> 104624<tb> keratin <SEP> 8 <SEP> Hs. <SEP> 104624 <tb> KIAA0008 <SEP> gene <SEP> product <SEP> Hs. <SEP> 77695<tb> KIAA0008 <SEP> gene <SEP> product <SEP> Hs. <SEP> 77695 <tb> KIAA0042 <SEP> gene <SEP> product <SEP> Hs. <SEP> 3104<tb> KIAA0042 <SEP> gene <SEP> product <SEP> Hs. <SEP> 3104 <tb> KIAAOO74 <SEP> protein <SEP> Hs. <SEP> 1192<tb> KIAAOO74 <SEP> protein <SEP> Hs. <SEP> 1192 <tb> KIAA0101 <SEP> gene <SEP> product <SEP> Hs. <SEP> 81892<tb> KIAA0101 <SEP> gene <SEP> product <SEP> Hs. <SEP> 81892 <tb> KIAA0125 <SEP> gene <SEP> product <SEP> Hs. <SEP> 38365<tb> KIAA0125 <SEP> gene <SEP> product <SEP> Hs. <SEP> 38365 <tb> KIAA0159 <SEP> gene <SEP> product <SEP> Hs. <SEP> 5719<tb> KIAA0159 <SEP> gene <SEP> product <SEP> Hs. <SEP> 5719 <tb> KIAA0166 <SEP> qene <SEP> product <SEP> Hs. <SEP> 115778<tb> KIAA0166 <SEQ> qene <SEP> product <SEP> Hs. <SEP> 115778 <tb> KIAA0430 <SEP> gene <SEP> product <SEP> Hs. <SEP> 166163<tb> KIAA0430 <SEP> gene <SEP> product <SEP> Hs. <SEP> 166163 <tb> KIAA0758 <SEP> protein <SEP> Hs. <SEP> 22039<tb> KIAA0758 <SEP> protein <SEP> Hs. <SEP> 22039 <tb> KIAA0788 <SEP> protein <SEP> Hs. <SEP> 181043<tb> KIAA0788 <SEP> protein <SEP> Hs. <SEP> 181043 <tb> Kiss-1 <SEP> Hs. <SEP> 95008<tb> Kiss-1 <SEP> Hs. <SEP> 95008 <tb> lactate <SEP> dehydroqenase <SEP> B <SEP> Hs. <SEP> 234489<tb> lactate <SEP> dehydroqenase <SEP> B <SEP> Hs. <SEP> 234489 <tb> <Tb> <Desc/Clms Page number 78> <Desc / Clms Page number 78>
Figure img00780001
Figure img00780001
 <tb> <Tb> <tb> ladinin <SEP> 1 <SEP> Hs. <SEP> 18141<tb> ladinin <SEP> 1 <SEP> Hs. <SEP> 18141 <tb> lamin <SEP> B2 <SEP> Hs. <SEP> 76084<tb> lamin <SEP> B2 <SEP> Hs. <SEP> 76084 <tb> laminin, <SEP> alpha <SEP> 3 <SEP> (nicein <SEP> (150kD), <SEP> kalinin <SEP> (165kD), <SEP> BM600 <SEP> (150kD), <SEP> epilegrin) <SEP> Hs. <SEP> 83450<tb> laminin, <SEP> alpha <SEP> 3 <SEP> (nicein <SEP> (150kD), <SEP> kalinin <SEP> (165kD), <SEP> BM600 <SEP> (150kD), <SEP> epilegrin) <SEP> Hs. <SEP> 83450 <tb> faminin, <SEP> gamma <SEP> 2 <SEP> (nicein <SEP> (100kD), <SEP> kalinin <SEP> (105kD), <SEP> BM600 <SEP> (100kD), <SEP> Perlit <SEP> Hs. <SEP> 54451<tb> faminin, <SEP> gamma <SEP> 2 <SEP> (nicein <SEP> (100kD), <SEP> kalinin <SEP> (105kD), <SEP> BM600 <SEP> (100kD), <SEP> Perlit <SEP> Hs. <SEP> 54451 <tb> junctional <SEP> epidermolysis <SEP> bullosa))<tb> junctional <SEP> epidermolysis <SEP> bullosa)) <tb> UM <SEP> and <SEP> SH <SEP> protein <SEP> 1 <SEP> HS. <SEP> 334851<tb> UM <SEP> and <SEP> SH <SEP> protein <SEP> 1 <SEP> HS. <SEP> 334851 <tb> LIM <SEP> binding <SEP> domain <SEP> 2 <SEP> Hs.4980<tb> LIM <SEP> Binding <SEP> domain <SEP> 2 <SEP> Hs.4980 <tb> LIM <SEP> domain <SEP> only <SEP> 4<tb> LIM <SEP> domain <SEP> only <SEP> 4 <tb> lipocalin <SEP> 1 <SEP> Hs. <SEP> 204238<tb> lipocalin <SEP> 1 <SEP> Hs. <SEP> 204238 <tb> lipoprotein <SEP> lipase <SEP> Hs. <SEP> 180878<tb> lipoprotein <SEP> lipase <SEP> Hs. <SEP> 180878 <tb> LPS-induced <SEP> TNF-alpha <SEP> factor <SEP> Hs. <SEP> 76507<tb> LPS-induced <SEP> TNF-alpha <SEP> factor <SEP> Hs. <SEP> 76507 <tb> lumican <SEP> Hs. <SEP> 79914<tb> lumican <SEP> Hs. <SEP> 79914 <tb> lymphocyte-specific <SEP> protein <SEP> tyrosine <SEP> kinase <SEP> Hs. <SEP> 1765<tb> lymphocyte-specific <SEP> protein <SEP> tyrosine <SEP> kinase <SEP> Hs. <SEP> 1765 <tb> MAD2 <SEP> (mitotic <SEP> arrest <SEP> deficient, <SEP> yeast, <SEP> homoloa) <SEP> -like <SEP> 1 <SEP> Hs. <SEP> 79078<tb> MAD2 <SEP> (mitotic <SEP> arrest <SEP> deficient, <SEP> yeast, <SEP> homolo) SEP> -like <SEP> 1 <SEP> Hs. <SEP> 79078 <tb> major <SEP> histocompatibility <SEP> complex, <SEP> class <SEP> II, <SEP> DQ <SEP> beta <SEP> 1 <SEP> Hs. <SEP> 73931<tb> major <SEP> histocompatibility <SEP> complex, <SEP> class <SEP> II, <SEP> DQ <SEP> beta <SEP> 1 <SEP> Hs. <SEP> 73931 <tb> mammaglobin <SEP> 1 <SEP> Hs. <SEP> 46452<tb> mammaglobin <SEP> 1 <SEP> Hs. <SEP> 46452 <tb> manic <SEP> fringe <SEP> (Drosophila) <SEP> homolog <SEP> Hs. <SEP> 31939<tb> manic <SEP> fringe <SEP> (Drosophila) <SEP> homolog <SEP> Hs. <SEP> 31939 <tb> matrix <SEP> metalloproteinase <SEP> 11 <SEP> (stromelysin <SEP> 3) <SEP> Hs. <SEP> 155324<tb> matrix <SEP> metalloproteinase <SEP> 11 <SEP> (stromelysin <SEP> 3) <SEP> Hs. <SEP> 155324 <tb> matrix <SEP> metalloproteinase <SEP> 13 <SEP> Hs. <SEP> 2936<tb> matrix <SEP> metalloproteinase <SEP> 13 <SEP> Hs. <SEP> 2936 <tb> matrix <SEP> metalloproteinase <SEP> 14 <SEP> (membrane-inserted) <SEP> Hs. <SEP> 2399<tb> matrix <SEP> metalloproteinase <SEP> 14 <SEP> (membrane-inserted) <SEP> Hs. <SEP> 2399 <tb> matrix <SEP> metalloproteinase <SEP> 17 <SEP> Hs. <SEP> 159581<tb> matrix <SEP> metalloproteinase <SEP> 17 <SEP> Hs. <SEP> 159581 <tb> <Tb> <Desc/Clms Page number 79> <Desc / Clms Page number 79>
Figure img00790001
Figure img00790001
 <tb> <Tb> <tb> matrix <SEP> metalloproteinase <SEP> 9 <SEP> ; <SEP> qelatinase <SEP> B <SEP> Hs. <SEP> 151738<tb> matrix <SEP> metalloproteinase <SEP> 9 <SEP>; <SEP> qelatinase <SEP> B <SEP> Hs. <SEP> 151738 <tb> MAX-interacting <SEP> protein <SEP> 1 <SEP> Hs. <SEP> 118630<tb> MAX-interacting <SEP> protein <SEP> 1 <SEP> Hs. <SEP> 118630 <tb> Meis <SEP> (mouse) <SEP> homolog <SEP> 3 <SEP> Hs. <SEP> 117313<tb> Meis <SEP> (mouse) <SEP> peer <SEP> 3 <SEP> Hs. <SEP> 117313 <tb> metastasis <SEP> associated <SEP> 1 <SEP> Hs. <SEP> 101448<tb> metastasis <SEP> associated <SEP> 1 <SEP> Hs. <SEP> 101448 <tb> microsomal <SEP> glutathione <SEP> S-transferase <SEP> 1 <SEP> Hs. <SEP> 790<tb> microsomal <SEP> glutathione <SEP> S-transferase <SEP> 1 <SEP> Hs. <SEP> 790 <tb> minichromosome <SEP> maintenance <SEP> deficient <SEP> (S. <SEP> cerevisiae) <SEP> 2 <SEP> (mitotin) <SEP> Hs. <SEP> 57101<tb> minichromosome <SEP> maintenance <SEP> deficient <SEP> (S. <SEP> cerevisiae) <SEP> 2 <SEP> (mitotin) <SEP> Hs. <SEP> 57101 <tb> mucin1 <SEP> Hs. <SEP> 89603<tb> mucin1 <SEP> Hs. <SEP> 89603 <tb> multifunctional <SEP> polypeptide <SEP> similar <SEP> to <SEP> SAICAR <SEP> synthetase <SEP> and <SEP> AIR <SEP> Hs. <SEP> 117950<tb> multifunctional <SEP> polypeptide <SEP> similar <SEP> to <SEP> SAICAR <SEP> synthetase <SEP> and <SEP> AIR <SEP> Hs. <SEP> 117950 <tb> carboxylase<tb> carboxylase <tb> mut <SEP> L <SEP> (E. <SEP> coli) <SEP> homolog <SEP> 1 <SEP> (colon <SEP> cancer, <SEP> nonpolyposis <SEP> type <SEP> 2) <SEP> Hs. <SEP> 57301<tb> mut <SEP> L <SEP> (E. <SEP> coli) <SEP> homolog <SEP> 1 <SEP> (colon <SEP> cancer, <SEP> nonpolyposis <SEP> type <SEP> 2) <SEP> Hs. <SEP> 57301 <tb> mut <SEP> S <SEP> (E. <SEP> coli) <SEP> homoloa <SEP> 3 <SEP> Hs. <SEP> 42674<tb> mut <SEP> S <SEP> (E. <SEP> coli) <SEP> homology <SEP> 3 <SEP> Hs. <SEP> 42674 <tb> N-acetyltransferase <SEP> 1 <SEP> (arylamine <SEP> N-acetyltransferase) <SEP> Hs. <SEP> 155956<tb> N-acetyltransferase <SEP> 1 <SEP> (arylamine <SEP> N-acetyltransferase) <SEP> Hs. <SEP> 155956 <tb> neutrophil <SEP> cytosolic <SEP> factor <SEP> 1 <SEP> (47kD, <SEP> chronic <SEP> granulomatous <SEP> disease, <SEP> Hs. <SEP> 1583<tb> neutrophil <SEP> cytosolic <SEP> factor <SEP> 1 <SEP> (47kD, <sep> chronic <SEP> granulomatous <SEP> disease, <SEQ> Hs. <SEP> 1583 <tb> autosomal <SEP> 1)<tb> autosomal <SEP> 1) <tb> N-myc <SEP> downstream <SEP> requlated <SEP> Hs. <SEP> 75789<tb> N-myc <SEP> downstream <SEP> requlated <SEP> Hs. <SEP> 75789 <tb> non-metastatic <SEP> cells <SEP> 1, <SEP> protein <SEP> (NM23A) <SEP> expressed <SEP> in <SEP> Hs. <SEP> 118638<tb> non-metastatic <SEP> cells <SEP> 1, <SEQ> protein <SEP> (NM23A) <SEP> expressed <SEP> in <SEP> Hs. <SEP> 118638 <tb> non-POU-domain <SEP> containing, <SEP> octamer <SEP> binding <SEP> Hs. <SEP> 172207<tb> non-POU-domain <SEP> containing, <SEP> octamer <SEP> binding <SEP> Hs. <SEP> 172207 <tb> nuclear <SEP> receptor <SEP> coactivator <SEP> 3 <SEP> Hs. <SEP> 225977<tb> nuclear <SEP> receptor <SEP> coactivator <SEP> 3 <SEP> Hs. <SEP> 225977 <tb> nuclear <SEP> transcription <SEP> factor, <SEP> X-box <SEP> binding <SEP> 1 <SEP> Hs. <SEP> 3187<tb> nuclear <SEP> transcription <SEP> factor, <SEP> Xbox <SEP> binding <SEP> 1 <SEP> Hs. <SEP> 3187 <tb> nucleophosmin <SEP> (nucleolar <SEP> phosphoprotein <SEP> B23 <SEP> numatrin) <SEP> Hs. <SEP> 173205<tb> nucleophosmin <SEP> (nucleolar <SEP> phosphoprotein <SEP> B23 <SEP> numatrin) <SEP> Hs. <SEP> 173205 <tb> osteoblast <SEP> specific <SEP> factor <SEP> 2 <SEP> (fasciclin <SEP> l-like) <SEP> Hs. <SEP> 136348<tb> osteoblast <SEP> specific <SEP> factor <SEP> 2 <SEP> (fasciclin <SEP> l-like) <SEP> Hs. <SEP> 136348 <tb> <Tb> <Desc/Clms Page number 80> <Desc / Clms Page number 80>
Figure img00800001
Figure img00800001
 <tb> <Tb> <tb> arvalbumin <SEP> Hs <SEP> 295449<tb> arvalbumin <SEP> Hs <SEP> 295449 <tb> pescadillo <SEP> (zebrafish) <SEP> homolog <SEP> 1, <SEP> containing <SEP> BRCT <SEP> domain <SEP> Hs.13501<tb> pescadillo <SEP> (zebrafish) <SEP> peer <SEP> 1 <SEP> containing <SEP> BRCT <SEP> domain <SEP> Hs.13501 <tb> phosphofructokinase, <SEP> platelet <SEP> Hs.99910<tb> phosphofructokinase, <SEP> platelet <SEP> Hs.99910 <tb> phospholemman <SEP> Hs.160318<tb> phospholemman <SEP> Hs.160318 <tb> phospholipase <SEP> A2, <SEP> group <SEP> IIA <SEP> (platelets, <SEP> synovial <SEP> fluid) <SEP> Hs.76422<tb> phospholipase <SEP> A2, <SEP> group <SEP> IIA <SEP> (platelets, <SEP> synovial <SEP> fluid) <SEP> Hs.76422 <tb> phospholipid <SEP> scramblase <SEP> 1 <SEP> Hs.198282<tb> phospholipid <SEP> scramblase <SEP> 1 <SEP> Hs.198282 <tb> pituitary <SEP> tumor-transforming <SEP> 1 <SEP> Hs.181195<tb> pituitary <SEP> tumor-transforming <SEP> 1 <SEP> Hs.181195 <tb> plakoglobin <SEP> Hs. <SEP> 2340<tb> Plakoglobin <SEP> Hs. <SEP> 2340 <tb> plasminogen <SEP> Hs.75576<tb> plasminogen <SEP> Hs.75576 <tb> plasminogen <SEP> activator <SEP> inhibitor <SEP> 1 <SEP> Hs.82085<tb> plasminogen <SEP> activator <SEP> inhibitor <SEP> 1 <SEP> Hs.82085 <tb> platelet/endothelial <SEP> cell <SEP> adhesion <SEP> molecule <SEP> (CD31 <SEP> antigen) <SEP> Hs. <SEP> 78146<tb> platelet / endothelial <SEP> cell <SEP> adhesion <SEP> molecule <SEP> (CD31 <SEP> antigen) <SEP> Hs. <SEP> 78146 <tb> platelet-derived <SEP> growth <SEP> factor <SEP> receptor, <SEP> beta <SEP> polypeptide <SEP> Hs. <SEP> 76144<tb> platelet-derived <SEP> growth <SEP> factor <SEP> receptor, <SEP> beta <SEP> polypeptide <SEP> Hs. <SEP> 76144 <tb> polo <SEP> (Drosophia)-like <SEP> kinase <SEP> Hs. <SEP> 77597<tb> polo <SEP> (Drosophia) -like <SEP> kinase <SEP> Hs. <SEP> 77597 <tb> polymyositis/scleroderma <SEP> autoantigen <SEP> 1 <SEP> (75kD) <SEP> Hs. <SEP> 91728<tb> polymyositis / scleroderma <SEP> autoantigen <SEP> 1 <SEP> (75kD) <SEP> Hs. <SEP> 91728 <tb> postmeiotic <SEP> segregation <SEP> increased <SEP> 2-like <SEP> 3 <SEP> Hs.278467<tb> postmeiotic <SEP> segregation <SEP> increased <SEP> 2-like <SEP> 3 <SEP> Hs.278467 <tb> potassium <SEP> intermediate/small <SEP> conductance <SEP> calcium-activated <SEP> channel, <SEP> Hs.10082<tb> potassium <SEP> intermediate / small <SEP> calcium-activated <SEP> conductance <SEP> channel, <SEP> Hs.10082 <tb> subfamily <SEP> N, <SEP> member <SEP> 4<tb> subfamily <SEP> N, <SEP> member <SEP> 4 <tb> POU <SEP> domain, <SEP> class <SEP> 2, <SEP> transcription <SEP> factor <SEP> 2 <SEP> Hs. <SEP> 1101<tb> POU <SEP> domain, <SEP> class <SEP> 2, <SEP> transcription <SEP> factor <SEP> 2 <SEP> Hs. <SEP> 1101 <tb> primase, <SEP> polypeptide <SEP> 1 <SEP> (49kD) <SEP> Hs. <SEP> 82741<tb> primase, <SEP> polypeptide <SEP> 1 <SEP> (49kD) <SEP> Hs. <SEP> 82741 <tb> Progesterone <SEP> receptor <SEP> Hs. <SEP> 2905<tb> Progesterone <SEP> receptor <SEP> Hs. <SEP> 2905 <tb> proh <SEP> ! <SEP> bitin <SEP> Hs. <SEP> 75323<tb> proh <SEP>! <SEP> bitin <SEP> Hs. <SEP> 75323 <tb> <Tb> <Desc/Clms Page number 81> <Desc / Clms Page number 81>
Figure img00810001
Figure img00810001
 <tb> <Tb> <tb> prolactin <SEP> Hs. <SEP> 1905<tb> prolactin <SEP> Hs. <SEP> 1905 <tb> prolactin-induced <SEP> protein <SEP> Hs. <SEP> 99949<tb> prolactin-induced <SEP> protein <SEP> Hs. <SEP> 99949 <tb> proliferating <SEP> cell <SEP> nuclear <SEP> antigen <SEP> Hs. <SEP> 78996<tb> proliferating <SEP> cell <SEP> nuclear <SEP> antigen <SEP> Hs. <SEP> 78996 <tb> proliferation-associated <SEP> 2G4, <SEP> 38kDHs. <SEP> 5181<tb> proliferation-associated <SEP> 2G4, <SEP> 38kDHs. <SEP> 5181 <tb> protease <SEP> inhibitor <SEP> 12 <SEP> (neuroserpin) <SEP> Hs. <SEP> 78589<tb> protease <SEP> inhibitor <SEP> 12 <SEP> (neuroserpin) <SEP> Hs. <SEP> 78589 <tb> protease, <SEP> serine, <SEP> 8 <SEP> (prostasin) <SEP> Hs. <SEP> 75799<tb> protease, <SEP> serine, <SEP> 8 <SEP> (prostasin) <SEP> Hs. <SEP> 75799 <tb> proteasome <SEP> (prosome, <SEP> macropain) <SEP> 26S <SEP> subunit, <SEP> non-ATPase, <SEP> 12 <SEP> Hs. <SEP> 4295<tb> proteasome <SEP> (prosome, <SEP> macropain) <SEP> 26S <SEP> subunit, <SEP> non-ATPase, <SEP> 12 <SEP> Hs. <SEP> 4295 <tb> protein <SEP> phosphatase <SEP> 1, <SEP> catalytic <SEP> subunit, <SEP> beta <SEP> isoform <SEP> Hs. <SEP> 21537<tb> protein <SEP> phosphatase <SEP> 1, <SEP> catalytic <SEP> subunit, <SEP> beta <SEP> isoform <SEP> Hs. <SEP> 21537 <tb> protein <SEP> tyrosine <SEP> kinase <SEP> 6 <SEP> Hs. <SEP> 51133<tb> protein <SEP> tyrosine <SEP> kinase <SEP> 6 <SEP> Hs. <SEP> 51133 <tb> purinergic <SEP> receptor <SEP> P2X, <SEP> ligand-gated <SEP> ion <SEP> channel, <SEP> 4 <SEP> Hs. <SEP> 321709<tb> purinergic <SEP> receptor <SEP> P2X, <SEP> ligand-gated <SEP> ion <SEP> channel, <SEP> 4 <SEP> Hs. <SEP> 321709 <tb> RAD51Hs. <SEP> 343807<tb> RAD51Hs. <SEP> 343807 <tb> RAD54 <SEP> (S. <SEP> cerevisiae)-like <SEP> Hs. <SEP> 66718<tb> RAD54 <SEP> (S. <SEP> cerevisiae) -like <SEP> Hs. <SEP> 66718 <tb> RAP2A, <SEP> member <SEP> of <SEP> ras <SEP> oncogen <SEP> family <SEP> Hs. <SEP> 301746<tb> RAP2A, <SEP> member <SEP> of <SEP> ras <SEP> oncogen <SEP> family <SEP> Hs. <SEP> 301746 <tb> ras <SEP> homolog <SEP> gene <SEP> family, <SEP> member <SEP> B <SEP> (rhoB) <SEP> Hs. <SEP> 204354<tb> ras <SEP> peer <SEP> gene <SEP> family <SEP> member <SEP> B <SEP> (rhoB) <SEP> Hs. <SEP> 204354 <tb> ras <SEP> homolog <SEP> gene <SEP> family, <SEP> member <SEP> H <SEP> Hs. <SEP> 109918<tb> ras <SEP> peer <SEP> gene <SEP> family, <SEP> member <SEP> H <SEP> Hs. <SEP> 109918 <tb> regulator <SEP> of <SEP> G-protein <SEP> siqnalling <SEP> 5 <SEP> Hs. <SEP> 24950<tb> regulator <SEP> of <SEP> G-protein <SEP> siqnalling <SEP> 5 <SEP> Hs. <SEP> 24950 <tb> replication <SEP> factor <SEP> C <SEP> (activator <SEP> 1) <SEP> 4 <SEP> (37kD) <SEP> Hs. <SEP> 35120<tb> replication <SEP> factor <SEP> C <SEP> (activator <SEP> 1) <SEP> 4 <SEP> (37kD) <SEP> Hs. <SEP> 35120 <tb> RERG <SEP> (ds <SEP> collection <SEP> EST) <SEP> Hs. <SEP> 21594<tb> RERG <SEP> (ds <SEP> <SEP> EST Collection) <SEP> Hs. <SEP> 21594 <tb> retinoblastoma-like <SEP> 2 <SEP> (p130) <SEP> Hs. <SEP> 79362<tb> retinoblastoma-like <SEP> 2 <SEP> (p130) <SEP> Hs. <SEP> 79362 <tb> retinoic <SEP> acid <SEP> receptor <SEP> responder <SEP> (tazarotene <SEP> induced) <SEP> 1 <SEP> Hs. <SEP> 82547<tb> retinoic <SEP> acid <SEP> receptor <SEP> responder <SEP> (tazarotene <SEP> induced) <SEP> 1 <SEP> Hs. <SEP> 82547 <tb> <Tb> <Desc/Clms Page number 82> <Desc / Clms Page number 82>
Figure img00820001
Figure img00820001
 <tb> <Tb> <tb> retinol-binding <SEP> protein <SEP> 4, <SEP> interstitial <SEP> Hs. <SEP> 76461<tb> retinol-binding <SEP> protein <SEP> 4, <SEP> interstitial <SEP> Hs. <SEP> 76461 <tb> ribonucleotide <SEP> reductase <SEP> M1 <SEP> polypeptide <SEP> Hs. <SEP> 2934<tb> ribonucleotide <SEP> reductase <SEP> M1 <SEP> polypeptide <SEP> Hs. <SEP> 2934 <tb> ribosomal <SEP> protein <SEP> L13 <SEP> Hs. <SEP> 180842<tb> ribosomal <SEP> protein <SEP> L13 <SEP> Hs. <SEP> 180842 <tb> S100 <SEP> calcium <SEP> binding <SEP> prtoein <SEP> A4 <SEP> Hs. <SEP> 81256<tb> S100 <SEP> calcium <SEP> binding <SEP> pronein <SEP> A4 <SEP> Hs. <SEP> 81256 <tb> S100 <SEP> calcium-binding <SEP> protein <SEP> A2 <SEP> Hs. <SEP> 38991<tb> S100 <SEP> calcium-binding <SEP> protein <SEP> A2 <SEP> Hs. <SEP> 38991 <tb> S100 <SEP> calcium-binding <SEP> protein <SEP> A8 <SEP> Hs. <SEP> 100000<tb> S100 <SEP> calcium-binding <SEP> protein <SEP> A8 <SEP> Hs. <SEP> 100000 <tb> S100 <SEP> calcium-binding <SEP> protein <SEP> A9 <SEP> (calgranulin <SEP> B) <SEP> Hs. <SEP> 112405<tb> S100 <SEP> calcium-binding <SEP> protein <SEP> A9 <SEP> (calgranulin <SEP> B) <SEP> Hs. <SEP> 112405 <tb> 8100 <SEP> calcium-binding <SEP> protein <SEP> P <SEP> Hs. <SEP> 2962<tb> 8100 <SEP> calcium-binding <SEP> protein <SEP> P <SEP> Hs. <SEP> 2962 <tb> S100 <SEP> calcium-binding <SEP> protein, <SEP> beta <SEP> (neural) <SEP> Hs. <SEP> 83384<tb> S100 <SEP> calcium-binding <SEP> protein, <SEP> beta <SEP> (neural) <SEP> Hs. <SEP> 83384 <tb> secreted <SEP> frizzled <SEP> related <SEP> protein <SEP> 1 <SEP> Hs. <SEP> 7306<tb> secreted <SEP> frizzled <SEP> related <SEP> protein <SEP> 1 <SEP> Hs. <SEP> 7306 <tb> secretory <SEP> leukocyte <SEP> protease <SEP> inhibitor <SEP> (antileukoproteinase) <SEP> Hs. <SEP> 251754<tb> secretory <SEP> leukocyte <SEP> protease <SEP> inhibitor <SEP> (antileukoproteinase) <SEP> Hs. <SEP> 251754 <tb> selenium <SEP> binding <SEP> protein <SEP> 1 <SEP> Hs. <SEP> 334841<tb> selenium <SEP> binding <SEP> protein <SEP> 1 <SEP> Hs. <SEP> 334841 <tb> SELENOPHOSPHATE <SEP> SYNTHETASE <SEP> ; <SEP> Human <SEP> selenium <SEP> donor <SEP> protein <SEP> Hs. <SEP> 118725<tb> SELENOPHOSPHATE <SEP> SYNTHETASE <SEP>; <SEP> Human <SEP> selenium <SEP> donor <SEP> protein <SEP> Hs. <SEP> 118725 <tb> serine <SEP> proteinase <SEP> inhibitor, <SEP> clade <SEP> B, <SEP> member <SEP> 5 <SEP> (maspin) <SEP> Hs. <SEP> 55279<tb> serine <SEP> proteinase <SEP> inhibitor, <SEP> clade <SEP> B, <SEP> member <SEP> 5 <SEP> (maspin) <SEP> Hs. <SEP> 55279 <tb> serine/threonine <SEP> kinase <SEP> 15 <SEP> Hs. <SEP> 48915<tb> serine / threonine <SEP> kinase <SEP> 15 <SEP> Hs. <SEP> 48915 <tb> serum <SEP> constituent <SEP> protein <SEP> Hs.148101<tb> serum <SEP> constitute <SEP> protein <SEP> Hs.148101 <tb> singed <SEP> (Drosophila)-like <SEP> (sea <SEP> urchin <SEP> fascin <SEP> homolog <SEP> like) <SEP> Hs. <SEP> 118400<tb> singed <SEP> (Drosophila) -like <SEP> (sea <SEP> urchin <SEP> fascinate <SEP> homolog <SEP> like) <SEP> Hs. <SEP> 118400 <tb> sma <SEP> ! <SEP> ! <SEP> inducible <SEP> cytokine <SEP> subfamily <SEP> A <SEP> (Cys-Cys), <SEP> member <SEP> 18, <SEP> pulmonary <SEP> and <SEP> Hs. <SEP> 16530<tb> sma <SEP>! <SEP>! <SEP> inducible <SEP> cytokine <SEP> subfamily <SEP> A <SEP> (Cys-Cys), <SEP> member <SEP> 18, <SEQ> pulmonary <SEP> and <SEP> Hs. <SEP> 16530 <tb> activation-regulated<tb> activation-regulated <tb> small <SEP> inducible <SEP> cytokine <SEP> subfamily <SEP> D <SEP> (Cys-X3-Cys), <SEP> member <SEP> 1 <SEP> (fractalkine, <SEP> Hs. <SEP> 80420<tb> small <SEP> inducible <SEP> cytokine <SEP> subfamily <SEP> D <SEP> (Cys-X3-Cys), <SEP> member <SEP> 1 <SEP> (fractalkine, <SEP> Hs. <SEP> 80420 <tb> neurotactin)<tb> neurotactin) <tb> <Tb> <Desc/Clms Page number 83> <Desc / Clms Page number 83>
Figure img00830001
Figure img00830001
 <tb> <Tb> <tb> small <SEP> nuclear <SEP> ribonucleoprotein <SEP> polypeptide <SEP> B" <SEP> Hs. <SEP> 82575<tb> small <SEP> nuclear <SEP> ribonucleoprotein <SEP> polypeptide <SEP> B "<SEP> Hs. <SEP> 82575 <tb> solute <SEP> carrier <SEP> family <SEP> 7 <SEP> (cationic <SEP> amino <SEP> acid <SEP> transporter, <SEP> y+ <SEP> system), <SEP> member <SEP> 5 <SEP> Hs. <SEP> 184601<tb> solute <SEP> carrier <SEP> family <SEP> 7 <SEP> (cationic <SEP> amino <SEP> acid <SEP> transport, <SEP> y + <SEP> system), <SEP> member <SEP > 5 <SEP> Hs. <SEP> 184601 <tb> solute <SEP> carrier <SEP> family <SEP> 9 <SEP> (sodium/hydrogen <SEP> exchanger), <SEP> isoform <SEP> 3 <SEP> regulatory <SEP> Hs. <SEP> 184276<tb> solute <SEP> carrier <SEP> family <SEP> 9 <SEP> (sodium / hydrogen <SEP> exchanger), <SEP> isoform <SEP> 3 <SEP> regulatory <SEP> Hs. <SEP> 184276 <tb> factor <SEP> 1<tb> factor <SEP> 1 <tb> splicing <SEP> factor, <SEP> arginine/serine-rich <SEP> 5 <SEP> Hs. <SEP> 166975<tb> splicing <SEP> factor, <SEP> arginine / serine-rich <SEP> 5 <SEP> Hs. <SEP> 166975 <tb> stanniocalcin <SEP> 2 <SEP> Hs. <SEP> 155223<tb> stanniocalcin <SEP> 2 <SEP> Hs. <SEP> 155223 <tb> superoxide <SEP> dismutase <SEP> 3, <SEP> extracellular <SEP> Hs. <SEP> 2420<tb> superoxide <SEP> dismutase <SEP> 3, <SEP> extracellular <SEP> Hs. <SEP> 2420 <tb> suppression <SEP> of <SEP> tumorogenicity <SEP> Hs. <SEP> 56937<tb> suppression <SEP> of <SEP> tumorogenicity <SEP> Hs. <SEP> 56937 <tb> suppression <SEP> of <SEP> tumorogenicity <SEP> Hs. <SEP> 301974<tb> suppression <SEP> of <SEP> tumorogenicity <SEP> Hs. <SEP> 301974 <tb> T-cell <SEP> receptor, <SEP> beta <SEP> cluster <SEP> Hs. <SEP> 2003<tb> T-cell <SEP> receptor, <SEP> beta <SEP> cluster <SEP> Hs. <SEP> 2003 <tb> T-cell <SEP> receptor, <SEP> delta <SEP> (V, <SEP> D, <SEP> J, <SEP> C) <SEP> Hs. <SEP> 2014<tb> T-cell <SEP> receptor, <SEP> delta <SEP> (V, <SEP> D, <SEP> J, <SEP> C) <SEP> Hs. <SEP> 2014 <tb> TEK <SEP> tyrosine <SEP> kinase, <SEP> endothelial <SEP> (venous <SEP> malformations, <SEP> multiple <SEP> cutaneous <SEP> Hs. <SEP> 89640<tb> TEK <SEP> tyrosine <SEP> kinase, <SEP> endothelial <SEP> (venous <SEP> malformations, <SEP> multiple <SEP> cutaneous <SEP> Hs. <SEP> 89640 <tb> and <SEP> mucosal)<tb> and <SEP> mucosal) <tb> Telomerase <SEP> reverse <SEP> transcriptase <SEP> Hs. <SEP> 115256<tb> Telomerase <SEP> reverse <SEP> transcriptase <SEP> Hs. <SEP> 115256 <tb> TGFBI-induced <SEP> anti-apoptotic <SEP> factor <SEP> 1 <SEP> Hs. <SEP> 75822<tb> TGFBI-induced <SEP> anti-apoptotic <SEP> factor <SEP> 1 <SEP> Hs. <SEP> 75822 <tb> thrombospondin <SEP> 1 <SEP> Hs. <SEP> 87409<tb> thrombospondin <SEP> 1 <SEP> Hs. <SEP> 87409 <tb> Thy-1 <SEP> cell <SEP> surface <SEP> antigen <SEP> Hs. <SEP> 125359<tb> Thy-1 <SEP> cell <SEP> surface <SEP> antigen <SEP> Hs. <SEP> 125359 <tb> thymidylate <SEP> synthetase <SEP> Hs.82962<tb> thymidylate <SEP> synthetase <SEP> Hs.82962 <tb> tissue <SEP> factor <SEP> pathway <SEP> inhibitor <SEP> (lipoprotein-associated <SEP> coagulation <SEP> inhibitor) <SEP> Hs.170279<tb> tissue <SEP> factor <SEP> pathway <SEP> inhibitor <SEP> (lipoprotein-associated <SEP> coagulation <SEP> inhibitor) <SEP> Hs.170279 <tb> tissue <SEP> inhibitor <SEP> of <SEP> metalloproteinase <SEP> 1 <SEP> (erythroid <SEP> potentiating <SEP> activity, <SEP> Hs. <SEP> 5831<tb> tissue <SEP> inhibitor <SEP> of <SEP> metalloproteinase <SEP> 1 <SEP> (erythroid <SEP> potentiating <SEP> activity, <SEQ> Hs. <SEP> 5831 <tb> co <SEP> ! <SEP> ! <SEP> agenase <SEP> inhibitor)<tb> co <SEP>! <SEP>! <SEP> agenase <SEP> inhibitor <tb> <Tb> <Desc/Clms Page number 84> <Desc / Clms Page number 84>
Figure img00840001
Figure img00840001
 <tb> <Tb> <tb> tissue <SEP> inhibtor <SEP> of <SEP> metalloproteinase <SEP> 3 <SEP> Hs.245188<tb> tissue <SEP> inhibitor <SEP> of <SEP> metalloproteinase <SEP> 3 <SEP> Hs.245188 <tb> TNF <SEP> associated <SEP> factor <SEP> 4 <SEP> Hs.8375<tb> TNF <SEP> associated <SEP> factor <SEP> 4 <SEP> Hs.8375 <tb> TNF <SEP> receptor-associated <SEP> factor <SEP> 6 <SEP> Hs.90957<tb> TNF <SEP> Receptor-Associated <SEP> Factor <SEP> 6 <SEP> Hs.90957 <tb> topoisomerase <SEP> (DNA) <SEP> II <SEP> alpha <SEP> (170kD) <SEP> Hs.156346<tb> topoisomerase <SEP> (DNA) <SEP> II <SEP> alpha <SEP> (170kD) <SEP> Hs.156346 <tb> topoisomerase <SEP> (DNA) <SEP> II <SEP> beta <SEP> (180kD) <SEP> Hs. <SEP> 75248<tb> topoisomerase <SEP> (DNA) <SEP> II <SEP> beta <SEP> (180kD) <SEP> Hs. <SEP> 75248 <tb> TP53 <SEP> Hs.149923<tb> TP53 <SEP> Hs.149923 <tb> transcription <SEP> factor <SEP> AP-2 <SEP> alpha <SEP> (activating <SEP> enhancer-binding <SEP> protein <SEP> 2 <SEP> alpha) <SEP> Hs. <SEP> 18387<tb> transcription <SEP> factor <SEP> AP-2 <SEP> alpha <SEP> (activating <SEP> enhancer-binding <SEP> protein <SEP> 2 <SEP> alpha) <SEP> Hs. <SEP> 18387 <tb> Transforming <SEP> growth <SEP> factor, <SEP> alpha <SEP> Hs. <SEP> 170009<tb> Transforming SEP> growth <SEP> factor, <SEP> alpha <SEP> Hs. <SEP> 170009 <tb> transforming <SEP> growth <SEP> factor, <SEP> beta <SEP> receptor <SEP> III <SEP> (betaglycan, <SEP> 3000kD) <SEP> Hs.79059<tb> transforming <SEP> growth <SEP> factor, <SEP> beta <SEP> receptor <SEQ> III <SEP> (betaglycan, <SEQ> 3000kD) <SEQ> Hs.79059 <tb> translin <SEP> Hs.75066<tb> translin <SEP> Hs.75066 <tb> Trefoil <SEP> factor <SEP> 1 <SEP> (breast <SEP> cancer, <SEP> estrogen-inducible <SEP> sequence <SEP> expressed <SEP> in) <SEP> Hs. <SEP> 1406<tb> Trefoil <SEP> factor <SEP> 1 <SEP> (breast <SEP> cancer, <SEP> estrogen-inducible <SEP> sequence <SEP> expressed <SEP> in) <SEP> Hs. <SEP> 1406 <tb> trophinin-assisting <SEP> protein <SEP> (tastin) <SEP> Hs. <SEP> 171955<tb> trophinin-assisting <SEP> protein <SEP> (tastin) <SEP> Hs. <SEP> 171955 <tb> troponin <SEP> I, <SEP> skeletal, <SEP> fast <SEP> Hs. <SEP> 83760<tb> troponin <SEP> I, <SEP> skeletal, <SEP> fast <SEP> Hs. <SEP> 83760 <tb> tryptophanyl-tRNA <SEP> synthetase <SEP> Hs. <SEP> 82030<tb> tryptophanyl-tRNA <SEP> synthetase <SEP> Hs. <SEP> 82030 <tb> tyrosine <SEP> kinase <SEP> withimmunoglobulin <SEP> and <SEP> EGF <SEP> homology <SEP> domains <SEP> Hs. <SEP> 78824<tb> tyrosine <SEP> kinase <SEP> withimmunoglobulin <SEP> and <SEP> EGF <SEP> homology <SEP> domains <SEP> Hs. <SEP> 78824 <tb> tyrosyl-tRNA <SEP> synthetase <SEP> Hs. <SEP> 239307<tb> tyrosyl-tRNA <SEP> synthetase <SEP> Hs. <SEP> 239307 <tb> UDP-galactose <SEP> transporter <SEP> related <SEP> Hs. <SEP> 154073<tb> UDP-galactose <SEP> transport <SEP> related <SEP> Hs. <SEP> 154073 <tb> UDP-N-acetyl-alpha-D-galactosamine <SEP> 3 <SEP> Hs.278611<tb> UDP-N-acetyl-alpha-D-galactosamine <SEP> 3 <SEP> Hs.278611 <tb> uracil-DNA <SEP> glycosylase <SEP> Hs. <SEP> 78853<tb> uracil-DNA <SEP> glycosylase <SEP> Hs. <SEP> 78853 <tb> uridine <SEP> monophosphate <SEP> synthetase <SEP> (orotate <SEP> phosphoribosyl <SEP> transferase <SEP> Hs.2057<tb> uridine <SEP> monophosphate <SEP> synthetase <SEP> (orotate <SEP> phosphoribosyl <SEP> transferase <SEP> Hs.2057 <tb> and <SEP> orotidine-5'-decarboxylase)<tb> and <SEP> orotidine-5'-decarboxylase) <tb> <Tb> <Desc/Clms Page number 85> <Desc / Clms Page number 85>
Figure img00850001
Figure img00850001
 <tb> <Tb> <tb> v-erb-b2 <SEP> avian <SEP> erythroblastic <SEP> leukemia <SEP> viral <SEP> oncogene <SEP> homolog <SEP> 2 <SEP> Hs. <SEP> 323910<tb> v-erb-b2 <SEP> avian <SEP> erythroblastic <SEP> leukemia <SEP> viral <SEP> oncogene <SEP> homolog <SEP> 2 <SEP> Hs. <SEP> 323910 <tb> very <SEP> low <SEP> density <SEP> lipoprotein <SEP> receptor <SEP> Hs. <SEP> 73729<tb> very <SEP> low <SEP> density <SEP> lipoprotein <SEP> receptor <SEP> Hs. <SEP> 73729 <tb> v-Ha-ras <SEP> Harvey <SEP> rat <SEP> sarcoma <SEP> viral <SEP> oncogene <SEP> homolog <SEP> Hs. <SEP> 37003<tb> v-Ha-ras <SEP> Harvey <SEP> rat <SEP> sarcoma <SEP> viral <SEP> oncogene <SEP> homolog <SEP> Hs. <SEP> 37003 <tb> vimentin <SEP> Hs. <SEP> 297753<tb> vimentin <SEP> Hs. <SEP> 297753 <tb> v-jun <SEP> avian <SEP> sarcoma <SEP> virus <SEP> 17 <SEP> oncogene <SEP> homolog <SEP> Hs. <SEP> 78465<tb> v-jun <SEP> avian <SEP> sarcoma <SEP> virus <SEP> 17 <SEP> oncogene <SEP> homolog <SEP> Hs. <SEP> 78465 <tb> v-myb <SEP> avian <SEP> myeloblastosis <SEP> viral <SEP> oncogene <SEP> homolog-like <SEP> 2 <SEP> Hs. <SEP> 179718<tb> v-myb <SEP> avian <SEP> myeloblastosis <SEP> viral <SEP> oncogene <SEP> homolog-like <SEP> 2 <SEP> Hs. <SEP> 179718 <tb> v-myc <SEP> avian <SEP> myelocytomatosis <SEP> viral <SEP> oncogene <SEP> homolog <SEP> Hs. <SEP> 79070<tb> v-myc <SEP> avian <SEP> myelocytomatosis <SEP> viral <SEP> oncogene <SEP> homolog <SEP> Hs. <SEP> 79070 <tb> von <SEP> Willebrand <SEP> factor <SEP> Hs. <SEP> 110802<tb> von <SEP> Willebrand <SEP> factor <SEP> Hs. <SEP> 110802 <tb> WNT1 <SEP> inducible <SEP> signaling <SEP> pathway <SEP> protein <SEP> 2 <SEP> Hs. <SEP> 194679<tb> WNT1 <SEP> inducible <SEP> signaling <SEP> pathway <SEP> protein <SEP> 2 <SEP> Hs. <SEP> 194679 <tb> X-box <SEP> binding <SEP> protein <SEP> 1 <SEP> Hs. <SEP> 149923<tb> X-box <SEP> binding <SEP> protein <SEP> 1 <SEP> Hs. <SEP> 149923 <tb> Zinc <SEP> finger <SEP> protein <SEP> 147 <SEP> (estrogen-responsive <SEP> finger <SEP> protein) <SEP> Hs. <SEP> 1579<tb> Zinc <SEP> finger <SEP> protein <SEP> 147 <SEP> (estrogen-responsive <SEP> finger <SEP> protein) <SEP> Hs. <SEP> 1579 <tb> zinc <SEP> finger <SEP> protein <SEP> 161 <SEP> Hs. <SEP> 167558<tb> Zinc <SEP> Finger <SEP> Protein <SEP> 161 <SEP> Hs. <SEP> 167558 <tb> zing <SEP> finger <SEP> protein <SEP> 217 <SEP> Hs. <SEP> 155040<tb> zing <SEP> Finger <SEP> Protein <SEP> 217 <SEP> Hs. <SEP> 155040 <tb> <Tb> 17 Biopuce selon l'une quelconque des revendications 1 16 caract ris e en ce qu'elle comporte comme module de recherche associ ou coupl un module de r paration de l'ADN qui comporte une s lection de sondes mol culaires adapt e, ci-dessous ( galement Annexe 2 SEQ 2) :  A biochip according to any one of claims 1 to 16, characterized in that it comprises as its associated or coupled search module a DNA repair module which comprises a selection of suitable molecular probes, hereinafter below (also Annex 2 SEQ 2): <Desc/Clms Page number 86><Desc / Clms Page number 86> MODULE REPARATION DE L'ADN : 130 SONDES MOLECULAIRES  DNA REPAIR MODULE: 130 MOLECULAR PROBES
Figure img00860001
Figure img00860001
 <tb> <Tb> <tb> Nom <SEP> du <SEP> gene <SEP> Unigene<tb> Name <SEP> of the <SEP> gene <SEP> Unigene <tb> 8-oxoguanine <SEP> DNA <SEP> glycosylase <SEP> Hs. <SEP> 96398<tb> 8-oxoguanine <SEP> DNA <SEP> glycosylase <SEP> Hs. <SEP> 96398 <tb> ADP-ribosyltransferase <SEP> (NAD+ <SEP> ; <SEP> poly <SEP> (ADP-ribose) <SEP> polymerase) <SEP> ; <SEP> poly <SEP> (ADP-Hs. <SEP> 177766<tb> ADP-ribosyltransferase <SEP> (NAD + <SEP>; <SEP> poly <SEP> (ADP-ribose) <SEP> polymerase) <SEP>; <SEP> poly <SEP> (ADP-Hs. <SEP> 177766 <tb> ribose) <SEP> polymerase<tb> ribose) <SEP> polymerase <tb> ADP-ribosyltransferase <SEP> (NAD+ <SEP> ; <SEP> poly <SEP> (ADP-ribose) <SEP> polymerase)-like <SEP> 2 <SEP> Hs. <SEP> 24284<tb> ADP-ribosyltransferase <SEP> (NAD + <SEP>; <SEP> poly <SEP> (ADP-ribose) <SEP> polymerase) -like <SEP> 2 <SEP> Hs. <SEP> 24284 <tb> alkylation <SEP> DNA <SEP> repair <SEP> protein <SEP> alkb <SEP> homolog <SEP> Hs. <SEP> 54418<tb> alkylation <SEP> DNA <SEP> repair <SEP> protein <SEP> alkb <SEP> homolog <SEP> Hs. <SEP> 54418 <tb> APEX <SEP> nuclease <SEP> (multifunctional <SEP> DNA <SEP> repair <SEP> enzyme) <SEP> ; <SEP> apurinic/apyridinic <SEP> Hs. <SEP> 73722<tb> APEX <SEP> nuclease <SEP> (multifunctional <SEP> DNA <SEP> repair <SEP> enzyme) <SEP>; <SEP> apurinic / apyridinic <SEP> Hs. <SEP> 73722 <tb> (abasic) <SEP> endonuclease<tb> (abasic) <SEP> endonuclease <tb> apurinic/apyrimidinic <SEP> endonuclease <SEP> (APEX <SEP> nuclease)-like <SEP> 2 <SEP> protein <SEP> Hs. <SEP> 154149<tb> apurinic / apyrimidinic <SEP> endonuclease <SEP> (APEX <SEP> nuclease) -like <SEP> 2 <SEP> protein <SEP> Hs. <SEP> 154149 <tb> ataxia <SEP> telangiectasia <SEP> and <SEP> Rad3 <SEP> related <SEP> Hs. <SEP> 77613<tb> ataxia <SEP> telangiectasia <SEP> and <SEP> Rad3 <SEP> related <SEP> Hs. <SEP> 77613 <tb> ataxia <SEP> telangiectasia <SEP> mutated <SEP> (includes <SEP> complementation <SEP> groups <SEP> A, <SEP> C <SEP> and <SEP> D) <SEP> Hs. <SEP> 194382<tb> ataxia <SEP> telangiectasia <SEP> mutated <SEP> (includes <SEP> complementation <SEP> groups <SEP> A <SEP> C <SEP> and <SEP> D) <SEP> Hs. <SEP> 194382 <tb> ataxia <SEP> telangiectasia <SEP> mutated <SEP> (includes <SEP> complementation <SEP> groups <SEP> A, <SEP> C <SEP> and <SEP> D) <SEP> Hs. <SEP> 194382<tb> ataxia <SEP> telangiectasia <SEP> mutated <SEP> (includes <SEP> complementation <SEP> groups <SEP> A <SEP> C <SEP> and <SEP> D) <SEP> Hs. <SEP> 194382 <tb> Bloom <SEP> syndrome <SEP> Hs. <SEP> 36820<tb> Bloom <SEP> syndrome <SEP> Hs. <SEP> 36820 <tb> breast <SEP> cancer <SEP> 1, <SEP> early <SEP> onset <SEP> Hs. <SEP> 194143<tb> breast <SEP> cancer <SEP> 1, <SEP> early <SEP> onset <SEP> Hs. <SEP> 194143 <tb> breast <SEP> cancer <SEP> 2, <SEP> early <SEP> onset <SEP> Hs. <SEP> 34012<tb> breast <SEP> cancer <SEP> 2, <SEP> early <SEP> onset <SEP> Hs. <SEP> 34012 <tb> caltractin <SEP> (20kD <SEP> calcium-binding <SEP> protein) <SEP> ; <SEP> centrin, <SEP> EF-hand <SEP> protein, <SEP> 2 <SEP> Hs. <SEP> 82794<tb> caltractin <SEP> (20kD <SEP> calcium-binding <SEP> protein) <SEP>; <SEP> centrin, <SEP> EF-hand <SEP> protein, <SEP> 2 <SEP> Hs. <SEP> 82794 <tb> CHK1 <SEP> (checkpoint, <SEP> S.pombe) <SEP> homolog <SEP> Hs.20295<tb> CHK1 <SEP> (checkpoint, <SEP> S.pombe) <SEP> peer <SEP> Hs.20295 <tb> CHK2 <SEP> (checkpoint, <SEP> S. <SEP> pombe) <SEP> homolog <SEP> Hs. <SEP> 146329<tb> CHK2 <SEP> (checkpoint, <SE> S. <SEP> pombe) <SEP> peer <SEP> Hs. <SEP> 146329 <tb> Cockayne <SEP> syndrome <SEP> I <SEP> (classical) <SEP> Hs. <SEP> 32967<tb> Cockayne <SEP> syndrome <SEP> I <SEP> (classical) <SEP> Hs. <SEP> 32967 <tb> <Tb> <Desc/Clms Page number 87> <Desc / Clms Page number 87>
Figure img00870001
Figure img00870001
 <tb> <Tb> <tb> cyclin <SEP> H <SEP> Hs. <SEP> 514<tb> cyclin <SEP> H <SEP> Hs. <SEP> 514 <tb> cyclin-dependent <SEP> kinase <SEP> 7 <SEP> (homolog <SEP> of <SEP> Xenopus <SEP> M015 <SEP> cdk-activating <SEP> Hs. <SEP> 184298<tb> cyclin-dependent <SEP> kinase <SEP> 7 <SEP> <SEP> of <SEP> Xenopus <SEP> M015 <SEP> cdk-activating <SEP> Hs. <SEP> 184298 <tb> kinase)<tb> kinase) <tb> damage-specific <SEP> DNA <SEP> b <SEP> ! <SEP> nding <SEP> protein <SEP> 1 <SEP> (48kD) <SEP> Hs. <SEP> 108327<tb> damage-specific <SEP> DNA <SEP> b <SEP>! <SEP> nding <SEP> protein <SEP> 1 <SEP> (48kD) <SEP> Hs. <SEP> 108327 <tb> damage-specific <SEP> DNA <SEP> binding <SEP> protein <SEP> 2 <SEP> (48kD) <SEP> Hs. <SEP> 77602<tb> damage-specific <SEP> DNA <SEP> binding <SEQ> protein <SEP> 2 <SEP> (48kD) <SEP> Hs. <SEP> 77602 <tb> DMC1 <SEP> HS. <SEP> 37181<tb> DMC1 <SEP> HS. <SEP> 37181 <tb> dUTP <SEP> pyrophosphatase <SEP> Hs. <SEP> 82113<tb> dUTP <SEP> pyrophosphatase <SEP> Hs. <SEP> 82113 <tb> ESTs/human <SEP> p53 <SEP> R2 <SEP> gene <SEP> for <SEP> ribonucleotide <SEP> reductase <SEP> Hs. <SEP> 94262<tb> ESTs / human <SEP> p53 <SEP> R2 <SEP> gene <SEP> for <SEP> ribonucleotide <SEP> reductase <SEP> Hs. <SEP> 94262 <tb> ESTs, <SEP> Weakly <SEP> similar <SEP> to <SEP> DNA <SEP> NUCLEOTIDYLEXOTRANSFERASE <SEP> Hs.46964<tb> ESTs, <SEP> Weakly <SEP> similar <SEP> to <SEP> DNA <SEP> NUCLEOTIDYLEXOTRANSFERASE <SEP> Hs.46964 <tb> [H. <SEP> sapiens]/similar <SEP> to <SEP> DNA <SEP> polymerase <SEP> <tb> [H. <SEP> sapiens] / similar <SEP> to <SEP> DNA <SEP> polymerase <SEP> <tb> excision <SEP> repair <SEP> cross-complementing <SEP> rodent <SEP> repair <SEP> deficiency, <SEP> Hs. <SEP> 99987<tb> excision <SEP> repair <SEP> cross-complementing <SEP> repair <SEP> repair <SEP> deficiency, <SEP> Hs. <SEP> 99987 <tb> complementation <SEP> group <SEP> (xeroderma <SEP> pigmentosum <SEP> group <SEP> D<tb> complementation <SEP> group <SEP> (xeroderma <SEP> pigmentosum <SEP> group <SEP> D <tb> complementing)<tb> complementing) <tb> excision <SEP> repair <SEP> cross-complementing <SEP> rodent <SEP> repair <SEP> deficiency, <SEP> Hs. <SEP> 59544<tb> excision <SEP> repair <SEP> cross-complementing <SEP> repair <SEP> repair <SEP> deficiency, <SEP> Hs. <SEP> 59544 <tb> complementation <SEP> group <SEP> 1 <SEP> (includes <SEP> overlapping <SEP> antisense <SEP> s quence)<tb> complementation <SEP> group <SEP> 1 <SEP> (includes <SEP> overlapping <SEP> antisense <SEP> squency) <tb> excision <SEP> repair <SEP> cross-complementing <SEP> rodent <SEP> repair <SEP> deficiency, <SEP> Hs. <SEP> 77929<tb> excision <SEP> repair <SEP> cross-complementing <SEP> repair <SEP> repair <SEP> deficiency, <SEP> Hs. <SEP> 77929 <tb> complementation <SEP> group <SEP> 3 <SEP> (xeroderma <SEP> pigmentosum <SEP> group <SEP> B<tb> complementation <SEP> group <SEP> 3 <SEP> (xeroderma <SEP> pigmentosum <SEP> group <SEP> B <tb> complementing)<tb> complementing) <tb> excision <SEP> repair <SEP> cross-complementing <SEP> rodent <SEP> repair <SEP> deficiency, <SEP> Hs. <SEP> 89296<tb> excision <SEP> repair <SEP> cross-complementing <SEP> repair <SEP> repair <SEP> deficiency, <SEP> Hs. <SEP> 89296 <tb> complementation <SEP> group <SEP> 4<tb> complementation <SEP> group <SEP> 4 <tb> excision <SEP> repair <SEP> cross-complementing <SEP> rodent <SEP> repair <SEP> deficiency, <SEP> Hs. <SEP> 48576<tb> excision <SEP> repair <SEP> cross-complementing <SEP> repair <SEP> repair <SEP> deficiency, <SEP> Hs. <SEP> 48576 <tb> complementation <SEP> group <SEP> 5 <SEP> (xeroderma <SEP> pigmentosum, <SEP> complementation<tb> complementation <SEP> group <SEP> 5 <SEP> (xeroderma <SEP> pigmentosum, <SEP> supplementation <tb> group <SEP> G <SEP> (Cockayne <SEP> syndrome))<tb> group <SEP> G <SEP> (Cockayne <SEP> Syndrome)) <tb> excision <SEP> repair <SEP> cross-complementing <SEP> rodent <SEP> repair <SEP> deficiency, <SEP> Hs. <SEP> 99924<tb> excision <SEP> repair <SEP> cross-complementing <SEP> repair <SEP> repair <SEP> deficiency, <SEP> Hs. <SEP> 99924 <tb> complementation <SEP> group <SEP> 6<tb> complementation <SEP> group <SEP> 6 <tb> <Tb> <Desc/Clms Page number 88> <Desc / Clms Page number 88>
Figure img00880001
Figure img00880001
 <tb> <Tb> <tb> exonuclease <SEP> 1 <SEP> Hs. <SEP> 47504<tb> exonuclease <SEP> 1 <SEP> Hs. <SEP> 47504 <tb> Fanconi <SEP> anemia, <SEP> complementation <SEP> group <SEP> A <SEP> Hs.86297<tb> Fanconi <SEP> anemia, <SEP> supplementation <SEP> group <SEP> A <SEP> Hs.86297 <tb> Fanconi <SEP> anemia, <SEP> complementation <SEP> group <SEP> B<tb> Fanconi <SEP> anemia, <SEP> supplementation <SEP> group <SEP> B <tb> Fanconi <SEP> anemia, <SEP> complementation <SEP> group <SEP> C <SEP> Hs.37953<tb> Fanconi <SEP> anemia, <SEP> supplementation <SEP> group <SEP> C <SEP> Hs.37953 <tb> Fanconi <SEP> anemia, <SEP> complementation <SEP> group <SEP> D1<tb> Fanconi <SEP> anemia, <SEP> supplementation <SEP> group <SEP> D1 <tb> Fanconi <SEP> anemia, <SEP> complementation <SEP> group <SEP> D2 <SEP> Hs.15607<tb> Fanconi <SEP> anemia, <SEP> supplementation <SEP> group <SEP> D2 <SEP> Hs.15607 <tb> Fanconi <SEP> anemia, <SEP> complementation <SEP> group <SEP> E <SEP> Hs. <SEP> 302003<tb> Fanconi <SEP> anemia, <SEP> complementation <SEP> group <SEP> E <SEP> Hs. <SEP> 302003 <tb> Fanconi <SEP> anemia, <SEP> complementation <SEP> group <SEP> F <SEP> Hs. <SEP> 65328<tb> Fanconi <SEP> anemia, <SEP> complementation <SEP> group <SEP> F <SEP> Hs. <SEP> 65328 <tb> Fanconi <SEP> anemia, <SEP> complementation <SEP> group <SEP> G <SEP> Hs. <SEP> 8047<tb> Fanconi <SEP> anemia, <SEP> complementation <SEP> group <SEP> G <SEP> Hs. <SEP> 8047 <tb> flap <SEP> structure-specific <SEP> endonuclease <SEP> 1 <SEP> Hs. <SEP> 4756<tb> flap <SEP> structure-specific <SEP> endonuclease <SEP> 1 <SEP> Hs. <SEP> 4756 <tb> general <SEP> transcription <SEP> factor <SEP> t) <SEP> H, <SEP> potypeptide <SEP> 1 <SEP> (62kD <SEP> subunit) <SEP> Hs. <SEP> 89578<tb> general <SEP> transcription <SEP> factor <SEP> t) <SEP> H, <SEP> potypeptide <SEP> 1 <SEP> (62kD <SEP> subunit) <SEP> Hs. <SEP> 89578 <tb> general <SEP> transcription <SEP> factor <SEP> IIH, <SEP> polypeptide <SEP> 2 <SEP> (30kD <SEP> subunit) <SEP> Hs. <SEP> 191356<tb> general <SEP> transcription <SEP> factor <SEP> IIH, <SEP> polypeptide <SEP> 2 <SEP> (30kD <SEP> subunit) <SEP> Hs. <SEP> 191356 <tb> general <SEP> transcription <SEP> factor <SEP> IIH, <SEP> polypeptide <SEP> 3 <SEP> (34kD <SEP> subunit) <SEP> Hs. <SEP> 90304<tb> general <SEP> transcription <SEP> factor <SEP> IIH, <SEP> polypeptide <SEP> 3 <SEP> (34kD <SEP> subunit) <SEP> Hs. <SEP> 90304 <tb> general <SEP> transcription <SEP> factor <SEP> IIH, <SEP> polypeptide <SEP> 4 <SEP> (52kD <SEP> subunit) <SEP> Hs. <SEP> 1 <SEP> 02910<tb> general <SEP> transcription <SEP> factor <SEP> IIH, <SEP> polypeptide <SEP> 4 <SEP> (52kD <SEP> subunit) <SEP> Hs. <SEP> 1 <SEP> 02910 <tb> H2A <SEP> histone <SEP> family, <SEP> member <SEP> X <SEP> Hs. <SEP> 147097<tb> H2A <SEP> histone <SEP> family, <SEP> member <SEP> X <SEP> Hs. <SEP> 147097 <tb> HCNP <SEP> protein <SEP> ; <SEP> XPA-bindin <SEP> rotein <SEP> 2 <SEP> Hs. <SEP> 9822<tb> HCNP <SEP> protein <SEP>; <SEP> XPA-bindin <SEP> rotein <SEP> 2 <SEP> Hs. <SEP> 9822 <tb> Homo <SEP> sapiens <SEP> mRNA; <SEP> cDNA <SEP> DKFp586G1122 <SEP> (from <SEP> clone <SEP> Hs. <SEP> 20555<tb> Homo <SEP> sapiens <SEP> mRNA; <SEP> cDNA <SEP> DKFp586G1122 <SEP> (from <SEP> clone <SEP> Hs. <SEP> 20555 <tb> DKFZp586G1122) <SEP> (MRE11A)<tb> DKFZp586G1122) <SEP> (MRE11A) <tb> HUS1 <SEP> (S. <SEP> pombe) <SEP> checkpoint <SEP> homoiogHs. <SEP> 152983<tb> HUS1 <SEP> (S. <SEP> pombe) <SEP> checkpoint <SEP> homoiogHs. <SEP> 152983 <tb> KIAA0086 <SEP> g ne <SEP> productHs. <SEP> 1560<tb> KIAA0086 <SEP> g <SEP> productHs. <SEP> 1560 <tb> ligase <SEP> I, <SEP> DNA, <SEP> ATP-dependent <SEP> Hs.1770<tb> ligase <SEP> I, <SEP> DNA, <SEP> ATP-dependent <SEP> Hs.1770 <tb> <Tb> <Desc/Clms Page number 89> <Desc / Clms Page number 89>
Figure img00890001
Figure img00890001
 <tb> <Tb> <tb> ligase <SEP> III, <SEP> DNA, <SEP> ATP-dependent <SEP> Hs. <SEP> 100299<tb> ligase <SEP> III, <SEP> DNA, <SEP> ATP-dependent <SEP> Hs. <SEP> 100299 <tb> ligase <SEP> IV, <SEP> DNA, <SEP> ATP-dependent <SEP> Hs. <SEP> 166091<tb> ligase <SEP> IV, <SEP> DNA, <SEP> ATP-dependent <SEP> Hs. <SEP> 166091 <tb> menage <SEP> a <SEP> trois <SEP> 1 <SEP> (CAK <SEP> assembly <SEP> factor <SEP> Hs. <SEP> 32380<tb> household <SEP> a <SEP> three <SEP> 1 <SEP> (CAK <SEP> assembly <SEP> factor <SEP> Hs. <SEP> 32380 <tb> methyl-CpG <SEP> binding <SEP> domain <SEP> protein <SEP> 4 <SEP> Hs.35947<tb> methyl-CpG <SEP> binding <SEP> domain <SEQ> protein <SEP> 4 <SEP> Hs.35947 <tb> mitotic <SEP> arrest <SEP> defience, <SEP> yeast, <SEP> -like2 <SEP> hs.19400<tb> mitotic <SEP> arrest <SEP> defiance, <SEP> yeast, <SEP> -like2 <SEP> hs.19400 <tb> MMS19 <SEP> (MET18 <SEP> S. <SEP> cerevisiae)- <SEP> like <SEP> Hs. <SEP> 288891<tb> MMS19 <SEP> (MET18 <SE> S. <SEP> cerevisiae) - <SEP> like <SEP> Hs. <SEP> 288891 <tb> mutL <SEP> (E. <SEP> co) <SEP> i) <SEP> homofog <SEP> 1 <SEP> (coton <SEP> cancer, <SEP> nonpo) <SEP> yposis <SEP> type <SEP> 2) <SEP> Hs. <SEP> 57301<tb> mutL <SEP> (E. <SEP> co) <SEP> i) <SEP> homofog <SEP> 1 <SEP> (cotton <SEP> cancer, <SEP> nonpo) <SEP> yposis <SEP> type <SEP> 2) <SEP> Hs. <SEP> 57301 <tb> mutL <SEP> (E. <SEP> coli) <SEP> homolog3 <SEP> Hs.279842<tb> mutL <SEP> (E. <SEP> coli) <SEP> homolog3 <SEP> Hs.279842 <tb> muts <SEP> (E. <SEP> coli) <SEP> homolog <SEP> 3 <SEP> Hs.42674<tb> muts <SEP> (E. <SEP> coli) <SEP> homolog <SEP> 3 <SEP> Hs.42674 <tb> mutS <SEP> (E. <SEP> coli) <SEP> homolog <SEP> 4 <SEP> Hs.115246<tb> mutS <SEP> (E. <SEP> coli) <SEP> homolog <SEP> 4 <SEP> Hs.115246 <tb> mutS <SEP> (E. <SEP> coli) <SEP> homolog <SEP> 5 <SEP> Hs.112193<tb> mutS <SEP> (E. <SEP> coli) <SEP> homolog <SEP> 5 <SEP> Hs.112193 <tb> mutS <SEP> (E. <SEP> coli) <SEP> homolog <SEP> 5 <SEP> Hs.112193<tb> mutS <SEP> (E. <SEP> coli) <SEP> homolog <SEP> 5 <SEP> Hs.112193 <tb> mutS <SEP> (E. <SEP> coli) <SEP> homolog <SEP> 2 <SEP> Hs.78934<tb> mutS <SEP> (E. <SEP> coli) <SEP> homolog <SEP> 2 <SEP> Hs.78934 <tb> mutS <SEP> (E.coli) <SEP> homolog <SEP> 2 <SEP> Hs.78934<tb> mutS <SEP> (E. coli) <SEP> homolog <SEP> 2 <SEP> Hs.78934 <tb> mutS <SEP> (E.coli) <SEP> homolog <SEP> 6 <SEP> Hs.3248<tb> mutS <SEP> (E.coli) <SEP> homolog <SEP> 6 <SEP> Hs.3248 <tb> mutY <SEP> (E.coli) <SEP> homolog <SEP> Hs.271353<tb> mutY <SEP> (E. coli) <SEP> homolog <SEP> Hs.271353 <tb> Nijmegen <SEP> breakage <SEP> syndrome <SEP> 1 <SEP> (nibrin) <SEP> Hs.25812<tb> Nijmegen <SEP> breakage <SEP> syndrome <SEP> 1 <SEP> (nibrin) <SEP> Hs.25812 <tb> N-methylpurine-DNA <SEP> glycosylase <SEP> Hs.79396<tb> N-methylpurine-DNA <SEP> glycosylase <SEP> Hs.79396 <tb> nth <SEP> (E. <SEP> coli <SEP> endonuclease <SEP> II)-like <SEP> 1 <SEP> Hs. <SEP> 66196<tb> nth <SEP> (E. <SEP> coli <SEP> endonuclease <SEP> II) -like <SEP> 1 <SEP> Hs. <SEP> 66196 <tb> nudix <SEP> (nucleoside <SEP> diphosphate <SEP> linked <SEP> moiety <SEP> X)-type <SEP> motif <SEP> 1 <SEP> Hs. <SEP> 388<tb> nudix <SEP> (nucleoside <SEP> diphosphate <SEP> linked <SEP> moiety <SEP> X) -type <SEP> pattern <SEP> 1 <SEP> Hs. <SEP> 388 <tb> O-6-methylguanine-DNA <SEP> methyltransferase <SEP> Hs. <SEP> 1384<tb> O-6-methylguanine-DNA <SEP> methyltransferase <SEP> Hs. <SEP> 1384 <tb> <Tb> <Desc/Clms Page number 90> <Desc / Clms Page number 90>
Figure img00900001
Figure img00900001
 <tb> <Tb> <tb> polymerase <SEP> (DNA <SEP> directed) <SEP> eta <SEP> Hs. <SEP> 155573<tb> polymerase <SEP> (DNA <SEP> directed) <SEP> eta <SEP> Hs. <SEP> 155573 <tb> polymerase <SEP> (DNA <SEP> directed) <SEP> gamma <SEP> Hs. <SEP> 80961<tb> polymerase <SEP> (DNA <SEP> directed) <SEP> gamma <SEP> Hs. <SEP> 80961 <tb> polymerase <SEP> (DNA <SEP> directed) <SEP> iota <SEP> Hs. <SEP> 271699<tb> polymerase <SEP> (DNA <SEP> directed) <SEP> iota <SEP> Hs. <SEP> 271699 <tb> polymerase <SEP> (DNA <SEP> directed) <SEP> kappa <SEP> Hs. <SEP> 135756<tb> polymerase <SEP> (DNA <SEP> directed) <SEP> kappa <SEP> Hs. <SEP> 135756 <tb> polymerase <SEP> (DNA <SEP> directed) <SEP> lambda <SEP> Hs. <SEP> 129903<tb> polymerase <SEP> (DNA <SEP> directed) <SEP> lambda <SEP> Hs. <SEP> 129903 <tb> polymerase <SEP> (DNA <SEP> directed) <SEP> lambda <SEP> Hs. <SEP> 225951<tb> polymerase <SEP> (DNA <SEP> directed) <SEP> lambda <SEP> Hs. <SEP> 225951 <tb> polymerase <SEP> (DNA <SEP> directed), <SEP> beta <SEP> Hs. <SEP> 180107<tb> polymerase <SEP> (DNA <SEP> directed), <SEP> beta <SEP> Hs. <SEP> 180107 <tb> polymerase <SEP> (DNA <SEP> directed), <SEP> delta <SEP> 1, <SEP> catalytic <SEP> subunit <SEP> (125kD) <SEP> Hs. <SEP> 99890<tb> polymerase <SEP> (DNA <SEP> directed), <SEP> delta <SEP> 1, <SEP> catalytic <SEP> subunit <SEP> (125kD) <SEP> Hs. <SEP> 99890 <tb> polymerase'DNA <SEP> directed), <SEP> epsilon <SEP> Hs. <SEP> 166846<tb> polymerase'DNA <SEP> directed), <SEP> epsilon <SEP> Hs. <SEP> 166846 <tb> polynucleotide <SEP> kinase <SEP> 3'phosphatase <SEP> Hs. <SEP> 78016<tb> polynucleotide <SEP> kinase <SEP> 3'phosphatase <SEP> Hs. <SEP> 78016 <tb> postmeiotic <SEP> segregation <SEP> increased <SEP> (S. <SEP> cerevisiae <SEP> 1 <SEP> HS. <SEP> 111749<tb> postmeiotic <SEP> segregation <SEP> increased <SEP> (S. <SEP> cerevisiae <SEP> 1 <SEP> HS. <SEP> 111749 <tb> postmeiotic <SEP> segregation <SEP> increased <SEP> (S. <SEP> cerevisiae) <SEP> 2 <SEP> Hs. <SEP> 177548<tb> postmeiotic <SEP> segregation <SEP> increased <SEP> (S. <SEP> cerevisiae) <SEP> 2 <SEP> Hs. <SEP> 177548 <tb> postmeiotic <SEP> segregation <SEP> increased <SEP> 2-like <SEP> 3 <SEP> Hs. <SEP> 278467<tb> postmeiotic <SEP> segregation <SEP> increased <SEP> 2-like <SEP> 3 <SEP> Hs. <SEP> 278467 <tb> postmeiotic <SEP> segregation <SEP> increased <SEP> 2-like <SEP> 4 <SEP> Hs. <SEP> 278468<tb> postmeiotic <SEP> segregation <SEP> increased <SEP> 2-like <SEP> 4 <SEP> Hs. <SEP> 278468 <tb> proliferating <SEP> cell <SEP> nuclear <SEP> antigen <SEP> Hs. <SEP> 78996<tb> proliferating <SEP> cell <SEP> nuclear <SEP> antigen <SEP> Hs. <SEP> 78996 <tb> protein <SEP> kinase, <SEP> DNA-activated, <SEP> catalytic <SEP> polypeptide <SEP> Hs.155637<tb> protein <SEP> kinase, <SEP> DNA-activated, <SEP> catalytic <SEP> polypeptide <SEP> Hs.155637 <tb> RAD1 <SEP> (S. <SEP> pombe) <SEP> homolog <SEP> Hs. <SEP> 7179<tb> RAD1 <SEP> (S. <SEP> pombe) <SEP> peer <SEP> Hs. <SEP> 7179 <tb> RAD18 <SEP> Hs.21320<tb> RAD18 <SEP> Hs.21320 <tb> RAD23 <SEP> (S. <SEP> cerevisiae) <SEP> homolog <SEP> A <SEP> Hs. <SEP> 180455<tb> RAD23 <SEP> (S. <SEP> cerevisiae) <SEP> homolog <SEP> A <SEP> Hs. <SEP> 180455 <tb> RAD23 <SEP> (S. <SEP> cerevisiae) <SEP> homolog <SEP> B <SEP> Hs. <SEP> 178658<tb> RAD23 <SEP> (S. <SEP> cerevisiae) <SEP> peer <SEP> B <SEP> Hs. <SEP> 178658 <tb> <Tb> <Desc/Clms Page number 91> <Desc / Clms Page number 91>
Figure img00910001
Figure img00910001
 <tb> <Tb> <tb> RAD50 <SEP> (S. <SEP> cerevisiae) <SEP> homolog <SEP> Hs. <SEP> 41587<tb> RAD50 <SEP> (S. <SEP> cerevisiae) <SEP> homolog <SEP> Hs. <SEP> 41587 <tb> RAD51 <SEP> (S. <SEP> cerevisiae) <SEP> homolog <SEP> (E <SEP> coli <SEP> RecA <SEP> homolog) <SEP> Hs. <SEP> 153667<tb> RAD51 <SEP> (S. <SEP> cerevisiae) <SEP> homolog <SEP> (E <SEP> coli <SEP> RecA <SEP> homolog) <SEP> Hs. <SEP> 153667 <tb> RAD51 <SEP> (S. <SEP> cerevislae) <SEP> homolog <SEP> C <SEP> Hs. <SEP> 11393<tb> RAD51 <SEP> (S. <SEP> cerevislae) <SEP> peer <SEP> C <SEP> Hs. <SEP> 11393 <tb> RAD51 <SEP> L1Hs. <SEP> 100669<tb> RAD51 <SEP> L1Hs. <SEP> 100669 <tb> RAD51 <SEP> L3 <SEP> Hs. <SEP> 125244<tb> RAD51 <SEP> L3 <SEP> Hs. <SEP> 125244 <tb> RAD52 <SEP> (S. <SEP> cerevisiae) <SEP> homolog <SEP> HS. <SEP> 89571<tb> RAD52 <SEP> (S. <SEP> cerevisiae) <SEP> homolog <SEP> HS. <SEP> 89571 <tb> RAD54 <SEP> (S. <SEP> cerevisiae)-like <SEP> Hs. <SEP> 66718<tb> RAD54 <SEP> (S. <SEP> cerevisiae) -like <SEP> Hs. <SEP> 66718 <tb> RAD54B <SEP> Hs. <SEP> 128501<tb> RAD54B <SEP> Hs. <SEP> 128501 <tb> RAD9 <SEP> (S. <SEP> pombe) <SEP> homolog <SEP> Hs. <SEP> 240457<tb> RAD9 <SEP> (S. <SEP> pombe) <SEP> peer <SEP> Hs. <SEP> 240457 <tb> RecQ <SEP> protein-like <SEP> 4 <SEP> Hs. <SEP> 31442<tb> RecQ <SEP> protein-like <SEP> 4 <SEP> Hs. <SEP> 31442 <tb> replication <SEP> protein <SEP> A1 <SEP> (70kD) <SEP> /GS2 <SEP> gene <SEP> (=C9) <SEP> Hs. <SEP> 84318<tb> replication <SEP> protein <SEP> A1 <SEP> (70kD) <SEP> / GS2 <SEP> gene <SEP> (= C9) <SEP> Hs. <SEP> 84318 <tb> replication <SEP> protein <SEP> A2 <SEP> (32kD) <SEP> Hs. <SEP> 79411<tb> replication <SEP> protein <SEP> A2 <SEP> (32kD) <SEP> Hs. <SEP> 79411 <tb> replication <SEP> protein <SEP> A2 <SEP> (32kD) <SEP> Hs. <SEP> 79411<tb> replication <SEP> protein <SEP> A2 <SEP> (32kD) <SEP> Hs. <SEP> 79411 <tb> replication <SEP> protein <SEP> A3 <SEP> (14kD) <SEP> Hs. <SEP> 1608<tb> replication <SEP> protein <SEP> A3 <SEP> (14kD) <SEP> Hs. <SEP> 1608 <tb> REV1 <SEP> (yeast <SEP> homoloa) <SEP> - <SEP> like <SEP> Hs. <SEP> 110347<tb> REV1 <SEP> (yeast <SEP> homolo) <SEP> - <SEP> like <SEP> Hs. <SEP> 110347 <tb> REV3 <SEP> (yeast <SEP> homolog)-like, <SEP> catalytic <SEP> subunit <SEP> of <SEP> DNA <SEP> polymerase <SEP> zeta <SEP> HS. <SEP> 115521<tb> REV3 <SEP> (yeast <SEP> homolog) -like, <SEP> catalytic <SEP> subunit <SEP> of <SEP> DNA <SEP> polymerase <SEP> zeta <SEP> HS. <SEP> 115521 <tb> single-strand <SEP> monofunctionnal <SEP> uracil <SEP> DNA <SEP> glycosylase <SEP> Hs.5212<tb> single-strand <SEP> monofunctional <SEP> uracil <SEP> DNA <SEP> glycosylase <SEP> Hs.5212 <tb> SPO11, <SEP> meiotic <SEP> protein <SEP> covalently <SEP> bound <SEP> to <SEP> DSB <SEP> (S-cerevisiae) <SEP> -like <SEP> Hs. <SEP> 159737<tb> SPO11, <SEP> meiotic <SEP> protein <SEP> covalently <SEP> bound <SEP> to <SEP> DSB <SEP> (S-cerevisiae) <SEP> -like <SEP> Hs. <SEP> 159737 <tb> three <SEP> time <SEP> reoair <SEP> exonuclease <SEP> 1 <SEP> Hs. <SEP> 278408<tb> three <SEP> time <SEP> reoair <SEP> exonuclease <SEP> 1 <SEP> Hs. <SEP> 278408 <tb> three <SEP> time <SEP> repair <SEP> exonuclease <SEP> 2 <SEP> Hs. <SEP> 251398<tb> three <SEP> time <SEP> repair <SEP> exonuclease <SEP> 2 <SEP> Hs. <SEP> 251398 <tb> <Tb> <Desc/Clms Page number 92> <Desc / Clms Page number 92>
Figure img00920001
Figure img00920001
 <tb> <Tb> <tb> thymidine-DNA <SEP> glycosylase <SEP> Hs. <SEP> 173824<tb> thymidine-DNA <SEP> glycosylase <SEP> Hs. <SEP> 173824 <tb> thyroid <SEP> autoant <SEP> ! <SEP> gen <SEP> 70kD <SEP> (Ku <SEP> antigen) <SEP> Hs. <SEP> 197345<tb> thyroid <SEP> selfing <SEP>! <SEP> gen <SEP> 70kD <SEP> (Ku <SEP> antigen) <SEP> Hs. <SEP> 197345 <tb> topoisomerase <SEP> retated <SEP> function <SEP> protein <SEP> 4-2 <SEP> Hs. <SEP> 294030<tb> topoisomerase <SEP> retated <SEP> function <SEP> protein <SEP> 4-2 <SEP> Hs. <SEP> 294030 <tb> tumor <SEP> protein <SEP> 53-binding <SEP> protein, <SEP> 1 <SEP> Hs. <SEP> 170263<tb> tumor <SEP> protein <SEP> 53-binding <SEP> protein, <SEP> 1 <SEP> Hs. <SEP> 170263 <tb> ubiquitin <SEP> activating <SEP> enzyme-2Hs. <SEP> 16695<tb> ubiquitin <SEP> activating <SEP> enzyme-2Hs. <SEP> 16695 <tb> ubiquitin-conjugating <SEP> enzyme <SEP> E2A <SEP> (RAD6 <SEP> homolog) <SEP> Hs. <SEP> 80612<tb> ubiquitin-conjugating <SEP> enzyme <SEP> E2A <SEP> (RAD6 <SEP> homolog) <SEP> Hs. <SEP> 80612 <tb> ubiquitin-conjugating <SEP> enzyme <SEP> E2A <SEP> variant <SEP> 2 <SEP> Hs. <SEP> 79300<tb> ubiquitin-conjugating <SEP> enzyme <SEP> E2A <SEP> variant <SEP> 2 <SEP> Hs. <SEP> 79300 <tb> ubiquitin-conjugating <SEP> enzyme <SEP> E2N <SEP> (homologous <SEP> to <SEP> yeast <SEP> UBC13) <SEP> Hs.75355<tb> ubiquitin-conjugating <SEP> enzyme <SEP> E2N <SEP> (homologous <SEP> to <SEP> yeast <SEP> UBC13) <SEP> Hs.75355 <tb> uracil-DNA <SEP> glycosylase <SEP> Hs. <SEP> 78853<tb> uracil-DNA <SEP> glycosylase <SEP> Hs. <SEP> 78853 <tb> Werner <SEP> syndrome <SEP> Hs. <SEP> 150477<tb> Werner <SEP> syndrome <SEP> Hs. <SEP> 150477 <tb> xeroderma <SEP> pigmentosum, <SEP> complementation <SEP> group <SEP> A <SEP> Hs.192803<tb> xeroderma <SEP> pigmentosum, <SEP> supplementation <SEP> group <SEP> A <SEP> Hs.192803 <tb> xeroderma <SEP> pigmentosum, <SEP> complementation <SEP> group <SEP> C <SEP> Hs.320<tb> xeroderma <SEP> pigmentosum, <SEP> supplementation <SEP> group <SEP> C <SEP> Hs.320 <tb> X-ray <SEP> repair <SEP> complementing <SEP> defective <SEP> repair <SEP> in <SEP> Chinese <SEP> hamster <SEP> cells <SEP> 1 <SEP> Hs.98493<tb> X-ray <SEP> <SEP> repair <SEP> <SEP> defective <SEP> repair <SEP> in <SEP> Chinese <SEP> hamster <SEP> cells <SEP> 1 <SEP> Hs.98493 <tb> X-ray <SEP> repair <SEP> comptementtng <SEP> defective <SEP> repair <SEP> in <SEP> Chinese <SEP> hamster <SEP> cefts <SEP> 2 <SEP> Hs. <SEP> 129727<tb> X-ray <SEP> repair <SEP> countingtng <SEP> defective <SEP> repair <SEP> in <SEP> Chinese <SEP> hamster <SEP> cefts <SEP> 2 <SEP> Hs. <SEP> 129727 <tb> X-ray <SEP> repair <SEP> complementing <SEP> defective <SEP> repair <SEP> in <SEP> Chinese <SEP> hamster <SEP> cells <SEP> 3 <SEP> Hs. <SEP> 99742<tb> X-ray <SEP> <SEP> repair <SEP> defective <SEP> repair <SEP> in <SEP> Chinese <SEP> hamster <SEP> cells <SEP> 3 <SEP> Hs. <SEP> 99742 <tb> X-ray <SEP> repair <SEP> complementing <SEP> defective <SEP> repair <SEP> in <SEP> Chinese <SEP> hamster <SEP> cells <SEP> 4 <SEP> Hs. <SEP> 150930<tb> X-ray <SEP> <SEP> repair <SEP> defective <SEP> repair <SEP> in <SEP> Chinese <SEP> hamster <SEP> cells <SEP> 4 <SEP> Hs. <SEP> 150930 <tb> X-ray <SEP> repair <SEP> complementing <SEP> defective <SEP> repair <SEP> in <SEP> Chinese <SEP> hamster <SEP> cells <SEP> 5 <SEP> Hs.84981<tb> X-ray <SEP> <SEP> repair <SEP> defective <SEP> repair <SEP> in <SEP> Chinese <SEP> hamster <SEP> cells <SEP> 5 <SEP> Hs.84981 <tb> (double-strand-break <SEP> rejoining <SEP> ; <SEP> Ku <SEP> autoantigen, <SEP> 80kD)<tb> (double-strand-break <SEP> rejoining <SEP>; <SEP> Ku <SEP> autoantigen, <SEP> 80kD) <tb> <Tb> 18 Biopuce selon l'une quelconque des revendications 1 17 caract ris e en ce qu'elle comporte comme module de recherche associ ou coupl un module de r paration de l'ADN qui comporte une s lection de sondes mol culaires adapt e, ci-dessous ( galement Annexe 3 SEQ 3) :  A biochip according to any one of claims 1 to 17, characterized in that it comprises as its associated or coupled search module a DNA repair module which comprises a selection of suitable molecular probes, hereinafter below (also Annex 3 SEQ 3): <Desc/Clms Page number 93><Desc / Clms Page number 93> MODULE DE CHIMIOSENSIBILITE  CHEMOSENSITIVITY MODULE
Figure img00930001
Figure img00930001
 <tb> <Tb> <tb> G nes <SEP> ! <SEP> gene <SEP> Ouster<tb> G nes <SEP>! <SEP> gene <SEP> Ouster <tb> ABCB1 <SEP> = <SEP> MDR1 <SEP> = <SEP> P-glycoprotein <SEP> 1 <SEP> (ATP-binding <SEP> cassette, <SEP> sub-family <SEP> B, <SEP> Hs. <SEP> 21330<tb> ABCB1 <SEP> = <SEP> MDR1 <SEP> = <SEP> P-glycoprotein <SEP> 1 <SEP> (ATP-binding <SEP> cassette, <SEP> sub-family <SEP> B, < SEP> Hs. <SEP> 21330 <tb> member <SEP> 1)<tb> member <SEP> 1) <tb> ABCB4 <SEP> = <SEP> MDR2 <SEP> =MDR3 <SEP> (ATP-b <SEP> ! <SEP> nd <SEP> ! <SEP> ng <SEP> cassette, <SEP> sub-famiiy <SEP> B, <SEP> member <SEP> 4) <SEP> Hs. <SEP> 73812<tb> ABCB4 <SEP> = <SEP> MDR2 <SEP> = MDR3 <SEP> (ATP-b <SEP>! <SEP> nd <SEP>! <SEP> ng <SEP> cassette, <SEP> sub- famiiy <SEP> B, <SEP> member <SEP> 4) <SEP> Hs. <SEP> 73812 <tb> ABCC1 <SEP> = <SEP> MRP1 <SEP> (ATP-binding <SEP> cassette, <SEP> sub-family <SEP> C, <SEP> member <SEP> 1) <SEP> Hs. <SEP> 89433<tb> ABCC1 <SEP> = <SEP> MRP1 <SEP> (ATP-binding <SEP> cassette, <SEP> sub-family <SEP> C, <SEP> member <SEP> 1) <SEP> Hs. <SEP> 89433 <tb> ABCC2 <SEP> = <SEP> MRP2 <SEP> (ATP-binding <SEP> cassette, <SEP> sub-family <SEP> C, <SEP> member <SEP> 2) <SEP> Hs. <SEP> 193852<tb> ABCC2 <SEP> = <SEP> MRP2 <SEP> (ATP-binding <SEP> cassette, <SEP> sub-family <SEP> C, <SEP> member <SEP> 2) <SEP> Hs. <SEP> 193852 <tb> ABCC3 <SEP> = <SEP> MRP3 <SEP> (ATP-binding <SEP> cassette, <SEP> sub-family <SEP> C, <SEP> member <SEP> 3) <SEP> Hs. <SEP> 90786<tb> ABCC3 <SEP> = <SEP> MRP3 <SEP> (ATP-binding <SEP> cassette, <SEP> sub-family <SEP> C, <SEP> member <SEP> 3) <SEP> Hs. <SEP> 90786 <tb> ABCC4 <SEP> = <SEP> MRP4 <SEP> (ATP-binding <SEP> cassette, <SEP> sub-family <SEP> C, <SEP> member <SEP> 4 <SEP> Hs. <SEP> 139336<tb> ABCC4 <SEP> = <SEP> MRP4 <SEP> (ATP-binding <SEP> cassette, <SEP> sub-family <SEP> C, <SEP> member <SEP> 4 <SEP> Hs. <SEP > 139336 <tb> ABCC5 <SEP> = <SEP> MRP5 <SEP> (ATP-binding <SEP> cassette, <SEP> sub-family <SEP> C, <SEP> member <SEP> 5) <SEP> Hs. <SEP> 108660<tb> ABCC5 <SEP> = <SEP> MRP5 <SEP> (ATP-binding <SEP> cassette, <SEP> sub-family <SEP> C, <SEP> member <SEP> 5) <SEP> Hs. <SEP> 108660 <tb> ABCC6 <SEP> = <SEP> MRP6 <SEP> = <SEP> ARA <SEP> (ATP-binding <SEP> cassette, <SEP> sub-family <SEP> C, <SEP> member <SEP> 6) <SEP> Hs. <SEP> 274260<tb> ABCC6 <SEP> = <SEP> MRP6 <SEP> = <SEP> ARA <SEP> (ATP-binding <SEP> cassette, <SEP> sub-family <SEP> C, <SEP> member <SEP> 6) <SEP> Hs. <SEP> 274260 <tb> ABCG2 <SEP> = <SEP> BCRP <SEP> (Breast <SEP> cancer <SEP> resistance <SEP> protein, <SEP> ATP-binding <SEP> cassette, <SEP> Hs. <SEP> 194720<tb> ABCG2 <SEP> = <SEP> BCRP <SEP> (Breast <SEP> cancer <SEP> resistance <SEP> protein, <SEP> ATP-binding <SEP> cassette, <SEP> Hs. <SEP> 194720 <tb> sub-family <SEP> G, <SEP> member <SEP> 2)<tb> sub-family <SEP> G, <SEP> member <SEP> 2) <tb> ABL1 <SEP> = <SEP> c-abl <SEP> (v-abl <SEP> Abelson <SEP> murine <SEP> leukemia <SEP> viral <SEP> oncogene <SEP> homolog <SEP> 1) <SEP> Hs. <SEP> 146355<tb> ABL1 <SEP> = <SEP> c-abl <SEP> (v-abl <SEP> Abelson <SEP> murine <SEP> leukemia <SEP> viral <SEP> oncogene <SEP> homolog <SEP> 1) <SEP> Hs. <SEP> 146355 <tb> ACTB <SEP> (Actin, <SEP> beta) <SEP> Hs. <SEP> 288061<tb> ACTB <SEP> (Actin, <SEP> beta) <SEP> Hs. <SEP> 288061 <tb> ACTG1 <SEP> (Actin, <SEP> gamma <SEP> 1) <SEP> Hs. <SEP> 14376<tb> ACTG1 <SEP> (Actin, <SEP> gamma <SEP> 1) <SEP> Hs. <SEP> 14376 <tb> ADPRT <SEP> = <SEP> PARP <SEP> ADP-ribosyltransferase <SEP> polymerase <SEP> Hs. <SEP> 177766<tb> ADPRT <SEP> = <SEP> PARP <SEP> ADP-ribosyltransferase <SEP> polymerase <SEP> Hs. <SEP> 177766 <tb> AKT1 <SEP> (v-akt <SEP> murine <SEP> thymona <SEP> viral <SEP> oncogene <SEP> homolog <SEP> 1) <SEP> Hs. <SEP> 71816<tb> AKT1 <SEP> (v-akt <SEP> murine <SEP> thymona <SEP> viral <SEP> oncogene <SEP> homolog <SEP> 1) <SEP> Hs. <SEP> 71816 <tb> AKT2 <SEP> (v-akt <SEP> murine <SEP> thymona <SEP> viral <SEP> oncogene <SEP> homolog <SEP> 2) <SEP> Hs. <SEP> 326445<tb> AKT2 <SEP> (v-akt <SEP> murine <SEP> thymona <SEP> viral <SEP> oncogene <SEP> homolog <SEP> 2) <SEP> Hs. <SEP> 326445 <tb> AKR1 <SEP> B1 <SEP> Aldo-keto <SEP> reductase <SEP> family <SEP> 1, <SEP> member <SEP> B1 <SEP> (aldose <SEP> reductase)) <SEP> Hs. <SEP> 75313<tb> AKR1 <SEP> B1 <SEP> Aldo-keto <SEP> reductase <SEP> family <SEP> 1, <SEP> member <SEP> B1 <SEP> (aldose <SEP> reductase)) <SEP> Hs . <SEP> 75313 <tb> <Tb> <Desc/Clms Page number 94> <Desc / Clms Page number 94>
Figure img00940001
Figure img00940001
 <tb> <Tb> <tb> ALDH1A1 <SEP> (Aldehyde <SEP> dehydrogenase <SEP> 1) <SEP> Hs. <SEP> 76392<tb> ALDH1A1 <SEP> (Aldehyde <SEP> dehydrogenase <SEP> 1) <SEP> Hs. <SEP> 76392 <tb> ALDH3A <SEP> 1 <SEP> (Aldehyde <SEP> dehydroaenase <SEP> 3) <SEP> Hs. <SEP> 575<tb> ALDH3A <SEP> 1 <SEP> (Aldehyde <SEP> dehydroaenase <SEP> 3) <SEP> Hs. <SEP> 575 <tb> ANGPT1 <SEP> (Angiopoietin <SEP> 1) <SEP> Hs. <SEP> 2463<tb> ANGPT1 <SEP> (Angiopoietin <SEP> 1) <SEP> Hs. <SEP> 2463 <tb> ANXA <SEP> 1 <SEP> (Annexin <SEP> 1 <SEP> ; <SEP> lipocortin <SEP> 1) <SEP> Hs. <SEP> 78225<tb> ANXA <SEP> 1 <SEP> (Annexin <SEP> 1 <SEP>; <SEP> lipocortin <SEP> 1) <SEP> Hs. <SEP> 78225 <tb> ANXA4 <SEP> (Annexin <SEP> IV) <SEP> Hs. <SEP> 77840<tb> ANXA4 <SEP> (Annexin <SEP> IV) <SEP> Hs. <SEP> 77840 <tb> AP3S2 <SEP> (Adaptor-related <SEP> protein <SEP> complex <SEP> 3, <SEP> sigma <SEP> 2 <SEP> subunit) <SEP> Hs. <SEP> 154782<tb> AP3S2 <SEP> (Adaptor-related <SEP> protein <SEP> complex <SEP> 3, <SEP> sigma <SEP> 2 <SEP> subunit) <SEP> Hs. <SEP> 154782 <tb> APAF1 <SEP> (Apoptotic <SEP> protease <SEP> activating <SEP> factor <SEP> 1) <SEP> Hs. <SEP> 77579<tb> APAF1 <SEP> (Apoptotic <SEP> protease <SEP> activating <SEP> factor <SEP> 1) <SEP> Hs. <SEP> 77579 <tb> APP <SEP> (Amyloid <SEP> beta <SEP> A4 <SEP> precursor <SEP> protein) <SEP> Hs. <SEP> 177486<tb> APP <SEP> (Amyloid <SEP> beta <SEP> A4 <SEP> precursor <SEP> protein) <SEP> Hs. <SEP> 177486 <tb> APRT <SEP> (Adenine <SEP> phosphoribosyltransferase) <SEP> Hs. <SEP> 28914<tb> APRT <SEP> (Adenine <SEP> Phosphoribosyltransferase) <SEP> Hs. <SEP> 28914 <tb> ARHB <SEP> (Rho <SEP> B) <SEP> Hs. <SEP> 204354<tb> ARHB <SEP> (Rho <SEP> B) <SEP> Hs. <SEP> 204354 <tb> ARPC3 <SEP> (Actin <SEP> related <SEP> protein <SEP> 2/3 <SEP> complex, <SEP> subunit <SEP> 3,21 <SEP> kD) <SEP> Hs. <SEP> 6895<tb> ARPC3 <SEP> (Actin <SEP> related <SEP> protein <SEP> 2/3 <SEP> complex, <SEP> subunit <SEP> 3.21 <SEP> kD) <SEP> Hs. <SEP> 6895 <tb> ATF4 <SEP> (Activating <SEP> transcription <SEP> factor <SEP> 4 <SEP> (tax-responsive <SEP> enhancer <SEP> element <SEP> Hs. <SEP> 181243<tb> ATF4 <SEP> (Activating <SEP> transcription <SEP> factor <SEP> 4 <SEP> (tax-responsive <SEP> enhancer <SEP> element <SEP> Hs. <SEP> 181243 <tb> B67))<tb> B67)) <tb> ATM <SEP> (Ataxia <SEP> Telangiectasia <SEP> mutated <SEP> (includes <SEP> complementation <SEP> group <SEP> A, <SEP> C <SEP> Hs. <SEP> 194382<tb> ATM <SEP> (Ataxia <SEP> Telangiectasia <SEP> mutated <SEP> (includes <SEP> complementation <SEP> group <SEP> A <SEP> C <SEP> Hs. <SEP> 194382 <tb> and <SEP> D))<tb> and <SEP> D)) <tb> BAD <SEP> (BCL2-antagonist <SEP> of <SEP> cell <SEP> death) <SEP> Hs. <SEP> 76366<tb> BAD <SEP> (BCL2-antagonist <SEP> of <SEP> cell <SEP> death) <SEP> Hs. <SEP> 76366 <tb> BAK1 <SEP> (BCL2-antaaonist/killer <SEP> 1) <SEP> Hs. <SEP> 93213<tb> BAK1 <SEP> (BCL2-antaaonist / killer <SEP> 1) <SEP> Hs. <SEP> 93213 <tb> BAX <SEP> (BCL2-associated <SEP> X <SEP> protein) <SEP> Hs. <SEP> 159428<tb> BAX <SEP> (BCL2-associated <SEP> X <SEP> protein) <SEP> Hs. <SEP> 159428 <tb> BCAR1 <SEP> (Breast <SEP> cancer <SEP> anti-estrogen <SEP> resistance <SEP> 1) <SEP> Hs. <SEP> 273219<tb> BCAR1 <SEP> (Breast <SEP> cancer <SEP> anti-estrogen <SEP> resistance <SEP> 1) <SEP> Hs. <SEP> 273219 <tb> BCAR3 <SEP> (Breast <SEP> cancer <SEP> anti-estrogen <SEP> resistance <SEP> 3) <SEP> Hs. <SEP> 6564<tb> BCAR3 <SEP> (Breast <SEP> cancer <SEP> anti-estrogen <SEP> resistance <SEP> 3) <SEP> Hs. <SEP> 6564 <tb> BCL2 <SEP> (B-cell <SEP> CLUlymphoma <SEP> 2) <SEP> Hs. <SEP> 79241<tb> BCL2 <SEP> (B-cell <SEP> CLUlymphoma <SEP> 2) <SEP> Hs. <SEP> 79241 <tb> <Tb> <Desc/Clms Page number 95> <Desc / Clms Page number 95>
Figure img00950001
Figure img00950001
 <tb> <Tb> <tb> BCL2A1 <SEP> = <SEP> BFL1 <SEP> (BCL2-related <SEP> protein <SEP> A1) <SEP> Hs. <SEP> 227817<tb> BCL2A1 <SEP> = <SEP> BFL1 <SEP> (BCL2-related <SEP> Protein <SEP> A1) <SEP> Hs. <SEP> 227817 <tb> BCL2L1 <SEP> =BCL-XL <SEP> (BCL2-like <SEP> 1) <SEP> Hs. <SEP> 305890<tb> BCL2L1 <SEP> = BCL-XL <SEP> (BCL2-like <SEP> 1) <SEP> Hs. <SEP> 305890 <tb> BCR <SEP> (Breakpo <SEP> ! <SEP> nt <SEP> c <SEP> ! <SEP> uster <SEP> région) <SEP> Hs. <SEP> 234799<tb> BCR <SEP> (Breakpo <SEP>! <SEP> nt <SEP> c <SEP>! <SEP> uster <SEP> region) <SEP> Hs. <SEP> 234799 <tb> BIRC1 <SEP> (Baculoviral <SEP> IAP <SEP> repeat-containing <SEP> 1) <SEP> Hs. <SEP> 79019<tb> BIRC1 <SEP> (Baculoviral <SEP> IAP <SEP> repeat-containing <SEP> 1) <SEP> Hs. <SEP> 79019 <tb> BIRC2=clAP1 <SEP> (Baculoviral <SEP> IAP <SEP> repeat-containing <SEP> 2 <SEP> Hs. <SEP> 289107<tb> BIRC2 = clAP1 <SEP> (Baculoviral <SEP> IAP <SEP> repeat-containing <SEP> 2 <SEP> Hs. <SEP> 289107 <tb> BIRC3 <SEP> = <SEP> clAP2 <SEP> BaculovirallAP <SEP> re <SEP> eat-containin <SEP> 3 <SEP> Hs. <SEP> 127799<tb> BIRC3 <SEP> = <SEP> clAP2 <SEP> BaculovirallAP <SEP> res <SEP> eat-containin <SEP> 3 <SEP> Hs. <SEP> 127799 <tb> BIRC4 <SEP> = <SEP> Xiap <SEP> (Baculoviral <SEP> IAP <SEP> repeat-containing <SEP> 4) <SEP> Hs. <SEP> 172777<tb> BIRC4 <SEP> = <SEP> Xiap <SEP> (Baculoviral <SEP> IAP <SEP> repeat-containing <SEP> 4) <SEP> Hs. <SEP> 172777 <tb> BIRC5 <SEP> = <SEP> Survivin <SEP> (Baculoviral <SEP> IAP <SEP> repeat-containing <SEP> 5) <SEP> Hs. <SEP> 1578<tb> BIRC5 <SEP> = <SEP> Survivin <SEP> (Baculoviral <SEP> IAP <SEP> repeat-containing <SEP> 5) <SEP> Hs. <SEP> 1578 <tb> BLMH <SEP> (Bleomycin <SEP> hydrolase) <SEP> Hs. <SEP> 78943<tb> BLMH <SEP> (Bleomycin <SEP> hydrolase) <SEP> Hs. <SEP> 78943 <tb> BRCA1 <SEP> (Breast <SEP> cancer <SEP> 1, <SEP> early <SEP> onset) <SEP> Hs. <SEP> 194143<tb> BRCA1 <SEP> (Breast <SEP> cancer <SEP> 1, <SEP> early <SEP> onset) <SEP> Hs. <SEP> 194143 <tb> BRCA2 <SEP> (Breast <SEP> cancer <SEP> 2, <SEP> early <SEP> onset) <SEP> Hs. <SEP> 34012<tb> BRCA2 <SEP> (Breast <SEP> cancer <SEP> 2, <SEP> early <SEP> onset) <SEP> Hs. <SEP> 34012 <tb> CACNA1D <SEP> (Calcium <SEP> channd, <SEP> vottage-dpdt, <SEP> Ltype, <SEP> a <SEP> ! <SEP> pha <SEP> 1D <SEP> subunit) <SEP> Hs. <SEP> 23838<tb> CACNA1D <SEP> (Calcium <SEP> channd, <SEP> Voting-dpdt, <SEP> Ltype, <SEP> a <SEP>! <SEP> pha <SEP> 1D <SEP> subunit) <SEP> Hs. <SEP> 23838 <tb> CASP1 <SEP> (Caspase <SEP> 1, <SEP> apoptosis-related <SEP> cysteine <SEP> protease) <SEP> Hs. <SEP> 2490<tb> CASP1 <SEP> (Caspase <SEP> 1, <SEP> apoptosis-related <SEP> cysteine <SEP> protease) <SEP> Hs. <SEP> 2490 <tb> CASP3 <SEP> (Caspase <SEP> 3, <SEP> apoptosis-related <SEP> cysteine <SEP> protease) <SEP> Hs. <SEP> 74552<tb> CASP3 <SEP> (Caspase <SEP> 3, <SEP> apoptosis-related <SEP> cysteine <SEP> protease) <SEP> Hs. <SEP> 74552 <tb> CASP6 <SEP> (Caspase <SEP> 6, <SEP> apoptosis-related <SEP> cysteine <SEP> protease) <SEP> Hs. <SEP> 3280<tb> CASP6 <SEP> (Caspase <SEP> 6, <SEP> apoptosis-related <SEP> cysteine <SEP> protease) <SEP> Hs. <SEP> 3280 <tb> CASP7 <SEP> (Caspase <SEP> 7, <SEP> apoptosis-related <SEP> cysteine <SEP> protease) <SEP> Hs. <SEP> 9216<tb> CASP7 <SEP> (Caspase <SEP> 7, <SEP> apoptosis-related <SEP> cysteine <SEP> protease) <SEP> Hs. <SEP> 9216 <tb> CASP8 <SEP> (Caspase <SEP> 8, <SEP> apoptosis-related <SEP> cysteine <SEP> protease) <SEP> Hs. <SEP> 19949<tb> CASP8 <SEP> (Caspase <SEP> 8, <SEP> apoptosis-related <SEP> cysteine <SEP> protease) <SEP> Hs. <SEP> 19949 <tb> CASP9 <SEP> (Caspase <SEP> 9, <SEP> apoptosis-related <SEP> cysteine <SEP> protease) <SEP> Hs. <SEP> 100641<tb> CASP9 <SEP> (Caspase <SEP> 9, <SEP> apoptosis-related <SEP> cysteine <SEP> protease) <SEP> Hs. <SEP> 100641 <tb> CAV1 <SEP> (Caveolin <SEP> 1, <SEP> caveolae <SEP> protein, <SEP> 22kD) <SEP> Hs. <SEP> 323469<tb> CAV1 <SEP> (Caveolin <SEP> 1, <SEP> caveolae <SEP> protein, <SEP> 22kD) <SEP> Hs. <SEP> 323469 <tb> CCNB1 <SEP> (Cyclin <SEP> B1) <SEP> Hs. <SEP> 23960<tb> CCNB1 <SEP> (Cyclin <SEP> B1) <SEP> Hs. <SEP> 23960 <tb> <Tb> <Desc/Clms Page number 96> <Desc / Clms Page number 96>
Figure img00960001
Figure img00960001
 <tb> <Tb> <tb> CCND1 <SEP> (CydinDI) <SEP> Hs. <SEP> 82932<tb> CCND1 <SEP> (CydinDI) <SEP> Hs. <SEP> 82932 <tb> CCNE1 <SEP> (CydinEl) <SEP> Hs. <SEP> 9700<tb> CCNE1 <SEP> (CydinEl) <SEP> Hs. <SEP> 9700 <tb> CCNG1 <SEP> (Cyclin <SEP> G1) <SEP> Hs. <SEP> 79101<tb> CCNG1 <SEP> (Cyclin <SEP> G1) <SEP> Hs. <SEP> 79101 <tb> CD63 <SEP> (Melanoma <SEP> 1 <SEP> antigen) <SEP> Hs. <SEP> 76294<tb> CD63 <SEP> (Melanoma <SEP> 1 <SEP> antigen) <SEP> Hs. <SEP> 76294 <tb> CDA <SEP> (Cytidine <SEP> deaminase) <SEP> Hs. <SEP> 72924<tb> CDA <SEP> (Cytidine <SEP> deaminase) <SEP> Hs. <SEP> 72924 <tb> CDC2 <SEP> = <SEP> p34 <SEP> = <SEP> CDK1 <SEP> (Cell <SEP> division <SEP> cycle <SEP> 2) <SEP> Hs. <SEP> 184572<tb> CDC2 <SEP> = <SEP> p34 <SEP> = <SEP> CDK1 <SEP> (Cell <SEP> division <SEP> cycle <SEP> 2) <SEP> Hs. <SEP> 184572 <tb> CDC25C= <SEP> CDC25 <SEP> (Cell <SEP> division <SEP> cycle <SEP> 25C) <SEP> Hs. <SEP> 656<tb> CDC25C = <SEP> CDC25 <SEP> (Cell <SEP> division <SEP> cycle <SEP> 25C) <SEP> Hs. <SEP> 656 <tb> CDC27 <SEP> (Cell <SEP> division <SEP> cycle <SEP> 27) <SEP> Hs. <SEP> 172405<tb> CDC27 <SEP> (Cell <SEP> division <SEP> cycle <SEP> 27) <SEP> Hs. <SEP> 172405 <tb> CDH1 <SEP> (Cadherin, <SEP> type <SEP> 1, <SEP> E-cadherin <SEP> (epithelial)) <SEP> Hs. <SEP> 194657<tb> CDH1 <SEP> (Cadherin, <SEP> type <SEP> 1, <SEQ> E-cadherin <SEP> (epithelial)) <SEP> Hs. <SEP> 194657 <tb> CDK2 <SEP> (Cyclin-dpt <SEP> kinase <SEP> 2) <SEP> Hs. <SEP> 19192<tb> CDK2 <SEP> (Cyclin-dpt <SEP> kinase <SEP> 2) <SEP> Hs. <SEP> 19192 <tb> CDK4 <SEP> (Cyclin-dpt <SEP> kinase <SEP> 4) <SEP> Hs. <SEP> 95577<tb> CDK4 <SEP> (Cyclin-dpt <SEP> kinase <SEP> 4) <SEP> Hs. <SEP> 95577 <tb> CDK6 <SEP> (Cyclin-dpt <SEP> kinase <SEP> 6) <SEP> Hs. <SEP> 38481<tb> CDK6 <SEP> (Cyclin-dpt <SEP> Kinase <SEP> 6) <SEP> Hs. <SEP> 38481 <tb> CDKN1A=p21 <SEP> (Cyclin-dpt <SEP> kinase <SEP> inhibitor <SEP> 1A <SEP> (p21, <SEP> Cip1)) <SEP> Hs. <SEP> 179665<tb> CDKN1A = p21 <SEP> (Cyclin-dpt <SEP> kinase <SEP> inhibitor <SEP> 1A <SEP> (p21, <SEP> Cip1)) <SEP> Hs. <SEP> 179665 <tb> CDKN1B <SEP> = <SEP> p27KIP1 <SEP> (Cyclin-dpt <SEP> kinase <SEP> inhibitor <SEP> 1B <SEP> (p27, <SEP> Kips) <SEP> Hs. <SEP> 238990<tb> CDKN1B <SEP> = <SEP> p27KIP1 <SEP> (Cyclin-dpt <SEP> kinase <SEP> inhibitor <SEP> 1B <SEP> (p27, <SEP> Kips) <SEP> Hs. <SEP> 238990 <tb> CDKN2A <SEP> = <SEP> p16 <SEP> (Cyclin-dpt <SEP> kinase <SEP> inhibitor <SEP> 2A <SEP> (melanoma, <SEP> p16, <SEP> inhibits <SEP> Hs. <SEP> 1174<tb> CDKN2A <SEP> = <SEP> p16 <SEP> (Cyclin-dpt <SEP> kinase <SEP> inhibitor <SEP> 2A <SEP> (melanoma, <SEP> p16, <SEP> inhibits <SEP> Hs <SEP> 1174 <tb> CDK4)<tb> CDK4) <tb> CGA <SEP> = <SEP> Chorionic <SEP> gonadotrophin <SEP> alpha <SEP> subunit <SEP> (Glycoprotein <SEP> hormones, <SEP> Hs. <SEP> 119689<tb> CGA <SEP> = <SEP> Chorionic <SEP> gonadotrophin <SEP> alpha <SEP> subunit <SEP> (Glycoprotein <SEP> hormones, <SEP> Hs. <SEP> 119689 <tb> alpha <SEP> polypeptide)<tb> alpha <SEP> polypeptide) <tb> CHEK1 <SEP> = <SEP> CHK1 <SEP> (Checkpoint <SEP> homolog) <SEP> Hs. <SEP> 20295<tb> CHEK1 <SEP> = <SEP> CHK1 <SEP> (Checkpoint <SEP> peer) <SEP> Hs. <SEP> 20295 <tb> CKS1 <SEP> (CDC28 <SEP> protein <SEP> kinase <SEP> 1) <SEP> Hs. <SEP> 334883<tb> CKS1 <SEP> (CDC28 <SEP> protein <SEP> kinase <SEP> 1) <SEP> Hs. <SEP> 334883 <tb> CLU <SEP> = <SEP> TRPM-2 <SEP> (Clusterin <SEP> (complement <SEP> lysis <SEP> inhibitor, <SEP> SP-40, <SEP> sulfated <SEP> Hs. <SEP> 75106<tb> CLU <SEP> = <SEP> TRPM-2 <SEP> (Clusterin <SEP> (complement <SEP> lysis <SEP> inhibitor, <SEP> SP-40, <SEA> sulfated <SEP> Hs. < SEP> 75106 <tb> <Tb> <Desc/Clms Page number 97> <Desc / Clms Page number 97>
Figure img00970001
Figure img00970001
 <tb> <Tb> <tb> glycoprotein <SEP> 2, <SEP> testosterone-repressed <SEP> prostate <SEP> message <SEP> 2, <SEP> apolipoprotein<tb> glycoprotein <SEP> 2, <SEQ> testosterone-repressed <SEP> prostate <SEP> message <SEP> 2, <SEP> apolipoprotein <tb> J<tb> J <tb> COL3A1 <SEP> (Collagen, <SEP> type <SEP> III, <SEP> alpha <SEP> 1) <SEP> Hs. <SEP> 119571<tb> COL3A1 <SEP> (Collagen, <SEP> type <SEP> III, <SEP> alpha <SEP> 1) <SEP> Hs. <SEP> 119571 <tb> COL4A2 <SEP> (Collagen, <SEP> type <SEP> IV, <SEP> alpha <SEP> 2) <SEP> Hs. <SEP> 75617<tb> COL4A2 <SEP> (Collagen, <SEP> type <SEP> IV, <SEP> alpha <SEP> 2) <SEP> Hs. <SEP> 75617 <tb> COL4A3 <SEP> (Collagen, <SEP> type <SEP> IV, <SEP> alpha <SEP> 3) <SEP> Hs. <SEP> 530<tb> COL4A3 <SEP> (Collagen, <SEP> type <SEP> IV, <SEP> alpha <SEP> 3) <SEP> Hs. <SEP> 530 <tb> COL4A5 <SEP> (Collagen, <SEP> type <SEP> IV, <SEP> alpha <SEP> 5) <SEP> Hs. <SEP> 169825<tb> COL4A5 <SEP> (Collagen, <SEP> type <SEP> IV, <SEP> alpha <SEP> 5) <SEP> Hs. <SEP> 169825 <tb> COL4A6 <SEP> (Collagen, <SEP> type <SEP> IV, <SEP> alpha <SEP> 6) <SEP> Hs. <SEP> 408<tb> COL4A6 <SEP> (Collagen, <SEP> type <SEP> IV, <SEP> alpha <SEP> 6) <SEP> Hs. <SEP> 408 <tb> COX4 <SEP> (Cytochrome <SEP> c <SEP> oxidase <SEP> subunit <SEP> IV) <SEP> Hs. <SEP> 347969<tb> COX4 <SEP> (Cytochrome <SEP> c <SEP> oxidase <SEP> subunit <SEP> IV) <SEP> Hs. <SEP> 347969 <tb> CRA <SEP> = <SEP> Cisplatin <SEP> resistance <SEP> associated <SEP> Hs. <SEP> 166066<tb> CRA <SEP> = <SEP> Cisplatin <SEP> resistance <SEP> associated <SEP> Hs. <SEP> 166066 <tb> CRABP2 <SEP> (Cellular <SEP> retinoic <SEP> acid-binding <SEP> protein <SEP> 2) <SEP> Hs. <SEP> 183650<tb> CRABP2 <SEP> (Cellular <SEP> retinoic <SEP> acid-binding <SEP> protein <SEP> 2) <SEP> Hs. <SEP> 183650 <tb> CRADD <SEP> (CASP2 <SEP> and <SEP> RIPK1 <SEP> domain <SEP> containing <SEP> adaptor <SEP> with <SEP> death <SEP> domain) <SEP> Hs. <SEP> 155566<tb> CRADD <SEP> (CASP2 <SEP> and <SEP> RIPK1 <SEP> domain <SEP> containing <SEP> adaptor <SEP> with <SEP> death <SEP> domain) <SEP> Hs. <SEP> 155566 <tb> CRMP1 <SEP> (Cotlapsin <SEP> responsemediator <SEP> protein <SEP> 1) <SEP> Hs. <SEP> 155392<tb> CRMP1 <SEP> (Cotlapsin <SEP> responsemediator <SEP> protein <SEP> 1) <SEP> Hs. <SEP> 155392 <tb> CRR9P <SEP> (Cisplatin <SEP> resistance <SEP> related <SEP> protein) <SEP> Hs. <SEP> 323769<tb> CRR9P <SEP> (Cisplatin <SEP> resistance <SEP> related <SEP> protein) <SEP> Hs. <SEP> 323769 <tb> CSDA <SEP> (Cold <SEP> shock <SEP> domain <SEP> protein <SEP> A) <SEP> Hs. <SEP> 1139<tb> CSDA <SEP> (Cold <SEP> Shock <SEP> domain <SEP> Protein <SEP> A) <SEP> Hs. <SEP> 1139 <tb> CSF1 <SEP> R <SEP> (Colony <SEP> stimulating <SEP> factor <SEP> 1 <SEP> receptor) <SEP> Hs. <SEP> 174142<tb> CSF1 <SEP> R <SEP> (Colony <SEP> stimulating <SEP> factor <SEP> 1 <SEP> receptor) <SEP> Hs. <SEP> 174142 <tb> CYP1A1 <SEP> (Cytochrome <SEP> P450, <SEP> subfamily <SEP> I <SEP> (aromatic <SEP> compound-inducible). <SEP> Hs. <SEP> 72912<tb> CYP1A1 <SEP> (Cytochrome <SEP> P450, <SEQ> subfamily <SEP> I <SEP> (aromatic <SEP> compound-inducible). <SEP> Hs. <SEP> 72912 <tb> polypeptide <SEP> 1)<tb> polypeptide <SEP> 1) <tb> P450, <SEP> (Cytochrome <SEP> P450, <SEP> subfamily <SEP> I <SEP> (dioxin-inducible), <SEP> polypeptide <SEP> 1 <SEP> Hs. <SEP> 154654<tb> P450, <SEP> (Cytochrome <SEP> P450, <SE>> subfamily <SEP> I <SEP> (dioxin-inducible), <SEP> polypeptide <SEP> 1 <SEP> Hs. <SEP> 154654 <tb> (glaucoma <SEP> 3, <SEP> primary <SEP> infantile))<tb> (infant glaucoma <SEP> 3, <SEP> primary <SEP>)) <tb> CYP19 <SEP> (Aromatase) <SEP> Hs. <SEP> 79946<tb> CYP19 <SEP> (Aromatase) <SEP> Hs. <SEP> 79946 <tb> DAD1 <SEP> (Defender <SEP> against <SEP> cell <SEP> death <SEP> 1) <SEP> Hs. <SEP> 82890<tb> DAD1 <SEP> (Defender <SEP> against <SEP> <SEP> death <SEP> 1) <SEP> Hs. <SEP> 82890 <tb> DDB1 <SEP> (Damage-specific <SEP> DNA <SEP> binding <SEP> protein <SEP> 1 <SEP> (127kD)) <SEP> Hs. <SEP> 108327<tb> DDB1 <SEP> (Damage-specific <SEP> DNA <SEP> binding <SEP> protein <SEP> 1 <SEP> (127kD)) <SEP> Hs. <SEP> 108327 <tb> <Tb> <Desc/Clms Page number 98> <Desc / Clms Page number 98>
Figure img00980001
Figure img00980001
 <tb> <Tb> <tb> DDB2 <SEP> (Damage-specific <SEP> DNA <SEP> binding <SEP> protein <SEP> 2 <SEP> (48kD) <SEP> Hs. <SEP> 77602<tb> DDB2 <SEP> (Damage-specific <SEP> DNA <SEP> binding <SEQ ID> protein <SEP> 2 <SEP> (48kD) <SEQ> Hs. <SEP> 77602 <tb> DDIT3=GADD153 <SEP> (DNA-damage-inducible <SEP> transcript <SEP> 3) <SEP> Hs. <SEP> 337761<tb> DDIT3 = GADD153 <SEP> (DNA-damage-inducible <SEP> transcript <SEP> 3) <SEP> Hs. <SEP> 337761 <tb> DDR1 <SEP> (Discoidin <SEP> domain <SEP> receptor <SEP> family, <SEP> member <SEP> 1) <SEP> Hs. <SEP> 75562<tb> DDR1 <SEP> (Discoidin <SEP> domain <SEP> Receiver <SEP> family, <SEP> member <SEP> 1) <SEP> Hs. <SEP> 75562 <tb> DFNA5 <SEP> (Deafness, <SEP> autosomal <SEP> dominant <SEP> 5) <SEP> Hs. <SEP> 13530<tb> DFNA5 <SEP> (Deafness, <SE> autosomal <SEP> dominant <SEP> 5) <SEP> Hs. <SEP> 13530 <tb> DHFR <SEP> (Dihydrofolate <SEP> reductase) <SEP> Hs. <SEP> 83765<tb> DHFR <SEP> (Dihydrofolate <SEP> reductase) <SEP> Hs. <SEP> 83765 <tb> DIA4 <SEP> = <SEP> DT-diaphorase <SEP> (Diaphorase <SEP> (NADH/NADPH) <SEP> (cytochrome <SEP> b-5 <SEP> Hs. <SEP> 80706<tb> DIA4 <SEP> = <SEP> DT-diaphorase <SEP> (Diaphorase <SEP> (NADH / NADPH) <SEP> (cytochrome <SEP> b-5 <SEP> Hs. <SEP> 80706 <tb> reductase))<tb> reductase)) <tb> DSP <SEP> (Desmoplakin <SEP> (DPI, <SEP> DPII)) <SEP> Hs. <SEP> 74316<tb> DSP <SEP> (Desmoplakin <SEP> (DPI, <SEP> DPII)) <SEP> Hs. <SEP> 74316 <tb> DUSP1=CL100/MKP-1 <SEP> (Dual <SEP> specificity <SEP> phosphatase <SEP> 1) <SEP> Hs. <SEP> 171695<tb> DUSP1 = CL100 / MKP-1 <SEP> (Dual <SEP> Specificity <SEP> Phosphatase <SEP> 1) <SEP> Hs. <SEP> 171695 <tb> DUSP8 <SEP> = <SEP> HVH-5 <SEP> (Dual <SEP> specificity <SEP> phosphatase <SEP> 8) <SEP> Hs. <SEP> 41688<tb> DUSP8 <SEP> = <SEP> HVH-5 <SEP> (Dual <SEP> specificity <SEP> phosphatase <SEP> 8) <SEP> Hs. <SEP> 41688 <tb> ECGF1 <SEP> (Endothelial <SEP> cell <SEP> growth <SEP> factor <SEP> 1 <SEP> (platelet-derived)) <SEP> Hs. <SEP> 73946<tb> ECGF1 <SEP> (Endothelial <SEP> cell <SEP> growth <SEP> factor <SEP> 1 <SEP> (platelet-derived)) <SEP> Hs. <SEP> 73946 <tb> EEF1A1 <SEP> (Eukaryotic <SEP> translation <SEP> elongation <SEP> factor <SEP> 1 <SEP> alpha <SEP> 1) <SEP> Hs. <SEP> 181165<tb> EEF1A1 <SEP> (Eukaryotic <SEP> translation <SEP> elongation <SEP> factor <SEP> 1 <SEP> alpha <SEP> 1) <SEP> Hs. <SEP> 181165 <tb> EGF <SEP> (Epidermal <SEP> growth <SEP> factor) <SEP> Hs. <SEP> 2230<tb> EGF <SEP> (Epidermal <SEP> growth <SEP> factor) <SEP> Hs. <SEP> 2230 <tb> EGFR <SEP> (Epidermal <SEP> growth <SEP> factor <SEP> receptor <SEP> (avian <SEP> erythroblastic <SEP> leukemia <SEP> (v-Hs. <SEP> 77432<tb> EGFR <SEP> (Epidermal <SEP> growth <SEP> factor <SEP> receptor <SEP> (avian <SEP> erythroblastic <SEP> leukemia <SEP> (v-Hs. <SEP> 77432 <tb> erb-b) <SEP> oncogene <SEP> homolog))<tb> erb-b) <SEP> oncogene <SEP> homolog)) <tb> ELK1 <SEP> (Member <SEP> of <SEP> ETS <SEP> oncogene <SEP> fami <SEP> ! <SEP> y) <SEP> Hs. <SEP> 181128<tb> ELK1 <SEP> (Member <SEP> of <SEP> ETS <SEP> oncogene <SEP> fami <SEP>! <SEP> y) <SEP> Hs. <SEP> 181128 <tb> EN01 <SEP> (Enolase <SEP> 1, <SEP> alpha) <SEP> Hs. <SEP> 254105<tb> EN01 <SEP> (Enolase <SEP> 1, <SEP> alpha) <SEP> Hs. <SEP> 254105 <tb> EPAS1 <SEP> = <SEP> HIF <SEP> 2 <SEP> al <SEP> ha <SEP> Endothelial <SEP> PAS <SEP> domain <SEP> protein <SEP> 1) <SEP> Hs. <SEP> 8136<tb> EPAS1 <SEP> = <SEP> HIF <SEP> 2 <SEP> al <SEP> ha <SEP> Endothelial <SEP> NOT <SEP> domain <SEP> protein <SEP> 1) <SEP> Hs. <SEP> 8136 <tb> EPHX1 <SEP> (Epoxide <SEP> hydrolase <SEP> 1, <SEP> microsomal <SEP> (xenobiotic)) <SEP> Hs. <SEP> 89649<tb> EPHX1 <SEP> (Epoxide <SEP> hydrolase <SEP> 1, <SEP> microsomal <SEP> (xenobiotic)) <SEP> Hs. <SEP> 89649 <tb> ERBB2 <SEP> = <SEP> HER-2 <SEP> (v-erb-b2 <SEP> avian <SEP> erythroblastic <SEP> leukemia <SEP> viral <SEP> oncogen <SEP> Hs. <SEP> 323910<tb> ERBB2 <SEP> = <SEP> HER-2 <SEP> (v-erb-b2 <SEP> avian <SEP> erythroblastic <SEP> leukemia <SEP> viral <SEP> oncogen <SEP> Hs. <SEP > 323910 <tb> homolog <SEP> 2)<tb> peer <SEP> 2) <tb> <Tb> <Desc/Clms Page number 99> <Desc / Clms Page number 99>
Figure img00990001
Figure img00990001
 <tb> <Tb> <tb> ERBB3 <SEP> (v-erb-b2 <SEP> avian <SEP> erythrobalstic <SEP> leukemia <SEP> viral <SEP> oncogene <SEP> homolog <SEP> 3) <SEP> Hs. <SEP> 199067<tb> ERBB3 <SEP> (v-erb-b2 <SEP> avian <SEP> erythrobalstic <SEP> leukemia <SEP> viral <SEP> oncogene <SEP> homolog <SEP> 3) <SEP> Hs. <SEP> 199067 <tb> ERBB4=(v-erb-b2 <SEP> avian <SEP> erythroblastic <SEP> leukemia <SEP> viral <SEP> oncogene <SEP> homolog <SEP> 4) <SEP> Hs. <SEP> 1939<tb> ERBB4 = (v-erb-b2 <SEP> avian <SEP> erythroblastic <SEP> leukemia <SEP> viral <SEP> oncogene <SEP> homolog <SEP> 4) <SEP> Hs. <SEP> 1939 <tb> ERCC1 <SEP> (Excision <SEP> repair <SEP> cross-complementing <SEP> rodent <SEP> repair <SEP> deficiency, <SEP> Hs. <SEP> 59544<tb> ERCC1 <SEP> (Excision <SEP> repair <SEP> cross-complementing <SEP> repair <SEP> repair <SEP> deficiency, <SEQ> Hs. <SEP> 59544 <tb> complementation <SEP> group <SEP> 1)<tb> complementation <SEP> group <SEP> 1) <tb> ERCC2 <SEP> = <SEP> XPD <SEP> (Excision <SEP> repair <SEP> cross-complementing <SEP> rodent <SEP> repair <SEP> Hs. <SEP> 99987<tb> ERCC2 <SEP> = <SEP> XPD <SEP> (Excision <SEP> repair <SEP> cross-complementing <SEP> repair <SEP> repair <SEP> Hs. <SEP> 99987 <tb> deficiency, <SEP> complementation <SEP> group <SEP> 2)<tb> deficiency, <SEP> complementation <SEP> group <SEP> 2) <tb> ERCC3 <SEP> = <SEP> XPB <SEP> (Excision <SEP> repair <SEP> cross-complementing <SEP> rodent <SEP> repair <SEP> Hs. <SEP> 77929<tb> ERCC3 <SEP> = <SEP> XPB <SEP> (Excision <SEP> repair <SEP> cross-complementing <SEP> repair <SEP> repair <SEP> Hs. <SEP> 77929 <tb> deficiency, <SEP> complementation <SEP> group <SEP> 3)<tb> deficiency, <SEP> complementation <SEP> group <SEP> 3) <tb> ERCC4 <SEP> = <SEP> XPF <SEP> (Excision <SEP> repair <SEP> cross-complementing <SEP> rodent <SEP> repair <SEP> Hs. <SEP> 89296<tb> ERCC4 <SEP> = <SEP> XPF <SEP> (Excision <SEP> repair <SEP> cross-complementing <SEP> repair <SEP> repair <SEP> Hs. <SEP> 89296 <tb> deficiency, <SEP> complementation <SEP> group <SEP> 4)<tb> deficiency, <SEP> complementation <SEP> group <SEP> 4) <tb> ERCC5 <SEP> = <SEP> XPGC <SEP> (Excision <SEP> repair <SEP> cross-complementing <SEP> rodent <SEP> repair <SEP> Hs. <SEP> 48576<tb> ERCC5 <SEP> = <SEP> XPGC <SEP> (Excision <SEP> repair <SEP> cross-complementing <SEP> repair <SEP> repair <SEP> Hs. <SEP> 48576 <tb> deficiency, <SEP> complementation <SEP> group <SEP> 5)<tb> deficiency, <SEP> complementation <SEP> group <SEP> 5) <tb> ERCC6 <SEP> (Excision <SEP> repair <SEP> cross-complementing <SEP> rodent <SEP> repair <SEP> deficiency, <SEP> Hs. <SEP> 99924<tb> ERCC6 <SEP> (Excision <SEP> repair <SEP> cross-complementing <SEP> repair <SEP> repair <SEP> deficiency, <SEP> Hs. <SEP> 99924 <tb> complementation <SEP> group <SEP> 6)<tb> complementation <SEP> group <SEP> 6) <tb> ESR1 <SEP> (Estrogen <SEP> receptor <SEP> 1 <SEP> (alpha)) <SEP> Hs. <SEP> 1657<tb> ESR1 <SEP> (Estrogen <SEP> receptor <SEP> 1 <SEP> (alpha)) <SEP> Hs. <SEP> 1657 <tb> ESR2 <SEP> (Estrogen <SEP> receptor <SEP> 2 <SEP> (beta)) <SEP> Hs. <SEP> 103504<tb> ESR2 <SEP> (Estrogen <SEP> receptor <SEP> 2 <SEP> (beta)) <SEP> Hs. <SEP> 103504 <tb> FDFT1 <SEP> (Farnesyitransferase <SEP> 1) <SEP> Hs. <SEP> 48876<tb> FDFT1 <SEP> (Farnesyitransferase <SEP> 1) <SEP> Hs. <SEP> 48876 <tb> FGF1 <SEP> (Fibroblast <SEP> growth <SEP> factor <SEP> (acidic) <SEP> ) <SEP> Hs. <SEP> 75297<tb> FGF1 <SEP> (Fibroblast <SEP> growth <SEP> factor <SEP> (acidic) <SEP>) <SEP> Hs. <SEP> 75297 <tb> FGF2 <SEP> (Fibroblast <SEP> growth <SEP> factor <SEP> (basic) <SEP> ) <SEP> Hs. <SEP> 284244<tb> FGF2 <SEP> (Fibroblast <SEP> growth <SEP> factor <SEP> (basic) <SEP>) <SEP> Hs. <SEP> 284244 <tb> FGFR1 <SEP> (Fibroblast <SEP> growth <SEP> factor <SEP> receptor <SEP> 1) <SEP> Hs. <SEP> 748<tb> FGFR1 <SEP> (Fibroblast <SEP> growth <SEP> factor <SEP> receptor <SEP> 1) <SEP> Hs. <SEP> 748 <tb> FGFR2 <SEP> (Fibroblast <SEP> growth <SEP> factor <SEP> receptor <SEP> 2) <SEP> Hs. <SEP> 278581<tb> FGFR2 <SEP> (Fibroblast <SEP> growth <SEP> factor <SEP> receptor <SEP> 2) <SEP> Hs. <SEP> 278581 <tb> FGFR4 <SEP> (Fibroblast <SEP> growth <SEP> factor <SEP> receptor <SEP> 4) <SEP> Hs. <SEP> 165950<tb> FGFR4 <SEP> (Fibroblast <SEP> growth <SEP> factor <SEP> receptor <SEP> 4) <SEP> Hs. <SEP> 165950 <tb> FKBPL <SEP> = <SEP> D) <SEP> R1 <SEP> (FK506-binding <SEP> protein <SEP> iike) <SEP> Hs. <SEP> 99134<tb> FKBPL <SEP> = <SEP> D) <SEP> R1 <SEP> (FK506-binding <SEP> protein <SEP> iike) <SEP> Hs. <SEP> 99134 <tb> <Tb> <Desc/Clms Page number 100> <Desc / Clms Page number 100>
Figure img01000001
Figure img01000001
 <tb> <Tb> <tb> FL <SEP> T1 <SEP> (fms-related <SEP> tyrosine <SEP> kinase <SEP> 1 <SEP> (vascular <SEP> endothelial <SEP> growth <SEP> factor <SEP> Hs. <SEP> 138671<tb> FL <SEP> T1 <SEP> (fms-related <SEP> tyrosine <SEP> kinase <SEP> 1 <SEP> (vascular <SEP> endothelial <SEP> growth <SEP> factor <SEP> Hs. < SEP> 138671 <tb> vascular <SEP> permeability <SEP> factor <SEP> receptor))<tb> vascular <SEP> permeability <SEP> factor <SEP> receptor)) <tb> FN1 <SEP> (Fibronectin <SEP> 1) <SEP> Hs. <SEP> 287820<tb> FN1 <SEP> (Fibronectin <SEP> 1) <SEP> Hs. <SEP> 287820 <tb> FOLR1=Folate <SEP> binding <SEP> protein <SEP> alpha <SEP> (Folate <SEP> receptor <SEP> 1 <SEP> (adult)) <SEP> Hs. <SEP> 73769<tb> FOLR1 = Folate <SEP> binding <SEP> protein <SEP> alpha <SEP> (Folate <SEP> receptor <SEP> 1 <SEP> (adult)) <SEP> Hs. <SEP> 73769 <tb> FOS=c-fos <SEP> (v-fos <SEP> FBJ <SEP> murine <SEP> osteosarcoma <SEP> viral <SEP> oncogene <SEP> homolog) <SEP> Hs. <SEP> 25647<tb> FOS = c-fos <SEP> (v-fos <SEP> FBJ <SEP> murine <SEP> osteosarcoma <SEP> viral <SEP> oncogene <SEP> homolog) <SEP> Hs. <SEP> 25647 <tb> G6PD <SEP> (Glucose-6-phosphate <SEP> dehydrogenase) <SEP> Hs. <SEP> 80206<tb> G6PD <SEP> (Glucose-6-phosphate <SEP> dehydrogenase) <SEP> Hs. <SEP> 80206 <tb> GADD45A <SEP> (Growth <SEP> arrest <SEP> and <SEP> DNA-damage-inducible, <SEP> alpha) <SEP> Hs. <SEP> 80409<tb> GADD45A <SEP> (Growth <SEP> arrest <SEP> and <SEP> DNA-damage-inducible, <SEP> alpha) <SEP> Hs. <SEP> 80409 <tb> GAPD <SEP> (Glyceraldehyde-3-phosphate <SEP> dehydrogenase) <SEP> Hs. <SEP> 169476<tb> GAPD <SEP> (Glyceraldehyde-3-phosphate <SEP> dehydrogenase) <SEP> Hs. <SEP> 169476 <tb> GCLC <SEP> (Glutamate-cysteine <SEP> ligase, <SEP> catalytic <SEP> subunit) <SEP> Hs. <SEP> 151393<tb> GCLC <SEP> (Glutamate-Cysteine <SEP> Ligase, <SEP> Catalyst <SEP> Subunit) <SEP> Hs. <SEP> 151393 <tb> GD <SEP> ! <SEP> 1 <SEP> (GDP <SEP> dissociation <SEP> inhibitor <SEP> 1) <SEP> Hs. <SEP> 74576<tb> GD <SEP>! <SEP> 1 <SEP> (GDP <SEP> dissociation <SEP> inhibitor <SEP> 1) <SEP> Hs. <SEP> 74576 <tb> GGH <SEP> (Gamma-glutamyl <SEP> hydrolase <SEP> (conjugase, <SEP> folylpolygammaglutamyl <SEP> Hs. <SEP> 78619<tb> GGH <SEP> (Gamma-glutamyl <SEP> hydrolase <SEP> (conjugase, <SEP> folylpolygammaglutamyl <SEP> Hs. <SEP> 78619 <tb> hydrolase))<tb> hydrolase)) <tb> GGT1 <SEP> (Gamma-glutamyltransferase <SEP> 1) <SEP> Hs. <SEP> 284380<tb> GGT1 <SEP> (Gamma-glutamyltransferase <SEP> 1) <SEP> Hs. <SEP> 284380 <tb> GGT2 <SEP> (Gamma-glutamyltransferase <SEP> 2) <SEP> Hs. <SEP> 289098<tb> GGT2 <SEP> (Gamma-glutamyltransferase <SEP> 2) <SEP> Hs. <SEP> 289098 <tb> GLO1 <SEP> (Glyoxalase <SEP> I) <SEP> Hs. <SEP> 75207<tb> GLO1 <SEP> (Glyoxalase <SEP> I) <SEP> Hs. <SEP> 75207 <tb> GM2A <SEP> (GM2 <SEP> ganglioside <SEP> activator <SEP> protein) <SEP> Hs. <SEP> 289082<tb> GM2A <SEP> (GM2 <SEP> ganglioside <SEP> activator <SEP> protein) <SEP> Hs. <SEP> 289082 <tb> GNAS1 <SEP> (Guanine <SEP> nucleotide <SEP> binding <SEP> protein <SEP> (G <SEP> protein), <SEP> alpha <SEP> stimulating <SEP> Hs. <SEP> 273385<tb> GNAS1 <SEP> (Guanine <SEP> nucleotide <SEP> binding <SEQ> protein <SEP> (G <SEP> protein), <SEP> alpha <SEP> stimulating <SEP> Hs. <SEP> 273385 <tb> activity <SEP> polypeptide <SEP> 1)<tb> activity <SEP> polypeptide <SEP> 1) <tb> GPX1 <SEP> (Glutathione <SEP> peroxidase <SEP> 1) <SEP> Hs. <SEP> 76686<tb> GPX1 <SEP> (Glutathione <SEP> peroxidase <SEP> 1) <SEP> Hs. <SEP> 76686 <tb> GRN <SEP> (Granulin) <SEP> Hs. <SEP> 180577<tb> GRN <SEP> (Granulin) <SEP> Hs. <SEP> 180577 <tb> GSS <SEP> (Glutathione <SEP> synthetase) <SEP> Hs. <SEP> 82327<tb> GSS <SEP> (Glutathione <SEP> synthetase) <SEP> Hs. <SEP> 82327 <tb> <Tb> <Desc/Clms Page number 101> <Desc / Clms Page number 101>
Figure img01010001
Figure img01010001
 <tb> <Tb> <tb> GSTA1 <SEP> (Glutathione <SEP> S-transferase <SEP> A1 <SEP> NM001320<tb> GSTA1 <SEP> (Glutathione <SEP> S-transferase <SEP> A1 <SEP> NM001320 <tb> GST <SEP> A2 <SEP> Glutathione <SEP> S-transferase <SEP> A2) <SEP> Hs. <SEP> 89552<tb> GST <SEP> A2 <SEP> Glutathione <SEP> S-transferase <SEP> A2) <SEP> Hs. <SEP> 89552 <tb> GSTA3 <SEP> (Glutathione <SEP> S-transferase <SEP> A3) <SEP> Hs. <SEP> 102484<tb> GSTA3 <SEP> (Glutathione <SEP> S-transferase <SEP> A3) <SEP> Hs. <SEP> 102484 <tb> GSTA4 <SEP> (Glutathione <SEP> S-transferase <SEP> A4) <SEP> Hs. <SEP> 169907<tb> GSTA4 <SEP> (Glutathione <SEP> S-transferase <SEP> A4) <SEP> Hs. <SEP> 169907 <tb> GSTM1 <SEP> (Glutathione <SEP> S-transferase <SEP> M1) <SEP> Hs. <SEP> 324730<tb> GSTM1 <SEP> (Glutathione <SEP> S-transferase <SEP> M1) <SEP> Hs. <SEP> 324730 <tb> GSTP1 <SEP> (Glutathione <SEP> S-transferase <SEP> pi) <SEP> Hs. <SEP> 226795<tb> GSTP1 <SEP> (Glutathione <SEP> S-transferase <SEP> pi) <SEP> Hs. <SEP> 226795 <tb> HDAC1 <SEP> (Histone <SEP> deacetylase <SEP> 1) <SEP> Hs. <SEP> 88556<tb> HDAC1 <SEP> (Histone <SEP> deacetylase <SEP> 1) <SEP> Hs. <SEP> 88556 <tb> HDAC2 <SEP> (Histone <SEP> deacetylase <SEP> 2) <SEP> Hs. <SEP> 3352<tb> HDAC2 <SEP> (Histone <SEP> deacetylase <SEP> 2) <SEP> Hs. <SEP> 3352 <tb> HGF <SEP> (Hepatocyte <SEP> growth <SEP> factor <SEP> (hepapoietin, <SEP> scatter <SEP> factor)) <SEP> Hs. <SEP> 809<tb> HGF <SEP> (Hepatocyte <SEP> growth <SEP> factor <SEP> (hepapoietin, <SEP> scatter <SEP> factor)) <SEP> Hs. <SEP> 809 <tb> HIF1A <SEP> (Hypoxia-inducible <SEP> factor <SEP> 1, <SEP> alpha <SEP> subunit) <SEP> Hs. <SEP> 197540<tb> HIF1A <SEP> (Hypoxia-inducible <SEP> factor <SEP> 1, <SEP> alpha <SEP> subunit) <SEP> Hs. <SEP> 197540 <tb> HMG1 <SEP> (High-mobility <SEP> group <SEP> (nonhistone <SEP> chromosomal) <SEP> protein <SEP> 1) <SEP> Hs. <SEP> 337757<tb> HMG1 <SEP> (High-mobility <SEP> group <SEP> (nonhistone <SEP> chromosomal) <SEP> protein <SEP> 1) <SEP> Hs. <SEP> 337757 <tb> HRAS <SEP> (v-Ha-ras <SEP> Harvey <SEP> rat <SEP> sarcoma <SEP> viral <SEP> oncogene <SEP> homolog) <SEP> Hs. <SEP> 37003<tb> HRAS <SEP> (v-Ha-ras <SEP> Harvey <SEP> rat <SEP> sarcoma <SEP> viral <SEP> oncogene <SEP> homolog) <SEP> Hs. <SEP> 37003 <tb> HSPA2 <SEP> = <SEP> HS72 <SEP> (Heat <SEP> shock <SEP> 70kD <SEP> protein <SEP> 2) <SEP> Hs. <SEP> 75452<tb> HSPA2 <SEP> = <SEP> HS72 <SEP> (Heat <SEP> Shock <SEP> 70kD <SEP> Protein <SEP> 2) <SEP> Hs. <SEP> 75452 <tb> HSPA4 <SEP> = <SEP> HSP70 <SEP> (Heat <SEP> shock <SEP> 70kD <SEP> protein <SEP> 4) <SEP> Hs. <SEP> 90093<tb> HSPA4 <SEP> = <SEP> HSP70 <SEP> (Heat <SEP> Shock <SEP> 70kD <SEP> Protein <SEP> 4) <SEP> Hs. <SEP> 90093 <tb> HSPA5 <SEP> = <SEP> GRP78 <SEP> (Heat <SEP> shock <SEP> 70kD <SEP> protein <SEP> 5 <SEP> (glucose-regulated <SEP> protein, <SEP> Hs. <SEP> 75410<tb> HSPA5 <SEP> = <SEP> GRP78 <SEP> (Heat <SEP> Shock <SEP> 70kD <SEP> Protein <SEP> 5 <SEP> (glucose-regulated <SEP> protein, <SEP> Hs. <SEP> 75410 <tb> 78kD))<tb> 78kD)) <tb> HSPA8 <SEP> = <SEP> HSC70 <SEP> (Heat <SEP> shock <SEP> 70kDa <SEP> protein <SEP> 8) <SEP> Hs. <SEP> 180414<tb> HSPA8 <SEP> = <SEP> HSC70 <SEP> (Heat <SEP> Shock <SEP> 70kDa <SEP> Protein <SEP> 8) <SEP> Hs. <SEP> 180414 <tb> HSPB1 <SEP> = <SEP> HSP27 <SEP> (Heat <SEP> shock <SEP> 27kD <SEP> protein <SEP> 1) <SEP> Hs. <SEP> 76067<tb> HSPB1 <SEP> = <SEP> HSP27 <SEP> (Heat <SEP> Shock <SEP> 27kD <SEP> Protein <SEP> 1) <SEP> Hs. <SEP> 76067 <tb> HSPCB <SEP> = <SEP> HSP90beta <SEP> (Heat <SEP> shock <SEP> 90kD <SEP> protein <SEP> 1, <SEP> beta) <SEP> Hs. <SEP> 74335<tb> HSPCB <SEP> = <SEP> HSP90beta <SEP> (Heat <SEP> shock <SEP> 90kD <SEP> protein <SEP> 1, <SEP> beta) <SEP> Hs. <SEP> 74335 <tb> HSPD1 <SEP> HSP60 <SEP> (Heat <SEP> shock <SEP> 60kD <SEP> protein <SEP> 1 <SEP> (chaperon <SEP> ! <SEP> n)) <SEP> Hs. <SEP> 79037<tb> HSPD1 <SEP> HSP60 <SEP> (Heat <SEP> shock <SEP> 60kD <SEP> protein <SEP> 1 <SEP> (chaperone <SEP>! <SEP> n)) <SEP> Hs. <SEP> 79037 <tb> ICAM1 <SEP> = <SEP> CD54 <SEP> (Intercellular <SEP> adhesion <SEP> molecule <SEP> 1, <SEP> human <SEP> rhinovirus <SEP> Hs. <SEP> 168383<tb> ICAM1 <SEP> = <SEP> CD54 <SEP> (Intercellular <SEP> adhesion <SEP> molecule <SEP> 1, <SEP> human <SEP> rhinovirus <SEP> Hs. <SEP> 168383 <tb> <Tb> <Desc/Clms Page number 102> <Desc / Clms Page number 102>
Figure img01020001
Figure img01020001
 <tb> <Tb> <tb> receptor<tb> receptor <tb> IGF1 <SEP> (Insulin <SEP> growth <SEP> factor <SEP> 1 <SEP> (somatomedin <SEP> c)) <SEP> Hs. <SEP> 85112<tb> IGF1 <SEP> (Insulin <SEP> growth <SEP> factor <SEP> 1 <SEP> (somatomedin <SEP> c)) <SEP> Hs. <SEP> 85112 <tb> IGF2=(Insulin <SEP> growth <SEP> factor <SEP> 2 <SEP> (somatomedin <SEP> a)) <SEP> Hs. <SEP> 251664<tb> IGF2 = (Insulin <SEP> growth <SEP> factor <SEP> 2 <SEP> (somatomedin <SEP> a)) <SEP> Hs. <SEP> 251664 <tb> IGF1 <SEP> R <SEP> (Insulin <SEP> growth <SEP> factor <SEP> 1 <SEP> receptor) <SEP> Hs. <SEP> 239176<tb> IGF1 <SEP> R <SEP> (Insulin <SEP> growth <SEP> factor <SEP> 1 <SEP> receptor) <SEP> Hs. <SEP> 239176 <tb> IGFBP1 <SEP> (Insulin <SEP> growth <SEP> factor <SEP> binding <SEP> protein <SEP> 1) <SEP> Hs. <SEP> 102122<tb> IGFBP1 <SEP> (Insulin <SEP> growth <SEP> factor <SEP> binding <SEP> protein <SEP> 1) <SEP> Hs. <SEP> 102122 <tb> IGFBP3 <SEP> () <SEP> nsu) <SEP> in <SEP> growth <SEP> factor <SEP> binding <SEP> protein <SEP> 3) <SEP> Hs. <SEP> 77326<tb> IGFBP3 <SEP> () <SEP> nsu) <SEP> in <SEP> growth <SEP> binding <SEP> binding <SEP> protein <SEP> 3) <SEP> Hs. <SEP> 77326 <tb> IGFBP4 <SEP> (insulin <SEP> growth <SEP> factor <SEP> binding <SEP> protein <SEP> 4) <SEP> Hs. <SEP> 1516<tb> IGFBP4 <SEP> (insulin <SEP> growth <SEP> factor <SEP> binding <SEP> protein <SEP> 4) <SEP> Hs. <SEP> 1516 <tb> ILLA <SEP> (interleukin <SEP> 1, <SEP> alpha) <SEP> Hs. <SEP> 1722<tb> ILLA <SEP> (interleukin <SEP> 1, <SEP> alpha) <SEP> Hs. <SEP> 1722 <tb> IL1B <SEP> (Interleukin <SEP> 1, <SEP> beta) <SEP> Hs. <SEP> 126256<tb> IL1B <SEP> (Interleukin <SEP> 1, <SEP> beta) <SEP> Hs. <SEP> 126256 <tb> IL6 <SEP> ( <SEP> ! <SEP> nterleukin <SEP> 6 <SEP> (interferon, <SEP> beta <SEP> 2)) <SEP> Hs. <SEP> 93913<tb> IL6 <SEP> (<SEP>! <SEP> nterleukin <SEP> 6 <SEP> (interferon, <SEP> beta <SEP> 2)) <SEP> Hs. <SEP> 93913 <tb> IL8 <SEP> (Interleukin <SEP> 8) <SEP> Hs. <SEP> 624<tb> IL8 <SEP> (Interleukin <SEP> 8) <SEP> Hs. <SEP> 624 <tb> ISGF3G <SEP> = <SEP> IRF9 <SEP> (Interferon-stimulated <SEP> transcription <SEP> factor <SEP> 3, <SEP> gamma) <SEP> Hs. <SEP> 1706<tb> ISGF3G <SEP> = <SEP> IRF9 <SEP> (Interferon-stimulated <SEP> transcription <SEP> factor <SEP> 3, <SEP> gamma) <SEP> Hs. <SEP> 1706 <tb> ITGA2 <SEP> (Integrin, <SEP> alpha <SEP> 2 <SEP> (CD49B, <SEP> alpha <SEP> 2 <SEP> subunit <SEP> of <SEP> VLA-2 <SEP> receptor)) <SEP> Hs. <SEP> 271986<tb> ITGA2 <SEP> (Integrin, <SEP> alpha <SEP> 2 <SEP> (CD49B, <SEP> alpha <SEP> 2 <SEP> subunit <SEP> of <SEP> VLA-2 <SEP> receptor )) <SEP> Hs. <SEP> 271986 <tb> ITGA3 <SEP> (Integrin, <SEP> alpha <SEP> 3 <SEP> (antigen <SEP> CD49C, <SEP> alpha <SEP> 3 <SEP> subunit <SEP> of <SEP> VLA-3 <SEP> Hs. <SEP> 265829<tb> ITGA3 <SEP> (Integrin, <SEP> alpha <SEP> 3 <SEP> (antigen <SEP> CD49C, <SEP> alpha <SEP> 3 <SEP> subunit <SEP> of <SEP> VLA-3 <SEP> Hs. <SEP> 265829 <tb> receptor))<tb> receptor)) <tb> ITGA4 <SEP> (Integrin, <SEP> alpha <SEP> 4 <SEP> (antigen <SEP> CD49D, <SEP> alpha <SEP> 4 <SEP> subunit <SEP> of <SEP> VLA-4 <SEP> Hs. <SEP> 40034<tb> ITGA4 <SEP> (Integrin, <SEP> alpha <SEP> 4 <SEP> (antigen <SEP> CD49D, <SEP> alpha <SEP> 4 <SEP> subunit <SEP> of <SEP> VLA-4 <SEP> Hs. <SEP> 40034 <tb> receptor))<tb> receptor)) <tb> ITGA6(Integrin, <SEP> alpha <SEP> 6) <SEP> Hs. <SEP> 227730<tb> ITGA6 (Integrin, <SEP> alpha <SEP> 6) <SEP> Hs. <SEP> 227730 <tb> ITGB1 <SEP> (Integrin, <SEP> beta <SEP> 1 <SEP> (fibronectin <SEP> receptor, <SEP> beta <SEP> polypeptide, <SEP> antigen <SEP> Hs. <SEP> 287797<tb> ITGB1 <SEP> (Integrin, <SEP> beta <SEP> 1 <SEP> (fibronectin <SEP> receptor, <SEP> beta <SEP> polypeptide, <SEP> antigen <SEP> Hs. <SEP> 287797 <tb> CD29 <SEP> includes <SEP> MDF2, <SEP> MSK12))<tb> CD29 <SEP> includes <SEP> MDF2, <SEP> MSK12)) <tb> ITGB3 <SEP> (Integrin, <SEP> beta <SEP> 3) <SEP> Hs. <SEP> 87149<tb> ITGB3 <SEP> (Integrin, <SEP> beta <SEP> 3) <SEP> Hs. <SEP> 87149 <tb> JUN=c-jun <SEP> avian <SEP> sarcoma <SEP> virus <SEP> 17 <SEP> oncogene <SEP> homolog <SEP> Hs. <SEP> 78465<tb> JUN = c-jun <SEP> avian <SEP> sarcoma <SEP> virus <SEP> 17 <SEP> oncogene <SEP> homolog <SEP> Hs. <SEP> 78465 <tb> <Tb> <Desc/Clms Page number 103> <Desc / Clms Page number 103>
Figure img01030001
Figure img01030001
 <tb> <Tb> <tb> K-ALPHA-1 <SEP> (Tubulin, <SEP> alpha, <SEP> ubiquitous) <SEP> Hs. <SEP> 334842<tb> K-ALPHA-1 <SEP> (Tubulin, <SEP> alpha, <SEP> ubiquitous) <SEP> Hs. <SEP> 334842 <tb> KDR <SEP> = <SEP> FLK1 <SEP> (Kinase <SEP> insert <SEP> domain <SEP> receptor <SEP> (a <SEP> type <SEP> III <SEP> receptor <SEP> tyrosine <SEP> Hs. <SEP> 12337<tb> KDR <SEP> = <SEP> FLK1 <SEP> (Kinase <SEP> insert <SEP> domain <SEP> receptor <SEP> (a <SEP> type <SEP> III <SEP> receptor <SEP> tyrosine <SEP> Hs. <SEP> 12337 <tb> kinase)) <SEP> = <SEP> vegfr2<tb> kinase)) <SEP> = <SEP> vegfr2 <tb> KRAS2 <SEP> (v-ki-ras2 <SEP> Kirsten <SEP> rat <SEP> sarcoma <SEP> 2 <SEP> viral <SEP> oncogene <SEP> homolog) <SEP> Hs. <SEP> 184050<tb> KRAS2 <SEP> (v-ki-ras2 <SEP> Kirsten <SEP> rat <SEP> sarcoma <SEP> 2 <SEP> viral <SEP> oncogene <SEP> homolog) <SEP> Hs. <SEP> 184050 <tb> KRT6A <SEP> (Keratin <SEP> 6A) <SEP> Hs. <SEP> 334309<tb> KRT6A <SEP> (Keratin <SEP> 6A) <SEP> Hs. <SEP> 334309 <tb> KRT8 <SEP> (Keratin <SEP> 8) <SEP> Hs. <SEP> 242463<tb> KRT8 <SEP> (Keratin <SEP> 8) <SEP> Hs. <SEP> 242463 <tb> KRT18 <SEP> (Keratin <SEP> 18) <SEP> Hs. <SEP> 65114<tb> KRT18 <SEP> (Keratin <SEP> 18) <SEP> Hs. <SEP> 65114 <tb> KRT19 <SEP> (Keratin <SEP> 19) <SEP> Hs. <SEP> 182265<tb> KRT19 <SEP> (Keratin <SEP> 19) <SEP> Hs. <SEP> 182265 <tb> LAMA2 <SEP> (Laminin, <SEP> alpha <SEP> 2) <SEP> Hs. <SEP> 75279<tb> LAMA2 <SEP> (Laminin, <SEP> alpha <SEP> 2) <SEP> Hs. <SEP> 75279 <tb> LAMA3 <SEP> (Laminin, <SEP> alpha <SEP> 3) <SEP> Hs. <SEP> 83450<tb> LAMA3 <SEP> (Laminin, <SEP> alpha <SEP> 3) <SEP> Hs. <SEP> 83450 <tb> LIF <SEP> (Leukemia <SEP> inhibitory <SEP> factor <SEP> (cholinergic <SEP> differentiation <SEP> factor)) <SEP> Hs. <SEP> 2250<tb> LIF <SEP> (Leukemia <SEP> inhibitory <SEP> factor <SEP> (cholinergic <SEP> differentiation <SEP> factor)) <SEP> Hs. <SEP> 2250 <tb> LMNB1 <SEP> (LaminBI) <SEP> Hs. <SEP> 89497<tb> LMNB1 <SEP> (LaminBI) <SEP> Hs. <SEP> 89497 <tb> LMNB2 <SEP> (Lamin <SEP> B2) <SEP> Hs. <SEP> 334709<tb> LMNB2 <SEP> (Lamin <SEP> B2) <SEP> Hs. <SEP> 334709 <tb> LSP1 <SEP> (Lymphocyte-specific <SEP> protein <SEP> 1) <SEP> Hs. <SEP> 56729<tb> LSP1 <SEP> (Lymphocyte-specific <SEP> protein <SEP> 1) <SEP> Hs. <SEP> 56729 <tb> LTBP1 <SEP> (Latent <SEP> transforming <SEP> growth <SEP> factor <SEP> beta <SEP> binding <SEP> protein <SEP> 1) <SEP> Hs. <SEP> 241257<tb> LTBP1 <SEP> (Latent <SEP> transforming <SEP> growth <SEP> factor <SEP> <SEP> binding <SEP> protein <SEP> 1) <SEP> Hs. <SEP> 241257 <tb> LUC7A <SEP> = <SEP> CROP <SEP> (Cisp <SEP> ! <SEP> atin <SEP> resistance-associated <SEP> overexpressed) <SEP> Hs. <SEP> 3688<tb> LUC7A <SEP> = <SEP> CROP <SEP> (Cisp <SEP>! <SEP> atin <SEP> resistance-associated <SEP> overexpressed) <SEP> Hs. <SEP> 3688 <tb> MAP2 <SEP> (Microtubule-associated <SEP> protein <SEP> 2) <SEP> Hs. <SEP> 167<tb> MAP2 <SEP> (Microtubule-associated <SEP> protein <SEP> 2) <SEP> Hs. <SEP> 167 <tb> MAP2K1 <SEP> = <SEP> MEK1 <SEP> (Mitogen-activated <SEP> protein <SEP> kinase <SEP> kinase <SEP> 1) <SEP> Hs. <SEP> 3446<tb> MAP2K1 <SEP> = <SEQ> MEK1 <SEP> (Mitogen-activated <SEP> protein <SEP> kinase <SEP> kinase <SEP> 1) <SEP> Hs. <SEP> 3446 <tb> MAP2K2 <SEP> = <SEP> MEK2 <SEP> (Mitogen-activated <SEP> protein <SEP> kinase <SEP> kinase <SEP> 2) <SEP> Hs. <SEP> 72241<tb> MAP2K2 <SEP> = <SEQ> MEK2 <SEP> (Mitogen-activated <SEP> protein <SEP> kinase <SEP> kinase <SEP> 2) <SEP> Hs. <SEP> 72241 <tb> MAP3K3 <SEP> (Mitogen-activated <SEP> protein <SEP> kinase <SEP> kinase <SEP> kinase <SEP> 3) <SEP> Hs. <SEP> 29282<tb> MAP3K3 <SEP> (Mitogen-activated <SEP> protein <SEP> kinase <SEP> kinase <SEP> kinase <SEP> 3) <SEP> Hs. <SEP> 29282 <tb> MAPK1 <SEP> = <SEP> ERK2 <SEP> (Mitogen-activated <SEP> protein <SEP> kinase <SEP> 1) <SEP> Hs. <SEP> 324473<tb> MAPK1 <SEP> = <SEQ> ERK2 <SEP> (Mitogen-activated <SEP> protein <SEP> kinase <SEP> 1) <SEP> Hs. <SEP> 324473 <tb> <Tb> <Desc/Clms Page number 104> <Desc / Clms Page number 104>
Figure img01040001
Figure img01040001
 <tb> <Tb> <tb> MAPK3 <SEP> = <SEP> ERK1 <SEP> (Mitogen-activated <SEP> protein <SEP> kinase <SEP> 3) <SEP> Hs. <SEP> 861<tb> MAPK3 <SEP> = <SEQ> ERK1 <SEP> (Mitogen-activated <SEP> protein <SEP> kinase <SEP> 3) <SEP> Hs. <SEP> 861 <tb> MAPK8 <SEP> = <SEP> JNK1 <SEP> (Mitogen-activated <SEP> protein <SEP> kinase <SEP> 8) <SEP> Hs. <SEP> 190913<tb> MAPK8 <SEP> = <SEP> JNK1 <SEP> (Mitogen-activated <SEP> protein <SEP> kinase <SEP> 8) <SEP> Hs. <SEP> 190913 <tb> MAPK9 <SEP> = <SEP> JNK2 <SEP> (Mitogen-activated <SEP> protein <SEP> kinase <SEP> 9) <SEP> Hs. <SEP> 246857<tb> MAPK9 <SEP> = <SEP> JNK2 <SEP> (Mitogen-activated <SEP> protein <SEP> kinase <SEP> 9) <SEP> Hs. <SEP> 246857 <tb> MAPK11=p38 <SEP> beta <SEP> (Mitogen-activated <SEP> protein <SEP> kinase <SEP> 11) <SEP> Hs. <SEP> 57732<tb> MAPK11 = p38 <SEP> beta <SEP> (Mitogen-activated <SEP> protein <SEP> kinase <SEP> 11) <SEP> Hs. <SEP> 57732 <tb> MAPK12 <SEP> =p38 <SEP> gamma <SEP> (Mitogen-activated <SEP> protein <SEP> kinase <SEP> 12) <SEP> Hs. <SEP> 55039<tb> MAPK12 <SEP> = p38 <SEP> gamma <SEP> (Mitogen-activated <SEP> protein <SEP> kinase <SEP> 12) <SEP> Hs. <SEP> 55039 <tb> MAPK13 <SEP> = <SEP> p38 <SEP> deita <SEP> (Mitogen-activated <SEP> protein <SEP> kinase <SEP> 13) <SEP> Hs. <SEP> 178695<tb> MAPK13 <SEP> = <SEP> p38 <SEP> deita <SEP> (Mitogen-activated <SEP> protein <SEP> kinase <SEP> 13) <SEP> Hs. <SEP> 178695 <tb> MAPK14 <SEP> = <SEP> p38 <SEP> (Mitogen-activated <SEP> protein <SEP> kinase <SEP> 14) <SEP> Hs. <SEP> 79107<tb> MAPK14 <SEP> = <SEP> p38 <SEP> (Mitogen-activated <SEP> protein <SEP> kinase <SEP> 14) <SEP> Hs. <SEP> 79107 <tb> MCL1 <SEP> (Myelo d <SEP> cell <SEP> leukemia <SEP> sequence <SEP> 1, <SEP> BCL2-related) <SEP> Hs. <SEP> 86386<tb> MCL1 <SEP> (Myelo d <SEP> cell <SEP> leukemia <SEP> sequence <SEP> 1, <SEP> BCL2-related) <SEP> Hs. <SEP> 86386 <tb> MDM2 <SEP> (Mouse <SEP> double <SEP> minute <SEP> 2, <SEP> human <SEP> homolog <SEP> of <SEP> p53-binding <SEP> protein) <SEP> Hs. <SEP> 170027<tb> MDM2 <SEP> (Mouse <SEP> double <SEP> minute <SEP> 2, <SEP> human <SEP> homolog <SEP> of <SEP> p53-binding <SEP> protein <SEP> Hs. <SEP> 170027 <tb> MGMT <SEP> (06-methylguanine-DNA <SEP> methyltransferase) <SEP> Hs. <SEP> 1384<tb> MGMT <SEP> (06-methylguanine-DNA <SEP> methyltransferase) <SEP> Hs. <SEP> 1384 <tb> MKI67 <SEP> (Antigen <SEP> identified <SEP> by <SEP> monoclonal <SEP> antibody <SEP> Ki-67) <SEP> Hs. <SEP> 80976<tb> MKI67 <SEP> (Antigen <SEP> identified <SEP> by <SEP> monoclonal <SEP> antibody <SEP> Ki-67) <SEP> Hs. <SEP> 80976 <tb> MLH1 <SEP> (mutL <SEP> homo <SEP> ! <SEP> og <SEP> 1 <SEP> (co <SEP> ! <SEP> on <SEP> cancer, <SEP> nonpo <SEP> ! <SEP> yposis <SEP> type <SEP> 2)) <SEP> Hs. <SEP> 57301<tb> MLH1 <SEP> (mutL <SEP> homo <SEP>! <SEP> og <SEP> 1 <SEP> (co <SEP>! <SEP> on <SEP> cancer, <SEP> nonpo <SEP> ! <SEP> yposis <SEP> type <SEP> 2)) <SEP> Hs. <SEP> 57301 <tb> MMP1 <SEP> (Matrix <SEP> metalloproteinase <SEP> 1 <SEP> (interstitial <SEP> collagenase)) <SEP> Hs. <SEP> 83169<tb> MMP1 <SEP> (Matrix <SEP> metalloproteinase <SEP> 1 <SEP> (interstitial <SEP> collagenase)) <SEP> Hs. <SEP> 83169 <tb> MMP2 <SEP> (Matrix <SEP> metalloproteinase <SEP> 2 <SEP> (gelatinase <SEP> A, <SEP> 72kD <SEP> gelatinase, <SEP> 72kD <SEP> type <SEP> Hs. <SEP> 111301<tb> MMP2 <SEP> (Matrix <SEP> metalloproteinase <SEP> 2 <SEP> (gelatinase <SEP> A, <SEP> 72kD <SEP> gelatinase, <SEP> 72kD <SEP> type <SEP> Hs. < SEP> 111301 <tb> IV <SEP> collagenase))<tb> IV <SEP> collagenase)) <tb> MMP3 <SEP> (Matrix <SEP> metalloproteinase <SEP> 3 <SEP> (stromelysin <SEP> 1, <SEP> progelatinase)) <SEP> Hs. <SEP> 83326<tb> MMP3 <SEP> (Matrix <SEP> metalloproteinase <SEP> 3 <SEP> (stromelysin <SEP> 1, <SEP> progelatinase)) <SEP> Hs. <SEP> 83326 <tb> MMP9 <SEP> (Matrix <SEP> metalloproteinase <SEP> 9 <SEP> (gelatinase <SEP> b) <SEP> ) <SEP> Hs. <SEP> 151738<tb> MMP9 <SEP> (Matrix <SEP> metalloproteinase <SEP> 9 <SEP> (gelatinase <SEP> b) <SEP>) <SEP> Hs. <SEP> 151738 <tb> MMP10 <SEP> (Matrix <SEP> metalloproteinase <SEP> 10 <SEP> (stromelysin <SEP> 2) <SEP> ) <SEP> Hs. <SEP> 2258<tb> MMP10 <SEP> (Matrix <SEP> metalloproteinase <SEP> 10 <SEP> (stromelysin <SEP> 2) <SEP>) <SEP> Hs. <SEP> 2258 <tb> MMP11 <SEP> (Matrix <SEP> metalloproteinase <SEP> 11 <SEP> (stromelysin <SEP> 3)) <SEP> Hs. <SEP> 155324<tb> MMP11 <SEP> (Matrix <SEP> metalloproteinase <SEP> 11 <SEP> (stromelysin <SEP> 3)) <SEP> Hs. <SEP> 155324 <tb> MMP13 <SEP> (Matrix <SEP> metalloproteinase <SEP> 13 <SEP> (collagenase <SEP> 3)) <SEP> Hs. <SEP> 2936<tb> MMP13 <SEP> (Matrix <SEP> Metalloproteinase <SEP> 13 <SEP> (collagenase <SEP> 3)) <SEP> Hs. <SEP> 2936 <tb> MMP16 <SEP> (Matrix <SEP> metalloproteinase <SEP> 16 <SEP> (membrane-inserted)) <SEP> Hs. <SEP> 90800<tb> MMP16 <SEP> (Matrix <SEP> Metalloproteinase <SEP> 16 <SEP> (membrane-inserted)) <SEP> Hs. <SEP> 90800 <tb> <Tb> <Desc/Clms Page number 105> <Desc / Clms Page number 105>
Figure img01050001
Figure img01050001
 <tb> <Tb> <tb> MSH2 <SEP> (mutS <SEP> homolog <SEP> 2 <SEP> (colon <SEP> cancer, <SEP> nonpolyposis <SEP> type <SEP> 1)) <SEP> Hs. <SEP> 78934<tb> MSH2 <SEP> (mutS <SEP> homolog <SEP> 2 <SEP> (colon <SEP> cancer, <SEP> nonpolyposis <SEP> type <SEP> 1)) <SEP> Hs. <SEP> 78934 <tb> MSH3 <SEP> mutS <SEP> homolo <SEP> 3 <SEP> Hs. <SEP> 42674<tb> MSH3 <SEP> mutS <SEP> homolo <SEP> 3 <SEP> Hs. <SEP> 42674 <tb> MSH6 <SEP> (mutS <SEP> homolog <SEP> 6) <SEP> Hs. <SEP> 3248<tb> MSH6 <SEP> (mutS <SEP> homolog <SEP> 6) <SEP> Hs. <SEP> 3248 <tb> MSLN <SEP> (Mesothelin, <SEP> CAK1) <SEP> Hs. <SEP> 155981<tb> MSLN <SEP> (Mesothelin, <SEP> CAK1) <SEP> Hs. <SEP> 155981 <tb> MT1E <SEP> (Metallothionein <SEP> 1E <SEP> (functionat)) <SEP> Hs. <SEP> 74170<tb> MT1E <SEP> (Metallothionein <SEP> 1E <SEP> (functionat)) <SEP> Hs. <SEP> 74170 <tb> MT1X <SEP> (Metallothionein <SEP> 1X <SEP> Hs. <SEP> 278462<tb> MT1X <SEP> (Metallothionein <SEP> 1X <SEQ> Hs. <SEP> 278462 <tb> MT2A <SEP> Metallothionein <SEP> 2A <SEP> Hs. <SEP> 118786<tb> MT2A <SEP> Metallothionein <SEP> 2A <SEP> Hs. <SEP> 118786 <tb> MTC01 <SEP> (Cytochrome <SEP> c <SEP> oxidase <SEP> I <SEP> NC~001807<tb> MTC01 <SEP> (Cytochrome <SEP> c <SEP> Oxidase <SEP> I <SEP> NC ~ 001807 <tb> MTCO2 <SEP> (Cytochrome <SEP> c <SEP> oxidase <SEP> II) <SEP> NC~001807<tb> MTCO2 <SEP> (Cytochrome <SEP> c <SEP> Oxidase <SEP> II) <SEP> NC ~ 001807 <tb> MTND1 <SEP> (NADH <SEP> dehydrogenase <SEP> subunit <SEP> 1 <SEP> (Complex <SEP> I)) <SEP> NC~001807<tb> MTND1 <SEP> (NADH <SEP> dehydrogenase <SEP> subunit <SEP> 1 <SEP> (Complex <SEP> I)) <SEP> NC ~ 001807 <tb> MTND2 <SEP> (NADH <SEP> dehydrogenase <SEP> subunit <SEP> 2 <SEP> (Complex <SEP> I)) <SEP> NC~001807<tb> MTND2 <SEP> (NADH <SEP> dehydrogenase <SEP> subunit <SEP> 2 <SEP> (Complex <SEP> I)) <SEP> NC ~ 001807 <tb> MTND3 <SEP> (NADH <SEP> dehydrogenase <SEP> subunit <SEP> 3 <SEP> (Compex <SEP> !)) <SEP> NC001807<tb> MTND3 <SEP> (NADH <SEP> dehydrogenase <SEP> subunit <SEP> 3 <SEP> (Compex <SEP>!)) <SEP> NC001807 <tb> MTND4 <SEP> (NADH <SEP> dehydrogenase <SEP> subunit <SEP> 4 <SEP> (Complex <SEP> I)) <SEP> NC~001807<tb> MTND4 <SEP> (NADH <SEP> dehydrogenase <SEP> subunit <SEP> 4 <SEP> (Complex <SEP> I)) <SEP> NC ~ 001807 <tb> MTND4L <SEP> (NADH <SEP> dehydrogenase <SEP> subunit <SEP> 4L <SEP> (Complex <SEP> I)) <SEP> NC~001807<tb> MTND4L <SEP> (NADH <SEP> dehydrogenase <SEP> subunit <SEP> 4L <SEP> (Complex <SEP> I)) <SEP> NC ~ 001807 <tb> MTND5 <SEP> (NADH <SEP> dehydrogenase <SEP> subunit <SEP> 5 <SEP> (Complex <SEP> I)) <SEP> NC~001807<tb> MTND5 <SEP> (NADH <SEP> dehydrogenase <SEP> subunit <SEP> 5 <SEP> (Complex <SEP> I)) <SEP> NC ~ 001807 <tb> MTND6 <SEP> (NADH <SEP> dehydrogenase <SEP> subunit <SEP> 6 <SEP> (Complex <SEP> I)) <SEP> NC~001807<tb> MTND6 <SEP> (NADH <SEP> dehydrogenase <SEP> subunit <SEP> 6 <SEP> (Complex <SEP> I)) <SEP> NC ~ 001807 <tb> MTND2 <SEP> (NADH <SEP> dehydrogenase <SEP> subunit <SEP> 2 <SEP> (Complex <SEP> I)) <SEP> NC~001807<tb> MTND2 <SEP> (NADH <SEP> dehydrogenase <SEP> subunit <SEP> 2 <SEP> (Complex <SEP> I)) <SEP> NC ~ 001807 <tb> MTND3 <SEP> (NADH <SEP> dehydrogenase <SEP> subunit <SEP> 3 <SEP> (Complex <SEP> I)) <SEP> NC~001807<tb> MTND3 <SEP> (NADH <SEP> dehydrogenase <SEP> subunit <SEP> 3 <SEP> (Complex <SEP> I)) <SEP> NC ~ 001807 <tb> MTND4 <SEP> (NADH <SEP> dehydrogenase <SEP> subunit <SEP> 4 <SEP> (Complex <SEP> I)) <SEP> NC~001807<tb> MTND4 <SEP> (NADH <SEP> dehydrogenase <SEP> subunit <SEP> 4 <SEP> (Complex <SEP> I)) <SEP> NC ~ 001807 <tb> MTND4L <SEP> (NADH <SEP> dehydrogenase <SEP> subunit <SEP> 4L <SEP> (Complex <SEP> I)) <SEP> NC~001807<tb> MTND4L <SEP> (NADH <SEP> dehydrogenase <SEP> subunit <SEP> 4L <SEP> (Complex <SEP> I)) <SEP> NC ~ 001807 <tb> MTND5 <SEP> (NADH <SEP> dehydrogenase <SEP> subunit <SEP> 5 <SEP> (Complex <SEP> I)) <SEP> NC~001807<tb> MTND5 <SEP> (NADH <SEP> dehydrogenase <SEP> subunit <SEP> 5 <SEP> (Complex <SEP> I)) <SEP> NC ~ 001807 <tb> MTND6 <SEP> (NADH <SEP> dehydrogenase <SEP> subunit <SEP> 6 <SEP> (Complex <SEP> I)) <SEP> NC~001807<tb> MTND6 <SEP> (NADH <SEP> dehydrogenase <SEP> subunit <SEP> 6 <SEP> (Complex <SEP> I)) <SEP> NC ~ 001807 <tb> MUC1 <SEP> (Mucin <SEP> 1) <SEP> Hs. <SEP> 89603<tb> MUC1 <SEP> (Mucin <SEP> 1) <SEP> Hs. <SEP> 89603 <tb> MUC2 <SEP> (Mucin <SEP> 2, <SEP> intestinal/tracheal) <SEP> Hs. <SEP> 315<tb> MUC2 <SEP> (Mucin <SEP> 2, <SEP> intestinal / tracheal) <SEP> Hs. <SEP> 315 <tb> MVP <SEP> = <SEP> LRP <SEP> (Major <SEP> vault <SEP> protein <SEP> ; <SEP> lung <SEP> resistance-related <SEP> protein) <SEP> Hs. <SEP> 80680<tb> MVP <SEP> = <SEP> LRP <SEP> (Major <SEP> vault <SEP> protein <SEP>; <SEP> lung <SEP> resistance-related <SEP> protein) <SEP> Hs. <SEP> 80680 <tb> MYB <SEP> = <SEP> c-MYB <SEP> (v-myb <SEP> avian <SEP> myeloblastosis <SEP> viral <SEP> oncogene <SEP> homolog <SEP> Hs. <SEP> 1334<tb> MYB <SEP> = <SEP> c-MYB <SEP> (v-myb <SEP> avian <SEP> myeloblastosis <SEP> viral <SEP> oncogene <SEP> homolog <SEP> Hs. <SEP> 1334 <tb> <Tb> <Desc/Clms Page number 106> <Desc / Clms Page number 106>
Figure img01060001
Figure img01060001
 <tb> <Tb> <tb> MYBL2 <SEP> = <SEP> B-MYB <SEP> (v-myb <SEP> avian <SEP> myeloblastosis <SEP> viral <SEP> oncogene <SEP> homolog-like <SEP> 2) <SEP> Hs. <SEP> 179718<tb> MYBL2 <SEP> = <SEP> B-MYB <SEP> (v-myb <SEP> avian <SEP> myeloblastosis <SEP> viral <SEP> oncogene <SEP> homolog-like <SEP> 2) <SEP > Hs. <SEP> 179718 <tb> MYC=c-MYC <SEP> (v-myc <SEP> avian <SEP> myelocytomatosis <SEP> viral <SEP> oncogene <SEP> homolog <SEP> Hs. <SEP> 79070<tb> MYC = c-MYC <SEP> (v-myc <SEP> avian <SEP> myelocytomatosis <SEP> viral <SEP> oncogene <SEP> homolog <SEP> Hs. <SEP> 79070 <tb> MYCN <SEP> (v-myc <SEP> avian <SEP> myelocytomatosis <SEP> viral <SEP> related <SEP> oncogene, <SEP> Hs. <SEP> 25960<tb> MYCN <SEP> (v-myc <SEP> avian <SEP> myelocytomatosis <SEP> viral <SEP> related <SEP> oncogene, <SEP> Hs. <SEP> 25960 <tb> neuroblastoma <SEP> derived)<tb> neuroblastoma <SEP> derived) <tb> MYLK <SEP> (Myosin, <SEP> light <SEP> polypeptide <SEP> kinase) <SEP> Hs. <SEP> 211582<tb> MYLK <SEP> (Myosin, <SEP> light <SEP> polypeptide <SEP> kinase) <SEP> Hs. <SEP> 211582 <tb> NFKB1 <SEP> (Nuclear <SEP> factor <SEP> of <SEP> kappa <SEP> light <SEP> polypeptide <SEP> gene <SEP> enhancer <SEP> in <SEP> B-cells <SEP> 1 <SEP> Hs. <SEP> 83428<tb> NFKB1 <SEP> (Nuclear <SEP> factor <SEP> of <SEP> kappa <SEP> light <SEP> polypeptide <SEP> gene <SEP> enhancer <SEP> in <SEP> B-cells <SEP> 1 <SEP> Hs. <SEP> 83428 <tb> (pu05))<tb> (pu05)) <tb> NFKB2 <SEP> (Nuclear <SEP> factor <SEP> of <SEP> kappa <SEP> light <SEP> polypeptide <SEP> gene <SEP> enhancer <SEP> in <SEP> B-cells <SEP> 2 <SEP> Hs. <SEP> 73090<tb> NFKB2 <SEP> (Nuclear <SEP> factor <SEP> of <SEP> kappa <SEP> light <SEP> polypeptide <SEP> gene <SEP> enhancer <SEP> in <SEP> B-cells <SEP> 2 <SEP> Hs. <SEP> 73090 <tb> (p49/p100))<tb> (p49 / p100)) <tb> NFKBIA <SEP> = <SEP> IKBalpha <SEP> (Nuclear <SEP> factor <SEP> of <SEP> kappa <SEP> light <SEP> polypeptide <SEP> gene <SEP> Hs. <SEP> 81328<tb> NFKBIA <SEP> = <SEP> IKBalpha <SEP> (Nuclear <SEP> factor <SEP> of <SEP> kappa <SEP> light <SEP> polypeptide <SEP> gene <SEP> Hs. <SEP> 81328 <tb> enhancer <SEP> in <SEP> B-cells <SEP> inhibitor, <SEP> alpha)<tb> enhancer <SEP> in <SEP> B-cells <SEP> inhibitor, <SEP> alpha) <tb> NK4 <SEP> (Natural <SEP> killer <SEP> cell <SEP> transcript <SEP> 4) <SEP> Hs. <SEP> 943<tb> NK4 <SEP> (Natural <SEP> killer <SEP> cell <SEP> transcript <SEP> 4) <SEP> Hs. <SEP> 943 <tb> NME1 <SEP> = <SEP> nm23-H1 <SEP> (Non-metastatic <SEP> cells <SEP> 1, <SEP> protein <SEP> (NM23A) <SEP> expressed <SEP> in) <SEP> Hs. <SEP> 118638<tb> NME1 <SEP> = <SEP> nm23-H1 <SEP> (Non-metastatic <SEP> cells <SEP> 1, <SEQ> protein <SEP> (NM23A) <SEP> expressed <SEP> in) < SEP> Hs. <SEP> 118638 <tb> NNMT <SEP> (Nicotinamide <SEP> N-methyltransferase) <SEP> Hs. <SEP> 76669<tb> NNMT <SEP> (Nicotinamide <SEP> N-methyltransferase) <SEP> Hs. <SEP> 76669 <tb> NRAS <SEP> (Neuroblastoma <SEP> RAS <SEP> viral <SEP> (v-ras) <SEP> oncogene <SEP> homolog) <SEP> Hs. <SEP> 260523<tb> NRAS <SEP> (Neuroblastoma <SEP> RAS <SEP> viral <SEP> (v-ras) <SEP> oncogene <SEP> homolog) <SEP> Hs. <SEP> 260523 <tb> NRG1 <SEP> (Heregu <SEP> ! <SEP> in <SEP> a <SEP> ! <SEP> pha) <SEP> Hs. <SEP> 172816<tb> NRG1 <SEP> (Heregu <SEP>! <SEP> in <SEP> a <SEP>! <SEP> pha) <SEP> Hs. <SEP> 172816 <tb> NSEP1 <SEP> = <SEP> YB1 <SEP> Nuclease <SEP> sensitive <SEP> element <SEP> binding <SEP> protein <SEP> 1) <SEP> Hs. <SEP> 74497<tb> NSEP1 <SEP> = <SEP> YB1 <SEP> Nuclease <SEP> sensitive <SEP> element <SEP> binding <SEP> protein <SEP> 1) <SEP> Hs. <SEP> 74497 <tb> OXTR <SEP> (Oxytocin <SEP> receptor) <SEP> Hs. <SEP> 2820<tb> OXTR <SEP> (Oxytocin <SEP> receptor) <SEP> Hs. <SEP> 2820 <tb> p14ARF <SEP> (Locus <SEP> INK4alpha/ARF)<tb> p14ARF <SEP> (Locus <SEP> INK4alpha / ARF) <tb> PC4 <SEP> (Activated <SEP> RNA <SEP> polymerase <SEP> 11 <SEP> transcription <SEP> cofactor <SEP> 4) <SEP> Hs. <SEP> 74861<tb> PC4 <SEP> (Activated <SEP> RNA <SEP> Polymerase <SEP> 11 <SEP> Transcription <SEP> Cofactor <SEP> 4) <SEP> Hs. <SEP> 74861 <tb> PCNA <SEP> (Proliferating <SEP> cell <SEP> nuclear <SEP> antigen) <SEP> Hs. <SEP> 78996<tb> PCNA <SEP> (Proliferating <SEP> cell <SEP> nuclear <SEP> antigen) <SEP> Hs. <SEP> 78996 <tb> PDGFA <SEP> (Platelet-derived <SEP> growth <SEP> factor <SEP> a) <SEP> Hs. <SEP> 37040<tb> PDGFA <SEP> (Platelet-derived <SEP> growth <SEP> factor <SEP> a) <SEP> Hs. <SEP> 37040 <tb> <Tb> <Desc/Clms Page number 107> <Desc / Clms Page number 107>
Figure img01070001
Figure img01070001
 <tb> <Tb> <tb> PDGFB <SEP> (Plate <SEP> let-derived <SEP> growth <SEP> factor <SEP> b) <SEP> Hs. <SEP> 1976<tb> PDGFB <SEP> (Plate <SEP> let-derived <SEP> growth <SEP> factor <SEP> b) <SEP> Hs. <SEP> 1976 <tb> PES1 <SEP> (Pescadillo <SEP> homolog <SEP> 1, <SEP> containing <SEP> BRCT <SEP> domain <SEP> Hs. <SEP> 13501<tb> PES1 <SEP> (Pescadillo <SEP> SEP> 1 <SEP> containing <SEP> BRCT <SEP> domain <SEP> Hs. <SEP> 13501 <tb> PFDN4 <SEP> (Prefoldin <SEP> 4) <SEP> Hs. <SEP> 91161<tb> PFDN4 <SEP> (Prefoldin <SEP> 4) <SEP> Hs. <SEP> 91161 <tb> PGK1 <SEP> (Phosphoglycerate <SEP> kinase <SEP> 1) <SEP> Hs. <SEP> 78771<tb> PGK1 <SEP> (Phosphoglycerate <SEP> kinase <SEP> 1) <SEP> Hs. <SEP> 78771 <tb> PGR <SEP> (Progesterone <SEP> receptor) <SEP> Hs. <SEP> 2905<tb> PGR <SEP> (Progesterone <SEP> receptor) <SEP> Hs. <SEP> 2905 <tb> PHB <SEP> (Prohibitin) <SEP> Hs. <SEP> 75323<tb> PHB <SEP> (Prohibitin) <SEP> Hs. <SEP> 75323 <tb> PIG3 <SEP> (Quinone <SEP> oxidoreductase <SEP> homolog) <SEP> Hs. <SEP> 50649<tb> PIG3 <SEP> (Quinone <SEP> oxidoreductase <SEP> homolog) <SEP> Hs. <SEP> 50649 <tb> PIG11 <SEP> (p53-induced <SEP> protein) <SEP> Hs. <SEP> 96908<tb> PIG11 <SEP> (p53-induced <SEP> protein) <SEP> Hs. <SEP> 96908 <tb> PIK3CG <SEP> (Phosphatidyl <SEP> i <SEP> n <SEP> ositol-3- <SEP> ki <SEP> nase, <SEP> catalytic <SEP> subunit, <SEP> gamma <SEP> Hs. <SEP> 32942<tb> PIK3CG <SEP> (Phosphatidyl <SEP> i <SEP> n <SEP> ositol-3- <SEP> ki <SEP> nase, <SEP> catalytic <SEP> subunit, <SEP> gamma <SEP> Hs <SEP> 32942 <tb> polypeptide)<tb> polypeptide) <tb> PIK3R1 <SEP> (Phosphoinositide-3-kinase, <SEP> regulatory <SEP> subunit, <SEP> polypeptide <SEP> 1 <SEP> (p85 <SEP> Hs. <SEP> 6241<tb> PIK3R1 <SEP> (Phosphoinositide-3-kinase, <SEP> regulatory <SEP> subunit, <SEP> polypeptide <SEP> 1 <SEP> (p85 <SEP> Hs. <SEP> 6241 <tb> alpha))<tb> alpha)) <tb> PIK3R2 <SEP> (Phosphoinositide-3-kinase, <SEP> regulatory <SEP> subunit, <SEP> polypeptide <SEP> 2 <SEP> (p85 <SEP> Hs. <SEP> 211586<tb> PIK3R2 <SEP> (Phosphoinositide-3-kinase, <SEP> regulatory <SEP> subunit, <SEP> polypeptide <SEP> 2 <SEP> (p85 <SEP> Hs. <SEP> 211586 <tb> beta))<tb> beta)) <tb> PIK3R3 <SEP> (Phosphoinositide-3-kinase, <SEP> regulatory <SEP> subunit, <SEP> polypeptide <SEP> 3 <SEP> (p55 <SEP> Hs. <SEP> 88051<tb> PIK3R3 <SEP> (Phosphoinositide-3-kinase, <SEP> regulatory <SEP> subunit, <SEP> polypeptide <SEP> 3 <SEP> (p55 <SEP> Hs. <SEP> 88051 <tb> gamma))<tb> gamma)) <tb> PLAU <SEP> (Plasminogen <SEP> activator, <SEP> urokinase) <SEP> Hs. <SEP> 77274<tb> PLAU <SEP> (Plasminogen <SEP> activator, <SEP> urokinase) <SEP> Hs. <SEP> 77274 <tb> PLAUR <SEP> (Plasminogen <SEP> activator, <SEP> urokinase <SEP> receptor <SEP> (Upar)) <SEP> Hs. <SEP> 179657<tb> PLAUR <SEP> (Plasminogen <SEP> activator, <SEP> urokinase <SEP> receptor <SEP> (Upar)) <SEP> Hs. <SEP> 179657 <tb> PLS3 <SEP> = <SEP> T-plastin <SEP> (Plastin <SEP> 3 <SEP> T <SEP> lsoform) <SEP> Hs. <SEP> 4114<tb> PLS3 <SEP> = <SEP> T-plastin <SEP> (Plastin <SEP> 3 <SEP> T <SEP> lsoform) <SEP> Hs. <SEP> 4114 <tb> PLK <SEP> (Polo <SEP> (Drosophia)-like <SEP> kinase <SEP> Hs. <SEP> 77597<tb> PLK <SEP> (Polo <SEP> (Drosophia) -like <SEP> Kinase <SEP> Hs. <SEP> 77597 <tb> PMS1 <SEP> (Postmeiotic <SEP> segregation <SEP> increased <SEP> 1) <SEP> Hs. <SEP> 111749<tb> PMS1 <SEP> (Postmeiotic <SEP> Segregation <SEP> Increased <SEP> 1) <SEP> Hs. <SEP> 111749 <tb> PMS2 <SEP> (Postmeiotic <SEP> segregation <SEP> increased <SEP> 2) <SEP> Hs. <SEP> 177548<tb> PMS2 <SEP> (Postmeiotic <SEP> Segregation <SEP> Increased <SEP> 2) <SEP> Hs. <SEP> 177548 <tb> <Tb> <Desc/Clms Page number 108> <Desc / Clms Page number 108>
Figure img01080001
Figure img01080001
 <tb> <Tb> <tb> POLR2J <SEP> (Polymerase <SEP> RNA <SEP> II <SEP> polypeptide <SEP> J <SEP> (13.3kD)) <SEP> Hs. <SEP> 80475<tb> POLR2J <SEP> (Polymerase <SEP> RNA <SEP> II <SEP> polypeptide <SEP> J <SEP> (13.3kD)) <SEP> Hs. <SEP> 80475 <tb> PRAME <SEP> (Preferentially <SEP> expressed <SEP> antigen <SEP> in <SEP> melanoma) <SEP> Hs. <SEP> 30743<tb> PRAME <SEP> (Preferentially <SEP> expressed <SEP> antigen <SEP> in <SEP> melanoma) <SEP> Hs. <SEP> 30743 <tb> PRDX1 <SEP> Peroxiredoxin <SEP> 1 <SEP> Hs. <SEP> 180909<tb> PRDX1 <SEP> Peroxiredoxin <SEP> 1 <SEP> Hs. <SEP> 180909 <tb> PRDX2 <SEP> (Peroxiredoxin <SEP> 2) <SEP> Hs. <SEP> 146354<tb> PRDX2 <SEP> (Peroxiredoxin <SEP> 2) <SEP> Hs. <SEP> 146354 <tb> PRG1 <SEP> = <SEP> Serglycin <SEP> (Proteoglycan <SEP> 1, <SEP> secretory <SEP> granule) <SEP> Hs. <SEP> 278687<tb> PRG1 <SEP> = <SEP> Serglycin <SEP> (Proteoglycan <SEP> 1, <SEP> secretory <SEP> granule) <SEP> Hs. <SEP> 278687 <tb> PRG2 <SEP> = <SEP> BMPG <SEP> (Proteoglycan <SEP> 2, <SEP> bone <SEP> marrow <SEP> proteoglycan) <SEP> Hs. <SEP> 99962<tb> PRG2 <SEP> = <SEP> BMPG <SEP> (Proteoglycan <SEP> 2, <SEP> bone <SEP> marrow <SEP> proteoglycan) <SEP> Hs. <SEP> 99962 <tb> PRKAR1 <SEP> (Protein <SEP> kinase, <SEP> cAMP-dpt, <SEP> regulatory, <SEP> type <SEP> I, <SEP> alpha <SEP> (tissue <SEP> Hs. <SEP> 183037<tb> PRKAR1 <SEP> (Protein <SEP> kinase, <SEP> cAMP-dpt, <SEP> regulatory, <SEP> type <SEP> I, <SEP> alpha <SEP> (tissue <SEP> Hs. < SEP> 183037 <tb> specific <SEP> extinguisher <SEP> 1) <SEP> )<tb> specific <SEP> extinguisher <SEP> 1) <SEP>) <tb> PRKAR1B <SEP> (Protein <SEP> kinase, <SEP> cAMP-dot, <SEP> regulatory, <SEP> type <SEP> l, <SEP> beta) <SEP> Hs. <SEP> 1519<tb> PRKAR1B <SEP> (Protein <SEP> kinase, <SEP> cAMP-dot, <SEP> regulatory, <SEP> type <SEP> l, <SEP> beta) <SEP> Hs. <SEP> 1519 <tb> PRKCA <SEP> (Protein <SEP> kinase <SEP> C, <SEP> alpha) <SEP> Hs. <SEP> 169449<tb> PRKCA <SEP> (Protein <SEP> kinase <SEP> C, <SEP> alpha) <SEP> Hs. <SEP> 169449 <tb> PRKCB1 <SEP> (Protein <SEP> kinase <SEP> C, <SEP> beta <SEP> 1) <SEP> Hs. <SEP> 77202<tb> PRKCB1 <SEP> (Protein <SEP> kinase <SEP> C, <SEP> beta <SEP> 1) <SEP> Hs. <SEP> 77202 <tb> PRKCD <SEP> Protein <SEP> kinase <SEP> C, <SEP> delta <SEP> Hs. <SEP> 155342<tb> PRKCD <SEP> Protein <SEP> kinase <SEP> C, <SEP> delta <SEP> Hs. <SEP> 155342 <tb> PRKCE <SEP> (Protein <SEP> kinase <SEP> C, <SEP> epsilon) <SEP> Hs. <SEP> 211592<tb> PRKCE <SEP> (Protein <SEP> kinase <SEP> C, <SEP> epsilon) <SEP> Hs. <SEP> 211592 <tb> PRKCG <SEP> (Protein <SEP> kinase <SEP> C, <SEP> gamma) <SEP> Hs. <SEP> 2890<tb> PRKCG <SEP> (Protein <SEP> kinase <SEP> C, <SEP> gamma) <SEP> Hs. <SEP> 2890 <tb> PRKCH <SEP> (Protein <SEP> kinase <SEP> C, <SEP> eta) <SEP> Hs. <SEP> 315366<tb> PRKCH <SEP> (Protein <SEP> kinase <SEP> C, <SEP> eta) <SEP> Hs. <SEP> 315366 <tb> PRKCI <SEP> (Protein <SEP> kinase <SEP> C, <SEP> iota) <SEP> Hs. <SEP> 1904<tb> PRKCI <SEP> (Protein <SEP> kinase <SEP> C, <SEP> iota) <SEP> Hs. <SEP> 1904 <tb> PRKCN <SEP> (Protein <SEP> kinase <SEP> C, <SEP> nu) <SEP> Hs. <SEP> 143460<tb> PRKCN <SEP> (Protein <SEP> kinase <SEP> C, <SEP> nude) <SEP> Hs. <SEP> 143460 <tb> PRKCQ <SEP> (Protein <SEP> kinase <SEP> C, <SEP> theta) <SEP> Hs. <SEP> 211593<tb> PRKCQ <SEP> (Protein <SEP> kinase <SEP> C, <SEP> theta) <SEP> Hs. <SEP> 211593 <tb> PRKCZ <SEP> (Protein <SEP> kinase <SEP> C, <SEP> zeta) <SEP> Hs. <SEP> 78793<tb> PRKCZ <SEP> (Protein <SEP> kinase <SEP> C, <SEP> zeta) <SEP> Hs. <SEP> 78793 <tb> PRKDC <SEP> = <SEP> XRCC7 <SEP> (Protein <SEP> kinase, <SEP> DNA-activated, <SEP> catalytic <SEP> polypeptide) <SEP> Hs. <SEP> 155637<tb> PRKDC <SEP> = <SEP> XRCC7 <SEP> (Protein <SEP> kinase, <SEP> DNA-activated, <SEP> catalytic <SEP> polypeptide) <SEP> Hs. <SEP> 155637 <tb> PRNP <SEP> (Prion <SEP> protein <SEP> (p27-30)) <SEP> Hs. <SEP> 74621<tb> PRNP <SEP> (Prion <SEP> protein <SEP> (p27-30)) <SEP> Hs. <SEP> 74621 <tb> <Tb> <Desc/Clms Page number 109> <Desc / Clms Page number 109>
Figure img01090001
Figure img01090001
 <tb> <Tb> <tb> PSMC1 <SEP> (Proteasome <SEP> (prosome, <SEP> macropain) <SEP> 26S <SEP> subunit, <SEP> ATPase, <SEP> 1) <SEP> Hs. <SEP> 4745<tb> PSMC1 <SEP> (Proteasome <SEP> (prosome, <SEP> macropain) <SEP> 26S <SEP> subunit, <SEP> ATPase, <SEP> 1) <SEP> Hs. <SEP> 4745 <tb> PSME1 <SEP> (Proteasome <SEP> (prosome, <SEP> macropain) <SEP> activator <SEP> subunit <SEP> 1, <SEP> PA28 <SEP> alpha) <SEP> Hs. <SEP> 75348<tb> PSME1 <SEP> (Proteasome <SEP> (prosome, <SEP> macropain) <SEP> activator <SEP> subunit <SEP> 1, <SEP> PA28 <SEP> alpha) <SEP> Hs. <SEP> 75348 <tb> PTGES <SEP> = <SEP> PIG12 <SEP> (Prostagiandin <SEP> E <SEP> synthase) <SEP> Hs. <SEP> 146688<tb> PTGES <SEP> = <SEP> PIG12 <SEP> (Prostagiandin <SEP> E <SEP> synthase) <SEP> Hs. <SEP> 146688 <tb> PTGS1 <SEP> = <SEP> COX-1 <SEP> (Prostag <SEP> ! <SEP> andin-endoperoxide <SEP> synthase <SEP> 1) <SEP> Hs. <SEP> 88474<tb> PTGS1 <SEP> = <SEP> COX-1 <SEP> (Prostag <SEP>! <SEP> andin-endoperoxide <SEP> synthase <SEP> 1) <SEP> Hs. <SEP> 88474 <tb> PTGS2 <SEP> = <SEP> COX-2 <SEP> (Prostaglandin-endoperoxide <SEP> synthase <SEP> 2 <SEP> (prostaglandin <SEP> Hs. <SEP> 196384<tb> PTGS2 <SEP> = <SEP> COX-2 <SEP> (Prostaglandin-Endoperoxide <SEP> Synthase <SEP> 2 <SEP> (Prostaglandin <SEP> Hs. <SEP> 196384 <tb> G/H <SEP> synthase <SEP> and <SEP> cyclooxygenase))<tb> G / H <SEP> synthase <SEP> and <SEP> cyclooxygenase)) <tb> PTK2 <SEP> = <SEP> FAK <SEP> (Protein <SEP> tyrosine <SEP> kinase <SEP> 2) <SEP> Hs. <SEP> 740<tb> PTK2 <SEP> = <SEP> FAK <SEP> (Protein <SEP> tyrosine <SEP> kinase <SEP> 2) <SEP> Hs. <SEP> 740 <tb> PTPN1 <SEP> (Protein <SEP> tyrosine <SEP> phosphatase, <SEP> non-receptor <SEP> type <SEP> 1) <SEP> Hs. <SEP> 155894<tb> PTPN1 <SEP> (Protein <SEP> tyrosine <SEP> phosphatase, <SEP> non-receptor <SEP> type <SEP> 1) <SEP> Hs. <SEP> 155894 <tb> RAB6C <SEP> (Rab6-like <SEP> protein) <SEP> Hs. <SEP> 333139<tb> RAB6C <SEP> (Rab6-like <SEP> protein) <SEP> Hs. <SEP> 333139 <tb> RABGGTA <SEP> (Geranyl <SEP> transferase, <SEP> alpha <SEP> subunit) <SEP> Hs. <SEP> 78920<tb> RABGGTA <SEP> (Geranyl <SEP> transferase, <SEP> alpha <SEP> subunit) <SEP> Hs. <SEP> 78920 <tb> RABGGTB <SEP> (Geranyl <SEP> transferase, <SEP> beta <SEP> subunit) <SEP> Hs. <SEP> 78948<tb> RABGGTB <SEP> (Geranyl <SEP> transferase, <SEP> beta <SEP> subunit) <SEP> Hs. <SEP> 78948 <tb> RAF1 <SEP> (v-raf-1 <SEP> murine <SEP> leukemia <SEP> viral <SEP> oncogene <SEP> homolog <SEP> 1) <SEP> Hs. <SEP> 85181<tb> RAF1 <SEP> (v-raf-1 <SEP> murine <SEP> leukemia <SEP> viral <SEP> oncogene <SEP> homolog <SEP> 1) <SEP> Hs. <SEP> 85181 <tb> RANGAP1 <SEP> (Ran <SEP> GTPase <SEP> activating <SEP> protein <SEP> 1) <SEP> Hs. <SEP> 183800<tb> RANGAP1 <SEP> (Ran <SEP> GTPase <SEP> activating <SEP> protein <SEP> 1) <SEP> Hs. <SEP> 183800 <tb> RB1 <SEP> (Retinoblastoma <SEP> 1) <SEP> Hs. <SEP> 75770<tb> RB1 <SEP> (Retinoblastoma <SEP> 1) <SEP> Hs. <SEP> 75770 <tb> RCV1 <SEP> (Recoverin) <SEP> Hs. <SEP> 80539<tb> RCV1 <SEP> (Recoverin) <SEP> Hs. <SEP> 80539 <tb> RELA <SEP> = <SEP> NFKB3 <SEP> (v-rel <SEP> avian <SEP> reticuloendotheliosis <SEP> viral <SEP> homolog <SEP> A <SEP> (nuclear <SEP> Hs. <SEP> 75569<tb> RELA <SEP> = <SEP> NFKB3 <SEP> (v-rel <SEP> avian <SEP> reticuloendotheliosis <SEP> viral <SEP> homolog <SEP> A <SEP> (nuclear <SEP> Hs. < SEP> 75569 <tb> factor <SEP> of <SEP> kappa <SEP> light <SEP> polypeptide <SEP> gene <SEP> enhancer <SEP> in <SEP> B-cells <SEP> 3 <SEP> (p65))<tb> factor <SEP> of <SEP> kappa <SEP> light <SEP> polypeptide <SEP> gene <SEP> enhancer <SEP> in <SEP> B-cells <SEP> 3 <SEP> (p65)) <tb> RPL9 <SEP> (Ribosomal <SEP> protein <SEP> L9 <SEP> Hs. <SEP> 157850<tb> RPL9 <SEP> (Ribosomal <SEP> Protein <SEP> L9 <SEP> Hs. <SEP> 157850 <tb> RPL12 <SEP> (Ribosomal <SEP> protein <SEP> L12) <SEP> Hs. <SEP> 182979<tb> RPL12 <SEP> (Ribosomal <SEP> protein <SEP> L12) <SEP> Hs. <SEP> 182979 <tb> RPL15 <SEP> (Ribosoma <SEP> ! <SEP> protein <SEP> L15) <SEP> Hs. <SEP> 74267<tb> RPL15 <SEP> (Ribosoma <SEP>! <SEP> protein <SEP> L15) <SEP> Hs. <SEP> 74267 <tb> RPL27A <SEP> (Ribosomal <SEP> protein <SEP> L27a) <SEP> Hs. <SEP> 76064<tb> RPL27A <SEP> (Ribosomal <SEP> protein <SEP> L27a) <SEP> Hs. <SEP> 76064 <tb> <Tb> <Desc/Clms Page number 110> <Desc / Clms Page number 110>
Figure img01100001
Figure img01100001
 <tb> <Tb> <tb> RPL41 <SEP> (Ribosomal <SEP> protein <SEP> L41) <SEP> Hs. <SEP> 324406<tb> RPL41 <SEP> (Ribosomal <SEP> protein <SEP> L41) <SEP> Hs. <SEP> 324406 <tb> RPLPO <SEP> (Ribosoma <SEP> ! <SEP> prote <SEP> ! <SEP> n, <SEP> ! <SEP> arge, <SEP> PO) <SEP> Hs. <SEP> 73742<tb> RPLPO <SEP> (Ribosoma <SEP>! <SEP> prote <SEP>! <SEP> n, <SEP>! <SEP> arge, <SEP> PO) <SEP> Hs. <SEP> 73742 <tb> RPS3A <SEP> (Ribosomal <SEP> protein <SEP> S3A) <SEP> Hs. <SEP> 77039<tb> RPS3A <SEP> (Ribosomal <SEP> protein <SEP> S3A) <SEP> Hs. <SEP> 77039 <tb> RPS6 <SEP> (Ribosoma <SEP> ! <SEP> protein <SEP> S6) <SEP> Hs. <SEP> 241507<tb> RPS6 <SEP> (Ribosoma <SEP>! <SEP> protein <SEP> S6) <SEP> Hs. <SEP> 241507 <tb> RPS15A <SEP> (Ribosomal <SEP> protein <SEP> S15a) <SEP> Hs. <SEP> 2953<tb> RPS15A <SEP> (Ribosomal <SEP> protein <SEP> S15a) <SEP> Hs. <SEP> 2953 <tb> RPS28 <SEP> (Ribosomal <SEP> protein <SEP> S28) <SEP> Hs. <SEP> 153177<tb> RPS28 <SEP> (Ribosomal <SEP> protein <SEP> S28) <SEP> Hs. <SEP> 153177 <tb> SCA2 <SEP> (Spinocerebellar <SEP> ataxia <SEP> 2 <SEP> (olivopontocerebellar <SEP> ataxia <SEP> 2, <SEP> autosomal <SEP> Hs. <SEP> 76253<tb> SCA2 <SEP> (Spinocerebellar <SEP> ataxia <SEP> 2 <SEP> (olivopontocerebellar <SEP> ataxia <SEP> 2, <SE> autosomal <SEP> Hs. <SEP> 76253 <tb> dominant, <SEP> ataxin <SEP> 2))<tb> dominant, <SEP> ataxin <SEP> 2)) <tb> SEMA3C <SEP> = <SEP> Semaphorin <SEP> E <SEP> (Sema <SEP> domain, <SEP> immunoglobulin <SEP> domain <SEP> (lg), <SEP> short <SEP> Hs. <SEP> 171921<tb> SEMA3C <SEP> = <SEP> Semaphorin <SEP> E <SEP> (Sema <SEP> domain, <SEQ> immunoglobulin <SEP> domain <SEP> (lg), <SEP> short <SEP> Hs. <SEP> 171921 <tb> basic <SEP> domain, <SEP> secreted, <SEP> (semaphorin) <SEP> 3C)<tb> basic <SEP> domain, <SEP> secreted, <SEP> (semaphorin) <SEP> 3C) <tb> SERPIN <SEP> B5 <SEP> (Maspin) <SEP> Hs.55279<tb> SERPIN <SEP> B5 <SEP> (Maspin) <SEP> Hs.55279 <tb> SERPIN <SEP> C1 <SEP> (Antithrombin <SEP> III) <SEP> Hs. <SEP> 75599<tb> SERPIN <SEP> C1 <SEP> (Antithrombin <SEP> III) <SEP> Hs. <SEP> 75599 <tb> SERPINE1 <SEP> (Plasminogen <SEP> activator <SEP> inhibitor, <SEP> type <SEP> 1 <SEP> (Pai1)) <SEP> Hs. <SEP> 82085<tb> SERPINE1 <SEP> (Plasminogen <SEP> activator <SEP> inhibitor, <SEP> type <SEP> 1 <SEP> (Pai1)) <SEP> Hs. <SEP> 82085 <tb> SLC19A1 <SEP> = <SEP> Reduced <SEP> folate <SEP> carrier <SEP> (Solute <SEP> carrier <SEP> family <SEP> 19 <SEP> (folate <SEP> Hs. <SEP> 84190<tb> SLC19A1 <SEP> = <SEP> Reduced <SEP> folate <SEP> Carrier <SEP> (solute <SEP> Carrier <SEP> family <SEP> 19 <SEP> (folate <SEP> Hs. <SEP> 84190 <tb> transporter) <SEP> member <SEP> 1)<tb> transport) <SEP> member <SEP> 1) <tb> SLC29A1 <SEP> = <SEP> Equilibrative <SEP> nucleoside <SEP> transporter <SEP> 1 <SEP> (Solute <SEP> carrier <SEP> family <SEP> 29 <SEP> Hs. <SEP> 25450<tb> SLC29A1 <SEP> = <SEP> Equilibrative <SEP> nucleoside <SEP> transport <SEP> 1 <SEP> (Solute SEP carrier <SEP> family <SEP> 29 <SEP> Hs. <SEP> 25450 <tb> (nucleoside <SEP> transporter), <SEP> member <SEP> 1)<tb> (nucleoside <SEP> transport), <SEP> member <SEP> 1) <tb> SNCG <SEP> = <SEP> BCSG1 <SEP> (Synuclein, <SEP> gamma <SEP> (breast <SEP> cancer-specific <SEP> protein <SEP> 1)) <SEP> Hs. <SEP> 63236<tb> SNCG <SEP> = <SEP> BCSG1 <SEP> (Synuclein, <SEP> gamma <SEP> (breast <SEP> cancer-specific <SEP> protein <SEP> 1)) <SEP> Hs. <SEP> 63236 <tb> SOD2 <SEP> (Superoxide <SEP> dismutase <SEP> 2, <SEP> mitochondria) <SEP> Hs. <SEP> 318885<tb> SOD2 <SEP> (Superoxide <SEP> dismutase <SEP> 2, <SEP> mitochondria) <SEP> Hs. <SEP> 318885 <tb> SRC <SEP> (v-src <SEP> avian <SEP> sarcoma <SEP> viral <SEP> oncogene <SEP> homolog) <SEP> Hs. <SEP> 198298<tb> SRC <SEP> (v-src <SEP> avian <SEP> sarcoma <SEP> viral <SEP> oncogene <SEP> homolog) <SEP> Hs. <SEP> 198298 <tb> SRI <SEP> (Sorcin) <SEP> Hs. <SEP> 300741<tb> SRI <SEP> (Sorcine) <SEP> Hs. <SEP> 300741 <tb> STAT1 <SEP> (Signal <SEP> transducer <SEP> and <SEP> activator <SEP> of <SEP> transcription <SEP> 1, <SEP> 91kD) <SEP> Hs. <SEP> 21486<tb> STAT1 <SEP> (Signal <SEP> transducer <SEP> and <SEP> activator <SEP> of <SEP> transcription <SEP> 1, <SEP> 91kD) <SEP> Hs. <SEP> 21486 <tb> <Tb> <Desc/Clms Page number 111> <Desc / Clms Page number 111>
Figure img01110001
Figure img01110001
 <tb> <Tb> <tb> STAT3 <SEP> (Signal <SEP> transducer <SEP> and <SEP> activator <SEP> of <SEP> transcription <SEP> 3 <SEP> (acute-phase <SEP> Hs. <SEP> 321677<tb> STAT3 <SEP> (SEP signal> transducer <SEP> and <SEP> activator <SEP> of <SEP> transcript <SEP> 3 <SEP> (acute-phase <SEP> Hs. <SEP> 321677 <tb> response <SEP> factor))<tb> response <SEP> factor)) <tb> STK4 <SEP> must1 <SEP> Hs. <SEP> 35140<tb> STK4 <SEP> must1 <SEP> Hs. <SEP> 35140 <tb> STK6 <SEP> (Aurora <SEP> IPL1-like <SEP> kinase) <SEP> Hs. <SEP> 333116<tb> STK6 <SEP> (Aurora <SEP> IPL1-like <SEP> Kinase) <SEP> Hs. <SEP> 333116 <tb> STK13 <SEP> (Serine/threonine <SEP> kinase <SEP> 13 <SEP> Aurora/IPL <SEP> 1-like <SEP> Hs. <SEP> 98338<tb> STK13 <SEP> (Serine / threonine <SEP> Kinase <SEP> 13 <SEP> Aurora / IPL <SEP> 1-like <SEP> Hs. <SEP> 98338 <tb> STMN1 <SEP> (Stathmin <SEP> 1, <SEP> oncoprotein <SEP> 18) <SEP> Hs. <SEP> 81915<tb> STMN1 <SEP> (Stathmin <SEP> 1, <SEP> oncoprotein <SEP> 18) <SEP> Hs. <SEP> 81915 <tb> SYT1 <SEP> (Synaptotagmin <SEP> !) <SEP> Hs. <SEP> 154679<tb> SYT1 <SEP> (Synaptotagmin <SEP>!) <SEP> Hs. <SEP> 154679 <tb> TAF2H <SEP> (TATA <SEP> box <SEP> binding <SEP> protein <SEP> (TBP)-associated <SEP> factor, <SEP> RNA <SEP> polymerase <SEP> Hs. <SEP> 89657<tb> TAF2H <SEP> (TATA <SEP> box <SEP> binding <SEP> protein <SEP> (TBP) -associated <SEP> factor, <SEP> RNA <SEP> polymerase <SEP> Hs. <SEP> 89657 <tb> Il, <SEP> H, <SEP> 30kD)<tb> It, <SEP> H, <SEP> 30kD) <tb> TAP1 <SEP> = <SEP> ABCB2 <SEP> (Transporter <SEP> 1, <SEP> ATP-binding <SEP> cassette, <SEP> sub-family <SEP> B) <SEP> Hs. <SEP> 158164<tb> TAP1 <SEP> = <SEP> ABCB2 <SEP> (Transporter <SEP> 1, <SEP> ATP-binding <SEP> cassette, <SEP> sub-family <SEP> B) <SEP> Hs. <SEP> 158164 <tb> TAP2 <SEP> = <SEP> ABCB3 <SEP> (Transporter <SEP> 2, <SEP> ATP-binding <SEP> cassette, <SEP> sub-family <SEP> B) <SEP> Hs. <SEP> 502<tb> TAP2 <SEP> = <SEP> ABCB3 <SEP> (Transporter <SEP> 2, <SEP> ATP-binding <SEP> cassette, <SEP> sub-family <SEP> B) <SEP> Hs. <SEP> 502 <tb> TEK <SEP> = <SEP> TIE-2 <SEP> (Tyrosine <SEP> kinase, <SEP> endothelial <SEP> (venous <SEP> malformations, <SEP> multiple <SEP> Hs. <SEP> 89640<tb> TEK <SEP> = <SEP> TIE-2 <SEP> (Tyrosin <SEP> kinase, <SEP> endothelial <SEP> (venous <SEP> malformations, <SEP> multiple <SEP> Hs. <SEP> 89640 <tb> cutaneous <SEP> and <SEP> mucosal))<tb> cutaneous <SEP> and <SEP> mucosal)) <tb> TERC <SEP> = <SEP> hTR <SEP> (Telomerase <SEP> RNA <SEP> component) <SEP> U86046<tb> TERC <SEP> = <SEP> hTR <SEP> (Telomerase <SEP> RNA <SEP> component) <SEP> U86046 <tb> TERT <SEP> (Telomerase <SEP> reverse <SEP> transcriptase) <SEP> Hs. <SEP> 115256<tb> TERT <SEP> (Telomerase <SEP> reverse <SEP> transcriptase) <SEP> Hs. <SEP> 115256 <tb> TFF1 <SEP> = <SEP> HPS2 <SEP> (Trefoil <SEP> factor <SEP> 1 <SEP> (breast <SEP> cancer, <SEP> estrogen-inducible <SEP> sequence <SEP> Hs. <SEP> 337764<tb> TFF1 <SEP> = <SEP> HPS2 <SEP> (Trefoil <SEP> factor <SEP> 1 <SEP> (breast <SEP> cancer, <SEP> estrogen-inducible <SEP> sequence <SEP> Hs. <SEP> 337764 <tb> expressed <SEP> in))<tb> expressed <SEP> in)) <tb> TFRC <SEP> (Transferrin <SEP> receptor <SEP> (p90, <SEP> CD71)) <SEP> Hs. <SEP> 77356<tb> TFRC <SEP> (Transferrin <SEP> receptor <SEP> (p90, <SEP> CD71)) <SEP> Hs. <SEP> 77356 <tb> TGFA <SEP> (Transforming <SEP> growth <SEP> factor, <SEP> alpha <SEP> Hs. <SEP> 170009<tb> TGFA <SEP> (Transforming <SEP> Growth <SEP> Factor, <SEP> Alpha <SEP> Hs. <SEP> 170009 <tb> TGFB1 <SEP> (Transforming <SEP> growth <SEP> factor, <SEP> beta <SEP> 1) <SEP> Hs. <SEP> 1103<tb> TGFB1 <SEP> (Transforming <SEP> growth <SEP> factor, <SEP> beta <SEP> 1) <SEP> Hs. <SEP> 1103 <tb> TGFBR2 <SEP> (Transforming <SEP> growth <SEP> factor, <SEP> b ta <SEP> receptor)) <SEP> (70-80kD)) <SEP> Hs. <SEP> 82028<tb> TGFBR2 <SEP> (Transforming <SEP> growth <SEP> factor, <SEP> bt <SEP> receptor)) <SEP> (70-80kD)) <SEP> Hs. <SEP> 82028 <tb> TGFBR3 <SEP> (Transforming <SEP> growth <SEP> factor, <SEP> beta <SEP> receptor <SEP> III <SEP> (betaglycan, <SEP> 300kD)) <SEP> Hs. <SEP> 342874<tb> TGFBR3 <SEP> (Transforming <SEP> growth <SEP> factor, <SEP> beta <SEP> receptor <SEP> III <SEP> (betaglycan, <SEP> 300kD)) <SEP> Hs. <SEP> 342874 <tb> <Tb> <Desc/Clms Page number 112> <Desc / Clms Page number 112>
Figure img01120001
Figure img01120001
 <tb> <Tb> <tb> THBS1 <SEP> (Thrombospondin <SEP> 1) <SEP> Hs. <SEP> 87409<tb> THBS1 <SEP> (Thrombospondin <SEP> 1) <SEP> Hs. <SEP> 87409 <tb> TIE <SEP> = <SEP> TIE-1 <SEP> (Tyrosine <SEP> kinase <SEP> with <SEP> immunoglobulin <SEP> and <SEP> epidermal <SEP> growth <SEP> Hs. <SEP> 78824<tb> TIE <SEP> = <SEP> TIE-1 <SEP> (Tyrosine <SEP> kinase <SEP> with <SEQ> immunoglobulin <SEP> and <SEP> epidermal <SEP> growth <SEP> Hs. <SEP > 78824 <tb> factor <SEP> homology <SEP> domains)<tb> factor <SEP> homology <SEP> domains <tb> TIMP2 <SEP> (Tissue <SEP> inhibitor <SEP> of <SEP> metalloproteinase <SEP> 2) <SEP> Hs. <SEP> 325495<tb> TIMP2 <SEP> (Tissue <SEP> inhibitor <SEP> of <SEP> metalloproteinase <SEP> 2) <SEP> Hs. <SEP> 325495 <tb> TK1 <SEP> (Thymidine <SEP> kinase <SEP> 1) <SEP> Hs. <SEP> 105097<tb> TK1 <SEP> (Thymidine <SEP> kinase <SEP> 1) <SEP> Hs. <SEP> 105097 <tb> TNFRSF6 <SEP> = <SEP> APO-1/CD95 <SEP> = <SEP> Fas <SEP> (Tumor <SEP> necrosis <SEP> factor <SEP> receptor <SEP> subfamily, <SEP> Hs. <SEP> 82359<tb> TNFRSF6 <SEP> = <SEP> APO-1 / CD95 <SEP> = <SEP> Fas <SEP> (Tumor <SEP> necrosis <SEP> factor <SEP> receptor <SEP> subfamily, <SEP> Hs <SEP> 82359 <tb> member <SEP> 6)<tb> member <SEP> 6) <tb> TNFSF6 <SEP> = <SEP> CD95L <SEP> = <SEP> FasL <SEP> (Tumor <SEP> necrosis <SEP> factor <SEP> (ligand) <SEP> superfamily, <SEP> Hs. <SEP> 2007<tb> TNFSF6 <SEP> = <SEP> CD95L <SEP> = <SEP> FasL <SEP> (Tumor <SEP> necrosis <SEP> factor <SEP> (ligand) <SEP> superfamily, <SEP> Hs. < SEP> 2007 <tb> member <SEP> 6)<tb> member <SEP> 6) <tb> TOP1 <SEP> (Topoisomerase <SEP> DNA <SEP> 1) <SEP> Hs. <SEP> 317<tb> TOP1 <SEP> (Topoisomerase <SEP> DNA <SEP> 1) <SEP> Hs. <SEP> 317 <tb> TOP2A <SEP> (Topoisomerase <SEP> DNA <SEP> Il <SEP> aloha <SEP> (170kO)) <SEP> Hs. <SEP> 156346<tb> TOP2A <SEP> (Topoisomerase <SEP> DNA <SEP> It <SEP> aloha <SEP> (170kO)) <SEP> Hs. <SEP> 156346 <tb> TOP2B <SEP> (Topoisomerase <SEP> DNA <SEP> II <SEP> beta <SEP> (180kD)) <SEP> Hs. <SEP> 75248<tb> TOP2B <SEP> (Topoisomerase <SEP> DNA <SEP> II <SEP> beta <SEP> (180kD)) <SEP> Hs. <SEP> 75248 <tb> TP53 <SEP> (Tumor <SEP> orotein <SEP> 053 <SEP> (Li-Fraumeni <SEP> syndrome)) <SEP> Hs. <SEP> 1846<tb> TP53 <SEP> (Tumor <SEP> orotein <SEP> 053 <SEP> (Li-Fraumeni <SEP> Syndrome)) <SEP> Hs. <SEP> 1846 <tb> TP73 <SEP> (Tumor <SEP> protein <SEP> p73) <SEP> Hs. <SEP> 247753<tb> TP73 <SEP> (Tumor <SEP> protein <SEP> p73) <SEP> Hs. <SEP> 247753 <tb> TPI1 <SEP> (Triosephosphate <SEP> isomerase <SEP> 1) <SEP> Hs. <SEP> 83848<tb> TPI1 <SEP> (Triosephosphate <SEP> isomerase <SEP> 1) <SEP> Hs. <SEP> 83848 <tb> TRAF1 <SEP> (TNF <SEP> receptor-associated <SEP> factor <SEP> 1) <SEP> Hs. <SEP> 2134<tb> TRAF1 <SEP> (TNF <SEP> receptor-associated <SEP> factor <SEP> 1) <SEP> Hs. <SEP> 2134 <tb> TRAG3 <SEP> (TXL <SEP> resistance <SEP> associated <SEP> gene <SEP> 3) <SEP> Hs. <SEP> 251377<tb> TRAG3 <SEP> (TXL <SEP> resistance <SEP> associated <SEP> gene <SEP> 3) <SEP> Hs. <SEP> 251377 <tb> TUBB <SEP> (Tubulin, <SEP> beta <SEP> polypeptide) <SEP> Hs. <SEP> 336780<tb> TUBB <SEP> (Tubulin, <SEP> beta <SEP> polypeptide) <SEP> Hs. <SEP> 336780 <tb> TUBB <SEP> (Tubulin, <SEP> beta <SEP> 1) <SEP> Hs. <SEP> 303023<tb> TUBB <SEP> (Tubulin, <SEP> beta <SEP> 1) <SEP> Hs. <SEP> 303023 <tb> TUBB2 <SEP> (Tubulin, <SEP> beta <SEP> 2) <SEP> Hs. <SEP> 251653<tb> TUBB2 <SEP> (Tubulin, <SEP> beta <SEP> 2) <SEP> Hs. <SEP> 251653 <tb> TUBB4 <SEP> = <SEP> Tubulin <SEP> beta <SEP> III <SEP> (Tubulin, <SEP> beta, <SEP> 4) <SEP> Hs. <SEP> 159154<tb> TUBB4 <SEP> = <SEP> Tubulin <SEP> beta <SEP> III <SEP> (Tubulin, <SEP> beta, <SEP> 4) <SEP> Hs. <SEP> 159154 <tb> <Tb> <Desc/Clms Page number 113> <Desc / Clms Page number 113>
Figure img01130001
Figure img01130001
 <tb> <Tb> <tb> TXN <SEP> (Thioredoxin) <SEP> Hs. <SEP> 76136<tb> TXN <SEP> (Thioredoxin) <SEP> Hs. <SEP> 76136 <tb> TYMS <SEP> = <SEP> TS <SEP> (Thymidylate <SEP> synthetase) <SEP> Hs. <SEP> 82962<tb> TYMS <SEP> = <SEP> TS <SEP> (Thymidylate <SEP> synthetase) <SEP> Hs. <SEP> 82962 <tb> UMPS <SEP> (Undine <SEP> monophosphate <SEP> synthetase <SEP> (orotate <SEP> Hs. <SEP> 2057<tb> UMPS <SEP> (Undine <SEP> Monophosphate <SEP> Synthetase <SEP> (orotate <SEP> Hs. <SEP> 2057 <tb> phosphoribosyltransferase <SEP> and <SEP> orotidine-5'-decarbox <SEP> lase<tb> phosphoribosyltransferase <SEP> and <SEP> orotidine-5'-decarbox <SEP> lase <tb> UP <SEP> (Undine <SEP> phosphorylase) <SEP> Hs. <SEP> 77573<tb> UP <SEP> (Undine <SEP> phosphorylase) <SEP> Hs. <SEP> 77573 <tb> VEGF <SEP> (Vascular <SEP> endothelial <SEP> growth <SEP> factor) <SEP> Hs. <SEP> 73793<tb> VEGF <SEP> (Vascular <SEP> endothelial <SEP> growth <SEP> factor) <SEP> Hs. <SEP> 73793 <tb> VHL <SEP> (Von <SEP> hippel <SEP> lindau <SEP> syndrome) <SEP> Hs. <SEP> 174007<tb> VHL <SEP> (Von <SEP> hippel <SEP> lindau <SEP> syndrome) <SEP> Hs. <SEP> 174007 <tb> VIM <SEP> (Vimentin) <SEP> Hs. <SEP> 297753<tb> VIM <SEP> (Vimentin) <SEP> Hs. <SEP> 297753 <tb> XPA <SEP> (Xeroderma <SEP> pigmentosum, <SEP> complementation <SEP> group <SEP> A) <SEP> Hs. <SEP> 192803<tb> XPA <SEP> (Xeroderma <SEP> Pigmentosa, <SEP> Complementation <SEP> group <SEP> A) <SEP> Hs. <SEP> 192803 <tb> XRCC1 <SEP> (x-ray <SEP> repair <SEP> complementing <SEP> defective <SEP> repair <SEP> in <SEP> Chinese <SEP> hamster <SEP> Hs. <SEP> 98493<tb> XRCC1 <SEP> (x-ray <SEP> repair <SEP> complementing <SEP> defective <SEP> repair <SEP> in <SEP> Chinese <SEP> hamster <SEP> Hs. <SEP> 98493 <tb> cells <SEP> 1<tb> cells <SEP> 1 <tb> ZNF161 <SEP> (Zinc <SEP> finger <SEP> protein <SEP> 161) <SEP> Hs. <SEP> 6557<tb> ZNF161 <SEP> (Zinc <SEP> Finger <SEP> Protein <SEP> 161) <SEP> Hs. <SEP> 6557 <tb> <Tb>
Figure img01130002
Figure img01130002
 19 Biopuces selon l'une quelconque des revendications 1 18 caract ris es en ce qu'elles sont pr par es, ainsi que leurs sondes mol culaires, par un proc d de tr s haute qualit comportant une combinaison de 10 tapes : 1 Extractiond'ADN plasmidiques.  19 Microarrays according to any one of claims 1 18 characterized in that they are prepared, as well as their molecular probes, by a process of high quality tr with a combination of 10 steps: 1 Extractiond ' Plasmid DNAs. 2 Dosage des ADN plasmidiques ; 3 Dilution des ADN plasmidiques. 2 Assay of plasmid DNAs; 3 Dilution of plasmid DNAs. 4 Amplification des ADN compl mentaires (ADNc) ou fragments d'ADNc, ou fragment d'ADN, 5 Purification des produits d'amplification obtenus. Amplification of Complementary DNAs (cDNA) or cDNA fragments, or DNA fragment. Purification of the obtained amplification products. 6 Dosage de ces produits. 6 Dosage of these products. 7 Dilution une m me concentration. 7 Dilution the same concentration. 8 Pr paration d'un plaque o tous les ADNc sont la m me quantit . 8 Preparation of a plate where all cDNAs are the same amount. <Desc/Clms Page number 114> <Desc / Clms Page number 114> 9 S quen age des ADNc.  9 Sequence of the cDNAs. 10 D pt sur le support (lame de verre ou tout autre support).  10 D pt on the support (glass slide or other support). 20 Biopuce selon la revendication 19 caract ris e en ce que ledit proc d comporte au moins les tapes 6 (dosage), 7 (dilution) et 9 (s quen age). Biochip according to claim 19, characterized in that said method comprises at least steps 6 (assay), 7 (dilution) and 9 (s quen age). 21 Biopuce selon la revendication 20 caract ris e en ce que ledit proc d comporte galement l' tape 5 de purification. The biochip of claim 20 characterized in that said method also includes purification step 5. 22 Biopuce selon l'une quelconque des revendications 1 21 caract ris e en ce que comme support on utilise un support de verre, ou verre-silice, ou des supports polym res par exemple mati res plastiques ou membrane de Nylon TM, ou tout autre supports sur lesquels sont fix s ou d pos s ( < < spotted ) des fragments de g nes, des ADNc ou des fragments d'ADNc, ou des oligonucl otides, et des surfaces plots lectroniques, en faisant appel l'attraction lectrostatique de charges + et-, ou des supports coupl s des semi-conducteurs, pour fixer ou d poser les acides nucl iques chantillons. 22 Biochip according to any one of claims 1 21 characterized in that as support is used a glass support, or glass-silica, or polym res supports for example plastic materials or Nylon TM membrane, or any other supports on which are fixed or spotted fragments of cDNAs, cDNAs or cDNA fragments, or oligonucleotides, and electronically plotted surfaces, using electrostatic charge attraction + and-, or coupled supports of the semiconductors, for fixing or laying down the nucleic acid samples. 23 Application des biopuces selon l'une quelconque des revendications 1 22 pour la d finition d'un traitement en m decine humaine, notamment en oncologie, notamment pour le cancer mammaire. 23 Application of biochips according to any one of claims 1 22 for the definition of a treatment in human medicine, especially oncology, especially for breast cancer. 24 Application des biopuces selon l'une quelconque des revendications 1 22 comme moyen de diagnostic dans le domaine de toutes les sciences du vivant. 24 Application of biochips according to any one of claims 1 22 as diagnostic means in the field of all life sciences. 25 Application selon la revendication 33 dans le domaine v t rinaire. Application according to claim 33 in the field of practice. 26 Application selon la revendication 33 dans le domaine phytosanitaire. Application according to claim 33 in the phytosanitary field. 27 Combinaison de sondes mol culaires telle que d crite dans la revendication 16 (Annexe 1 SEQ 1). 27 A combination of molecular probes as described in claim 16 (Appendix 1 SEQ 1). <Desc/Clms Page number 115><Desc / Clms Page number 115> 28 Combinaison de sondes mol culaires telle que d crite dans la revendication 17 (Annexe 2 SEQ 2).  Combination of Molecular Probes as described in Claim 17 (Annex 2 SEQ 2). 29 Combinaison de sondes mol culaires telle que d crite dans la revendication 18 (Annexe 3 SEQ 3). 29 A combination of molecular probes as described in claim 18 (Appendix 3 SEQ 3). 30 Utilisation des combinaisons de sondes mol culaires selon la revendication 28 ou 29 comme module de recherche associ ou coupl au moins une biopuce th matique. Use of the molecular probe combinations according to claim 28 or 29 as an associative or coupled search module for at least one thematic biochip. 31 Utilisation des biopuces et combinaisons de sondes mol culaires selon l'une quelconque des revendications 1 29 comme moyen de diagnostic dans toutes les sciences du vivant, notamment le domaine m dical, v t rinaire, phytosanitaire ; galement toute tude de g nome connu par exemple g nome bovin, v g tal, bact rien ; pour v rifier la fonctionnalit d'un g ne chez des organismes g n tiquement modifi s ; et en virologie, les biopuces tant alors utilis es pour caract riser la pr sence et le type de virus infectant un organisme ; et pour l'appr ciation des m canismes mis en jeu et de la qualit de la r paration des l sions de l'ADN, et notamment en oncologie, notamment pour le cancer mammaire ; et comme moyen de diagnostic dans le domaine de toutes les sciences du vivant, et notamment dans le domaine m dical ou v t rinairedans le domaine phytosanitaire. des biopuces et des proc d s selon l'invention comme moyen de diagnostic et l' tude de toutes les grandes fonctions cellulaires, notamment apoptose, cycle cellulaire, transduction du signal, prolif ration cellulaire, prot olyse, mobilit et invasivit cellulaire, etc.... et tous les types de maladies, notamment inflammatoires, infectieuses, endocriniennes, autoimmunes, h r ditaires, nutritionnelles, d g naratives, chroniques ou aiges, etc....31 Use of biochips and molecular probe combinations according to any one of claims 1 to 29 as diagnostic means in all life sciences, in particular the medical, veterinary, phytosanitary field; also any study of known genome such as cattle, cattle, bact nothing; to verify the functionality of a gene in genetically modified organisms; and in virology, the biochips then used to characterize the presence and type of virus infecting an organism; and for the evaluation of the mechanisms involved and the quality of the repair of DNA lesions, and in particular in oncology, in particular for breast cancer; and as a means of diagnosis in the field of all life sciences, and particularly in the medical or veterinary field in the phytosanitary field. biochips and methods according to the invention as a means of diagnosis and the study of all the major cellular functions, in particular apoptosis, cell cycle, signal transduction, cellular proliferation, protolysis, mobility and cellular invasivit, etc. .. and all types of diseases, including inflammatory, infectious, endocrine, autoimmune, hereditary, nutritional, narative, chronic or acute diseases, etc.
FR0116962A 2001-12-20 2001-12-20 Thematic biochip, useful e.g. for diagnosis, particularly of breast cancer, and treatment selection, comprises thematic probes and probes for interpretation Pending FR2833968A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR0116962A FR2833968A1 (en) 2001-12-20 2001-12-20 Thematic biochip, useful e.g. for diagnosis, particularly of breast cancer, and treatment selection, comprises thematic probes and probes for interpretation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0116962A FR2833968A1 (en) 2001-12-20 2001-12-20 Thematic biochip, useful e.g. for diagnosis, particularly of breast cancer, and treatment selection, comprises thematic probes and probes for interpretation

Publications (1)

Publication Number Publication Date
FR2833968A1 true FR2833968A1 (en) 2003-06-27

Family

ID=8871040

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0116962A Pending FR2833968A1 (en) 2001-12-20 2001-12-20 Thematic biochip, useful e.g. for diagnosis, particularly of breast cancer, and treatment selection, comprises thematic probes and probes for interpretation

Country Status (1)

Country Link
FR (1) FR2833968A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2875512A1 (en) * 2004-09-17 2006-03-24 Diagnogene S A Sa DIAGNOSTIC BIOPUCE OF THE METASTATIC OR LOCALIZED CHARACTER OF A MAMMARY TUMOR, METHOD AND KIT OF USE
FR2888252A1 (en) * 2005-07-07 2007-01-12 Biomerieux Sa METHOD FOR THE DIAGNOSIS OF BREAST CANCER
US11608535B2 (en) 2018-04-12 2023-03-21 The University Of Liverpool Detection of bacterial infections

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998028444A2 (en) * 1996-12-23 1998-07-02 The University Of Chicago Customized oligonucleotide microchips as multiple biosensors
WO2001046477A1 (en) * 1999-12-15 2001-06-28 Conagra Grocery Products Companies Multispecies food testing and characterization
US20010039015A1 (en) * 2000-01-21 2001-11-08 Edward Sauter Nipple aspirate fluid specific microarrays

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998028444A2 (en) * 1996-12-23 1998-07-02 The University Of Chicago Customized oligonucleotide microchips as multiple biosensors
WO2001046477A1 (en) * 1999-12-15 2001-06-28 Conagra Grocery Products Companies Multispecies food testing and characterization
US20010039015A1 (en) * 2000-01-21 2001-11-08 Edward Sauter Nipple aspirate fluid specific microarrays

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
ALIZADEH A ET AL: "THE LYMPHOCHIP: A SPECIALIZED CDNA MICROARRAY FOR THE GENOMIC-SCALE ANALYSIS OF GENE EXPRESSION IN NORMAL AND MALIGNANT LYMPHOCYTES", COLD SPRING HARBOR SYMPOSIA ON QUANTITATIVE BIOLOGY, BIOLOGICAL LABORATORY, COLD SPRING HARBOR, NY, US, vol. 64, no. 1, 1999, pages 71 - 78, XP001099007, ISSN: 0091-7451 *
BERTUCCI F ET AL: "[DNA arrays: technological aspects and applications.]", BULLETIN DU CANCER. FRANCE MAR 2001, vol. 88, no. 3, March 2001 (2001-03-01), pages 243 - 252, XP008010010, ISSN: 0007-4551 *
BERTUCCI F ET AL: "GENE EXPRESSION PROFILING OF CANCER BY USE OF DNA ARRAYS: HOW FAR FROM THE CLINIC?", LANCET ONCOLOGY, LANCET PUBLISHING GROUP, LONDON, GB, vol. 2, no. 11, November 2001 (2001-11-01), pages 674 - 682, XP001097948, ISSN: 1470-2045 *
EYSTER K M ET AL: "Molecular medicine: a primer for clinicians. Part XII: DNA microarrays and their application to clinical medicine.", SOUTH DAKOTA JOURNAL OF MEDICINE. UNITED STATES FEB 2001, vol. 54, no. 2, February 2001 (2001-02-01), pages 57 - 61, XP008010408, ISSN: 0038-3317 *
GOLUB T R ET AL: "Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 286, no. 5439, 15 October 1999 (1999-10-15), pages 531 - 537, XP002207658, ISSN: 0036-8075 *
LACROIX M. ET AL: "A low-density DNA microarray for analysis of markers in breast cancer (review article)", THE INTERNATIONAL JOURNAL OF BIOMARKERS, vol. 17, no. 1, 2002, pages 5 - 23, XP008010290 *
MILLER G ET AL: "IMAGE cDNA Clones, UniGene Clustering, and ACeDB: An Integrated Resource for Expressed Sequence Information", GENOME RESEARCH, COLD SPRING HARBOR LABORATORY PRESS, US, vol. 7, October 1997 (1997-10-01), pages 1027 - 2032, XP002210119, ISSN: 1088-9051 *
MITTAL V: "DNA array technology, in SAMBROOK et RUSSEL: Molecular cloning, a laboratory manual", February 2001, COLD SPRING HARBOR LABORATORY PRESS, COLD SPRING HARBOR, NEW-YORK, XP002221380 *
POLLACK J R ET AL: "Genome-wide analysis of DNA copy-number changes using cDNA microarrays.", NATURE GENETICS. UNITED STATES SEP 1999, vol. 23, no. 1, September 1999 (1999-09-01), pages 41 - 46, XP002221379, ISSN: 1061-4036 *
ZARRINKAR P P ET AL: "Arrays of arrays for high-throughput gene expression profiling.", GENOME RESEARCH. UNITED STATES JUL 2001, vol. 11, no. 7, July 2001 (2001-07-01), pages 1256 - 1261, XP002222536, ISSN: 1088-9051 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2875512A1 (en) * 2004-09-17 2006-03-24 Diagnogene S A Sa DIAGNOSTIC BIOPUCE OF THE METASTATIC OR LOCALIZED CHARACTER OF A MAMMARY TUMOR, METHOD AND KIT OF USE
WO2006032769A1 (en) * 2004-09-17 2006-03-30 Diagnogene Sa Biochip for diagnosis of the metastatic or localized character of a mammary tumour, method and kit for use
FR2888252A1 (en) * 2005-07-07 2007-01-12 Biomerieux Sa METHOD FOR THE DIAGNOSIS OF BREAST CANCER
WO2007006911A2 (en) * 2005-07-07 2007-01-18 Biomerieux S.A. Method for breast cancer diagnosis
WO2007006911A3 (en) * 2005-07-07 2007-08-02 Biomerieux Sa Method for breast cancer diagnosis
US11608535B2 (en) 2018-04-12 2023-03-21 The University Of Liverpool Detection of bacterial infections

Similar Documents

Publication Publication Date Title
AU2006307849B2 (en) Method and device for the in vitro analysis of mRNA of genes involved in haematological neoplasias
US12060611B2 (en) Gene expression profiles associated with sub-clinical kidney transplant rejection
US20230193396A1 (en) Circulating microrna signatures for ovarian cancer
US20170088900A1 (en) Test Kits and Uses Thereof
US20110136683A1 (en) Systems and Methods for Expression-Based Discrimination of Distinct Clinical Disease States in Prostate Cancer
US20060063156A1 (en) Outcome prediction and risk classification in childhood leukemia
US20160041153A1 (en) Biomarker compositions and markers
EP2631301B1 (en) Methods for determining a graft tolerant phenotype in a subject
JP2024107255A (en) Hydroxymethylation analysis of cell-free nucleic acid samples for assigning tissue of origin and related methods of use - Patents.com
CA2670872A1 (en) Gene expression profiling for identification, monitoring, and treatment of colorectal cancer
JP2024009855A (en) Non-coding rna for detection of cancer
EP3825416A2 (en) Gene expression profiles associated with sub-clinical kidney transplant rejection
US20130040833A1 (en) Use of microvesicles in analyzing nucleic acid profiles
AU2019201377A1 (en) Proliferation signature and prognosis for gastrointestinal cancer
FR2833968A1 (en) Thematic biochip, useful e.g. for diagnosis, particularly of breast cancer, and treatment selection, comprises thematic probes and probes for interpretation
US7601532B2 (en) Microarray for predicting the prognosis of neuroblastoma and method for predicting the prognosis of neuroblastoma
EP1683862B1 (en) Microarray for assessing neuroblastoma prognosis and method of assessing neuroblastoma prognosis
CN115029438A (en) Application of RARES 2 gene in diagnosis and treatment of breast cancer brain metastasis
CA3227133A1 (en) Compositions and methods for cancer detection
FR2833969A1 (en) Biochip that carries high purity molecular probes, useful e.g. for diagnosis, specifically of breast cancer, and for analysis of DNA repair
WO2023004078A2 (en) Compositions and methods for detection of breast cancer
FR2875512A1 (en) DIAGNOSTIC BIOPUCE OF THE METASTATIC OR LOCALIZED CHARACTER OF A MAMMARY TUMOR, METHOD AND KIT OF USE
WO2005043164A2 (en) Method for distinguishing cbf-positive aml subtypes from cbf-negative aml subtypes